UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 20172019

Or

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File Number: 001-37815

 

Global Medical REIT Inc.

 

(Exact name of registrant as specified in its charter)

 

Maryland 46-4757266

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

   

2 Bethesda Metro Center, Suite 440

Bethesda, MD

 20814
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: 202-524-6851

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Classeach class:Trading Symbol:  Name of Each Exchange On Which Registeredeach exchange on which registered:
Common Stock, $0.001 par value $0.001 per share New York Stock Exchange
GMRE NYSE
Series A Preferred Stock, $0.001 par value $0.001 per share New York Stock ExchangeGMRE PrANYSE

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨  No xþ

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨  No xþ

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes xþ  No ¨

 

Indicate by a check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes .Yesxþ  No¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of "large“large accelerated filer," "accelerated” “accelerated filer," "smaller” “smaller reporting company," and "emerging“emerging growth company"company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer¨Accelerated filerxþ
Non-accelerated filer¨ (Do not check if a smaller reporting company)Smaller reporting company¨þ
  Emerging growth company¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨  No xþ

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $188.7$324.4 million as of June 30, 2017.2019.

 

As of March 2, 20182020 there were 21,630,67544,259,739 shares of the registrant’s common stock, par value of $0.001 per share, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant's definitive Proxy Statement filed in connection with the registrant’s 20182020 Annual Meeting of Stockholders are incorporated by reference into Part III of the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.2019. The Registrant expects to file its definitive Proxy Statement with the United States Securities and Exchange Commission within 120 days after December 31, 2017.2019.

 

 

 

 

 

TABLE OF CONTENTS

 

PART I
Item 1.Business45
Item 1A.Risk Factors14
Item 1B.Unresolved Staff Comments3435
Item 2.Properties3435
Item 3.Legal Proceedings35
Item 4.Mine Safety Disclosures35
  
PART II
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities35
Item 6.Selected Financial Data3637
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations38
Item 7A.Quantitative and Qualitative Disclosures About Market Risk5248
Item 8.Consolidated Financial Statements and Supplementary Data5349
Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure8887
Item 9A.Controls and Procedures8887
Item 9B.Other Information89
   
PART III
Item 10.Directors, Executive Officers and Corporate Governance90
Item 11.Executive Compensation91
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters91
Item 13.Certain Relationships and Related Transactions, and Director Independence91
Item 14.Principal Accounting Fees and Services91
 
PART IV
Item 15.Exhibits and Financial Statement Schedules91
Item 16.Form 10-K Summary9697
Signatures9798

 

2

2

 

 

Special Note Regarding Forward-Looking Statements

 

This Annual Report on Form 10-K (this “Report”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). In particular, statements pertaining to our trends, liquidity, capital resources, and the healthcare industry and healthcare real estate opportunity,opportunities, among others, contain forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

 

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

 

 ·defaults on or non-renewal of leases by tenants;

 ·decreased rental rates or increased vacancy rates;rates, including expected rent levels on acquired properties;

 ·difficulties in identifying healthcare facilities to acquire and completing such acquisitions;

 ·adverse economic or real estate conditions or developments, either nationally or in the markets in which our facilities are located;

 ·our failure to generate sufficient cash flows to service our outstanding obligations;

 ·fluctuations in interest rates and increased operating costs;
 ·our failure to effectively hedge our interest rate risk;
·our ability to satisfy our short and long-term liquidity requirements;

 ·our ability to deploy the debt and equity capital we raise;

 ·our ability to raise additional equity and debt capital on terms that are attractive or at all;

 ·our ability to make distributions on shares of our common and preferred stock;
 ·expectations regarding the timing and/or completion of any acquisition;

·general volatility of the market price of our common and preferred stock;
·our lack of a significant operating history;

 ·changes in our business or our investment or financing strategy;
 ·changes in our management internalization plans;

 ·our dependence upon key personnel whose continued service is not guaranteed;

 ·the ability of our andexternal manager, Inter-American Management LLC’s (the “Advisor”), ability to identify, hire and retain highly qualified personnel in the future;

 ·the degree and nature of our competition;


 ·changes in healthcare laws, governmental regulations, tax rates and similar matters;
 ·changes in current healthcare and healthcare real estate trends;
 ·changes in expected trends in Medicare, Medicaid and commercial insurance reimbursement trends;

 ·competition for investment opportunities;

 ·our failure to successfully integrate acquired healthcare facilities;
 ·our expected tenant improvement expenditures;

 ·changes in accounting policies generally accepted in the United States of America (“GAAP”);

 ·lack of or insufficient amounts of insurance;

 ·other factors affecting the real estate industry generally;
 ·changes in the tax treatment of our distributions;

 ·our failure to qualify and maintain our qualification as a real estate investment trust (“REIT”) for U.S. federal income tax purposes; and

 ·limitations imposed on our business and our ability to satisfy complex rules relating to REIT qualification for U.S. federal income tax purposes.

 

See Item 1A. Risk Factors in this Annual Report on Form 10-K for the year ended December 31, 2017 for further discussion of these and other risks, as well as the risks, uncertainties and other factors discussed in this Report and identified in other documents we may file with the United States Securities and Exchange Commission (the “SEC” or the “Commission”) from time to time. You should carefully consider these risks before making any investment decisions in our company. New risks and uncertainties may also emerge from time to time that could materially and adversely affect us. While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this Report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements.

 

3

4

 

 

PART I

 

ITEM 1.BUSINESS

 

Organization

 

Global Medical REIT Inc. (the “Company,” “we,” “us,” or “our”) was formed in 2011, re-domiciled as a Maryland corporation in 2014, and is a Maryland corporation engaged primarily in the acquisition of licensed, purpose-built specialized healthcare facilities and the leasing of thesethose facilities to strong clinical operatorshealthcare systems and physician groups with leading market share. We are externally managed and advised by our Advisor. See “—Our Advisor and our Management Agreement” for a description of our Advisor and the terms of our management agreement.

We elected to be taxed as a REIT for U.S. federal income tax purposes commencing with our taxable year ended December 31, 2016.

 

We hold our facilities and conduct our operations through a Delaware limited partnership subsidiary named Global Medical REIT L.P. (the “Operating Partnership”). We, through a wholly-owned subsidiary, serve as the sole general partner of the Operating Partnership. As of December 31, 2017,2019, we were the 93.63%91.82% limited partner of the Operating Partnership, with the remaining 6.37%8.18% owned by holders of long-term incentive plan units granted under our equity compensation plan (“LTIP”LTIP Units”) units and third-party holders oflimited partners who contributed properties or services to the Operating Partnership Unitsin exchange for limited partnership units (“OP Units”). The Operating Partnership holds our healthcare facilities through wholly-owned Delaware limited liability company subsidiaries.

 

We elected to be taxed as a REIT for U.S. federal income tax purposes commencing with our taxable year endedOn December 31, 2016.

Prior to the end of the calendar quarter occurring immediately after the date in which our stockholders’ equity (as defined in our management agreement) exceeds $500 million, we have agreed with our Advisor that13, 2019, our board of directors will establishestablished a special committee of independent and disinterested directors to discuss with our Advisor whether it would be in our stockholders’ best interestinterests to internalize management. See “—Agreement to Evaluate Internalization” for a more detailed description of our agreement to evaluate an internalization transaction.

 

Business Overview

  

We believe that the aging of America and the decentralization of healthcare services are increasing the need for purpose-built specialized healthcare facilities leased tooperated by strong practicephysician groups and healthcare systems that will capture the growth in age-related procedures performed away from acute-care hospital campuses.systems. Accordingly, we seek to invest in these purpose-built, specialized facilities, such as medical office buildings, surgery centers, specialty hospitals, and in-patient rehabilitation facilities to align our portfolio with contemporary trends in the delivery of healthcare services. We target markets with high demand for premium healthcare services, and within those markets, assets that are strategically located to take advantage of the decentralization of healthcare, such as facilities located away from hospital campuses. We believe that our investment in the confluence of specialized medical facilities, strong tenants and strategic sub-markets provides attractive, risk-adjusted returns to our stockholders.

 

Our healthcare facilities are typically leased under long-term, triple-net leases. Most of our tenants are physician groups, regional or national healthcare systems, community hospitals for-profit regional and national healthcare operators, and combinations thereof. Our facilities are primarily located in secondary markets.

 

Our Business Objectives and Investment Strategy

 

Our principal business objective is to provide attractive, risk-adjusted returns to our stockholders through a combination of (i) sustainable and increasing rental income that allows us to pay reliable increasing dividends and (ii) potential long-term appreciation in the value of our healthcare facilities and common and preferred stock.capital appreciation. Our primary strategies to achieve our business objective are to:

 

 ·construct a property portfolio that consists substantially of off-campus, purpose-built, licensed medical facilities, such as medical office buildings (MOBs), specialty hospitals, in-patient rehabilitation facilities (IRFs) and ambulatory surgery centers (ASCs), that are primarily located in secondary markets and are situated to take advantage of the aging of the U.S. population and the decentralization of healthcare;
·focus on practice types that will be utilized by an aging population and are highly dependent on their purpose-built real estate to deliver core medical procedures, such as cardiovascular treatment, rehabilitation, eye surgery, gastroenterology, oncology treatment and orthopedics;
·set aside a portion of our property portfolio for opportunistic acquisitions, including (i) certain acute-care hospitals and long-term acute care facilities (LTACs), that we believe provide premium, risk-adjusted returns and (ii) health system corporate office and administrative buildings, which we believe will help us develop relationships with larger health systems;
 ·lease our facilities under long-term, triple-net leases with contractual annual rent escalations and with initial (year one) capitalization rates that exceed our cost of capital (as opposed to factoring in future contractual rent escalations in determining whether investment returns will exceed our cost of capital);escalations;

4

·lease each facility to medical providers with a track record of successfully managing excellent clinical and profitable practices; and
 ·receive credit protections from our tenants or their affiliates, including personal and corporate guaranties, rent reserves and rent coverage requirements; and
·utilize traditional and non-traditional acquisition strategies, such as providing loans that contain purchase options.requirements.

5

 

Our Properties

 

As of December 31, 2017,2019, our portfolio consisted of 3768 facilities with an aggregate of (i) approximately 1.32.8 million rentable square feet and (ii) approximately $35.7$70.4 million of annualized base rent (iii) an approximate weighted average capitalization rate of 7.6% and (iv) approximately 10.5 weighted average lease years remaining.rent. The tabletables below summarizessummarize information about our portfolio as of December 31, 2017:

Property Location Rentable
Square Feet
(RSF)
  % of
Portfolio
RSF
   Annualized
Base Rent (in
thousands)(1)
  % of
Portfolio
Annualized
Base Rent
  Cap. Rate(2)  Lease Years
Remaining(3)
 
                     
Select Medical Hospital Omaha, NE  41,113   3.1% $1,762   5.0%  8.1%  5.6 
Orthopedic Surgery Center of Asheville Asheville, NC  8,840   0.7%  238   0.7%  9.8%  4.2 
Associates in Ophthalmology West Mifflin, PA  27,193   2.0%  784   2.2%  6.9%  12.7 
Gastro One Memphis, TN  52,266   3.9%  1,300   3.7%  6.5%  10.0 
Star Medical Center Plano, TX  24,000   1.8%  1,278   3.6%  7.3%  18.1 
Surgical Institute of Michigan Westland, MI  15,018   1.1%  389   1.1%  8.2%  8.2 
Marina Towers Melbourne, FL  75,899   5.7%  1,105   3.1%  7.2%  8.2 
Berks Eye Physicians & Surgeons Wyomissing, PA  17,000   1.3%  449   1.3%  7.5%  8.6 
Berkshire Eye Surgery Center Reading, PA  6,500   0.5%  241   0.7%  7.5%  8.6 
East Orange General Hospital East Orange, NJ  60,442   4.5%  962   2.7%  8.1%  8.8 
Brown Clinic Watertown, SD  48,132   3.6%  721   2.0%  8.0%  13.8 
Northern Ohio Medical Specialists (NOMS) Sandusky, OH  55,760   4.2%  864   2.4%  7.7%  9.8 
Carson Medical Group Clinic Carson City, NV  20,632   1.6%  354   1.0%  9.4%  5.8 
Piedmont Healthcare Ellijay, GA  44,162   3.3%  364   1.0%  7.4%  8.5 
Encompass (Mesa) Mesa, AZ  51,903   3.9%  1,762   4.9%  7.9%  6.8 
Encompass (Altoona) Altoona, PA  70,007   5.2%  1,672   4.7%  7.8%  3.4 
Encompass (Mechanicsburg) Mechanicsburg, PA  78,836   5.9%  1,877   5.3%  7.8%  3.4 
Southwest Florida Neurological & Rehab Cape Coral, FL  25,814   1.9%  529   1.5%  7.3%  9.1 
Geisinger Specialty Care Lewisburg, PA  28,480   2.1%  542   1.5%  7.4%  5.3 
Las Cruces Orthopedic Las Cruces, NM  15,761   1.2%  355   1.0%  7.3%  11.1 
Thumb Butte Medical Center Prescott, AZ  12,000   0.9%  371   1.0%  8.2%  9.2 
Southlake Heart & Vascular Institute Clermont, FL  18,152   1.4%  369   1.0%  7.1%  4.9 
Oklahoma Center for Orthopedic & Multi-specialty Surgery (OCOM) Oklahoma City, OK  97,406   7.6%  3,535   9.9%  7.1%  15.4 
Great Bend Regional Hospital Great Bend, KS  63,978   4.8%  2,144   6.0%  8.7%  14.3 
Unity Family Medicine Brockport, NY  29,497   2.2%  621   1.7%  7.2%  12.9 
Lonestar Endoscopy Flower Mound, TX  10,062   0.8%  294   0.8%  7.3%  8.8 
Texas Digestive Fort Worth, TX  18,084   1.4%  431   1.2%  6.9%  10.5 
Carrus Specialty Hospital Sherman, TX  69,352   5.2%  2,346   6.6%  9.0%  19.5 
Cardiologists of Lubbock Lubbock, TX  27,280   2.0%  600   1.7%  7.3%  11.7 
Conrad Pearson Clinic Germantown, TN  33,777   2.5%  1,459   4.1%  9.2%  6.4 
Central Texas Rehabilitation Clinic Austin, TX  59,258   4.4%  2,885   8.1%  7.1%  9.3 
Heartland Clinic Moline, IL  34,020   2.5%  892   2.5%  7.7%  15.5 
Albertville Medical Building Albertville, MN  21,486   1.6%  481   1.3%  7.1%  11.0 
Amarillo Bone & Joint Clinic Amarillo, TX  23,298   1.8%  594   1.7%  6.9%  12.0 
Kansas City Cardiology Lee’s Summit, MO  12,180   0.9%  275   0.8%  7.2%  7.0 
Zion Eye Institute St. George, UT  16,000   1.2%  400   1.1%  7.0%  12.0 
Respiratory Specialists Wyomissing, PA  17,598   1.3%  405   1.1%  7.2%  10.0 
Totals / Weighted Average    1,331,186   100.0% $35,650   100.0%  7.6%  10.5 

(1) Monthly base rent2019. Also see “Schedule III – Consolidated Real Estate and Accumulated Depreciation,” for December 2017 multiplied by 12.additional information about our properties.

(2) Annualized base rent for December 2017 divided by contractual purchase price.

(3) Does not include tenant renewal options.

5

 

Summary of Investments by Type

 

The following table contains information ofabout our portfolio by type of property as of December 31, 2017:2019:

 

Type(1) Rentable Square Feet
(RSF)
  % of Portfolio RSF  Annualized Base Rent
(in thousands)(2)
  % of Portfolio
Annualized Base Rent
 
Inpatient Rehab. Facility (IRF)/Rehab. Hospital(3)  329,356   24.7% $10,542   29.6%
Medical Office Building (MOB)(4)  561,557   42.2%  10,279   28.8%
MOB/ASC  170,259   12.8%  5,083   14.3%
Surgical Hospital  110,510   8.3%  4,425   12.4%
Acute-Care Hospital  63,978   4.8%  2,144   6.0%
Long-Term Acute Care Facility (LTAC)  41,113   3.1%  1,763   4.9%
Stand-alone Ambulatory Surgery Center (ASC)  36,298   2.7%  1,160   3.3%
Total  1,313,073   98.7% $35,396   99.3%

Type Rentable Square
Feet (RSF)
  % of RSF  Annualized Base Rent
(in thousands)(2)
  % of Annualized
Base Rent
 
Medical Office Building (MOB)(1)  1,614,773   58.07% $38,002   53.94%
Inpatient Rehab. Facility (IRF)  536,560   19.29%  18,182   25.81%
Surgical Hospital  174,984   6.29%  6,397   9.08%
Healthcare Office  136,183   4.90%  2,381   3.38%
Acute Care Hospital  236,314   8.50%  2,289   3.25%
Long-term Acute Care (LTAC) Hospital  53,537   1.93%  2,279   3.24%
Other(3)  28,500   1.02%  917   1.30%
Total  2,780,851   100.00% $70,447   100.00%

 

 

(1) A small portion of our portfolio (approximately 1.3% of our aggregate square feet) consists of office and other administrative or ancillary facilities.MOB includes buildings with special uses such as surgery centers, imaging, labs, urgent care, dialysis, etc.

(2) Monthly base rent for December 20172019 multiplied by 12.

(3) Includes one facility that is both an IRF and an LTAC.a free standing emergency department.

(4) Our MOB category includes medical office buildings that also include imaging centers.

6

Geographic Concentration

 

The following table contains information regarding the geographic concentration of our portfolio as of December 31, 2017.2019. Adverse economic or other conditions (including significant weather events) in the states that contain a high concentration of our facilities could adversely affect us. See “Risk Factors—We have significant geographic concentration in a small number of states, including Texas, Ohio, Pennsylvania, Arizona, Oklahoma, Tennessee, Kansas, ArizonaFlorida and Florida.Illinois. Economic and other conditions that negatively affect those states and our tenants in those states could have a greater effect on our revenues than if our properties were more geographically diverse.”

 

State(1) Rentable Square Feet
(RSF)
  % of Portfolio RSF  Annualized Base Rent
(in thousands)(2)
  % of Portfolio
Annualized Base Rent
  Rentable Square
Feet (RSF)
 % of RSF Annualized Base Rent
(in thousands)(1)
 % of Annualized
Base Rent
 
Texas  231,334   17.4% $8,429   23.6%  611,633   21.99% $15,305   21.73%
Ohio  256,073   9.21%  7,326   10.40%
Pennsylvania  245,614   18.5%  5,970   16.7%  245,614   8.83%  6,204   8.81%
Arizona  171,835   6.18%  5,850   8.30%
Oklahoma  97,406   7.3%  3,535   9.9%  150,855   5.42%  5,561   7.89%
Tennessee  74,620   5.6%  2,445   6.9%
Kansas  63,978   4.8%  2,144   6.0%
Arizona  63,903   4.8%  2,133   6.0%
Florida  119,865   9.0%  2,003   5.6%  254,076   9.14%  5,502   7.81%
Illinois  220,222   7.92%  4,206   5.97%
Other(2)  870,543   31.31%  20,493   29.09%
Total  896,720   67.4% $26,659   74.7%  2,780,851   100.00% $70,447   100.00%

 

(1) Other than theMonthly base rent for December 2019 multiplied by 12.

(2) Our remaining properties are located in 20 other states, listed in the table above,with no state accountsaccounting for more than 5.0% of our annualized base rent.

(2) Monthly rent for December 2017 multiplied by 12.

 


Significant Tenants

 

The following tenants each account for a significant percentageat least 5% of our total revenue andannualized base rent generated from our portfolio.as of December 31, 2019. Adverse changes to any of their financial conditions or our failure to renew our leases with these tenants could adversely affect us. See “Risk Factors—The inability of any of our significant tenants to pay rent to us could have a disproportionate negative affect on our revenues.” and“Risk Factors—Most of our healthcare facilities are occupied by a single tenant, and we may have difficulty finding suitable replacement tenants in the event of a tenant default or non-renewal of our leases, especially for our healthcare facilities located in smaller markets.

 

Tenant Rentable
Square
Feet (RSF)
  % of RSF  Annualized Base Rent
 (in thousands)(1)
  % of Annualized
Base Rent
  Rentable Square
Feet (RSF)
  % of RSF  Annualized Base Rent
(in thousands)(1)
  % of Annualized
Base Rent
 
Encompass Health Corporation(2)  200,746   15.1% $5,311   14.9%  254,006   9.13% $7,082   10.05%
Memorial Health System  155,600   5.60%  5,482   7.78%
Kindred Healthcare Inc.(2)  112,707   4.05%  4,979   7.07%
Oklahoma Center for Orthopedic & Multi-specialty Surgery (OCOM)  97,406   7.3%  3,535   9.9%  97,406   3.50%  3,642   5.17%
Seton Healthcare Family/Kindred Healthcare Inc.(3)  59,258   4.5%  2,885   8.1%
Carrus Hospitals  69,352   5.2%  2,346   6.6%
Great Bend Regional Hospital, LLC  63,978   4.8%  2,144   6.0%
Total  490,740   36.9% $16,221   45.5%  619,719   22.28% $21,185   30.07%

 

(1)Monthly base rent for December 20172019 multiplied by 12.

(2) Formerly HealthSouth Corporation.

(3) Tenant is a joint venture between Seton Healthcare Family andIncludes two Kindred Healthcare Inc. joint ventures with a local health system.

Lease Expirations

 

The following table contains information regarding the lease expiration dates of the leases in our portfolio as of December 31, 2017.2019.

 

Year Number of
Leases
  Rentable
Square Feet
  Annualized Base
Rent
(in thousands)(1)
  Number of Leases  Leased RSF   Annualized Base
Rent (in thousands)(1)
  % of Annualized
Base Rent
 
2018  -   -  $- 
2019  -   -   - 
2020  -   -   -   3   6,753  $113   0.16%
2021  3   159,338   3,765   6   163,116   3,976   5.64%
2022  3   19,736   1,460   12   60,887   1,242   1.76%
2023  4   90,225   2,659   12   137,748   3,990   5.66%
2024  8   105,517   3,649   22   244,305   7,482   10.62%
2025  -   -   -   7   200,539   5,268   7.48%
2026  7   229,083   3,804   14   273,263   5,062   7.19%
2027  7   222,696   6,353   14   331,572   9,970   14.15%
2028  2   39,570   912   4   66,952   1,579   2.24%
2029  10   233,965   6,691   9.50%
Thereafter  15   465,021   13,048   38   1,055,013   25,074   35.60%
Total  49   1,331,186  $35,650   142   2,774,113  $70,447   100.00%

.

(1) Monthly base rent for December 20172019 multiplied by 12.

7

 

Ground Leases

 

As of December 31, 2017,2019, we leased the land upon which twofive of our facilitiesbuildings are built,located, representing approximately 4.4%3.6% of our total rentable square feet and approximately 5.9%4.6% of our December 20172019 annualized base rent. The ground leases subject these properties to certain restrictions, including restrictions on our ability to re-let such facilities to tenants not affiliated with the healthcare delivery system that owns the underlying land, rights of first offer and refusal with respect to sales of the facilities and restrictions that limit the types of medical procedures that may be performed at the facilities.

 


Recent Developments

 

2020 Completed Acquisitions and Properties Under Contract

Since December 31, 2019, we have closed and placed under contract the following properties:

Closed Acquisitions

 

During the period beginning on January 1, 2018 and ending on March 1, 2018, we completed four acquisitions with an aggregate purchase price of $48.4 million, an aggregate of 323,400 net rentable square feet and a weighted average capitalization rate of approximately 8.6%. The table below summarizes our post-2017 acquisitions:

Property City Type Rentable
Square Feet
(RSF)
  Purchase Price(1)
(in thousands)
  Annualized
Base Rent(2)
(in thousands)
  Cap. Rate(3)  Lease
Years
Remaining
 
Quad City Kidney Center Moline, IL MOB  27,173  $6,706  $548   8.17%  14 
NOMS Fremont, OH MOB  25,893   8,286   608   7.34%  12 
Gainesville Eye Gainesville, GA MOB/ASC  34,020   10,400   776   7.46%  12 
City Hospital of White Rock Dallas, TX Acute-care Hospital  236,314   23,000   2,230   9.70%  20 
Total/Weighted Average      323,400  $48,392  $4,162   8.60%  16 
Property City 

Rentable
Square Feet

(RSF)

  

Purchase
Price(1)
(in thousands)

  

Annualized
Base Rent(2)
(in thousands)

  

Capitalization
Rate(3)

 
Wake Forest Baptist Health High Point, NC  97,811  $24,750  $1,832   7.4%
Medical Associates Clinton, IA  115,142   11,350   1,282   11.3%
Ascension St. Mary’s Hospital West Allis, WI  33,670   9,025   664   7.4%
Totals/Weighted Average    246,623  $45,125  $3,778   8.4%

 

(1) Represents the contractual purchase price.

(2)Monthly base rent in the month ofat acquisition multiplied by 12.

(3)Capitalization rates are calculated based on current lease terms and do not give effect to future rent escalations.

 

Properties Under Contract

Summary information about transactions weWe have under purchase agreements as of March 6, 2018 is presented in the table below: 

Property City 

Rentable

Square Feet

(RSF)

  

Purchase

Price(1)

(in thousands)

  

Annualized

Base Rent(2)

(in thousands)

  

Cap.

Rate(3)

 
Orlando Health Orlando, FL  59,594  $16,200  $1,340   8.27%
Memorial Health System Belpre, OH  155,600   64,200   5,040   7.85%
Totals/Weighted Average    215,194  $80,400  $6,380   7.94%

(1) Represents contractual purchase price.

(2)Monthly base rent in the month placedfive properties under contract multiplied by 12.

(3)Capitalization rates are calculated based on current lease terms and do not give effect to future rent escalations.

We entered into thefor an aggregate purchase and sale agreements for the Orlando and Belpre transactions on January 24, 2018 and March 6, 2018, respectively.price of approximately $84.9 million. We are currently in the due diligence periodsperiod for these transactions.our properties under contract. If we identify problems with theany of these properties or the operatorsoperator of the propertiesany property during our due diligence review, we may not close the transactionstransaction on a timely basis or we may terminate the purchase agreementsagreement and not close the transactions.transaction.

Increase in Capacity of our Revolving Credit Facility

On March 6, 2018, we amended our revolving credit facility to increase the aggregate size of the facility by $90 million to $340 million. As of December 31, 2017, we had $164.9 million of outstanding borrowings under this facility.

8

 

Healthcare Industry and Healthcare Real Estate Market Opportunity

 

We believe the U.S. healthcare industry is continuing its rapid pace of growth due to increasing healthcare expenditures, favorable demographic trends, evolving patient preferences and evolving government initiatives. Furthermore, we believe these factors are contributing to the increasing need for healthcare providers to enhance the delivery of healthcare by, among other things, integrating real estate solutions that freesfree up capital for reinvestment in their practices and allowsallow healthcare providers to focus on providing healthcare services and not real estate management.

U.S. Healthcare Spending Expected to Increase 5.6%by an Average of 5.7% per Year Over Next DecadeBetween 2020 and 2027

 

According to the United States Department of Health and Human Services, or HHS, healthcare spending wasgrew by 4.8% in 2019 to $3.8 trillion, or approximately 17.8% of U.S. gross domestic product or GDP, in 2015, the first year that the Patient Protection and Affordable Care Act’s (the “Affordable Care Act”) coverage provisions were in effect, and is expected to increase 5.6%by an average of 5.7% per year over the next decade. The anticipated continuing increase in demand for healthcare services, together with an evolving complexbetween 2020 and costly regulatory environment, changes in medical technology and reductions in government reimbursements, are expected to pressure capital-constrained healthcare providers to find cost effective solutions for their real estate needs.2027. We believe the demand for healthcare facilities by healthcare providers will increase as health spending in the United States continues to increase, which will increase the potential supply of healthcare facilities in the market.

 

Aging U.S. Population Driving Increase in Demand for Healthcare Services

 

The general aging of the population, driven by the baby boomer generation and advances in medical technology and services which increase life expectancy, is a key driver of the growth in healthcare expenditures. According to the 2010 U.S. Census, the segment of the population consisting of people 65 years or older comprise the fastest growing segment of the overall U.S. population. We believe that demographic trends in the United States, including, in particular, an aging population, will result in continued growth in the demand for healthcare services utilized by an aging population, which in turn will lead to an increasing need for a greater supply of specialized, well-located healthcare facilities.

 

Clinical Care Continues to Shift Away from Large, Centralized Facilities

 

We believe the continued shift in the delivery of healthcare services away from large, centralized facilities to smaller, more specialized facilities will increase the need for smaller, more specialized and efficient hospitals and outpatient facilities that take advantage of these shifting trends. Procedures traditionally performed in large, general hospitals, such as certain types of surgeries, are increasingly moving to more conveniently-located, specialized facilities driven by advances in clinical science, shifting consumer preferences, limited or inefficient space in existing hospitals and lower costs in the non-hospital environment.

 

We believe that healthcare is delivered more cost effectively and with higher patient satisfaction when it is provided outside of a large, centralized hospital environment. Increased specialization within the medical field is also driving demand for medical facilities that are purpose-built for particular specialties.

 


Opportunistic Acquisitions in Acute-Care Facilities

 

Despite the continued shift in the delivery of healthcare services to smaller, more specialized facilities, we believe opportunities exist to acquire larger, acute-care facilities, such as acute-care hospitals and LTACs, with very attractive submarket fundamentals at compelling valuations and strong EBITDAR coverage.  Despite the trends away from acute-care facilities, we believe that certain, well-located acute-care hospitals and LTACs will still be critical components of the U.S. healthcare system. 

We also opportunistically invest in large health system’s corporate and administrative office buildings. We believe investments in these types of facilities helps us build relationships with large health systems, which could lead to us becoming a preferred landlord for such health systems’ medical facilities.

Although not the primary focus of our investment strategy, we believe allocating a portion of our portfolio for opportunistic acute-care facilities acquisitions helps diversify our portfolio and is consistent with our strategy of aligning ourselves with strong operators.

  

Our Advisor and our Management Agreement

 

We are externally managed and advised by our Advisor pursuant to a management agreement, subject to the oversight of our board of directors. Our Advisor provides substantially all of the services related to the operation of our company and business, including services related to the location, selection, acquisition and financing of healthcare facilities, the collection of rents, the payment of dividends, the preparation of reports to our investors, and the disposition of healthcare facilities. Pursuant to the management agreement, we are the only investment vehicle our Advisor can manage that focuses on our asset classes. Each of our officers is an employee of our Advisor.

 

ZH InternationalZensun Enterprises Limited (“Zensun”) is the 85% owner of our Advisor and the owner of ZH USA, LLC, which held approximately 12%8.4% of our common stock as of December 31, 2017,2019, which we believe aligns the Advisor’s interests with those of our stockholders. A public company traded on the Hong Kong exchange, ZH InternationalZensun is engaged in global real estate development, investment, management and sales and REIT management. Our director, Zhang Jingguo, is the Chairman, Executive Director and Chief Executive Officer of Zensun and affiliates of Mr. Zhang own a controlling interest in Zensun. Our President, Chief Executive Officer and Chairman, Mr. Jeffrey Busch, owns the remaining 15% of our Advisor.

 

The terms of the management agreement, including the fee arrangements, expense provisions and termination fee provisions, are summarized below.

 

9

Type Description
Base Management Fee 1.5% of our stockholders’ equity per annum, calculated quarterly for the most recently completed fiscal quarter and payable in quarterly installments in arrears in cash.
   
  For purposes of calculating the base management fee, our stockholders’ equity means: (a) the sum of (1) our stockholders’ equity as of March 31, 2016, (2) the aggregate amount of the conversion price (including interest) for the conversion of our outstanding convertible debentures into our common stock as of the completion of our initial public offering and (3) the net proceeds from (or equity value assigned to) all issuances of our equity and equity equivalent securities (including common stock, common stock equivalents, preferred stock, LTIP unitsUnits and OP unitsUnits issued by us or our Operating Partnership) (allocated on a pro rata daily basis for such issuances during the fiscal quarter of any such issuance), less (b) any amount that we pay to repurchase shares of our common stock or equity securities of our Operating Partnership. Our stockholders’ equity also excludes (1) any unrealized gains and losses and other non-cash items (including depreciation and amortization) that have impacted stockholders’ equity as reported in our financial statements prepared in accordance with accounting principles generally accepted in the United States, or GAAP, and (2) one-time events pursuant to changes in GAAP, and certain non-cash items not otherwise described above, in each case after discussions between our Advisor and our independent directors and approval by a majority of our independent directors. As a result, our stockholders’ equity, for purposes of calculating the base management fee, could be greater or less than the amount of stockholders’ equity shown on our financial statements.


Incentive Fee An incentive fee payable with respect to each calendar quarter (or part thereof that the management agreement is in effect) in arrears. The incentive fee will be an amount, not less than zero, equal to the difference between (1) the product of (x) 20% and (y) the difference between (i) our AFFO (as defined below) for the previous 12-month period, and (ii) the product of (A) the weighted average of the issue price of equity securities offerings and transactions of the Company and the Operating Partnership, multiplied by the weighted average number of all shares of common stock outstanding on a fully-diluted basis (including any restricted stock units, any restricted shares of common stock, OP units,Units, LTIP unitUnit awards and shares of common stock underlying awards granted under the Global Medical REIT Inc. 2016 Equity Incentive Plan (the “2016 Equity Incentive Plan”) or any future plan in the previous 12-month period, and (B) 8%, and (2) the sum of any incentive fee paid to our Advisor with respect to the first three calendar quarters of such previous 12-month period; provided, however, that no incentive fee is payable with respect to any calendar quarter unless AFFO is greater than zero for the four most recently completed calendar quarters.
   
  AFFO is calculated by adjusting our funds from operations, or FFO, by adding back acquisition and disposition costs, stock-based compensation expenses, amortization of deferred financing costs, amortization of above and below market leases, and any other non-recurring or non-cash expenses, which are costs that do not relate to the operating performance of our properties, and subtracting loss on extinguishment of debt, straight line rent adjustment, recurring tenant improvements, recurring leasing commissions and recurring capital expenditures.
   
Expense Reimbursement We are required to reimburse our Advisor for operating expenses related to us that are incurred by our Advisor, including expenses relating to legal, accounting, due diligence and other services. Except with respect to a portion of our General Counsel and Secretary’s compensation, weWe do not reimburse any compensation expenses incurred by the Advisor. Our reimbursement obligation is not subject to any dollar limitation. Expenses are reimbursed in cash on a quarterly basis.
   
Termination Fee Upon any termination of the management agreement by us, other than for cause, any non-renewal of the management agreement by us or any termination of the management agreement by our Advisor due to our material breach of the management agreement, our Advisor will be paid a termination fee equal to three times the sum of the average annual base management fee and the average annual incentive fee with respect to the previous eight fiscal quarters ending on the last day of the fiscal quarter prior to termination.

 

10

For the year ended December 31, 2017,2019, we paid aggregate base management fees to our Advisor of approximately $3.1$5.7 million and did not pay any incentive fees. Additionally, exceptExcept for the base management fee and incentive fee, we do not pay any additional fees to our Advisor, which we believe distinguishes us from other externally-managed REITs that may charge other fees in addition to base management and incentive fees, such as acquisition fees and financing fees. Furthermore, as stated above, an affiliate of our Advisor, Zensun, owned approximately 12%8.4% of our common stock as of December 31, 2017,2019, which we believe aligns the interest of our Advisor and our stockholders.

 

We believe our externally-managed structure has been indispensable to us during the early stages of our business as our Advisor has provided us with an operational infrastructure on a cost-effective basis. However, as we continue to grow our equity base, it may become more cost effective to internalize our management or modify the terms of our management agreement with our Advisor.

 

Agreement to EvaluateManagement Internalization Evaluation

 

Prior to the end of the calendar quarter occurring immediately after the date in which our stockholders’ equity (as defined in our management agreement) exceeds $500 million, we have agreed with our Advisor thatOn December 13, 2019, our board of directors will establishformed a special committee of three independent and disinterested directors to discuss with our Advisor whether it would be in our stockholders’ best interest to internalize management.

If we electthe pursuit of an internalization transaction is determined to internalize management asbe in the best interests of the Company and its stockholders, upon the approval of two-thirds of our independent directors, the special committee shall negotiate an internalization transaction with our Advisor. After an internalization transaction has been negotiated between the special committee and the Advisor, a resultmajority of such discussions, we would expectour independent directors must approve the transaction and, if required by law or New York Stock Exchange (“NYSE”) rules, the internalization transaction may be subject to terminatestockholder approval. Pursuant to the management agreement, with our Advisorthe gross value of the consideration paid by the Company for any internalization transaction shall equal three times the average annual base management fee and hire certain employees of our Advisor while also potentially entering into other service agreements with our Advisor that would allowaverage annual incentive fee paid or payable by us to continuethe Advisor during the previous eight fiscal quarters prior to utilize certain personnel and resourcesthe date of ourthe internalization transaction, which is equal to the termination fee the Company would be obligated to pay the Advisor that would not be acquired by us in the internalization transaction. event of a termination of the management agreement by the Company for any reason other than for cause. 


It is also possible that, as a result of such discussions between us and our Advisor, we may elect to preserve our external management structure but with modifications to the terms of the management agreement between us and our Advisor that, among other things, alter our expenses to mirror more closely what our expenses would be if we were internally managed.

 

To complete an internalization transaction, the special committee of our board and our Advisor wouldwill need to negotiate and reach a mutually acceptable agreement relating to such transaction. We cannot assure you that such negotiations will result in a mutually acceptable agreement, that we will be able to complete any such a transaction, or on what terms it may be completed, including the amount of consideration we may be required to pay to our Advisor. In addition, to the extent required by law or under the listing rules of the New York Stock ExchangeNYSE or other exchange upon which our shares of common stock are then listed, any such transaction may require the approval of our stockholders. Consequently, no assurance can be given that an agreement will be reached or that internalization of our Advisor will be achieved.

 

Qualification as a REIT

 

We elected to be taxed as a REIT commencing with our taxable year ended December 31, 2016. Subject to a number of significant exceptions, a corporation that qualifies as a REIT generally is not subject to U.S. federal corporate income taxes on income and gains that it distributes to its stockholders, thereby reducing its corporate levelcorporate-level taxes. In order to qualify as a REIT, a substantial percentage of our assets must be qualifying real estate assets and a substantial percentage of our income must be rental revenue from real property or interest on mortgage loans. We believe that we have been organized and have operated in such a manner as to qualify for taxation as a REIT, and we intend to continue to operate in such a manner. However, we cannot provide assurances that we will continue to operate in a manner so as to qualify or remain qualified as a REIT.

 

Competition

 

We compete with many other real estate investors for acquisitions of healthcare properties, including healthcare operators, and real estate investors such as private equity firms and other REITs, some of whom may have greater financial resources and lower costs of capital than we do. The competition for healthcare properties may significantly increase the price that we must pay for healthcare properties, and our competitors may succeed in acquiring those properties or assets themselves. In addition, our potential acquisition targets may find our competitors to be more attractive because they may have greater resources, may be willing to pay more for the properties or may have a more compatible operating philosophy.

 

Additionally, our healthcare facilities and tenants often face competition from nearby hospitals, other medical practices and other healthcare facilities, including urgent care and other primary care facilities, that provide comparable services. If our tenants’ competitors have greater geographic coverage, improved access and convenience to physicians and patients, provide or are perceived to provide higher quality services, recruit physicians to provide competing services at their facilities, expand or improve their services or obtain more favorable managed-care contracts, our tenants may not be able to successfully compete.

 

11

Government Laws and Regulation

 

Affordable Care Act

 

 The Affordable Care Act is a comprehensive healthcare reform law that contains various provisions that may directly impact our tenants.  The primary goal of the Affordable Care Act is to broaden insurance coverage for the uninsured population by expanding Medicaid coverage, creating health insurance exchanges and mandating that uninsured individuals purchase health insurance. The Affordable Care Act also contains provisions aimed at lowering the cost of healthcare, including lowering increases in Medicare payment rates and promoting alternate reimbursement methods for providers that focus on patient outcomes rather than volume. In addition to expanding coverage and controlling costs, the Affordable Care Act also contains provisions intended to combat healthcare fraud, including Medicare fraud and abuse. On June 28, 2012, the United States Supreme Court partially invalidated the expansion of Medicaid and allowed states not to participate in the expansion without losing their existing Medicaid funding. 

  


Since the enactment of the Affordable Care Act, there have been multiple attempts through legislative action and legal challenge to repeal or amend the Affordable Care Act. Although there continue to be judicial challenges to the Affordable Care Act, the Supreme Court has thus far upheld the Affordable Care Act, including, most recently, in their June 25, 2015 ruling onKing v. Burwell. On January 20, 2017, President Trump issued an executive order aimed at seeking the prompt repeal of the Affordable Care Act and directed the heads of all executive departments and agencies to minimize the economic and regulatory burdens of the Affordable Care Act to the maximum extent permitted by law. In addition, on December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act of 2017, or the TCJA. The TCJA repealed the individual mandate provision of the Affordable Care Act starting in 2019. Also, on December 14, 2018, inTexas v. Azar, the U.S. District Court of the Northern District of Texas invalidated the Affordable Care Act based on the removal of the individual mandate provision by the TCJA, and on January 9, 2020, the Firth Circuit Court of Appeals affirmed the lower court’s decision that the individual mandate component of the Affordable Care Act was unconstitutional, but did not invalidate the entire law. The Fifth Circuit Court of Appeals remanded the question of whether the remainder of the Affordable Care Act can exist without the individual mandate back to the lower court for further analysis. We cannot predict whether any future attempts to amend or repeal the Affordable Care Act will be successful.successful or that the decision inTexas v. Azar will be overturned or confirmed on appeal by the Supreme Court of the United States. The future of the Affordable Care Act is uncertain and any changes to existing laws and regulations, including the Affordable Care Act’s repeal, modification or replacement, could have a long-term financial impact on the delivery of and payment for healthcare. Both our tenants and us may be adversely affected by the law or its repeal, modification or replacement.

 

Although the Affordable Care Act’s expansion of insurance coverage may benefit our tenants by increasing their number of insured patients, these benefits may be offset by the fact that (i) many of the newly insured under the Affordable Care Act are insured by policies that have high deductibles (and, thus, create higher patient credit risks for our tenants), (ii) some states have not implemented the Medicaid expansion or have implemented Medicaid expansion in such ways that may reduce potential enrollment (such as implementing work requirements), and, (iii) even if theystates have expanded Medicare, Medicaid may not be accepted by some of our tenants. For our tenants that do accept Medicaid, they may receive lower reimbursements for Medicaid patients than for patients with Medicare or commercial insurance. Additionally, although the migration from Medicare fee-for-service, or volume-based, payments to an outcome-based reimbursement model may lower overall healthcare costs, these changes could negatively affect our tenants if they are unable to adapt to a more outcome-oriented healthcare delivery model.

 

Medicare and Medicaid Programs

 

Sources of revenue for our tenants typically include the Medicare and Medicaid programs. Healthcare providers continue to face increased government pressure to control or reduce healthcare costs and significant reductions in healthcare reimbursement, including reduced reimbursements and changes to payment methodologies under the Affordable Care Act. In some cases, private insurers rely on all or portions of the Medicare payment systems to determine payment rates, which may result in decreased reimbursement from private insurers.

  

If the United States economy enters a recession or slower growth, this could negatively affect state budgets, thereby putting pressure on states to decrease spending on Medicaid. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in Medicaid programs due to unemployment and declines in family incomes. Historically, states have often attempted to reduce Medicaid spending by limiting benefits and tightening Medicaid eligibility requirements. Additionally, in early 2018, the Centers for Medicare and Medicaid Services issued guidance that would allow states to impose work requirements as a condition to Medicaid eligibility, which could dampen enrollment in the program.

 

Efforts by Medicare and Medicaid to reduce reimbursements will likely continue, which could negatively affect our tenant’s revenues and their ability to pay rent to us.

 

Fraud and Abuse Laws

 

There are various federal and state laws prohibiting fraudulent and abusive business practices by healthcare providers who participate in, receive payments from, or are in a positionable to make referrals in connection with, government-sponsored healthcare programs, including the Medicare and Medicaid programs. Our leases with certain tenants may also be subject to these fraud and abuse laws. These laws include, without limitation:

 

·The Federal Anti-Kickback Statute, which prohibits, among other things, the offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, the referral of any U.S. federal or state healthcare program patients;

12

·The Federal Physician Self-Referral Prohibition (commonly called the “Stark Law”), which, subject to specific exceptions, restricts physicians who have financial relationships with healthcare providers from making referrals for designated health services for which payment may be made under Medicare or Medicaid programs to an entity with which the physician, or an immediate family member, has a financial relationship;

·The False Claims Act, which prohibits any person from knowingly presenting false or fraudulent claims for payment to the federal government, including under the Medicare and Medicaid programs;

·The Civil Monetary Penalties Law, which authorizes the Department of Health and Human Services to impose monetary penalties for certain fraudulent acts; and

·State anti-kickback, anti-inducement, anti-referral and insurance fraud laws which may be generally similar to, and potentially more expansive than, the federal laws set forth above.

 

Violations of these laws may result in criminal and/or civil penalties that range from punitive sanctions, damage assessments, penalties, imprisonment, denial of Medicare and Medicaid payments and/or exclusion from the Medicare and Medicaid programs. In addition, the Affordable Care Act clarifies that the submission of claims for items or services generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the False Claims Act. The federal government has taken the position, and some courts have held, that violations of other laws, such as the Stark Law, can also be a violation of the False Claims Act. Additionally, certain laws, such as the False Claims Act, allow for individuals to bring whistleblower actions on behalf of the government for violations thereof. Imposition of any of these penalties upon one of our tenants could jeopardize that tenant’s ability to operate or to make rent payments to us. Further, we enter into leases and other financial relationships with healthcare delivery systems that are subject to or impacted by these laws. In the future we may have other investors who are healthcare providers in certain of our subsidiaries that own our healthcare facilities. If any of our relationships, including those related to the other investors in our subsidiaries, are found not to comply with these laws, we and our physician investors may be subject to civil and/or criminal penalties.

 

Other Regulations

 

The healthcare industry is heavily regulated by U.S. federal, state and local governmental authorities. Our tenants generally will be subject to laws and regulations covering, among other things, licensure, and certification for participation in government programs, billing for services, privacy and security of health information, including the Health Insurance Portability and Accountability Act of 1996, which provides for the privacy and security of certain individually identifiable health information, and relationships with physicians and other referral sources. In addition, new laws and regulations, changes in existing laws and regulations or changes in the interpretation of such laws or regulations could negatively affect our financial condition and the financial condition of our tenants. These changes, in some cases, could apply retroactively. The enactment, timing or effect of legislative or regulatory changes cannot be predicted.

 

Many states regulate the construction of healthcare facilities, the expansion of healthcare facilities, the construction or expansion of certain services, including by way of example specific bed types and medical equipment, as well as certain capital expenditures through certificate of need, or CON, laws. Under such laws, the applicable state regulatory body must determine a need exists for a project before the project can be undertaken. If one of our tenants seeks to undertake a CON-regulated project but is not authorized by the applicable regulatory body to proceed with the project, the tenants would be prevented from operating in its intended manner.

 

Failure to comply with these laws and regulations could adversely affect us directly and our tenantstenants’ ability to make rent payments to us.

 

Environmental Matters

 

Under various U.S. federal, state and local laws, ordinances and regulations, current and prior owners and tenants of real estate may be jointly and severally liable for the costs of investigating, remediating and monitoring certain hazardous substances or other regulated materials on or in such healthcare facility. In addition to these costs, the past or present owner or tenant of a healthcare facility from which a release emanates could be liable for any personal injury or property damage that results from such releases,release, including for the unauthorized release of asbestos-containing materials and other hazardous substances into the air, as well as any damages to natural resources or the environment that arise from such releases. These environmental laws often impose such liability without regard to whether the current or prior owner or tenant knew of, or was responsible for, the presence or release of such substances or materials. Moreover, the release of hazardous substances or materials, or the failure to properly remediate such substances or materials, may adversely affect the owner’s or tenant’s ability to lease, sell, develop or rent such healthcare facility or to borrow by using such healthcare facility as collateral. Persons who transport or arrange for the disposal or treatment of hazardous substances or other regulated materials may be liable for the costs of removal or remediation of such substances at a disposal or treatment facility, regardless of whether or not such facility is owned or operated by such person.

 

13

Certain environmental laws impose compliance obligations on owners and tenants of real property with respect to the management of hazardous substances and other regulated materials. For example, environmental laws govern the management and removal of asbestos-containing materials and lead-based paint. Failure to comply with these laws can result in penalties or other sanctions.

 

Employees

 

The Company is externally managed by the Advisor and, therefore, has no employees. The Advisor provides the services of the officers and other management personnel of the Company.

 

13

Available Information

We maintain a website atwww.globalmedicalreit.com. The information on our website is not incorporated by reference in this Annual Report on Form 10-K, and our web address is included as an inactive textual reference only.

 

We file registration statements, proxy statements, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, with the SEC.Our website address is www.globalmedicalreit.com. We make available, free of charge through the Investors portion of the website, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Reports of beneficial ownership filed pursuant to Section 16(a) of the Exchange Act are also available on our website. These reports and other information are also available, free of charge, at www.sec.gov. Alternatively, the public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330.

 

ITEM 1A.RISK FACTORS

 

The following summarizes the material risks of purchasing or owning our securities. Our business, financial condition and/or results of operations and our ability to make distributions to our stockholders may be materially adversely affected by the nature and impact of these risks. In such case, the market value of our securities could be detrimentally affected, and investors may lose part or all of the value of their investment. You should carefully consider the risks and uncertainties described below. 

 

Risks Related to Our Business and Our Healthcare Facilities 

 

We ourare dependent on our tenants for substantially all of our revenues. Our tenants face a wide range of business risks, including economic, competitive, government reimbursement and regulatory risks, any of which could cause our tenants to be unable to pay rent to us.

We ourare dependent on our tenants for substantially all of our revenues. Our tenants face a wide range of business risks, including economic, competitive, government reimbursement and regulatory risks, which may adversely affect their businesses and, in turn, their ability to pay rent to us. If any of our tenants were unable to pay their rent to us and we had insufficient credit protections in place (such as rent reserves, guarantees, security deposits and letters of credit), our revenues and operating cash flows could be materially adversely affected, which in turn could affect our liquidity, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

Our assets are concentrated in healthcare-related facilities, making us more economically vulnerable to specific industry-related risks than if our assets were diversified across different industries.

 

We acquire and own healthcare-related facilities. We are subject to risks inherent in concentrating investments in real estate, and specifically healthcare real estate. Any adverse effects that result from these risks could be more pronounced than if we diversified our investments outside of the healthcare industry. Any healthcare industry downturn could adversely affect the ability of our tenants to pay us rents and our ability to maintain current rental and occupancy rates. Our tenant mix could become even more concentrated if a significant portion of our tenants practice in a particular medical field or are reliant upon a particular healthcare delivery system. Accordingly, a downturn in the healthcare industry generally, or a particular medical field or healthcare delivery system specifically, may have a material adverse effect on our revenues and operating cash flows, which in turn could affect our liquidity, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

14

We finance a majoritymost of our portfolio with secured floating rate debt from our revolving credit facility.Credit Facility. We are subject to the risks associated with secured, floating-rate debt, including the potential of an increase in our interest expense, covenant restrictions and the risk of foreclosure.

 

As of December 31, 2017,2019, our total outstanding debt, net of unamortized debt issuance costs, was approximately $203.4$386.2 million, of which $164.9$347.5 million was secured floating-rate debt from our revolving credit facilityCredit Facility with approximately 80%91% of our properties pledged as security thereunder. Although the weighted average interest rate on our floating rate debt did not increase significantly in 2017, we anticipate additional increases in 2018. We currently do not hedge our interest rate risk, therefore, ifIf interest rates were to continue to rise, or the interest rate spread on our Credit Facility increases based on our consolidated leverage ratios, our borrowing costs would increase, which could, among other things, increase our cost of capital (which would affect our ability to acquire assets) and decrease our earnings, liquidity, cash available to make distributions to our shareholdersstockholders and the trading price of our common and preferred stock.

 


The terms of our debt agreements require us to comply with a number ofseveral customary financial and other covenants, such as maintaining certain leverage and coverage ratios and minimum tangible net worth requirements. For example, under our revolving credit facility, we are subject to, among other things, (i)See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” for a maximum consolidated leverage ratiodescription of 65%, (ii) a minimum fixed charge coverage ratio of 1.5:1, and (iii) a minimum net worth of approximately $120 million.these covenants. Our continued ability to incur additional debt, make distributions and to conduct business in general is subject to our compliance with these covenants, which limit our operational flexibility. Additionally, pursuant to our revolving credit facility, the interest rate spread on our revolving credit facility may increase based on our consolidated leverage ratio. Breaches of these covenants could result in defaults under the instruments governing the applicable indebtedness, in addition to any other indebtedness cross-defaulted against such instruments, which could accelerate the principal balance of our debt and cause our lenders to institute foreclosure proceedings against us. Therefore, any such default could have a material adverse impact on our business, liquidity, financial condition, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

Our interest rate hedges may not be successful in mitigating our interest rate risks.

We use derivative instruments to hedge exposure to changes in interest rates on certain of our variable rate loans. As of December 31, 2019, we had five interest rate swap agreements that fixed the LIBOR component of our rates on $300 million of our outstanding Credit Facility balance. There is no assurance that our hedging instruments will adequately mitigate our interest rate risk or that our hedging strategy will not result in losses. Additionally, a hedging counterparty may fail to honor its obligations to us. If our interest rate hedges are unsuccessful in mitigating our interest rate risk, or if a hedging counterparty fails to honor its obligations to us, our borrowing costs would increase, which could, among other things, increase our cost of capital and decrease our earnings, liquidity, cash available to make distributions to our stockholders and the trading price of our common and preferred stock.

The inability of any of our significant tenants to pay rent to us could have a disproportionate negative affect on our revenues.

As of December 31, 2019, the annualized base rent from our top four tenants represented approximately 30% of our portfolio-wide annualized base rent, including our Encompass facilities, which comprised approximately 10% of our annualized base rent; our Belpre facilities, which comprised approximately 8% of our annualized base rent; our Kindred Healthcare facilities, which comprised approximately 7% of our annualized base rent, and our OCOM facilities, which compromised approximately 5% of our annualized base rent.

We have no control over the success or failure of our significant tenants’ businesses and, at any time, our significant tenants may fail to make rent payments when due, which, in turn, may have a disproportionate adverse effect on our business, revenues and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

Our leases are generally long-term leases with annual rent escalators, however, mostsome of our debt financing is subject to floating interest rates. An increase in interest rates may not be matched by an increase in our rent payments, which could expose us to a funding imbalance if interest rate increases are not offset by rental payment increases.imbalance.

 

Our revenues are generated by our tenant leases, which are typically long-term leases in which thewith fixed rental rate is generally fixed,rates, subject to annual rent escalators. A significantThe unhedged portion of our Credit Facility debt is subject to floating rates, typically based on LIBOR. The generally fixed nature of revenues and the variable rate of our debt obligations create interest rate risk for us. Increases in interest rates may not be matched by increases in our rental income, which could increase our expenses and materially adversely affect our business, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

We rely on external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.

 

In order to qualify as a REIT, we are required, among other things, to distribute each year to our stockholders at least 90% of our taxable income, without regard to the deduction for dividends paid and excluding net capital gain. Because of this distribution requirement, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely on external sources of capital, including debt and equity financing, to fund future capital needs. Our access to capital will depend upon a number ofseveral factors, many of which we have little or no control, including:

 

·The extent of investor interest;
·Our ability to satisfy the distribution requirements applicable to REITs;
·The general reputation of REITs and the attractiveness of their equity securities in comparison to other equity securities, including securities issued by other real estate-based companies;
·Our financial performance and that of our tenants;
·Analyst reports about us and the REIT industry;
·General stock and bond market conditions, including changes in interest rates on fixed income securities, which may lead prospective purchasers of our stock to demand a higher annual yield from future distributions;


·A failure to maintain or increase our dividend which is dependent, in large part, upon our funds from operations, or FFO, which, in turn, depends upon increased revenue from additional acquisitions and rental increases; and
·Other factors such as governmental regulatory action and changes in REIT tax laws.

  

If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature, which, in turn, could materially adversely affect our business prospects, liquidity, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

15

The inability of any of our significant tenants to pay rent to us could have a disproportionate negative affect on our revenues.

Until we grow our asset base significantly, we are dependent on a relatively small number of tenants, some of which account for a significant percentage of our rental revenue. As of December 31, 2017, the annualized base rent from our top five tenants represented approximately 46% of our portfolio-wide annualized base rent, including our Encompass (formerly HealthSouth) facilities, which comprised approximately 15% of our annualized base rent; our Omaha facility, which comprised approximately 10% of our annualized base rent; and our Austin facility, which compromised approximately 8% of our annualized base rent.

We have no control over the success or failure of our significant tenants’ businesses and, at any time, our significant tenants may fail to make rent payments when due, which, in turn, may have a disproportionate adverse effect on our business, revenues and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

The bankruptcy of any of our tenants could bar our efforts to collect pre-bankruptcy debts from the tenant or evict the tenant and take back control of the property.

 

Any bankruptcy filings by or relating to one of our tenants could bar all efforts by us to collect pre-bankruptcy debts from that tenant or evict the tenant and take back control of the property, unless we receive an order permitting us to do so from a bankruptcy court, which we may be unable to obtain. A tenant bankruptcy could also delay our efforts to collect past due balances under the relevant leases and could ultimately preclude full collection of these sums. If a tenant rejects the lease while in bankruptcy, we would have only a general unsecured claim for pre-petition damages. Any unsecured claim that we hold may be paid only to the extent that funds are available and only in the same percentage as is paid to all other holders of unsecured claims. It is possible that we may recover substantially less than the full value of any unsecured claims that we hold, if any,or nothing at all, which may have a material adverse effect on our business, revenues and results of operations, our ability to make distributions to our stockholders and the trading price of our common stock and preferred stock. Furthermore, dealing with a tenant bankruptcy or other default may divert management’s attention and cause us to incur substantial legal and other costs.

Adverse economic or other conditions in our geographic markets could negatively affect our tenants’ ability to pay rent to us.

 

Adverse economic or other conditions in our geographic markets, including periods of economic slowdown or recession, industry slowdowns, periods of deflation, relocation of businesses, changing demographics, earthquakes and other natural disasters, fires, terrorist acts, public health crisis, pandemics and epidemics, such as the coronavirus (COVID-19), and civil disturbances or acts of war and other man-made disasters which may result in uninsured or underinsured losses, and changes in tax, real estate, zoning and other laws and regulations, may negatively affect our tenants’ businesses and ability to pay rents to us and, therefore, could have a material adverse effect on our revenues, business and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

Most of our healthcare facilities are occupied by a single tenant, and we may have difficulty finding suitable replacement tenants in the event of a tenant default or non-renewal of our leases, especially for our healthcare facilities located in smaller markets.

 

Nearly allMost of our healthcare facilities are occupied by a single tenant. Following expiration of a lease term or if we exercise our right to replace a tenant in default, rental payments on the related healthcare facilities could decline or cease altogether while we reposition such healthcare facility with a suitable replacement tenant. We also might not be successful in identifying suitable replacement tenants or entering into triple-net leases with new tenants on a timely basis, on favorable terms, or at all. Additionally, we may be required to fund certain expenses and obligations (e.g., real estate taxes, debt costs and maintenance expenses) to preserve the value of, and avoid the imposition of liens on, our healthcare facilities while they are being repositioned. Our ability to reposition our healthcare facilities with a suitable tenant could be significantly delayed or limited by state licensing, receivership, certificate of needCON or other laws, as well as by the Medicare and Medicaid change-of-ownership rules. We could also incur substantial additional expenses in connection with any licensing, receivership or change-of-ownership proceedings. In addition, our ability to locate suitable replacement tenants could be impaired by the specialized healthcare uses or contractual restrictions on use of the healthcare facilities, and we may be required to spend substantial amounts to adapt the healthcare facilities to other uses. Any such delays, limitations and expenses could adversely impact our ability to collect rent, obtain possession of leased healthcare facilities or otherwise exercise remedies for tenant default, which, in turn, could have a material adverse effect on our business, revenues and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

All of these risks may be greater in smaller markets, where there may be fewer potential replacement tenants, making it more difficult to replace tenants, especially for specialized space, like hospital or outpatient treatment facilities, located in our healthcare facilities.space. 

16

We have significant geographic concentration in a small number of states, including Texas, Ohio, Pennsylvania, Arizona, Oklahoma, Tennessee, Kansas, ArizonaFlorida and Florida.Illinois. Economic and other conditions that negatively affect those states and our tenants in those states could have a greater effect on our revenues than if our properties were more geographically diverse.

 


As of December 31, 2017,2019, approximately 23.6%22%, 16.7% 10%, 9.9%9%, 6.9%8%, 6.0%8%, 6.0%8%, and 5.6%6% of our total annualized base rent was derived from properties located in Texas, Ohio, Pennsylvania, Arizona, Oklahoma, Tennessee, Kansas, ArizonaFlorida and Florida,Illinois, respectively. As a result of this geographic concentration, we are particularly exposed to downturns in these states’ economies or other changes in local real estate market conditions. Any material change in the current payment programs or regulatory, economic, environmental or competitive conditions in these states could have an amplified effect on our overall business, revenues and results of operations, our ability to make distributions to our stockholders and liquiditythe trading price of our common and preferred stock than if our properties were more geographically diverse.

A pandemic, epidemic or outbreak of a contagious disease could affect the markets in which our tenants operate or otherwise impact our facilities.

If a pandemic or other public health crisis were to affect our markets, such as a major breakout of the Coronavirus in the United States, the businesses of our tenants could be adversely affected. Such a crisis could diminish the public trust in healthcare facilities, especially hospitals that fail to accurately or timely diagnose, or other facilities such as medical office buildings that are treating (or have treated) patients affected by contagious diseases. If any of our facilities were involved in treating patients for such a contagious disease, other patients might cancel elective procedures or fail to seek needed care from the tenants of our facilities. Further, a pandemic might adversely impact our tenants’ businesses by causing a temporary shutdown or diversion of patients, by disrupting or delaying production and delivery of materials and products in the supply chain or by causing staffing shortages in those facilities. The potential impact of a pandemic, epidemic or outbreak of a contagious disease with respect to our tenants or our facilities is difficult to predict and could have a material adverse impact on the operations of our tenants and, in turn, our business, financial condition, results of operations, our ability to pay distributions and the market price of our common and preferred stock.

We may be unable to successfully enter into definitive purchase agreements for or close the acquisition of the properties in our investment pipeline. 

 

There is no assurance that we will successfully enter into definitive purchase agreements for the facilities in our investment pipeline. We could also determine through a market analysis, a review of historical and projected financial statements of the property or the operator, a review of current insurance or other due diligence that the prospective facility does not meet our investment standards. We also may be unable to come to an agreement with the seller for the purchase of the facility. Additionally, there is no assurance that we will successfully close an acquisition once a purchase agreement has been signed. After a purchase agreement has been signed, we typically have a due diligence period of 45 to 60 days. If we identify problems with the property or the operator during our due diligence review, we may terminate the purchase agreement and not close. Failure to close acquisitions under contract or in our investment pipeline could restrict our growth opportunities, which, in turn, could materially adversely affect our business and the trading price of our common and preferred stock.

We may obtain only limited warranties when we purchase a property, which, in turn, would only provide us with limited recourse against the seller in the event thatif issues arise after our purchase of a property.

The seller of a property often sells such property in its “as is” condition on a “where is” basis and “with all faults,” without any warranties of merchantability or fitness for a particular use or purpose. In addition, purchase and sale agreements may contain only limited warranties, representations and indemnifications that will only survive for a limited period after the closing. The purchase of properties with limited warranties increases the risk of having little or no recourse against a seller if issues were to arise at such property. This, in turn, could cause us to have to write off our investment in the property, which could negatively affect our business, results of operations, our ability to pay distributions to our stockholders and the trading price of our common and preferred stock.

Our healthcare facilitiesbuildings that are subject to ground leases could restrict our use of such healthcare facilities.

 

TwoWe lease the land upon which five of our healthcare facilities,buildings are located, representing approximately 5.9%4.6% of our December 2019 annualized base rent as of December 31, 2017, are subject torent. These ground leases that contain certain restrictions. These restrictions include limits on our ability to re-let the facilities, rights of purchase and rights of first offer and refusal with respect to sales of the healthcare facility and limits on the types of medical procedures that may be performed at the facilities. These restrictions could affect our returns on these facilities which, in turn, could adversely affect our revenues, business and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock. 

 

Our healthcare facilities and our tenants may be unable to compete successfully, which could negatively affect our tenants’ businesses and ability to pay rent to us.

 

Our healthcare facilities often face competition from nearby hospitals and other healthcare facilities that provide comparable services. Similarly, our tenants face competition from other medical practices and service providers at nearby hospitals and other healthcare facilities,services, including urgent care and primary care facilities.facilities as well as home healthcare companies. These competitors may have greater geographic coverage, better access to physicians and patients and provide or are perceived to provide higher quality services. From time to time and for reasons beyond our control, managed care organizations may change their lists of preferred hospitals or in-network physicians, which may favor our tenants’ competitors. Furthermore, our tenants may lose physicians to their competitors. Any reduction in rental revenues resulting from the inability of our tenants or their associated healthcare delivery systems to compete in providing medical services and/or receiving sufficient rates of reimbursement for healthcare services rendered may have a material adverse effect on our revenues, business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

17

Long-term leases may result in below-marketbelow- market lease rates over time, which could decrease the market value of our properties.

Many of our leases are long-term leases with annual rent escalation provisions. However, if we do not accurately judge the potential for increases in market rental rates, we may set the terms of such long-term leases at levels such that even after contractual rental increases, the rent under our long-term leases could be less than then-current market rental rates. Further, we may have no ability to terminate those leases or to adjust the rent to then-prevailing market rates. As a result, the market value of our properties with long-term leases may be negatively affected.

 


We may incur uninsured losses or losses in excess of our insurance coverage, which may result in us having to absorb all or a portion of such loss. 

 

Our tenants are generally required (either directly or through a reimbursement arrangement with us) to maintain comprehensive property and casualty insurance covering our properties. SomeHowever, some types of losses may be uninsurable or too expensive to insure against. Insurance companies limit or exclude coverage against, certain types of losses, such as losses due to named windstorms, terrorist acts, earthquakes, and toxic mold. Accordingly, we may not have sufficientenough insurance coverage against certain types of losses and may experience decreases in the insurance coverage available. Should an uninsured loss or a loss in excess of insured limits occur, we could lose all or a portion of our investment in a property, as well as the anticipated future revenue from the property. In such an event, we might remain obligated for any mortgage debt or other financial obligation related to the property. Further, if any of our insurance carriers were to become insolvent, we would be forced to replace the existing coverage with another suitable carrier, and any outstanding claims would be at risk for collection. In such an event, we cannot be certain that we would be able to replace the coverage at similar or otherwise favorable terms.

 

We have obtained title insurance policies for each of our properties, typically in an amount equal to its original price. However, these policies may be for amounts less than the current or future values of our properties. In such an event, if there is a title defect relating to any of our properties, we could lose some of our investment in and anticipated profits from such property.

 

If we were to experience uninsured losses or if any of our insurance carriers were unable to pay insurance claims, we may lose all or a portion of our investment in a property and the revenues associated with such property, which could materially adversely affect our revenues, business, financial condition, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

We may incur environmental compliance costs and liabilities associated with owning, leasing, developing and operating our healthcare facilities. 

 

Under various U.S. federal, state and local laws, ordinances and regulations, current and prior owners and tenants of real estatehealthcare facilities may be jointly and severally liable for the costs of investigating, remediating and monitoring certain hazardous substances or other regulated materials on or in such healthcare facility. In addition to these costs, the past or present owner or tenant of a healthcare facility from which a release emanates could be liable for any personal injury or property damage that results from such releases, including for the unauthorized release of asbestos-containing materials and other hazardous substances into the air, as well as any damages to natural resources or the environment that arise from such releases. These environmental laws often impose such liability without regard to whether the current or prior owner or tenant knew of, or was responsible for, the presence or release of such substances or materials. Moreover, the release of hazardous substances or materials, or the failure to properly remediate such substances or materials, may adversely affect the owner’s or tenant’s ability to lease, sell, develop or rent such healthcare facility or to borrow against such healthcare facility. Persons who transport or arrange for the disposal or treatment of hazardous substances or other regulated materials may be liable for the costs of removal or remediation of such substances at a disposal or treatment facility, regardless of whether or not such facility is owned or operated by such person.

 

Certain environmental laws impose compliance obligations on owners and tenants of real property with respect to the management of hazardous substances and other regulated materials. For example, environmental laws govern the management and removal of asbestos-containing materials and lead-based paint. Failure to comply with these laws can result in penalties or other sanctions. If we are held liable under these laws, our business, andfinancial conditions, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock may be materially adversely affected. 

SomeA majority of our healthcare facilities are financed by mortgage or other term indebtedness and we may place mortgage or other term indebtedness on our healthcare facilities in the future. If we place mortgage or other term indebtedness on our healthcare facilities, we may not be able to refinance such debt when due or may be unable to refinance such debt on favorable terms.

 

As of December 31, 2017,2019, we had $38.5$337.6 million of term mortgage indebtedness outstanding (net of unamortized debt issuance costs), representing approximately 19%88% of our total debt. We may also place mortgage or other term indebtedness on our healthcare facilities in the future. If we place such debt on our healthcare facilities, weWe run the risk of being unable to refinance such debt when the loans come due or of being unable to refinance on favorable terms. If interest rates are higher when we refinance debt, our income could be reduced. We may be unable to refinance debt at appropriate times, which may require us to sell healthcare facilities on terms that are not advantageous to us or could result in the foreclosure of such healthcare facilities. Any of these events could have an adverse effect on our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.

18

We may in the future make investments in joint ventures, which could be adversely affected by our lack of decision-making authority, our reliance upon our joint venture partners’ financial condition, any disputes that may arise between us and our joint venture partners and our exposure to potential losses from the actions of our joint venture partners.

 


We may in the future make co-investments or re-finance existing properties with third parties through partnerships, joint ventures or other entities. Consequently, we may acquire non-controlling interests in or share responsibility for the management of the affairs of a healthcare facility, partnership, joint venture or other entity. Joint ventures generally involve risks not present with respect to our wholly-ownedwholly owned healthcare facilities, including the following:

  

·Our joint venture partners may make management, financial and operating decisions with which we disagree or that are not in our best interest;
·We may be prevented from taking actions that are opposed by our joint venture partners;
·Our ability to transfer our interest in a joint venture to a third party may be restricted;
·Our joint venture partners might become bankrupt or fail to fund their share of required capital contributions which may delay construction or development of a healthcare facility or increase our financial commitment to the joint venture;
·Our joint venture partners may have business interests or goals with respect to the healthcare facility that conflict with our business interests and goals which could increase the likelihood of disputes regarding the ownership, management or disposition of the healthcare facility;
·Disputes may develop with our joint venture partners over decisions affecting the healthcare facility or the joint venture which may result in litigation or arbitration that would increase our expenses and distract our officers and/or directors from focusing their time and effort on our business and possibly disrupt the daily operations of the healthcare facility; and
·We may suffer losses as a result of the actions of our joint venture partners with respect to our joint venture investments.

 

Joint venture investments involve risks that may not be present with other methods of ownership. In addition to those risks identified above, our partner might at any time have economic or other business interests or goals that are or become inconsistent with our interests or goals; that we could become engaged in a dispute with our partner, which could require us to expend additional resources to resolve such disputes and could have an adverse impact on the operations and profitability of the joint venture; and that our partner may be in a position to take action or withhold consent contrary to our instructions or requests. In addition, our ability to transfer our interest in a joint venture to a third party may be restricted. Also, we or our partner may have the right to trigger a buy-sell arrangement, which could cause us to sell our interest, or acquire our partner’s interest, at a time when we otherwise would not have initiated such a transaction. Our ability to acquire our partner’s interest may be limited if we do not have sufficientenough cash, available borrowing capacity or other capital resources. In such event, we may be forced to sell our interest in the joint venture when we would otherwise prefer to retain it. Joint ventures may require us to share decision-making authority with our partners, which could limit our ability to control the healthcare facilities in the joint ventures. Even when we have a controlling interest, certain major decisions may require partner approval, such as the sale, acquisition or financing of a healthcare facility. If any of the aforementioned risks associated with joint ventures were to materialize, our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock may be materially adversely affected.

The income from certain of our properties is dependent on the ability of our property managers to successfully manage those properties.

 

We depend upon the performance of our property managers to effectively manage certain of our properties and real estate assets.properties. We do not control these third-party property managers and are accordingly subject to various risks generally associated with outsourcing of management of day-to-day activities, including the risk that a property manager may not be able to successfully manage a property. Additionally, because we do not control our third-party property managers, any adverse events such as issues related to insufficient internal controls, cybersecurity incidents or other adverse events may impact the income we recognize from properties managed by such third-party property managers. We may be unable to anticipate such events or properly assess the magnitude of any such events because we do nonot control our third-party property managers. If our property managers are unable to successfully manage our properties, our business, financial condition, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock may be materially adversely affected.

19

We have now, and may have in the future, exposure to contingent rent escalators, which may hinder the growth of our rental income and therefore our profitability in the future.

 

We receive substantially all of our revenues by leasing our healthcare facilities under long-term, triple-net leases in which the rental rate is generally fixed with annual escalations, including escalations tied to changes in the Consumer Price Index.Index (“CPI”). If, as a result of weak economic conditions or other factors, the Consumer Price IndexCPI does not increase, our growth and profitability will be hindered by these triple-net leases, which could, in turn, materially adversely affect our results of business, financial conditions, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock may be adversely affected.stock.

We and our tenants face risks associated with security breaches through cyber-attacks, cyber intrusions,cyber-intrusions, or otherwise, as well as other significant disruptions of its information technology networks and related systems.

 


We and our tenants face risks associated with security breaches, whether through cyber-attacks or cyber intrusions over the Internet, malware, computer viruses, attachments to emails, persons inside the Company,company insiders, or persons with access to our and our tenants’ systems, and other significant disruptions of our and our tenants’ information technology ("IT"(“IT”) networks and related systems. The risk of a security breach or disruption, particularly through cyber-attack or cyber intrusion,cyber-intrusion, including by computer hackers, foreign governments and cyber terrorists,cyber-terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Our and our tenants’ IT networks and related systems are essential to the operation of its businesseach of our businesses and itsour and our tenants’ ability to perform day-to-day operations (including managing building systems) and, in some cases, may be critical to the operations of certain of our tenants.maintaining confidential patient data). Although we make efforts to maintain the security and integrity of these types ofour IT networks and related systems, and we have implemented various measures to manage the risk of a security breach or disruption, there can be no assurance that these security measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. Additionally, our tenants may not have enough risk mitigation measures in place or, even if they do, such measures may not be effective. Even the most well protected information, networks, systems, and facilities remain potentially vulnerable because the techniques used in such attempted security breaches evolve and generally are not recognized until launched against a target, and in some cases are designed not to be detected and may not be detected. Accordingly, we and our tenants may be unable to anticipate these techniques or to implement adequate security barriers or other preventative measures, and it is therefore impossible to entirely mitigate the risk.

 

A security breach or other significant disruption involving our or our tenants’ IT networknetworks and related systems could:

 

·Disrupt the proper functioning of our or our tenants’ networks and systems and therefore our operations and/or those of certainour tenants;
·Result in misstated financial reports, violations of loan covenants, missed reporting deadlines, and/or missed permitting deadlines;
·Result in our inability to properly monitor its compliance with the rules and regulations regarding our qualification as a REIT;
·Result in the unauthorized access to, and destruction, loss, theft, misappropriation or release of proprietary, confidential, sensitive, or otherwise valuable information about us, our tenants or others,our tenants’ patients, which others could use to compete against us or our tenants or which could expose itus or our tenants to regulatory action or damage claims by third-parties for disruption, destructive, third-parties;
·Result in misstated financial reports, violations of loan covenants, missed reporting deadlines, and/or otherwise harmful purposes or outcomes;missed permitting deadlines;
·Result in our inability to maintainproperly monitor our compliance with the rules and regulations regarding our qualification as a REIT;
·jeopardize the building systems relied upon by our tenants for the efficient use of their leased space;
·Require significant management attention and resources to remedy any damages that result;
·Subject us or our tenants to claims for breach of contract, damages, credits, penalties, or termination of leases or other agreements; or
·Damage our reputation amongand our tenants and investors generally.tenants’ reputations.

  

Any or all of the foregoing could have a material adverse effect on our business, financial condition and results of operations, our ability to pay distributions to our stockholders and the trading price of our common and preferred stock.

Changes in the method pursuant to which the LIBOR rates are determined and potential phasing out of LIBOR after 2021 may affect our financial results.

LIBOR and certain other interest “benchmarks” may be subject to regulatory guidance and/or reform that could cause interest rates under our current or future debt agreements to perform differently than in the past or cause other unanticipated consequences. In July 2017, the Financial Conduct Authority (the “FCA”), which regulates LIBOR, announced its intention to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee (“ARRC”) which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. The Credit Facility provides that, on or about the LIBOR cessation date (subject to an early opt-in election), LIBOR shall be replaced as a benchmark rate in the Credit Facility with a new benchmark rate to be agreed upon by the Company and the administrative agent, with such adjustments to cause the new benchmark rate to be economically equivalent to LIBOR. We are not able to predict when LIBOR will cease to be available or when there will be enough liquidity in the SOFR markets.

The Company has interest rate swap agreements that are indexed to LIBOR and is monitoring and evaluating the related risks. These risks arise in connection with transitioning contracts to a new alternative rate, including any resulting value transfer that may occur. The value of loans, securities, or derivative instruments tied to LIBOR could also be impacted if LIBOR is limited or discontinued. For some instruments, the method of transitioning to an alternative rate may be challenging, as they may require negotiation with the respective counterparty.


If a contract is not transitioned to an alternative rate and LIBOR is discontinued, the impact on our interest rate swap agreements is likely to vary by agreement. If LIBOR is discontinued or if the methods of calculating LIBOR change from their current form, interest rates on our current or future indebtedness may be adversely affected.

While the Company expects LIBOR to be available in substantially its current form until the end of 2021, it is possible that LIBOR will become unavailable prior to that point. This could result, for example, if sufficient banks decline to make submissions to the LIBOR administrator. In that case, the risks associated with the transition to an alternative reference rate will be accelerated and magnified.

 

Risks Related to the Healthcare Industry

 

Adverse trends in the healthcare industry may negatively affect our tenants’ businesses.  

 

The healthcare industry is currently experiencing, among other things:

 

·Changes in the demand for and methods of delivering healthcare services;
·Competition among healthcare providers;
·Consolidation of large health insurers;
·Regulatory and government reimbursement uncertainty resulting from the Affordable Care Act and other healthcare reform laws;
·Federal court decisions on cases challenging the legality of certain aspects of the Affordable Care Act;
·Federal and state government plans to reduce budget deficits and address debt ceiling limits by lowering healthcare provider Medicare and Medicaid payment rates;
·Changes in third-party reimbursement methods and policies; and
·Increased scrutiny of billing, referral and other practices by U.S. federal and state authorities.

20

 

These factors may adversely affect the economic performance of some or all of our tenants and, in turn, our lease revenues, which may have a material adverse effect on our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock. 

 

The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure or failure to obtain licensure could result in the inability of our tenants to make rent payments to us.  

 

The healthcare industry is heavily regulated by U.S. federal, state and local governmental authorities. Our tenants generally will be subject to laws and regulations covering, among other things, licensure, certification for participation in government programs, billing for services, privacy and security of health information and relationships with physicians and other referral sources. See “Business–Government Laws and Regulations” for a description of the laws and regulations that affect the healthcare industry. In addition, new laws and regulations, changes in existing laws and regulations or changes in the interpretation of such laws or regulations could affect our tenants’ ability to make rent payments to us, which, in turn, could have a material adverse effect on our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock. These changes, in some cases, could apply retroactively. The enactment, timing or effect of legislative or regulatory changes cannot be predicted.

 

Affordable Care Act

The Affordable Care Act is a comprehensive healthcare reform law that contains various provisions that may directly impact our tenants.  The primary goal of the Affordable Care Act is to broaden insurance coverage for the uninsured population by expanding Medicaid coverage, creating health insurance exchanges and mandating that uninsured individuals purchase health insurance. The Affordable Care Act also contains provisions aimed at lowering the costViolations of healthcare including lowering increases in Medicare payment rates and promoting alternate reimbursement methods for providers that focus on patient outcomes rather than volume. In addition to expanding coverage and controlling costs, the Affordable Care Act also contains provisions intended to combat healthcare fraud, including Medicare fraud and abuse. On June 28, 2012, the United States Supreme Court partially invalidated the expansion of Medicaid, and allowed states not to participate in the expansion without losing their existing Medicaid funding. 

Since the enactment of the Affordable Care Act, there have been multiple attempts through legislative action and legal challenge to repeal or amend the Affordable Care Act. Although there continue to be judicial challenges to the Affordable Care Act, the Supreme Court has thus far upheld the Affordable Care Act, including, most recently, in their June 25, 2015 ruling onKing v. Burwell. On January 20, 2017, President Trump issued an executive order aimed at seeking the prompt repeal of the Affordable Care Act, and directed the heads of all executive departments and agencies to minimize the economic and regulatory burdens of the Affordable Care Act to the maximum extent permitted by law. In addition, on December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act of 2017, or the TCJA. The TCJA repealed the individual mandate provision of the Affordable Care Act starting in 2019. We cannot predict whether any future attempts to amend or repeal the Affordable Care Act will be successful. The future of the Affordable Care Act is uncertain and any changes to existing laws and regulations, including the Affordable Care Act’s repeal, modification or replacement, could have a long-term financial impact on the delivery of and payment for healthcare. Both our tenants and us may be adversely affected by the law or its repeal, modification or replacement.

The repeal of the individual mandate may result in fewer people purchasing health insurance on the healthcare insurance exchanges created by the Affordable Care Act, which could in turn result in fewer people receiving healthcare services, including the services provided by our tenants, which could adversely affect our tenants’ ability to pay rent to us, which, in turn, may have an adverse effect on our revenue, business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

State Regulations

Many states regulate the construction of healthcare facilities, the expansion of healthcare facilities, the construction or expansion of certain services, including, by way of example, specific bed types and medical equipment, as well as certain capital expenditures through certificate of need, or CON, laws. Under such laws, the applicable state regulatory body must determine a need exists for a project before the project can be undertaken. If one of our tenants seeks to undertake a CON-regulated project, but is not authorized by the applicable regulatory body to proceed with the project, the tenant would be prevented from operating in its intended manner.

Failure to comply with these laws and regulations could adversely affect us directly and our tenants’ ability to make rent payments to us which may have an adverse effect on our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

21

Anti-fraud and Abuse Laws

There are various U.S. federal and state laws prohibiting fraudulent and abusive business practices by healthcare providers who participate in, receive payments from, or are in a position to make referrals in connection with, government-sponsored healthcare programs, including the Medicare and Medicaid programs. Our lease arrangements with certain tenants may also be subject to these fraud and abuse laws.

These laws include without limitation:

·The U.S. Federal Anti-Kickback Statute, which prohibits, among other things, the offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, the referral of any U.S. federal or state healthcare program patients;
·The U.S. Federal Physician Self-Referral Prohibition (commonly called the “Stark Law”), which, subject to specific exceptions, restricts physicians who have financial relationships with healthcare providers from making referrals for designated health services for which payment may be made under Medicare or Medicaid programs to an entity with which the physician, or an immediate family member, has a financial relationship;
·The False Claims Act, which prohibits any person from knowingly presenting false or fraudulent claims for payment to the U.S. federal government, including under the Medicare and Medicaid programs;
·The Civil Monetary Penalties Law, which authorizes the Department of Health and Human Services to impose monetary penalties for certain fraudulent acts; and
·State anti-kickback, anti-inducement, anti-referral and insurance fraud laws which may be generally similar to, and potentially more expansive than, the U.S. federal laws set forth above.

Violations of these laws may result in criminal and/or civil penalties that range from punitive sanctions, damage assessments, penalties, imprisonment, denial of Medicare and Medicaid payments and/or exclusion from the Medicare and Medicaid programs. In addition, the Affordable Care Act clarifies that the submission of claims for items or services generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the False Claims Act. The U.S. federal government has taken the position, and some courts have held that violations of other laws, such as the Stark Law, can also be a violation of the False Claims Act. Additionally, certain laws, such as the False Claims Act, allow for individuals to bring whistleblower actions on behalf of the government for violations thereof. Imposition of any of these penalties upon one of our tenants or strategic partners could jeopardize that tenants’ ability to operate or to make rent payments or affect the level of occupancy in our healthcare facilities, which may have a material adverse effect on our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 


Reductions in reimbursement from third-party payors, including Medicare and Medicaid, could adversely affect the profitability of our tenants and hinder their ability to make rent payments to us or renew their lease.leases.  

 

Sources of revenue for our tenants typically include the U.S. federal Medicare program, state Medicaid programs and private insurance payors and health maintenance organizations.payors. Healthcare providers continue to face increased government and private payor pressure to control or reduce healthcare costs and significant reductions in healthcare reimbursement, including reduced reimbursements and changes to payment methodologies under the Affordable Care Act. The Congressional Budget Office, or CBO, estimates the reductions required by the Affordable Care Act over the next ten years following enactment of the act will include $415 billion in cuts to Medicare fee-for-service payments, the majority of which will come from hospitals, and that some hospitals will become insolvent as a result of the reductions. In some cases, private insurers rely on all or portions of the Medicare payment systems to determine payment rates, which may result in decreased reimbursement from private insurers. The Affordable Care Act also imposes new requirements for the health insurance industry, including prohibitions upon excluding individuals based upon pre-existing conditions, which may increase private insurer costs and, thereby, cause private insurers to reduce their payment rates to providers. Any reductions in payments or reimbursements from third-party payors could adversely affect the reimbursement rates received by our tenants, the financial success of our tenants and strategic partners and, therefore, our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock. 

 

If the United States economy enters a recession or slower growth, this could negatively affect state budgets, thereby putting pressure on states to decrease spending on state programs including Medicaid. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in state Medicaid programs due to unemployment and declines in family incomes. Historically, states have often attempted to reduce Medicaid spending by limiting benefits and tightening Medicaid eligibility requirements. Many states have adopted, or are considering the adoption of, legislation designed to enroll Medicaid recipients in managed care programs and/or impose additional taxes on hospitals to help finance or expand the states’ Medicaid systems. Potential reductions to Medicaid program spending in response to state budgetary pressures could negatively impact the ability of our tenants to successfully operate their businesses, and, consequently, could have a material adverse effect on our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock. 

 

22

Efforts by payors to reduce healthcare costs will likely continue which may result in reductions or slower growth in reimbursement for certain services provided by some of our tenants. A reduction in reimbursements to our tenants from third-party payors for any reason could adversely affect our tenants’ ability to make rent payments to us which may have a material adverse effect on our revenues, business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

Our tenants may be subject to significant legal actions that could subject them to increased operating costs and substantial uninsured liabilities, which may affect their ability to pay their rent payments to us, and we could also be subject to healthcare industry violations.

 

As is typical in the healthcare industry, our tenants may often become subject to claims that their services have resulted in patient injury or other adverse effects. Many of these tenants may have experienced an increasing trend in the frequency and severity of professional liability and general liability insurance claims and litigation asserted against them. The insurance coverage maintained by these tenants may not cover all claims made against them nor continue to be available at a reasonable cost, if at all. In some states, insurance coverage for the risk of punitive damages arising from professional liability and general liability claims and/or litigation may not, in certain cases, be available to these tenants due to state law prohibitions or limitations of availability. As a result, these types of tenants of our healthcare facilities operating in these states may be liable for punitive damage awards that are either not covered or are in excess of their insurance policy limits.

 

We also believe that there has been, and will continue to be, an increase in governmental investigations of certain healthcare providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Insurance is not available to cover such losses. Any adverse determination in a legal proceeding or governmental investigation, any settlements of such proceedings or investigations in excess of insurance coverage, whether currently asserted or arising in the future, could have a material adverse effect on a tenant’s financial condition. If a tenant is unable to obtain or maintain insurance coverage, if judgments are obtained or settlements reached in excess of the insurance coverage, if a tenant is required to pay uninsured punitive damages, or if a tenant is subject to an uninsurable government enforcement action or investigation, the tenant could be exposed to substantial additional liabilities, which may affect the tenant’s ability to pay rent, which in turn could have a material adverse effect on our business, financial condition and results of operations, our ability to pay distributions to our stockholders and the trading price of our common and preferred stock.

 

Risks Related to the Real Estate Industry

Changes in the general real estate market conditions may adversely affect us.

 

Real estate investments are subject to various risks and fluctuations and cycles in value and demand, many of which are beyond our control. Certain market conditions that may affect our business are as follows:

 


·National or regional economic upturns could increase the value of real estate generally, which could make it more difficult for us to acquire new healthcare properties at attractive prices or prevent us from purchasing additional facilities at all;
·National or regional economic downturns could adversely affect our tenants’ businesses, or the businesses located in our tenants’ geographic region, which could adversely affect our tenants’ ability to pay rent and the value of our healthcare properties;
·A decrease in interest rates and financing costs could increase demand for real estate and, thus, the price of real estate. An increase in demand for real estate could make it more difficult for us to acquire additional healthcare facilities at attractive prices or prevent us from purchasing additional facilities at all; and
·An increase in interest rates and financing costs could decrease the demand for real estate and, thus, the price of real estate. A decrease in demand for real estate could make it more difficult for us to dispose of our healthcare facilities at attractive prices or prevent us from disposing of our facilities at all.

 

If we experience one or more of the risks described above, our business, financial condition, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock could be adversely affected.

Illiquidity of real estate investments could significantly impede our ability to respond to adverse changes in the performance of our healthcare facilities.

 

Because real estate investments are relatively illiquid, our ability to promptly sell one or more of our healthcare facilities in response to changing economic, financial and investment conditions is limited. The real estate market is affected by many factors, such as general economic conditions, availability of financing, interest rates and other factors, including supply and demand, that are beyond our control. We cannot predict whether we will be able to sell any of our healthcare facilities for the price or on the terms set by us or whether any price or other terms offered by a prospective purchaser would be acceptable to us. We also cannot predict the length of time needed to find a willing purchaser and to close the sale of any of our healthcare facilities. We may be required to expend funds to correct defects or to make improvements before a healthcare facility can be sold. We cannot assure you that we will have funds available to correct those defects or to make those improvements.

 

23

In acquiring a healthcare facility, we have in the past and may in the future agree to transfer restrictions that materially restrict us from selling that healthcare facility for a period of time or impose other restrictions, such as a limitation on the amount of debt that can be placed or repaid on that healthcare facility. These transfer restrictions would impede our ability to sell a healthcare facility even if we deem it necessary or appropriate. These facts and any others that would impede our ability to respond to adverse changes in the performance of our healthcare facilities may have a material adverse effect on our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.

Uncertain market conditions could cause us to sell our healthcare facilities at a loss in the future.

 

We intend to hold our various real estate investments until we determine that a sale or other disposition appears to be advantageous to achieve our investment objectives. Our senior management team and our board of directors may exercise their discretion as to whether and when to sell a healthcare facility, and we have no obligation to sell our facilities. We generally intend to hold our healthcare facilities for an extended period, of time, and we cannot predict with any certainty the various market conditions affecting real estate investments that will exist at any particular time in the future. Because of the uncertainty of market conditions that may affect the future disposition of our healthcare facilities, we may not be able to sell our buildings at a profit in the future or at all. We may incur prepayment penalties if we sell a healthcare facility subject to a mortgage earlier than we otherwise had planned. Additionally, we could be forced to sell healthcare facilities at inopportune times which could result in us selling the affected building at a substantial loss. Accordingly, the extent to which you will receive cash distributions and realize potential appreciation on our real estate investments will, among other things, be dependent upon fluctuating market conditions. Any inability to sell a healthcare facility could materially, adversely affect our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.

Our assets may become subject to impairment charges.

 

We will periodically evaluate our real estate investments and other assets for impairment indicators. The judgment regarding the existence of impairment indicators is based upon factors such as market conditions, lease re-negotiations, tenant performance and legal structure. For example, the termination of a lease by a major tenant may lead to an impairment charge. If we determine that an impairment has occurred, we would be required to make an adjustment to the net carrying value of the asset which could have a material adverse effect on our business, financial condition, results of operations and the trading price of our common and preferred stock. 


Costs associated with complying with the Americans with Disabilities Act of 1990 may result in unanticipated expenses. 

 

Under the Americans with Disabilities Act of 1990, or the ADA, all places of public accommodation are required to meet certain U.S. federal requirements related to access and use by disabled persons. A number ofSeveral additional U.S. federal, state and local laws may also require modifications to our healthcare facilities, or restrict certain further renovations of the buildings, with respect to access thereto by disabled persons. Noncompliance with the ADA could result in the imposition of fines, an award of damages to private litigants and/or an order to correct any non-complying feature which could result in substantial capital expenditures. Our leases typically provide that our tenants shall maintain our healthcare facilities in compliance with such laws, however, we have not conducted a detailed audit or investigation of all of our healthcare facilities to determine such compliance, and we cannot predict the ultimate cost of compliance with the ADA or other legislation. If one or more of our healthcare facilities is not in compliance with the ADA or other related legislation, then our tenants would be required to incur additional costs to bring the facility into compliance. These costs, if substantial, could have an adverse economic effect on our tenants, which could, in turn, materially adversely affect our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common stock may be adversely affected.and preferred stock.

24

 

Risks Related to Our Formation and Structure

We will have no direct operations and rely on funds received from our Operating Partnership and its subsidiaries to meet our obligations.

 

We conduct substantially all of our operations through our Operating Partnership. We own approximately 93.63%As of December 31, 2019, we owned 91.82% of the outstanding OP Units and apartUnits. Apart from this ownership interest in our Operating Partnership, we do not have any independent operations. As a result, we rely on distributions from our Operating Partnership to pay any dividends that we might declare on our common and preferred stock. We also rely on distributions from our Operating Partnership to meet our obligations, including tax liability on taxable income allocated to us from our Operating Partnership (which might make distributions to us not equal to the tax on such allocated taxable income). Stockholders’ claims will consequently be structurally subordinated to all existing and future liabilities and obligations (whether or not for borrowed money) of our Operating Partnership and its subsidiaries. Therefore, in the event of our bankruptcy, liquidation or reorganization, claims of our stockholders will be satisfied only after all of our and our Operating Partnership’s and its subsidiaries’ liabilities and obligations have been paid in full. If we do not receive sufficientenough funds from our Operating Partnership, our ability to make distributions to our stockholders and the trading price of our common and preferred stock may be materially, adversely affected.

Subject to certain requirements under Maryland law and REIT requirements, our board of directors has sole discretion to determine if we will pay distributions and the amount and frequency of such distributions, and past distribution amounts may not be indicative of future distribution amounts.

Any future distributions will be at the sole discretion of our board of directors and will depend upon a number of factors, including our actual and projected results of operations, the cash flow generated by our operations, FFO, AFFO, Normalized AFFO, liquidity, our operating expenses, our debt service requirements, capital expenditure requirements for the properties in our portfolio, prohibitions and other limitations under our financing arrangements, our REIT taxable income, the annual REIT distribution requirements, restrictions on making distributions under Maryland law and such other factors as our board of directors deems relevant. During 2017,2019, we declared distributions aggregating $0.80 and per share of common share.stock. The tax treatment of 20172019 dividends includesincluded a $0.67$0.61 return of capital.capital per share. We cannot assure you that our distribution policy will not change in the future or that our board of directors will continue to declare dividends at the same rate as in 2017,2019, especially if we are unable to reduce the amount of our distributions that are treated as returns of capital.

 

Our use of OP Units as currency to acquire healthcare facilities could result in stockholder dilution and/or limit our ability to sell such healthcare facilities, which could have a material adverse effect on us.

 

We have acquired, and in the future may acquire, healthcare facilities or portfolios of healthcare facilities through tax-deferred contribution transactions in exchange for OP Units, which may result in stockholder dilution. This acquisition structure may have the effect of, among other things, reducing the amount of tax depreciation we could deduct over the tax life of the acquired healthcare facilities, and has required, and may in the future require, that we agree to protect the contributors’ ability to defer recognition of taxable gain through restrictions on our ability to dispose of the acquired healthcare facilities or the allocation of partnership debt to the contributors to maintain their tax bases. These restrictions could limit our ability to sell healthcare facilities at a time, or on terms, that would be favorable absent such restrictions which, in turn, could materially, adversely affect our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.

24

 

Our Operating Partnership may issue additional OP Units to third parties without the consent of our stockholders, which would reduce our ownership percentage in our Operating Partnership and could have a dilutive effect on the amount of distributions made to us by our Operating Partnership and, therefore, the amount of distributions we can make to our stockholders.

 

We own 93.63%Holders of shares of our common stock will generally not have any voting rights with respect to activities of our Operating Partnership, including issuances of additional OP Units in amounts that do not exceed 20% of our outstanding shares of common stock. As of December 31, 2019, we owned 91.82% of the outstanding OP Units. Our Operating Partnership may, in connection with our acquisition of healthcare facilities or otherwise, issue additional OP Units to third parties. Such issuances would reduce our ownership percentage in our Operating Partnership and could affect the amount of distributions made to us by our Operating Partnership and, therefore, the amount of distributions we can make to our stockholders. Holders of shares of our common stock will generally not have any voting rights with respect to activities of our Operating Partnership, including issuances of additional OP Units in amounts that do not exceed 20% of our outstanding shares of common stock.

 

FailureWe may be unable to maintain effective internal controlcontrols over financial reporting could harm our business, results of operations and financial condition.reporting.

 

Pursuant to the Sarbanes-Oxley Act of 2002, we are required to provide a report by management on internal controlcontrols over financial reporting, including management’s assessment of the effectiveness of such control.controls. Because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud, effective internal controls over financial reporting may not prevent or detect misstatementmisstatements and can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls as a result of changes to our business or otherwise, or if we experience difficulties in their implementation, our business, results of operations and financial condition, our ability to make distributions to our stockholders and the trading price of our common and preferred stock could be materially adversely impacted and we could fail to meet our reporting obligations.

25

Conflicts of interest could arise as a result of our UPREIT structure.

 

Conflicts of interest could arise in the future as a result of the relationships between us and our affiliates, on the one hand, and our Operating Partnership or any partner thereof, on the other. Our directors and officers have duties to us under applicable Maryland law in connection with their management of our company. At the same time, we, as the sole member of the general partner of the Operating Partnership, have fiduciary duties to our Operating Partnership and to the limited partners under Delaware law in connection with the management of our Operating Partnership. Our duties, as the sole member of the general partner, to our Operating Partnership and its limited partners may come into conflict with the duties of our directors and officers to us.

 

Unless otherwise provided for in the relevant partnership agreement, Delaware law generally requires a general partner of a Delaware limited partnership to adhere to fiduciary duty standards under which it owes its limited partners the highest duties of good faith, fairness and loyalty and which generally prohibits such general partner from taking any action or engaging in any transaction as to which it has a conflict of interest.

 

Additionally, the partnership agreement expressly limits our liability by providing that we, as the sole member of the general partner of the Operating Partnership, and our directors or officers, will not be liable or accountable in damages to our Operating Partnership, the limited partners or assignees for errors in judgment, mistakes of fact or law or for any act or omission if the general partner or such director or officer acted in good faith. In addition, our Operating Partnership is required to indemnify us, our affiliates and each of our respective officers and directors, to the fullest extent permitted by applicable law against any and all losses, claims, damages, liabilities (whether joint or several), expenses (including, without limitation, attorneys’ fees and other legal fees and expenses), judgments, fines, settlements and other amounts arising from any and all claims, demands, actions, suits or proceedings, civil, criminal, administrative or investigative, that relate to the operations of theour Operating Partnership, provided that our Operating Partnership will not indemnify any such person for (1) acts or omissions committed in bad faith or that were the result of active and deliberate dishonesty, (2) any transaction for which such person received an improper personal benefit in money, healthcare facility or services, or (3) in the case of a criminal proceeding, the person had reasonable cause to believe the act or omission was unlawful.

Our charter restricts the ownership and transfer of our outstanding shares of stock which may have the effect of delaying, deferring or preventing a transaction or change of control of our company.

 

In order for us to qualify as a REIT, no more than 50% of the value of our outstanding shares of stock may be owned, beneficially or constructively, by five or fewer individuals at any time during the last half of each taxable year other than our initial REIT taxable year. Subject to certain exceptions, our charter prohibits any stockholder from owning actually or constructively more than 9.8% in value or number of shares, whichever is more restrictive, of any class or series of our outstanding shares. The constructive ownership rules under the Internal Revenue Code of 1986, as amended (the “Code”) are complex and may cause the outstanding shares owned by a group of related individuals or entities to be deemed to be constructively owned by one individual or entity. As a result, the acquisition of less than 9.8% of our outstanding shares of any class or series by an individual or entity could cause that individual or entity to own constructively in excess of 9.8% of any class or series of our outstanding beneficial interests and to be subject to our charter’s ownership limit. Our charter also prohibits any person from owning shares of our beneficial interests that would result in our being “closely held” under Section 856(h) of the Code or otherwise cause us to fail to qualify as a REIT. Any attempt to own or transfer shares of our beneficial interest in violation of these restrictions may result in the shares being automatically transferred to a charitable trust or may be void.


Certain provisions of Maryland law could inhibit changes of control, which may discourage third parties from conducting a tender offer or seeking other change of control transactions that could involve a premium price for shares of our common stock or that our stockholders otherwise believe to be in their best interests.

 

Certain provisions of the Maryland General Corporation Law, or MGCL, may have the effect of inhibiting a third party from making a proposal to acquire us or of impeding a change of control under circumstances that otherwise could provide our common stockholders with the opportunity to realize a premium over the then-prevailing market price of such shares, including:

 

·

“business combination” provisions that, subject to limitations, prohibit certain business combinations between us and an “interested stockholder” (defined generally as any person who beneficially owns 10% or more of the voting power of our shares of common stock or an affiliate thereof or an affiliate or associate of ours who was the beneficial owner, directly or indirectly, of 10% or more of the voting power of our shares of common stock at any time within the two-year period immediately prior to the date in question) for five years after the most recent date on which the stockholder becomes an interested stockholder, and thereafter imposes certain fair price and/or supermajority and stockholder voting requirements on these combinations; and

·“control share” provisions that provide that holders of “control shares” of our company (defined as shares that, when aggregated with other shares controlled by the stockholder, entitle the stockholder to exercise one of three increasing ranges of voting power in electing directors) acquired in a “control share acquisition” (defined as the direct or indirect acquisition of ownership or control of issued and outstanding “control shares”) have no voting rights with respect to their control shares, except to the extent approved by our stockholders by the affirmative vote of at least two-thirds of all the votes entitled to be cast on the matter, excluding all interested shares.

26

 

By resolution of our board of directors, we have opted out of the business combination provisions of the MGCL and provide that any business combination between us and any other person is exempt from the business combination provisions of the MGCL, provided that the business combination is first approved by our board of directors (including a majority of directors who are not affiliates or associates of such persons). In addition, pursuant to a provision in our bylaws, we have opted out of the control share provisions of the MGCL. However, our board of directors may by resolution elect to opt in to the business combination provisions of the MGCL and we may, by amendment to our bylaws, opt in to the control share provisions of the MGCL in the future.

 

Certain provisions of the MGCL permit our board of directors, without stockholder approval and regardless of what is currently provided in our charter or bylaws, to implement certain corporate governance provisions, some of which (for example, a classified board) are not currently applicable to us. If implemented, these provisions may have the effect of limiting or precluding a third party from making an unsolicited acquisition proposal for us or of delaying, deferring or preventing a change in control of us under circumstances that otherwise could provide our common stockholders with the opportunity to realize a premium over the then current market price. Our charter contains a provision whereby we have elected to be subject to the provisions of Title 3, Subtitle 8 of the MGCL relating to the filling of vacancies on our board of directors.

We could increase the number of authorized shares of common and preferred stock, classify and reclassify unissued shares and issue shares without stockholder approval.

 

Our board of directors, without stockholder approval, has the power under our charter to amend our charter to increase or decrease the aggregate number of shares or the number of shares of any class or series that we are authorized to issue, to authorize us to issue authorized but unissued shares of our common stock or preferred stock. In addition, under our charter, our board of directors has the power to classify or reclassify any unissued common or preferred stock into one or more classes or series of shares and set the preference, conversion or other rights, voting powers, restrictions, limitations as to dividends and other distributions, qualifications or terms or conditions of redemption for such newly classified or reclassified shares. As a result, we may issue series or classes of common or preferred stock with preferences, dividends, powers and rights, voting or otherwise, that are senior to, or otherwise conflict with, the rights of holders of our common or preferred stock. Although our board of directors has no such intention at the present time, it could establish a class or series of preferred stock that could, depending on the terms of such series, delay, defer or prevent a transaction or a change of control that might involve a premium price for shares of our common stock or that our stockholders otherwise believe to be in their best interests.


We may change our business, investment and financing strategies without stockholder approval.

 

We may change our business, investment and financing strategies without a vote of, or notice to, our stockholders, which could result in our making investments and engaging in business activities that are different from, and possibly riskier than, the investments and businesses described in this annual report. In particular, a change in our investment strategy, including the manner in which we allocate our resources across our portfolio or the types of assets in which we seek to invest, may increase our exposure to real estate market fluctuations. In addition, we may in the future increase the use of leverage at times and in amounts that we, in our discretion, deem prudent, and such decision would not be subject to stockholder approval. Furthermore, our board of directors may determine that healthcare facilities do not offer the potential for attractive risk-adjusted returns for an investment strategy. Changes to our strategies with regards to the foregoing could adversely affect our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

Our rights and the rights of our stockholders to take action against our directors and officers are limited, which could limit your recourse in the event that we take certain actions which are not in your best interests.

 

Under Maryland law, generally, directors and officers are required to perform their duties in good faith, in a manner that they reasonably believe to be in our best interests and with the care that an ordinarily prudent person in a like position would use under similar circumstances. Under Maryland law, directors and officers are presumed to have acted with this standard of care. Maryland law permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (a) actual receipt of an improper benefit or profit in money, property or services or (b) active and deliberate dishonesty established by a final judgment and which is material to the cause of action. Our charter contains such a provision which eliminates directors’ and officers’ liability to the maximum extent permitted by Maryland law.

27

 

Our charter authorizes us to indemnify our present and former directors and officers for actions taken by them in those and other capacities to the maximum extent permitted by Maryland law. Our bylaws obligate us to indemnify each present and former director or officer, to the maximum extent permitted by Maryland law, in the defense of any proceeding to which he or she is made, or threatened to be made, a party by reason of his or her service to us. In addition, we may be obligated to advance the defense costs incurred by our directors and officers. We have entered into indemnification agreements with our directors and officers granting them express indemnification rights. As a result, we and our stockholders may have more limited rights against our directors and officers than might otherwise exist absent the current provisions in our charter, bylaws and indemnification agreements or that might exist with other companies.

 

Our charter contains provisions that make removal of our directors difficult, which could make it difficult for our stockholders to effect changes to our management and may prevent a change in control of our company that is in the best interests of our stockholders. Our charter provides that a director may only be removed for cause upon the affirmative vote of holders of two-thirds of all the votes entitled to be cast generally in the election of directors. Vacancies may be filled only by a majority of the remaining directors in office, even if less than a quorum,.quorum. These requirements make it more difficult to change our management by removing and replacing directors and may prevent a change in control of our company that is in the best interests of our stockholders. 

Certain provisions in the partnership agreement of our Operating Partnership may delay or prevent unsolicited acquisitions of us.

 

Provisions in the partnership agreement of our Operating Partnership may delay, or make more difficult, unsolicited acquisitions of us or changes of our control. These provisions could discourage third parties from making proposals involving an unsolicited acquisition of us or change of our control, although some stockholders might consider such proposals, if made, desirable. These provisions include, among others:

 

·

Redemption rights;

·Redemption rights;
·A requirement that we may not be removed as the general partner of our Operating Partnership without our consent;
·Transfer restrictions on OP Units;
·Our ability, as the sole member of the general partner of our Operating Partnership, in some cases, to amend the partnership agreement and to cause the Operating Partnership to issue units with terms that could delay, defer or prevent a merger or other change of control of us or our Operating Partnership without the consent of the limited partners; and
·

The right of the limited partners to consent to direct or indirect transfers of the general partnership interest, including as a result of a merger or a sale of all or substantially all of our assets, in the event that such transfer requires approval by our common stockholders.

 


Our charter and bylaws, Maryland law and the partnership agreement of our Operating Partnership also contain other provisions that may delay, defer or prevent a transaction or a change of control that might involve a premium price for our shares of common stock or that our stockholders otherwise believe to be in their best interest.

 

Risks Related to Our Relationship with our Advisor and Other Conflicts of Interest

We have no employees and are entirely dependent upon our Advisor for all the services we require, and we cannot assure you that our Advisor will allocate the resources necessary to meet our business objectives or adequately perform its responsibilities under the management agreement.

 

Because we are externally managed, we do not retain our own personnel, but instead depend upon our Advisor, and its affiliates for virtually all of our services. Our Advisor selects and manages the acquisition of our healthcare facilities; administers the collection of rents,rents; monitors lease compliance and deals with vacancies and re-letting of our healthcare facilities; coordinates disposition of our healthcare facilities; provides financial and regulatory reporting services; communicates with our stockholders,stockholders; pays distributions and provide transfer agent services; and provides all of our other administrative services. Accordingly, our success is largely dependent upon the expertise and services of the executive officers and other key personnel of our Advisor and its affiliates. 

 

Our ability to achieve our objectives depends on our Advisor’s ability to identify and acquire healthcare facilities that meet our investment criteria. Accomplishing our objectives is largely a function of our Advisor’s structuring of our investment process, our access to financing on acceptable terms and general market conditions. Our stockholders will not have input into our investment decisions. All of these factors increase the uncertainty, and thus the risk, of investing in our common stock. The senior management team of our Advisor has substantial responsibilities under the management agreement. In order to implement certain strategies, our Advisor may need to hire, train, supervise and manage new employees successfully. Any failure to manage our future growth effectively could have a material adverse effect on our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

28

Our Advisor may be unable to obtain or retain key personnel.

 

Our success depends to a significant degree upon the executive officers and other key personnel of our Advisor. In particular, we rely on the services of Jeffrey Busch, our Chief Executive Officer and Chairman of our board of directors; Robert Kiernan, our Chief Financial Officer; Alfonzo Leon, our Chief Investment Officer; Danica Holley, our Chief Operating Officer; Allen Webb, our Senior Vice President, SEC Reporting and Technical Accounting and Jamie A. Barber, our Secretary and General Counsel, to manage our operations. We cannot guarantee that all, or any particular one of these key personnel, will remain affiliated with us or our Advisor. We do not separately maintain key person life insurance on any person. Failure of our Advisor to retain key employees and retain highly skilled managerial, operational and marketing personnel could have a material adverse effect on our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock. 

 

The base management fees payable to our Advisor are payable regardless of the performance of our portfolio, which may reduce our Advisor’s incentive to devote the time and effort to seeking profitable opportunities for our portfolio.

 

We pay our Advisor base management fees, which may be substantial, based on our stockholders’ equity (as defined in the management agreement) regardless of the performance of our portfolio. The base management fee takes into account the net issuance proceeds of both common and preferred stock offerings, as well as the issuance of OP Units. Our advisor’sAdvisor’s entitlement to non-performance-based compensation might reduce its incentive to devote the time and effort of its professionals to seeking profitable opportunities for our portfolio, which could result in a lower performance of our portfolio and materially adversely affect our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

The incentive fee payable to our Advisor under the management agreement may cause our Advisor to select investments in more risky assets to increase its incentive compensation. 

 

Our Advisor is entitled to receive incentive compensation based upon our achievement of targeted levels of AFFO (as defined in the management agreement). In evaluating investments and other management strategies, the opportunity to earn incentive compensation based on AFFO may lead our Advisor to place undue emphasis on the maximization of AFFO at the expense of other criteria, such as preservation of capital, in order to achieve higher incentive compensation. Investments with higher yield potential are generally riskier or more speculative. This could result in increased risk to the value of our investment portfolio, which, in turn, could materially, adversely affect our business, financial condition and results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock.


There are conflicts of interest in our relationships with our Advisor, which could result in outcomes that are not in the best interests of our stockholders.

 

We are subject to conflicts of interest arising out of our relationships with our Advisor. Pursuant to the management agreement, our Advisor is obligated to supply us with our management team. However, our Advisor is not obligated to dedicate any specific personnel exclusively to us, nor are the Advisor’s personnel obligated to dedicate any specific portion of their time to the management of our business. Additionally, our officers are employees of our Advisor. As a result, our Advisor, officers and directors may have conflicts between their duties to us and their duties to, and interests in, our Advisor.

 

In addition to our existing portfolio, we may acquire or sell healthcare facilities in which our Advisor or its affiliates have or may have an interest. Similarly, our Advisor or its affiliates may acquire or sell healthcare facilities in which we have or may have an interest. Although such acquisitions or dispositions may present conflicts of interest, we nonetheless may pursue and consummate such transactions. Additionally, we may engage in transactions directly with our Advisor or its affiliates, including the purchase and sale of all or a portion of a portfolio asset.

 

In deciding whether to issue additional debt or equity securities, we will rely in part on recommendations made by our advisor.Advisor. Our Advisor earns management fees that are based on the total amount of our equity capital. Our advisorAdvisor may have an incentive to recommend that we issue additional debt or equity securities or OP Units. Future offerings of debt securities, which would rank senior to our common stock upon liquidation, and future offerings of equity securities which would dilute the common stock holdings of our existing stockholders and may be senior to our common stock for the purposes of dividend and liquidating distributions, may adversely affect the market price of our common and preferred stock.

 

The officers of our Advisor and its affiliates will devote as much time to us as our Advisor deems appropriate, however, these officers may have conflicts in allocating their time and services between us and our Advisor and our Advisor’s other fund. During turbulent conditions in the real estate industries or other times when we will need focused support and assistance from our Advisor, may require greater focus and attention, placing our Advisor’s resources in high demand. In such situations, we may not receive the necessary support and assistance we require or would otherwise receive if we were internally managed.

29

The management agreement with our Advisor was not negotiated on an arm’s-length basis, may not be as favorable to us as if it had been negotiated with an unaffiliated third party and may be costly and difficult to terminate.

 

The management agreement with our Advisor was negotiated between related parties, and its terms, including fees payable, may not be as favorable to us as if it had been negotiated with an unaffiliated third party.

 

Termination of our management agreement without cause is subject to several conditions which may make such a termination difficult and costly. Termination of the management agreement with our Advisor may require us to pay our Advisor a substantial termination fee, which will increase the effective cost to us of terminating the management agreement, thereby making it more difficult for us to terminate our Advisor without cause.

 

If our Advisor ceases to be our Advisor pursuant to the management agreement, counterparties to our agreements may cease doing business with us. 

 

If our Advisor ceases to be our Advisor, it could constitute an event of default or early termination event under our financing agreements, upon which our counterparties would have the right to terminate their agreements with us. If our Advisor ceases to be our Advisor for any reason, including upon the non-renewal or termination of our management agreement, our business, financial condition and results of operations, and our ability to make distributions to our stockholders and the trading price of our common and preferred stock may be materially adversely affected.affected.

Risks Related to an Internalization Transaction

We cannot assure you that we will be able to complete an internalization transaction.

We cannot assure you that we will be able to complete an internalization transaction. There can be no guarantee that the special committee and our independent and disinterested directors will approve the internalization transaction or, if they do, that any of the closing conditions will be satisfied or that the internalization will be consummated. Failure to complete the internalization transaction in accordance with the terms of the management agreement, or not at all, could materially adversely delay our strategy of simplifying our business and lowering our costs.

If an internalization occurs, we will incur significant additional costs associated with being self-managed.

While we believe there may be substantial benefits to the internalization of the functions performed for us by our Advisor and of bringing onboard our Advisor’s management team, there is no assurance that an internalization will be beneficial to us and our stockholders, and internalizing our management functions could reduce our earnings. For example, we may not realize the perceived benefits or we may not be able to properly integrate a new staff of employees or we may not be able to effectively replicate the services provided previously by our Advisor or its affiliates. Internalization transactions have also, in some cases, been the subject of litigation. Even if such claims were without merit, we could be forced to spend significant amounts of money and management resources defending claims. All these factors could have a material adverse effect on our business, results of operations, financial condition, our ability to pay distributions to our stockholders and the trading price of our common and preferred stock.


The agreements to be entered into in connection with the internalization transaction will be negotiated between the special committee and certain of our officers and directors that are affiliated with our Advisor, which may create conflicts of interests and result in terms and conditions that may not be as favorable to us as if they had been negotiated with unaffiliated third parties.

Our Advisor is affiliated with certain of our officers and directors. Accordingly, those officers and directors may receive economic benefits as a result of the internalization transaction, which may differ from, and be in conflict with, our interests and the interests of our stockholders. Furthermore, the agreements to be entered into in connection with the internalization transaction will be negotiated between the special committee and affiliates of our Advisor, and their terms and conditions may not be as favorable to us as if they had been negotiated with unaffiliated third parties. Moreover, if any of the Advisor-related parties to the applicable transaction agreements were to breach any of the representations, warranties or covenants it makes therein, we may choose not to enforce, or to enforce less vigorously, our rights because of our desire to maintain our ongoing relationship with our Advisor and the certain of our officers and directors who are affiliated with our Advisor. Moreover, the representations, warranties, covenants and indemnities in any applicable transaction agreements are expected to be subject to limitations and qualifiers, which may also limit our ability to enforce any remedy under such agreements.

Following an internalization transaction, we may continue to be reliant on our Advisor for some period of time and certain officers of our Advisor may engage in activities that divert their attention from our business.

Following the consummation of an internalization transaction, we may remain reliant on certain employees of our Advisor for certain transitional services for a period of time after the closing, which may include but may not be limited to information technology, human resources, insurance, investor relations, legal, tax and accounting services. We can provide no assurances that we will be successful in internalizing those functions or identifying and engaging third-parties to provide those services to us. Moreover, certain of our officers and non-independent directors are also employees of our Advisor and have significant responsibilities for our Advisor’s other managed fund. As a result, those officers and directors will not devote 100% of their time to the management of our business and we may not receive the level of support and assistance that we otherwise might receive if those officers and directors did not have such outside obligations.

If we internalize our management functions, the interest of current stockholders’ in our Company could be diluted.

The consideration for an internalization transaction may take the form of our common stock or OP units redeemable for our common stock. If we issue common stock or OP Units in an internalization transaction, your interests as stockholder could be diluted.

 

Risks Related to Our Qualification and Operation as a REIT

Failure to remain qualified as a REIT would cause us to be taxed as a regular corporation, which would substantially reduce funds available for distributions to our stockholders.

 

If we fail to qualify as a REIT in any taxable year, we will face serious tax consequences that will substantially reduce the funds available for distributions to our stockholders because:

 

·We would not be allowed a deduction for dividends paid to stockholders in computing our taxable income and would be subject to U.S. federal income tax at regular corporate rates;
·We could be subject to increased state and local taxes; and
·Unless we are entitled to relief under certain U.S. federal income tax laws, we could not re-elect REIT status until the fifth calendar year after the year in which we failed to qualify as a REIT.

 

In addition, if we fail to qualify as a REIT, we will no longer be required to make distributions. As a result of all these factors, our failure to qualify as a REIT could impair our ability to expand our business and raise capital, and it would adversely affect our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.

30

Even if we continue to qualify as a REIT, we may face other tax liabilities that could reduce our cash flows and negatively impact our results of operations and financial condition.

 

Even if we continue to qualify for taxation as a REIT, we may be subject to certain U.S. federal, state and local taxes on our income and assets, including taxes on any undistributed income, taxtaxes on income from some activities conducted as a result of a foreclosure, and state or local income, property and transfer taxes. In addition, any taxable REIT subsidiary or TRS,(“TRS”) that we may form in the future will be subject to regular corporate U.S. federal, state and local taxes. In addition, if a TRS borrows funds either from us or a third party, it may be unable to deduct all or a portion of the interest paid, resulting in a higher corporate-level tax liability. Specifically, recently enacted tax reform legislationthe TCJA imposes a disallowance of deductions for business interest expense (even if paid to third parties) in excess of the sum of a taxpayer’s business interest income and 30% of the adjusted taxable income of the business, which is its taxable income computed without regard to business interest income or expense, net operating losses or the pass-through income deduction (and for taxable years before 2022, excludes depreciation and amortization). The TRS rules also impose a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s-length basis. Any of these taxes would decrease cash available for distributions to stockholders, which, in turn, could materially adversely affect our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.

30

 

Failure to make required distributions would subject us to U.S. federal corporate income tax.

 

In order to qualify as a REIT, we generally are required to distribute at least 90% of our REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gain, each year to our stockholders. To the extent that we satisfy this distribution requirement but distribute less than 100% of our REIT taxable income, we will be subject to U.S. federal corporate income tax on our undistributed taxable income. In addition, we will be subject to a 4% nondeductible excise tax if the actual amount that we pay out to our stockholders in a calendar year is less than a minimum amount specified under the Code. Any of these taxes would decrease cash available for distributions to stockholders which, in turn, could materially adversely affect our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.

Recharacterization of sale-leaseback transactions may cause us to lose our REIT status.

 

We have engaged, and expect to engage in the future, in transactions in which we purchase healthcare facilities and lease them back to the sellers of such healthcare facilities. Although we have structured, and intend to continue to structure, any such sale-leaseback transaction so that the lease will be characterized as a “true lease” for tax purposes, thereby allowing us to be treated as the owner of the healthcare facility for U.S. federal income tax purposes, we cannot assure you that the IRSInternal Revenue Service (the “IRS”) will not challenge such characterization. If any sale-leaseback transaction is challenged as a partnership for U.S. federal income tax purposes, all of the payments that we receive from the tenant may not be treated as qualifying income for the 75% or 95% gross income tests required for REIT qualification and we may fail to qualify as a REIT as a result. If any sale-leaseback transaction is challenged as a financing transaction or loan for U.S. federal income tax purposes, we would not be treated as the owner of the applicable healthcare facility and our deductions for depreciation and cost recovery relating to such healthcare facility would be disallowed. As a result, the amount of our REIT taxable income could be recalculated, which might cause us to fail to meet the distribution requirement required for REIT qualification. Although we may be able to cure such failure by making a distribution in a subsequent taxable year and paying an interest change,charge, no assurance can be provided that we will be able to make the required distribution or pay the required interest charge. If we lose our REIT status, our business, financial condition, results of operations, ability to make distributions to our stockholders and the trading price of our common and preferred stock could be materially adversely affected.

Complying with REIT requirements may cause us to forego otherwise attractive opportunities or liquidate otherwise attractive investments. 

 

To qualify as a REIT for U.S. federal income tax purposes, we must continually satisfy tests concerning, among other things, the sources of our income, the nature and diversification of our assets, the amounts we distribute to our stockholders and the ownership of our shares of stock. In order to meet these tests, we may be required to forego investments we might otherwise make. Thus, compliance with the REIT requirements may hinder our performance.

 

In particular, we must ensure that at the end of each calendar quarter, at least 75% of the value of our assets consists of cash, cash items, government securities and qualified real estate assets. The remainder of our investment in securities (other than government securities, securities of TRSs and qualified real estate assets) generally cannot include more than 10% of the outstanding voting securities of any one issuer or more than 10% of the total value of the outstanding securities of any one issuer. In addition, in general, no more than 5% of the value of our assets (other than government securities, securities of TRSs and qualified real estate assets) can consist of the securities of any one issuer, no more than 20% of the value of our total assets can be represented by the securities of one or more TRSs, and no more than 25% of our assets can be represented by debt of “publicly offered”offered REITs” (i.e., REITs that are required to file annual and periodic reports with the SEC under the Exchange Act) that is not secured by real property or interests in real property. If we fail to comply with these requirements at the end of any calendar quarter, we must correct the failure within 30 days after the end of the calendar quarter or qualify for certain statutory relief provisions to avoid losing our REIT qualification and suffering adverse tax consequences. As a result, we may be required to liquidate otherwise attractive investments. These actions could materially adversely affect our business, financial condition, results of operations, orour ability to make distributions to our stockholders and the trading price of our common and preferred stock.


Certain taxes may limit our ability to dispose of our healthcare facilities.

 

A REIT’s net income from prohibited transactions is subject to a 100% tax. In general, prohibited transactions are sales or other dispositions of property, other than foreclosure property, held primarily for sale to customers in the ordinary course of business. We may be subject to the prohibited transaction tax equal to 100% of net gain upon a disposition of real property. Although a safe harbor to the characterization of the sale of real property by a REIT as a prohibited transaction is available, we cannot assure you that we can comply with the safe harbor or that we will avoid owning property that may be characterized as held primarily for sale to customers in the ordinary course of business. Consequently, we may choose not to engage in certain sales of our healthcare facilities or may conduct such sales through any TRS that we may form, which would be subject to U.S. federal and state income taxation.

 

In addition, in the case of assets we owned as of January 1, 2016 (the start of our first REIT taxable year), we also will be subject to U.S. federal income tax at the highest regular corporate tax rate (currently 21%) on all or a portion of the gain recognized from a taxable disposition of any such asset occurring within the five-year period following January 1, 2016. The amount of the gain subject to tax would not exceed the difference between the fair market value of the asset sold as of January 1, 2016 and our adjusted tax basis in the asset on that date. Gain from a sale of such an asset occurring after the end of that five-year period will not be subject to this tax. We estimate that the aggregate amount of built-in gain in the assets we held at the start of our first REIT taxable year will not be significant. However, we are under no obligation to retain these assets to avoid this tax.

31

We may pay taxable dividends in our common stock and cash, in which case stockholders may sell shares of our common stock to pay tax on such dividends, placing downward pressure on the market price of our common stock.

 

We may satisfy the 90% distribution test with taxable distributions of our common stock. On August 11, 2017, theThe IRS has issued Revenue Procedure 2017-45 authorizing elective cash/stock dividends to be made by publicly offered REITs (e.g., REITs that are required to file annual and periodic reports with the SEC under the Exchange Act).REITs. Pursuant to Revenue Procedure 2017-45, effective for distributions declared on or after August 11, 2017, the IRS will treat the distribution of stock pursuant to an elective cash/stock dividend as a distribution of property under Section 301 of the Code (e.g.(i.e., a dividend), as long as at least 20% of the total dividend is available in cash and certain other parameters detailed in the Revenue Procedure are satisfied.

 

Although we have no current intention of paying dividends in our common stock, if we mademake a taxable dividend payable in cash and common stock, taxable stockholders receiving such dividends will be required to include the full amount of the dividend as income to the extent of our current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. As a result, stockholders may be required to pay income tax with respect to such dividends in excess of the cash dividends received. If a U.S. stockholder sells the common stock that it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of our common stock at the time of the sale. Furthermore, with respect to certain non-U.S. stockholders, we may be required to withhold U.S. federal income tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in common stock. If we mademake a taxable dividend payable in cash and our common stock and a significant number of our stockholders determine to sell shares of our common stock in order to pay taxes owed on dividends, it may put downward pressure on the trading price of our common stock.

The ability of our board of directors to revoke our REIT qualification without stockholder approval may cause adverse consequences to our stockholders.

 

Our charter provides that our board of directors may revoke or otherwise terminate our REIT election, without the approval of our stockholders, if it determines that it is no longer in our best interest to continue to qualify as a REIT. If we cease to qualify as a REIT, we would become subject to U.S. federal income tax on our taxable income and would no longer be required to distribute most of our taxable income to our stockholders, which could materially adversely affect our ability to make distributions to our stockholders and the trading price of our common and preferred stock.

AnyOur ownership of a TRS we may form in the future will be subject to limitations and our transactions with a TRS will cause us to be subject to a 100% penalty tax on certain income or deductions if those transactions are not conducted on arm’s-length terms.

 

Overall, no more than 20% of the value of a REIT’s assets may consist of stock or securities of one or more TRS. In addition,TRSs. Several provisions of the Code limitsregarding the deductibility of interest paid or accrued byarrangements between a REIT and its TRSs ensure that a TRS to its parent REIT to assure that the TRS iswill be subject to an appropriate level of corporateU.S. federal income taxation. TheFor example, the Code also imposes a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s-length basis. In addition, any income earned by a TRS that is attributable to services provided to its parent REIT, or on the REIT’s behalf to any of its tenants, that is less than the amounts that would have been charged based upon arm’s-length negotiations, will also be subject to a 100% excise tax. We will monitor the value of our respective investments in any TRS that we may form for the purpose of ensuring compliance with TRS ownership limitations and will structure our transactions with any TRS on terms that we believe are arm’s length to avoid incurring the 100% excise taxtaxes described above. There can be no assurance, however, that we will be able to comply with the 20% limitation or to avoid application of the 100% excise tax.taxes. If we are subject to theeither 100% excise tax, our business, financial condition, results of operations, our ability to make distributions to our stockholders and the trading price of our common and preferred stock could be materially adversely affected.


The formation of a TRS lessee would increase our overall tax liability.

 

We may, in the future, form one or more TRS lessees to lease “qualified health care properties” from us. Any TRS lessee we may form will be subject to U.S. federal and state income tax on its taxable income, which will consist of the revenues from the qualified healthcare facilities leased by the TRS lessee, net of the operating expenses for such healthcare facilities and rent payments to us. In addition, if a TRS borrows funds either from us or a third party, it may be unable to deduct all or a portion of the interest paid, resulting in a higher corporate-level tax liability. Specifically, recently enacted tax reform legislationthe TCJA imposes a disallowance of deductions for business interest expense (even if paid to third parties) in excess of the sum of a taxpayer’s business interest income and 30% of the adjusted taxable income of the business, which is its taxable income computed without regard to business interest income or expense, net operating losses or the pass-through income deduction (and for taxable years before 2022, excludes depreciation and amortization). Accordingly, although our ownership of a TRS lessee would allow us to participate in the operating income from our healthcare facilities leased to the TRS lessee on an after-tax basis in addition to receiving rent, that operating income would be fully subject to U.S. federal and state income tax, which could materially adversely affect our business, financial conditions, results of operations, ability to make distributions to our stockholders and the trading price of our common and preferred stock.

32

If leases of our healthcare facilities are not respected as true leases for U.S. federal income tax purposes, we would fail to qualify as a REIT and would be subject to higher taxes and have less cash available for distribution to our stockholders. 

 

To qualify as a REIT, we must satisfy two gross income tests, under which specified percentages of our gross income must be derived from certain sources, such as “rents from real property.” Rents paid to our Operating Partnership by third-party lessees and any TRS lessee that we may form in the future pursuant to the leases of our healthcare facilities will constitute substantially all of our gross income. In order for such rent to qualify as “rents from real property” for purposes of the gross income tests, the leases must be respected as true leases for U.S. federal income tax purposes and not be treated as service contracts, joint ventures or some other type of arrangement. If our leases are not respected as true leases for U.S. federal income tax purposes, we would fail to qualify as a REIT, which, in turn, could materially adversely affect our business, financial conditions, results of operations, ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

If a TRS lessee failed to qualify as a TRS or the facility operators engaged by a TRS lessee did not qualify as “eligible independent contractors,” we would fail to qualify as a REIT and would be subject to higher taxes and have less cash available for distribution to our stockholders.

 

Rent paid by a lessee that is a “related party tenant” of ours will not be qualifying income for purposes of the two gross income tests applicable to REITs. We may, in the future, lease certain of our healthcare facilities that qualify as “qualified health care properties” to a TRS lessee. So long as that TRS lessee qualifies as a TRS, it will not be treated as a “related party tenant” with respect to our healthcare facilities that are managed by an independent facility operator that qualifies as an “eligible independent contractor.” We would seek to structure any future arrangements with a TRS lessee such that the TRS lessee would qualify to be treated as a TRS for U.S. federal income tax purposes, but there can be no assurance that the IRS would not challenge the status of a TRS for U.S. federal income tax purposes or that a court would not sustain such a challenge. If the IRS were successful in disqualifying a TRS lessee from treatment as a TRS, it is possible that we would fail to meet the asset tests applicable to REITs and a significant portion of our income would fail to qualify for the gross income tests. If we failed to meet either the asset or gross income tests, we would likely lose our REIT qualification for U.S. federal income tax purposes, which, in turn, could materially adversely affect our business, financial condition, results of operations, ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

Additionally, if the facility operators engaged by a TRS lessee do not qualify as “eligible independent contractors,” we would fail to qualify as a REIT. Each of the facility operators that would enter into a management contract with any TRS lessee must qualify as an “eligible independent contractor” under the REIT rules in order for the rent paid to us by such a TRS lessee to be qualifying income for purposes of the REIT gross income tests. Among other requirements, in order to qualify as an eligible independent contractor a facility operator must not own, directly or indirectly, more than 35% of our outstanding shares and no person or group of persons can own more than 35% of our outstanding shares and the ownership interests of the facility operator, taking into account certain ownership attribution rules. The ownership attribution rules that apply for purposes of these 35% thresholds are complex. Although we would monitor ownership of our shares of common stock by any facility operators and their owners, there can be no assurance that these ownership levels will not be exceeded. 


You may be restricted from acquiring or transferring certain amounts of our common stock.

 

The stock ownership restrictions of the Code for REITs and the 9.8% share ownership limit in our charter may inhibit market activity in our capital stock and restrict our business combination opportunities.

 

In order to qualify as a REIT for each taxable year, five or fewer individuals, as defined in the Code, may not own, beneficially or constructively, more than 50% in value of our issued and outstanding shares of capital stock at any time during the last half of a taxable year. Attribution rules in the Code determine if any individual or entity beneficially or constructively owns our shares of capital stock under this requirement. Additionally, at least 100 persons must beneficially own our shares of capital stock during at least 335 days of a taxable year for each taxable year. To help insureensure that we meet these tests, our charter restricts the acquisition and ownership of shares of our capital stock.

 

Our charter, with certain exceptions, authorizes our directors to take such actions as are necessary and desirable to preserve our qualification as a REIT. Unless exempted by our board of directors, our charter prohibits any person from beneficially or constructively owning more than 9.8% in value or number of shares, whichever is more restrictive, of the outstanding shares of any class or series of our shares of capital stock. Our board of directors may not grant an exemption from this restriction to any proposed transferee whose ownership in excess of 9.8% of the value of our outstanding shares would result in our failing to qualify as a REIT.

33

Dividends payable by REITs do not qualify for the reduced tax rates available for some dividends.

 

The maximum U.S. federal income tax rate applicable to “qualified dividend income” payable to U.S. stockholders that are taxed at individual rates is 20% (plus the 3.8% surtax on net investment income, if applicable). Dividends payable by REITs, however, generally are not eligible for the reduced rates on qualified dividend income. Rather, under the recently-enacted TCJA, ordinary REIT dividends constitute “qualified business income” and thus a 20% deduction is available to individual taxpayers with respect to such dividends, resulting in a 29.6% maximum U.S. federal income tax rate (plus the 3.8% surtax on net investment income, if applicable) for individual U.S. stockholders. Additionally, withoutWithout further legislative action, the 20% deduction applicable to ordinary REIT dividends will expire on January 1, 2026. The more favorable rates applicable to regular corporate qualified dividends could cause investors who are taxed at individual rates to perceive investments in REITs to be relatively less attractive than investments in the stocksstock of non-REIT corporations that pay dividends, which could adversely affect the value of the shares of REITs, including our common and preferred stock.

We may be subject to adverse legislative or regulatory tax changes.

 

At any time, the U.S. federal income tax laws or regulations governing REITs or the administrative interpretations of those laws or regulations may be amended. We cannot predict when or if any new U.S. federal income tax law, regulation or administrative interpretation, or any amendment to any existing U.S. federal income tax law, regulation or administrative interpretation, will be adopted, promulgated or become effective and any such law, regulation, or interpretation may take effect retroactively. We and our stockholders could be adversely affected by any such change in the U.S. federal income tax laws, regulations or administrative interpretations which, in turn, could materially adversely affect our business, financial conditions, results of operation, ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 

The recently-enacted TCJA makesmade significant changes to the U.S. federal income tax rules for taxation of individuals and corporations. In the case of individuals, the tax brackets have beenwere adjusted, the top U.S. federal income tax rate has beenwas reduced to 37%, special rules reducereduced taxation of certain income earned through pass-through entities and reducereduced the top effective tax rate applicable to ordinary dividends from REITs to 29.6% (through a 20% deduction for ordinary REIT dividends received) and various deductions have beenwere eliminated or limited, including limitinga limitation on the deduction for state and local taxes to $10,000 per year. Most of the changes applicable to individuals are temporary and apply only to taxable years beginning after December 31, 2017 and before January 1, 2026. The top corporate income tax rate has beenwas reduced to 21%. There arewere only minor changes to the REIT rules (other than the 20% deduction applicable to individuals for ordinary REIT dividends received). The TCJA makesmade numerous other large and small changes to the tax rules that do not affect REITs directly but may affect our stockholders and may indirectly affect us.

If our Operating Partnership failed to qualify as a partnership for U.S. federal income tax purposes, we would cease to qualify as a REIT and suffer other adverse consequences.

 

We believe that our Operating Partnership will be treated as a partnership for U.S. federal income tax purposes. As a partnership, our Operating Partnership will not be subject to U.S. federal income tax on its income. Instead, each of its partners, including us, will be allocated, and may be required to pay tax with respect to, its share of our Operating Partnership’s income. We cannot assure you, however, that the IRS will not challenge the status of our Operating Partnership or any other subsidiary partnership in which we own an interest as a partnership for U.S. federal income tax purposes, or that a court would not sustain such a challenge. If the IRS were successful in treating our Operating Partnership or any such other subsidiary partnership as an entity taxable as a corporation for U.S. federal income tax purposes, we would fail to meet the gross income tests and certain of the asset tests applicable to REITs and, accordingly, we would likely cease to qualify as a REIT. Also, the failure of our Operating Partnership or any subsidiary partnerships to qualify as a partnership could cause it to become subject to U.S. federal and state corporate income tax, which, in turn, could materially adversely affect our business, financial condition, results of operations, ability to make distributions to our stockholders and the trading price of our common and preferred stock.

 


Tax protection agreements may limit our ability to sell or otherwise dispose of certain properties and may require our Operating Partnership to maintain certain debt levels that otherwise would not be required to operate our business.

In connection with contributions of properties to our Operating Partnership, our Operating Partnership has entered and may in the future enter into tax protection agreements under which it agrees to minimize the tax consequences to the contributing partners resulting from the sale or other disposition of the contributed properties. Tax protection agreements may make it economically prohibitive to sell any properties that are subject to such agreements even though it may otherwise be in our stockholders’ best interests to do so. In addition, we may be required to maintain a minimum level of indebtedness throughout the term of any tax protection agreement regardless of whether such debt levels are otherwise required to operate our business. Nevertheless, we have entered and may in the future enter into tax protection agreements to assist contributors of properties to our Operating Partnership in deferring the recognition of taxable gain as a result of and after any such contribution.

ITEM 1B.UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2.PROPERTIES

 

The information set forth under the caption “Our Properties” in Item 1 of this Annual Report on Form 10-K is incorporated by reference herein.

 

34

ITEM 3.LEGAL PROCEEDINGS

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition, or results of operations.operations, or cash flows. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, our preferred stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

ITEM 4.MINE SAFETY DISCLOSURES

 

Not applicable.

PART II

 

ITEM 5.MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock is quoted on the New York Stock Exchange under the ticker symbol “GMRE.” Prior to July 1, 2016 (the closing date

The Company declared and paid a dividend of our IPO), our stock was listed on the OTC pink tier$0.20 per share of the OTC Markets, Inc. under the symbol “GMRE” and trading of our common stock at that time was limited and sporadic. The following table sets forth, for the periods indicated, the high and low sale prices of our common stock foreach quarter within the fiscal years ended December 31, 20172019 and 2016, respectively, and the dividends paid by us with respect to those periods.

2017 High  Low  Dividends
per Share1
 
First quarter $9.18  $8.15  $0.20 
Second quarter $10.23  $8.22  $0.20 
Third quarter $9.45  $8.36  $0.20 
Fourth quarter $9.75  $8.19  $0.20 

2016 High  Low  Dividends
per Share1
 
First quarter $3.58  $0.125  $0.2556 
Second quarter $3.58  $0.125  $0.2556 
Third quarter $11.38  $9.52  $0.20 
Fourth quarter $9.89  $6.73  $0.20 

1Dividend information is for dividends declared with respect to that quarter.

2018. The declaration and payment of quarterly dividends remains subject to the review and approval of the Board of Directors, see “Risk Factors —Subject to certain requirements under Maryland law and REIT requirements, our board of directors has sole discretion to determine if we will pay distributions and the amount and frequency of such distributions, and past distribution amounts may not be indicative of future distribution amounts.


 

Performance Graph

 

This performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Global Medical REIT Inc. under the Securities Act or the Exchange Act.

 

The graph below compares the cumulative total return of our common shares,stock, the S&P 500, the MSCI US REIT Index, and the SNL U.S. REIT Healthcare Index from July 1, 2016 (the completion date of our IPO) through December 31, 2017.2019. The comparison assumes $100 was invested on July 1, 2016 in our common sharesstock and in each of the foregoing indexesindices and assumes reinvestment of dividends, as applicable. The MSCI USU.S. REIT Index consists of equity REITs that are included in the MSCI US Investable Market 2500 Index, except for specialty equity REITS that do not generate a majority of their revenue and income from real estate rental and leasing operations. The SNL U.SU.S. REIT Healthcare Index consists of all publicly traded (NYSE, NYSE MKT, NASDAQ, OTC) Healthcare REITs in SNL’s coverage universe. We have included the MSCI USU.S. REIT Index and the SNL U.S. REIT Healthcare Index because we believe that they are representative of the industry in which we compete and are relevant to an assessment of our performance.

 

35

 

 

 Period Ending   Period Ending 
Index 07/01/16  09/30/16  12/31/16  03/31/17  06/30/17  09/30/17  12/31/17  07/01/16  12/31/16  12/31/17  12/31/18  12/31/19 
Global Medical REIT Inc. $100.00  $98.05  $91.60  $95.47  $95.83  $98.43  $89.88  $100.00  $91.60  $92.05  $109.64  $175.34 
S&P 500 Index $100.00  $103.63  $107.59  $114.12  $117.64  $122.92  $131.08  $100.00  $107.59  $131.08  $125.34  $164.80 
MSCI U.S. REIT Index $100.00  $98.46  $95.55  $96.50  $98.09  $99.00  $100.39  $100.00  $95.55  $100.39  $95.80  $120.56 
SNL U.S. REIT Healthcare Index $100.00  $102.22  $91.98  $98.28  $103.38  $97.51  $91.84  $100.00  $91.98  $91.84  $97.53  $118.74 

As of March 2, 20182020, there were approximately 3432 record holders, and 21,630,67544,259,739 shares of common stock issued and outstanding. A substantially greater number of holders of our common stock are “street name” or beneficial holders, whose shares of record are held by banks, brokers and other financial institutions.As of December 31, 20172019 and 2016,2018, there were 21,630,67543,805,739 and 17,605,67525,944,484 outstanding shares of common stock, respectively.

 

Unregistered Sales of Equity Securities

 

None.

None.

36

 

Issuer Purchases of Equity Securities

 

None.

None.

 

ITEM 6.SELECTED FINANCIAL DATA

 

The following sets forth selected financial and operating data on a historical consolidated basis. The following data should be read in conjunction with the financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Annual Report on Form 10-K. Effective beginning with the year ended December 31, 2014, we changed our fiscal year from August 31 to the calendar twelve months ending December 31.  Accordingly, our 2014 fiscal period was shortened from twelve months to a four-month transition period that ended on December 31, 2014, with a comparative period presented below for the four-month period ended December 31, 2013. Our change in fiscal year was required based upon our intention to qualify and be taxed as a REIT for federal income tax purposes. The amounts in the following table are presented in thousands, except per share amounts.

 

36
  Year Ended December 31, 
  2019  2018  2017  2016  2015 
Statements of Operations Data                    
Total revenue $70,726  $53,192  $30,344  $8,211  $2,062 
Total expenses  61,138   46,306   30,431   14,564   3,671 
Income (loss) before gain on sale of investment property  9,588   6,886   (87)  (6,353)  (1,609)
Gain on sale of investment property  -   7,675   -   -   - 
Net income (loss)  9,588   14,561   (87)  (6,353)  (1,609)
Less: Preferred stock dividends  (5,822)  (5,822)  (1,714)  -   - 
Less: Net (income) loss attributable to noncontrolling interest  (354)  (1,071)  49   -   - 
Net income (loss) attributable to common stockholders $3,412  $7,668  $(1,752) $(6,353) $(1,609)
Dividends declared per share of common stock $0.80  $0.80  $0.80  $0.74  $1.02 
                     
Net income (loss) attributable to common stockholders per share – basic and diluted $0.10  $0.35  $(0.09) $(0.68) $(6.44)
                     
Weighted average shares outstanding – basic and diluted  33,865   21,971   19,617   9,302   250 

 

  As of December 31, 
  2019  2018  2017  2016  2015 
Balance Sheets Data                    
Net investment in real estate $849,026  $616,925  $457,913  $203,510  $55,149 
Total assets $884,934  $636,009  $471,821  $226,392  $65,329 
Credit Facility, net $347,518  $276,353  $162,150  $26,773  $- 
Notes payable, net $38,650  $38,654  $38,545  $38,413  $23,485 
Total liabilities $424,581  $336,349  $212,808  $71,364  $65,467 
Preferred stock $74,959  $74,959  $74,959  $-  $- 
Total stockholders’ equity (deficit) $430,270  $269,295  $246,335  $155,028  $(139)
Noncontrolling interest $30,083  $30,455  $12,678  $-  $- 
Total equity (deficit) $460,353  $299,750  $259,013  $155,028  $(139)

  Year Ended
December 31,
  Four Months Ended
December 31,
  Year Ended
August 31,
 
  2017  2016  2015  2014  2013  2014  2013 
Statement of Operations Data                            
Total revenue $30,344  $8,211  $2,062  $597  $-  $380  $- 
Total expenses  30,431   14,564   3,671   1,007   12   1,032   - 
Net loss  (87)  (6,353)  (1,609)  (410)  (12)  (652)  (45)1
Less: Preferred stock dividends  (1,714)  -   -   -   -   -   - 
Less: Net loss attributable to noncontrolling interest  49   -   -   -   -   -   - 
Net loss attributable to common stockholders $(1,752) $(6,353) $(1,609) $(410) $(12) $(652) $(45)
Dividends declared per share of common stock $0.80  $0.74  $1.02  $0.34  $-  $0.17  $- 
                             
Net loss attributable to common stockholders per share – basic and diluted $(0.09) $(0.68) $(6.44) $(1.64) $(0.61) $(13.49) $(2.32)1
                             
Weighted average shares outstanding – basic and diluted  19,617   9.302   250   250   20   48   20 
                             
  As of December 31,  As of August 31, 
  2017  2016  2015  2014  20133  2014  2013 
Balance Sheet Data                            
Net investment in real estate $457,913  $203,510  $55,149  $24,044  $-3 $21,738  $- 
Total assets $474,571  $227,319  $65,329  $24,640  $-3 $22,245  $42
Revolving Credit Facility $164,900  $27,700  $-  $-  $-3 $-  $- 
Notes payable – third parties, net of discount $38,545  $38,413  $23,485  $16,468  $-3 $14,750  $- 
Total liabilities $215,558  $72,291  $65,467  $22,914  $-3 $20,023  $192
Preferred stock $74,959  $-  $-  $-  $-3 $-  $- 
Noncontrolling interest $12,678  $-  $-  $-  $-3 $-  $- 
Total stockholders’ equity (deficit) $259,013  $155,028  $(139) $1,726  $-3 $2,221  $(16)2


1Represents loss and loss per share from discontinued operations, respectively.

2Represents the Company’s predecessor company’s balance. The predecessor was converted into the Company on January 15, 2014.

3The Company changed its fiscal year end to a December year end for the calendar year ended December 31, 2014. A balance sheet for the Company as of December 31, 2013 was not required to be filed and has not been filed.

 

37

ITEM 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with our financial statements, including the notes to those financial statements, included elsewhere in this Report. Some of the statements we make in this section are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section in this Report entitled “Forward-Looking“Special Note Regarding Forward-Looking Statements.” Certain risk factors may cause actual results, performance or achievements to differ materially from those expressed or implied by the following discussion. For a discussion of such risk factors, see the section in this Report entitled “Risk Factors.” Unless otherwise indicated all dollar and share amounts in the following discussion are presented in thousands.

 

Overview

 

Global Medical REIT Inc. (the “Company,” “us,” “we,” or “our”) is an externally-managed,externally managed, Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of thesethose facilities to strong clinical operatorshealthcare systems and physician groups with leading market share. The Company is externally managed and advised by Inter-American Management LLC (the “Advisor”).

  

We elected to be taxed as a REIT for U.S. federal income tax purposes commencing with our taxable year ended December 31, 2016. We conduct our business through an umbrella partnership real estate investment trust, or UPREIT, structure in which our properties are owned by wholly-ownedwholly owned subsidiaries of our operating partnership, Global Medical REIT L.P. (the “Operating Partnership”). Our wholly-ownedwholly owned subsidiary, Global Medical REIT GP, LLC, is the sole general partner of our Operating Partnership and, as of December 31, 2017,2019, we owned approximately 93.63%91.82% of the outstanding operating partnership units (“OP Units”) of our Operating Partnership.

 

Our Business Objectives and Investment Strategy

 

Our principal business objective is to provide attractive, risk-adjusted returns to our stockholders through a combination of (i) sustainable and increasing rental income that allows us to pay reliable increasing dividends and (ii) potential long-term appreciation in the value of our healthcare facilities and common stock.capital appreciation. Our primary strategies to achieve our business objective are to:

 

 ·Constructconstruct a property portfolio that consists substantially of off-campus, purpose-built, licensed medical facilities, such as medical office buildings (MOBs), specialty hospitals and ambulatory surgery centers (ASCs), and in-patient rehabilitation facilities that are primarily located in secondary markets and are situated to take advantage of the aging of the U.S. population and the decentralization of healthcare;
·Set aside a portion of our property portfolio for opportunistic acquisitions of non-core assets, such as acute-care hospitals and long-term acute care facilities (LTACs), that we believe provide premium, risk-adjusted returns;
·lease each facility to medical providers with a track record of successfully managing excellent clinical and profitable practices;
 ·focus on practice types that will be utilized by an aging population and that are highly dependent on their purpose-built real estate to deliver core medical procedures, such as cardiovascular treatment, rehabilitation, eye surgery, gastroenterology, oncology treatment and orthopedics;
 ·set aside a portion of our property portfolio for opportunistic acquisitions of non-core assets, such as (i) certain acute-care hospitals and long-term acute care facilities (LTACs), that we believe provide premium, risk-adjusted returns and (ii) health system corporate office and administrative buildings, which we believe will help us develop relationships with larger health systems;
·lease the facilities under long-term, triple-net leases with contractual rent escalationsescalations;
· lease each facility to medical providers with a track record of successfully managing excellent clinical and with initial (year one) capitalization rates that exceed our cost of capital (as opposed to factoring in future contractual rent escalations in determining whether investment returns will exceed our cost of capital);profitable practices; and
 ·efficientlyreceive credit protections from our tenants or their affiliates, including personal and rapidly grow our portfolio to drive economies of scalecorporate guaranties, rent reserves and diversification.rent coverage requirements.

 

20172019 Executive Summary

 

The following table summarizes the material changes in our business and operations during 2017:2019:

 

  Year Ended December 31, 
  2017  2016 
       
Rental revenue $28,511  $8,080 
Interest expense $7,435  $4,139 
General and administrative expense $5,489  $4,219 
Preferred stock dividends $1,714  $- 
Net loss attributable to common stockholders per share $(0.09) $(0.68)
AFFO per share(1) $0.54  $(0.03)
Dividends per common share $0.80  $0.74 
Weighted average common shares outstanding  19,617   9,302 

  Year Ended December 31, 
  2019  2018 
  (in thousands, except per share amounts) 
Rental revenue $70,515  $53,138 
Gain on sale of investment property $-  $7,675 
Depreciation and amortization expenses $24,635  $17,269 
Interest expense $17,472  $14,975 
General and administrative expense $6,536  $5,537 
Net income attributable to common stockholders per share $0.10  $0.35 
FFO per share and unit(1) $0.75  $0.76 
AFFO per share and unit(1) $0.75  $0.76 
Dividends per share of common stock $0.80  $0.80 
         
Weighted average shares of common stock outstanding  33,865   21,971 
Weighted average OP Units outstanding  3,144   1,704 
Weighted average LTIP Units outstanding  780   586 
Total weighted average shares and units outstanding  37,789   24,261 

 

(1)See “—Non-GAAP Financial Measures,” for a description of our non-GAAP financial measures and a reconciliation of our non-GAAP financial measures.

 

38

38

 

 

  As of December 31, 
  2017  2016 
       
Total investment in real estate, gross $471,507  $206,877 
Total debt $203,445  $66,534 
Weighted average interest rate  3.72%  4.29%
Total equity $259,013  $155,028 
         
Net rentable square feet  1,331   665 
  As of December 31, 
  2019  2018 
  (dollars in thousands) 
Total investment in real estate, gross $905,529  $647,550 
Total debt, net $386,168  $315,007 
Weighted average interest rate  3.90%  4.64%
Total equity (including noncontrolling interest) $460,353  $299,750 
Net leasable square feet  2,780,851   2,078,915 

 

WeOur Properties

During the year ended December 31, 2019, we completed our initial public offering in July 2016, issuing18 acquisitions encompassing an aggregate of 15 million shares of common stock at701,936 leasable square feet for an offeringaggregate contractual purchase price of $10.00 per share for aggregate net proceedsapproximately $253.5 million with annualized base rent of $137.3$19.0 million. We utilized the proceeds from this offering as well as credit received from banks to acquire real estate assets consistent withfunded our business objectives2019 acquisitions through a combination of equity issuances and investment strategy. During 2017, we completed a follow-on offering ofborrowings under our common stock issuing an aggregate of 4 million shares at an offering price of $9.00 share for aggregate net proceeds of $33.8 million. We also completed an underwritten public offering of our Series A Preferred Stock during 2017, issuing an aggregate of 3.1 million shares with a liquidation preference of $25.00 per share for aggregate net proceeds of $75 million. In addition to these offerings, during 2017 the Company established a revolving credit facility with a group of lenders, pursuant to which we have the ability to borrow up to $340 million and established a $50 million “at-the-market” program for our common stock. See “—Liquidity and Capital Resources” for additional detail regarding our debt and equity transactions.

Credit Facility. As of December 31, 2017, and 2016, the Company had2019, our portfolio consisted of gross investment in real estate of $471.5$905.5 million, which was comprised of 68 facilities with an aggregate of approximately 2.8 million leasable square feet and $206.9approximately $70.4 million respectively. of annualized base rent.

Capital Raising Activity

During the yearsyear ended December 31, 20172019, we raised $200.1 million of equity through a combination of common stock and 2016,OP Unit issuances at an average issuance price of $11.23 per share. Our equity issuances during the year ended December 31, 2019 included the following:

·underwritten public offerings of our common stock in March and December 2019, which resulted in the issuance of 15.1 million shares of our common stock at an average public offering price of $11.23 per share, generating gross proceeds of $170.0 million;
·at-the-market (“ATM”) offering issuances of 2.6 million shares of our common stock at an average public offering price of $11.24 per share, generating gross proceeds of $29.6 million: and
·an OP Unit issuance of 49 thousand units with a value of $506 thousand in connection with a facility acquisition, at a price of $10.30 per unit.

Debt Activity

During the year ended December 31, 2019, we generated rental revenueborrowed $244.3 million under the Credit Facility and repaid $173.2 million, for a net amount borrowed of $28.5$71.1 million. As of December 31, 2019, the net outstanding Credit Facility balance was $347.5 million.

On September 30, 2019, we entered into an amendment to our Credit Facility that, among other things, (i) increased the borrowings under the term-loan component (the “Term Loan”) from $175 million to $300 million, representing the exercise of the remaining $75 million accordion feature and a re-allocation of $50 million from the revolver component (the “Revolver”) to the Term Loan and (ii) added a new $150 million accordion feature. Additionally, on October 3, 2019, we hedged our interest rate risk on the Term Loan by entering into two interest rate swaps with an aggregate notional amount of $130 million and $8.1 million, respectively, from these investments. Reflectinga term of approximately five years, which effectively fixed the impactLIBOR component of the interest rate on a corresponding amount of the Term Loan at 1.21%. As of December 31, 2019, in total we had five interest rate swaps with three counterparties to hedge the LIBOR component of our increasing investment balances during 2017, our net loss attributableinterest rate risk related to common shareholders decreased to $1.8the entire Term Loan. Together, these swaps fix the LIBOR component of the entire $300 million Term Loan on a weighted average basis at 2.17%. An aggregate of $200 million of the swaps mature in 2017 from $6.4August 2024 and an additional $100 million matures in 2016.August 2023.

 


Recent Developments

 

During the period beginning on January 1, 2018 and ending on March 1, 2018, we completed four acquisitions with an aggregate purchase price of $48.4 million, an aggregate of 323,400 net rentable square feet and a weighted average capitalization rate of approximately 8.6%. The table below summarizes our post-2017 acquisitions:2020 Completed Acquisitions

 

Property City Type Rentable
Square Feet
(RSF)
  

 

Purchase Price(1)

(in thousands)

  Annualized
Base Rent(2)
(in thousands)
  Cap. Rate(3)  Lease
Years
Remaining
 
Quad City Kidney Center Moline, IL MOB  27,173  $6,706  $548   8.17%  14 
NOMS Fremont, OH MOB  25,893   8,286   608   7.34%  12 
Gainesville Eye Gainesville, GA MOB/ASC  34,020   10,400   776   7.46%  12 
City Hospital of White Rock Dallas, TX Hospital  236,314   23,000   2,230   9.70%  20 
Total/Weighted Average      323,400  $48,392  $4,162   8.60%  16 

Using borrowing capacity under the Revolver, since December 31, 2019, we have closed on the following properties:

Property City Rentable
Square Feet
(RSF)
  

Purchase

Price(1)
(in thousands)

  

Annualized
Base Rent(2)
(in thousands)

  

Capitalization
Rate(3)

 
Wake Forest Baptist Health High Point, NC  97,811  $24,750  $1,832   7.4%
Medical Associates Clinton, IA  115,142   11,350   1,282   11.3%
Ascension St. Mary’s Hospital West Allis, WI  33,670   9,025   664   7.4%
Totals/Weighted Average    246,623  $45,125  $3,778   8.4%

 

(1) Represents the contractual purchase price.

(2)Monthly base rent in the month ofat acquisition multiplied by 12.

(3)Capitalization rates are calculated based on current lease terms and do not give effect to future rent escalations.

 

Properties Under Contract

Summary information about transactions weWe have under purchase agreements as of March 6, 2018 is presented in the table below: 

Property City 

Rentable

Square Feet

(RSF)

  

Purchase

Price(1)

(in thousands)

  

Annualized

Base Rent(2)

(in thousands)

  

Cap. Rate(3)

 
Orlando Health Orlando, FL  59,594  $16,200  $1,340   8.27%
Memorial Health System Belpre, OH  155,600   64,200   5,040   7.85%
Totals/Weighted Average    215,194  $80,400  $6,380   7.94%

(1) Represents contractual purchase price.

(2)Monthly base rent in the month placedfive properties under contract multiplied by 12.

(3)Capitalization rates are calculated based on current lease terms and do not give effect to future rent escalations.

We entered into thefor an aggregate purchase and sale agreements for the Orlando and Belpre transactions on January 24, 2018 and March 6, 2018, respectively.price of approximately $84.9 million. We are currently in the due diligence periodsperiod for these transactions.our properties under contract. If we identify problems with theany of these properties or the operatorsoperator of the propertiesany property during our due diligence review, we may not close the transactionstransaction on a timely basis or we may terminate the purchase agreementsagreement and not close the transactions.transaction.

 

Increase in Capacity of our Revolving Credit FacilityManagement Internalization Evaluation

 

On March 6, 2018, we amendedDecember 13, 2019, our revolving credit facilityboard of directors formed a special committee of three independent and disinterested directors to increase the aggregate size of the facility by $90 million to $340 million. As of December 31, 2017, we had $164.9 million of outstanding borrowings under this facility.evaluate an internalization transaction.

 

See Item 1. Business “– Management Internalization Evaluation,” for additional information.

39

 

Trends Which May Influence our Business andOur Results of Operations

 

We believe the following trends may positively impact our business and results of operations:

 

 ·growingGrowing healthcare expenditures – According to the U.S. Department of Health and Human Services, overall healthcare expenditures are expected to grow at an average rate of 5.6%5.5% per year from 2016 through 2025.2027.  We believe the long-term growth in healthcare expenditures will correlate with the long-term leases at our properties and help maintain or increase the value of our healthcare real estate portfolio;

 ·anAn aging population – accordingAccording to the 2010 U.S. Census, the segment of the population consisting of people 65 years or older comprise the fastest growing segment of the overall U.S. population.  We believe this segment of the U.SU.S. population will utilize many of the services provideprovided at our healthcare facilities such as orthopedics, cardiac, gastroenterology and rehabilitation;
 ·aA continuing shift towards outpatient care – accordingAccording to the American Hospital Association, patients are demanding more outpatient operations.  We believe this shift in patient preference from inpatient to out-patientoutpatient facilities will benefit our tenants as most of our properties consistsconsist of medical office buildings, ambulatory surgery centers and specialty hospitals that provide an alternative to inpatient facilities such as acute-care hospitals;outpatient facilities;
 ·physicianPhysician practice group and hospital consolidation – According to Becker’s Hospital Review, the first half of 2017 saw a significant increase in physician practice group consolidation from the fourth quarter of 2016. We believe the trend towards physician group consolidation will serve to strengthen the credit quality of our tenants if our tenants merge or are consolidated with larger health systems; and
 ·aA highly fragmented healthcare real estate market.market – Despite the move toward consolidation with respect to healthcare services, we believe the healthcare real estate market continues to be highly fragmented, which will provide us with significant acquisition opportunities; and
·Increased supply of attractive acute-care hospital acquisition opportunities –We believe many hospital systems are moving towards investing more in out-patient facilities and divesting acute-care hospitals. Although not the primary focus of our investment strategy, we believe that the current supply and demand forces in the hospital market could provide opportunities to purchase high-quality, acute-care hospitals in desirable markets at attractive, risk-adjusted returns.opportunities.

  

We believe the following trends may negatively impact our business and results of operations:

 

·Increasing Market Volatility.  During 2018, the stock markets experienced extreme volatility. During this period of extreme volatility, the stock of healthcare REITs have struggled, with the FTSE Nareit Equity Healthcare Index dropping approximately 6.32% during the month of January.  If markets continue to experience extreme volatility, or healthcare REIT stocks continue to decline, we could have difficulty raising equity capital at attractive prices or at all, which could inhibit our ability to grow our portfolio;
·Increases in short-term interest rates. During 2018, the market interest rates on which our credit facility interest rate is based has increased.  If this trend continues and we are unable to hedge our interest rate exposure, our interest rate expense will increase, which would negatively affect our results of operations;
·Leverage restrictions.  Pursuant to our revolving credit facility, our consolidated leverage ratio, defined as the ratio of our total debts to total assets, cannot exceed 0.65:1 and our minimum fixed charge coverage ratio, defined as the ratio of Adjusted EBITDA and Fixed Charges, must be at least 1.50:1.  As of December 31, 2017, our total debt was approximately $203.4 million and our total interest expense plus preferred dividends was approximately $9.1 million, and our consolidated leverage  and fixed charge coverage ratios were 0.42 and 2.27, respectively.  Due to our leverage limitations, if we are unable to raise equity capital in sufficient amounts or at all in order to pay down our indebtedness, we will be limited in the amount of properties we may acquire;
·Increasing prices for our core assets.  The heavy pace of acquisitions in our core asset classes in 2017 led to a market-wide decrease in capitalization rates.  If this acquisition pace continues into 2018, we may see further decreases in the capitalization rates of our core asset classes, which will, due to our high cost of capital, make it harder to acquire accretive assets in our core asset class.  If we are unable to make accretive acquisitions in our core asset classes, we may not be able to acquire as many properties as we would like or may be forced to purchase more non-core assets or riskier assets in order to meet our business objectives; and
 ·Changes in third party reimbursement methods and policies. – As the price of healthcare services continues to increase, we believe third-party payors, such as Medicare and commercial insurance companies, will continue to scrutinize and reduce the types of healthcare services eligible for, and the amounts of, reimbursement under their health insurance plans.  Additionally, many employer-based insurance plans have continued to increase the percentage of insurance premiums for which covered individuals are responsible.  If these trends continue, our tenants may experience lower patient volumes as well as higher patient credit risks, which could negatively impact their business as well as their ability to pay rent to us.

 

40

Critical Accounting PoliciesPolicy

 

The preparation of financial statements in conformity with GAAP requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our financial statements. From time-to-time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. For a more detailed discussion of our significant accounting policies,policy, see Note 2 – “Summary of Significant Accounting Policies” in the footnotes to the accompanying financial statements. Below is a discussion of accounting policiespolicy that we consider critical in that theyit may require complex judgment in theirits application or require estimates about matters that are inherently uncertain.

 

40

Use of Estimates

The preparation of the financial statementsInvestment in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Purchase of Real Estate

 

TransactionsThe Company determines when an acquisition meets the definition of a business or alternatively should be accounted for as an asset acquisition in accordance with Accounting Standard Codification (“ASC”) Topic 805 “Business Combinations” (“ASC Topic 805”), which real estaterequires that, when substantially all of the fair value of an acquisition is concentrated in a single identifiable asset or a group of similar identifiable assets, are purchased that arethe asset or group of similar identifiable assets does not subjectmeet the definition of a business and therefore is required to be accounted for as an existing lease are treatedasset acquisition. Transaction costs continue to be capitalized for asset acquisitions and expensed as incurred for business combinations. ASC Topic 805 resulted in all of our post-January 1, 2018 acquisitions being accounted for as asset acquisitions andbecause substantially all of the fair value of the gross assets the Company acquires are recorded at theirconcentrated in a single asset or group of similar identifiable assets. For asset acquisitions that are “owner occupied” (meaning that the seller either is the tenant or controls the tenant), the purchase price, including capitalized acquisition costs, which iswill be allocated to land and building based uponon their relative fair values atwith no value allocated to intangible assets or liabilities. For asset acquisitions where there is a lease in place but not “owner occupied,” we will allocate the date of acquisition. Transactions in which real estatepurchase price to tangible assets are acquired either subject to an existing lease or as part of a portfolio level transaction with significant leasing activity are treated as a business combination under Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, and theany intangible assets acquired andor liabilities assumed including identified intangible assets and liabilities, are recorded atbased on their relative fair value.values. Fair value is determined based upon the guidance of ASC Topic 820, Fair“Fair Value Measurements and Disclosures, and generally are determined using Level 2 inputs, such as rent comparables, sales comparables, and broker indications. Although Level 3 Inputs are utilized, they are minor in comparison to the Level 2 data used for the primary assumptions. The determination of fair value involves the use of significant judgment and estimates. We make estimates to determine the fair value of the tangible and intangible assets acquired and liabilities assumed using information obtained from multiple sources, including pre-acquisition due diligence, and we routinely utilize the assistance of a third-party appraiser. Initial valuations are subject to change until the information is finalized, no later than 12 months from the acquisition date. We expense transaction costs associated with acquisitions accounted for as business combinations in the period incurred.

 

Valuation of tangible assets:

 

The fair value of land is determined using the sales comparison approach whereby recent comparable land sales and listings are gathered and summarized. The available market data is analyzed and compared to the land being valued and adjustments are made for dissimilar characteristics such as market conditions, size, and location. We estimate the fair value of buildings acquired on an as-if-vacant basis and depreciate the building value over its estimated remaining life. Fair value is primarily based on estimated cash flow projections that utilize discount and/or capitalization rates as well as available market information. We determine the fair value of site improvements (non-building improvements that include paving and other) using the cost approach, with a deduction for depreciation, and depreciate the site improvements over their estimated remaining useful lives. Tenant improvements represent fixed improvements to tenant spaces, the fair value of which is estimated using prevailing market tenant improvement allowances that would be given to attract a new tenant, estimated based on the assumption that it is a necessary cost of leasing up a vacant building.allowances. Tenant improvements are amortized over the remaining term of the lease. As of December 31, 2017, we recorded site improvements of $4.8 million and tenant improvement of $8.0 million, resulting from the acquisitions that were accounted for as business combinations.

 

Valuation of intangible assets:

 

In determining the fair value of in-place leases (the avoided cost associated with existing in-place leases) management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes reimbursable (based on market lease terms) real estate taxes, insurance, other operating expenses, as well as estimates of lost market rental revenue during the expected lease-up periods. The values assigned to in-place leases are amortized over the remaining term of the lease. As of December 31, 2017, we recorded in-place lease assets of $17.1 million, resulting from the acquisitions that were accounted for as business combinations.

 

The fair value of above-or-below market leases is estimated based on the present value (using an interest rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. An above market lease is classified as an intangible asset and a below market lease is classified as an intangible liability. The capitalized above-market or below-market lease intangibles are amortized as a reduction of or an addition to rental income over the estimated remaining term of the respective leases. As of December 31, 2017, we recorded above market lease assets of $5.1 million and below market lease liabilities of $1.4 million, resulting from the acquisitions that were accounted for as business combinations.

 


Intangible assets related to leasing costs consist of leasing commissions and legal fees. Leasing commissions are estimated by multiplying the remaining contract rent associated with each lease by a market leasing commission. Legal fees represent legal costs associated with writing, reviewing, and sometimes negotiating various lease terms. Leasing costs are amortized over the remaining useful life of the respective leases. As of December 31, 2017, we recorded leasing cost assets of $9.5 million resulting from the acquisitions that were accounted for as business combinations.

41

Impairment of Long Lived Assets

We evaluate our real estate assets for impairment periodically or whenever events or circumstances indicate that its carrying amount may not be recoverable. If an impairment indicator exists, we compare the expected future undiscounted cash flows against the carrying amount of an asset. If the sum of the estimated undiscounted cash flows is less than the carrying amount of the asset, we would record an impairment loss for the difference between the estimated fair value and the carrying amount of the asset. We determined that no impairment charges were warranted during the years ended December 31, 2017, 2016, and 2015.

Revenue Recognition

Our operations consist of rental revenue earned from tenants under leasing arrangements which provide for minimum rent and escalations. These leases are accounted for as operating leases. For operating leases with contingent rental escalators revenue is recorded based on the contractual cash rental payments due during the period. Revenue from leases with fixed annual rental escalators are recognized on a straight-line basis over the initial lease term, subject to a collectability assessment. If we determine that collectability of rents is not reasonably assured, future revenue recognition is limited to amounts contractually owed and paid, and, when appropriate, an allowance for estimated losses is established.

We consistently assess the need for an allowance for doubtful accounts, including an allowance for operating lease straight-line rent receivables, for estimated losses resulting from tenant defaults, or the inability of tenants to make contractual rent and tenant recovery payments. We also monitor the liquidity and creditworthiness of its tenants and operators on a continuous basis. This evaluation considers industry and economic conditions, property performance, credit enhancements and other factors. For operating lease straight-line rent amounts, our assessment is based on amounts estimated to be recoverable over the term of the lease. As of December 31, 2017 and December 31, 2016, no allowance was recorded as it was not deemed necessary.

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 creates a new Topic, ASC Topic 606, which is principle-based and provides a five-step model to determine when and how revenue is recognized. We will implement this standard effective with the interim period beginning January 1, 2018 and do not expect the standard to have a significant impact on our consolidated financial statements or related disclosures.

Fair Value of Financial Instruments

Fair value is a market-based measurement and should be determined based on the assumptions that market participants would use in pricing an asset or liability. In accordance with ASC Topic 820, the valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels are defined as follows:

• Level 1-Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets;

• Level 2-Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument; and

• Level 3-Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

We consider the carrying values of cash and cash equivalents, escrow deposits, accounts and other receivables, and accounts payable and accrued expenses to approximate the fair value for these financial instruments because of the short period of time since origination or the short period of time between origination of the instruments and their expected realization. Due to the short-term nature of these instruments, Level 1 and Level 2 inputs are utilized to estimate the fair value of these financial instruments. The fair values determined related to the Company’s transactions that are accounted for as business combinations primarily utilize Level 2 inputs since there is heavy reliance on market observable data such as rent comparables, sales comparables, and broker indications. Although some Level 3 inputs are utilized they are minor in comparison to the Level 2 date used for the primary assumptions as it relates to business combination valuations.

42

Stock-Based Compensation

We expense the fair value of LTIP unit awards in accordance with the fair value recognition requirements of ASC Topic 718, Compensation-Stock Compensation, and ASC Topic 505, Equity. Under ASC Topic 718, the Company’s independent directors are deemed to be employees and therefore compensation expense for these units is recognized based on the closing share price for the Company’s common stock at the date of grant, ratably over the 12-month service period, using the straight-line method. Under ASC Topic 505, the employees of the Advisor and its affiliates are deemed to be non-employees of the Company and therefore compensation expense for these units is recognized using the fair value of the award at the end of each reporting period, ratably over the respective service periods, depending on the grant terms, using the straight-line method.

 

Consolidated Results of Operations

 

The major factor that resulted in variances in our results of operations for each revenue and expense category for the year ended December 31, 2017,2019, compared to the year ended December 31, 20162018, was the increase in the size of our property portfolio. Our total investments in real estate, net of accumulated depreciation and amortization, was $457.9$849.0 million and $203.5$616.9 million as of December 31, 20172019 and 2016,2018, respectively.

 

Similarly,For a discussion related to our results of operations for the year ended December 31, 2016,2018 compared to 2015, the major factor that resulted in variancesyear ended December 31, 2017, refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our results of operationsAnnual Report on Form 10-K for each revenue and expense category was our June 2016 initial public offering and the increase in the size of our property portfolio during 2016. Our total investments in real estate, net of accumulated depreciation and amortization, was $203.5 million and $55.1 million as ofyear ended December 31, 2016 and 2015, respectively.2018, which was filed with the SEC on March 11, 2019.

 

Year Ended December 31, 20172019 Compared to Year Ended December 31, 20162018

 

 For the Year Ended December 31,     For the Year Ended December 31,    
 2017  2016  $ Change  2019  2018  $ Change 
Revenue                        
Rental revenue $28,511  $8,080  $20,431  $70,515  $53,138  $17,377 
Expense recoveries  1,712   -   1,712 
Other income  121   131   (10)  211   54   157 
Total revenue  30,344   8,211   22,133   70,726   53,192   17,534 
                        
Expenses                        
Acquisition fees  2,523   1,568   955 
Acquisition fees – related party  -   754   (754)
General and administrative  5,489   4,219   1,270   6,536   5,537   999 
Operating expenses  1,860   73   1,787   5,958   3,720   2,238 
Management fees – related party  3,123   1,434   1,689   6,266   4,422   1,844 
Depreciation expense  7,929   2,335   5,594   19,066   13,644   5,422 
Amortization expense  2,072   42   2,030   5,569   3,625   1,944 
Interest expense  7,435   4,139   3,296   17,472   14,975   2,497 
Preacquisition fees  271   383   (112)
Total expenses  30,431   14,564   15,867   61,138   46,306   14,832 
Net loss $(87) $(6,353) $6,266 
Income before gain from sale of investment property  9,588   6,886   2,702 
Gain on sale of investment property  -   7,675   (7,675)
Net income $9,588  $14,561  $(4,973)

Revenue

 

Total Revenue

 

Total revenue for the year ended December 31, 20172019 was $30.3$70.7 million, compared to $8.2$53.2 million for the same period in 2016,2018, an increase of $22.1$17.5 million. The increase iswas primarily the result of rental revenue earned from the facilities we acquired during 2017,2019, as well as from the recognition of a full year of rental revenue in 20172019 from acquisitions that were completed during 2016.2018. Additionally, $1.7rental revenue for the years ended December 31, 2019 and 2018 included $5.2 million and $3.6 million, respectively, in revenue that was recognized from expense recoveries during the year ended December 31, 2017, which related to tenant reimbursement of real estate taxes, insurance, and certain other operating expenses. We recognize these reimbursements and related expenses on a gross basis in our Consolidated Statements of Operations (i.e., we recognize an equivalent increase in revenue (expense recoveries) and expense (operating expenses)). We did not recognize any revenue from expense recoveries during the year ended December 31, 2016.recoveries.

 

Expenses

 

Acquisition Fees

Acquisition fees to unrelated parties for the year ended December 31, 2017 were $2.5 million, compared to $1.6 million for the same period in 2016, an increase of $0.9 million. These acquisition fees represent costs incurred on our acquisitions that were accounted for as business combinations. The increase results from the fact that in 2017 we had 12 acquisitions that were accounted for as business combinations versus only three during the same period in 2016. As discussed below in the “Acquisition Fees – related party” section, prior to July 1, 2016, the effective date of our amended management agreement (the “Amended Management Agreement”), our acquisition fees were payable to our Advisor.

43

Acquisition Fees – related party

Acquisition fees to a related party for the year ended December 31, 2017 was zero, compared to $0.8 million for the same period in 2016. Related party acquisition fees for the year ended December 31, 2016 consisted of $0.4 million, $0.3 million and $0.1 million that were expensed in connection with the acquisitions of the Plano Facility, the Melbourne Facility, and the Westland Facility, respectively. Pursuant to our original management agreement, the acquisition fees payable to our Advisor were computed at a rate of 2% of the purchase price of the facility.

General and Administrative

 

General and administrative expenses for the year ended December 31, 20172019 were $5.5$6.5 million, compared with $4.2to $5.5 million for the same period in 2016,2018, an increase of $1.3$1.0 million. Non-cash LTIP expenses included in general and administrative expense included $1.8 million in 2017 compared to $1.7 million in 2016. The remaining increase in general and administrative expenseswas primarily relatesrelated to an increase in professional fees incurred during 2017 reflecting a fullnon-cash LTIP compensation expense which was $3.3 million for the year of public company costs as well as Sarbanes-Oxley implementation costs.ended December 31, 2019, compared to $2.7 million for the same period in 2018.


Operating expensesExpenses

 

Operating expenses for the year ended December 31, 20172019 were $1.9$6.0 million, compared with $0.07$3.7 million for the same period in 2016,2018, an increase of $1.8$2.3 million. The increase primarily results from $1.7$5.2 million of reimbursable property operating expenses incurred during the year ended December 31, 2019, compared to $3.6 million for the same period in 20172018, and $0.4 million of expense from properties acquired in 2019 that we paid on behalf of certain of ourinclude tenants but for which we receive reimbursement from the tenant under the applicable lease.with gross leases.

 

Management Fees – related party

 

Management fees for the year ended December 31, 20172019 were $3.1$6.3 million, compared with $1.4$4.4 million for the same period in 2016,2018, an increase of $1.7$1.9 million. TheThis fee is calculated based on our stockholders’ equity balance and the increase results fromin 2019 is the result of our larger stockholders’ equity balance which is usedduring 2019 compared to calculate the fee, resulting fromprior year, reflecting the impact of our common stock and preferred stock issuances that were completed during 2017.2019 and the end of 2018.

 

Depreciation Expense

 

Depreciation expense for the year ended December 31, 20172019 was $7.9$19.1 million, compared with $2.3$13.6 million for the same period in 2016,2018, an increase of $5.6$5.5 million. The increase resultsresulted primarily from depreciation expense incurred on the facilities we acquired during 2017 and2019, as well as from the recognition of a full year of depreciation expense in 2017 related to2019 from acquisitions that were completed during 2016. 2018.

 

Amortization Expense

 

Amortization expense for the year ended December 31, 20172019 was $2.1$5.6 million, compared with $0.04$3.6 million for the same period in 2016,2018, an increase of $2.1$2.0 million. AmortizationThe increase resulted primarily from amortization expense was incurred on the in-place lease and leasing cost intangible assets recognizedrecorded related to the facilities we acquired during 2019, as well as from ourthe recognition of a full year of amortization expense in 2019 from acquisitions that were accounted for as business combinations. For the year ended December 31, 2017 we had 12 acquisitions that were accounted for as business combinations versus only threecompleted during the same period in 2016.2018.

 

Interest Expense

 

Interest expense for the year ended December 31, 20172019 was $7.4$17.5 million, compared with $4.1$15.0 million for the same period in 2016,2018, an increase of $3.3$2.5 million. This increase iswas primarily due to higher average borrowings during the year reflecting interest incurred onended December 31, 2019 compared to the outstanding borrowings fromsame period last year, the proceeds of which were used to finance our revolving credit facility as well as amortization of the deferred financing costs incurred to procure debt, which is recorded as interest expense.property acquisitions during that time period.

 

The weighted average interest rate of our debt for the year ended December 31, 2019 was 4.24%. Additionally, the weighted average interest rate and term of our debt was 3.72%3.90% and 2.943.76 years, respectively, at December 31, 2017,2019.

Preacquisition Fees

Preacquisition fees for the year ended December 31, 2019 were $0.3 million, compared to 4.29% and 6.04$0.4 million for the same period in 2018, a decrease of $0.1 million. Preacquisition fees for both the years respectively, atended December 31, 2016.2019 and 2018 represent costs associated with acquisitions that the Company did not, or does not expect to, complete and therefore were expensed.

Income Before Gain on Sale of Investment Property

 

Income before gain on sale of investment property for the year ended December 31, 2019 was $9.6 million, compared to $6.9 million for the same period in 2018, an increase of $2.7 million. The increase resulted primarily from an increase in rental revenue over the current year partially offset by the increase in expenses for 2019.

Gain on Sale of Investment Property

The Company had no property dispositions during the year ended December 31, 2019. During the year ended December 31, 2018, the Company disposed of the Great Bend Regional Hospital receiving gross proceeds of $32.5 million and resulting in a gain of $7.7 million.

Net LossIncome

 

Net lossincome for the year ended December 31, 20172019 was $0.09$9.6 million, compared with $6.4to $14.6 million for the same period in 2016,2018, a decrease in net loss of $6.3$5.0 million. The decrease in net lossresults from the $7.7 million gain on sale of the investment property that was primarilyrecorded during 2018, partially offset by the result of an increase in rental revenue earned from the facilities we acquired during 2017, as well as from the recognition of a full year of rental revenue in 2017 from acquisitions that were completed during 2016.

44

Year Ended December 31, 2016 Compared to Year Ended December 31, 2015

  For the Year Ended December 31,    
  2016  2015  $ Change 
Revenue            
Rental revenue $8,080  $2,049  $6,031 
Other income  131   13   118 
Total revenue  8,211   2,062   6,149 
             
Expenses            
Acquisition fees  1,568   -   1,568 
Acquisition fees – related party  754   627   127 
General and administrative  4,219   425   3,794 
Operating expenses  73   80   (7)
Management fees – related party  1,434   360   1,074 
Depreciation expense  2,335   660   1,675 
Amortization expense  42   -   42 
Interest expense  4,139   1,519   2,620 
Total expenses  14,564   3,671   10,893 
Net loss $(6,353) $(1,609) $(4,744)

Revenue

Total Revenue

Total revenue for the year ended December 31, 2016 was $8.2 million, compared to $2.1 million for the same period in 2015, an increase of$6.1 million.The increase is primarily the result of rental revenue derived from the facilities that we acquired during the year ended December 31, 2016, as well as from the recognition of a full year of rental revenue relating to acquisitions that occurred during 2015.

Expenses

Acquisition Fees

Acquisition fees to unrelated parties forthe year ended December 31, 2016 were $1.6 million, compared to zero for the same period in 2015. These acquisition fees during the year ended December 31, 2016 were primarily related to three acquisitions that were accounted for as business combinations. As discussed below in the “Acquisition Fees – related party” section, prior to July 1, 2016, the effective date of our Amended Management Agreement, our acquisition fees were payable to our Advisor.

Acquisition Fees – related party

Acquisition fees – related party forthe year ended December 31, 2016 were $0.8 million, compared to $0.6 millionfor the year ended December 31, 2015, an increase of $0.2 million. The 2016 expense included acquisition fees that were incurred and paid to our Advisor in accordance with the management agreement that was in place through June 30, 2016 (consisting of $0.4 million, $0.3 million and $0.1 million in connection with the acquisitions of the Plano, Melbourne, and Westland facilities, respectively) compared to $0.6 million of acquisition fees that were incurred and paid to our Advisor in the 2015 (consisting of $0.4 million and $0.2 million in connection with the acquisitions of the Tennessee and West Mifflin facilities, respectively). Pursuant to our original management agreement, the acquisition fees payable to our Advisor were computed at a rate of 2% of the purchase price of the facility.

General and Administrative

General and administrative expenses for the year ended December 31, 2016 were$4.2 million, compared to $0.4 million for the same period in 2015, an increase of$3.8 million.The increase primarily results from an increase of $1.7 million in non-cash compensation expense incurred related to the LTIP units during the year ended December 31, 2016 as well as from an increase in costs incurred during the same year related to Sarbanes-Oxley implementation and public company related costs such as capital market advisory and investor relations.

45

Operating expenses

Operating expenses for the year ended December 31, 2016 was $0.07 million, compared with $0.08 million for the same period in 2015, a decrease of $0.01 million. The decrease is primarily related to a decrease in ground rent expense recorded during the 2016 fiscal year.

Management Fees – related party

Management fees forthe year ended December 31, 2016 were $1.4 million, compared to $0.4 million for the same period in 2015, an increase of$1.0 million. The increase during the year ended December 31, 2016 was due primarily to the larger stockholders’ equity balance due to our initial public offering during 2016 as well as changes in the fee calculation as follows. The management fee for the period beginning on July 1, 2016 and ending on December 31, 2016 was calculated based on the terms of the Amended Management Agreement,2019, which became effective on July 1, 2016 and requires an annual base management fee equal to 1.5% of our stockholders’ equity balance (as defined in the Amended Management Agreement). The management fee for the period beginning on January 1, 2016 through June 30, 2016 and for the year ended December 31, 2015 was based on the terms of the original management agreement with a fixed fee of $0.03 million per month.

Depreciation Expense

Depreciation expenseforthe year ended December 31, 2016 was $2.3 million, compared to $0.7 millionfor the same period in 2015, an increase of $1.6 million. The increase results from depreciation expense incurred on the facilities acquired during the year ended December 31, 2016 and the recognition of depreciation expense for a full year related to acquisitions completed during the year ended December 31, 2015.

Amortization Expense

Amortization expense for the year ended December 31, 2016 was$0.04 million, compared to zero for the same period in 2015. Amortization expense was incurred on the in-place lease and leasing cost intangible assets recognized from our three acquisitions during 2016 that were accounted for as business combinations. We had no acquisitions that were accounted for as business combinations during the year ended December 31, 2015.

Interest Expense

Interest expenseforthe year ended December 31, 2016 was $4.1 million, compared to $1.5 millionfor the same period in 2015, an increase of $2.6 million. The increase results from increased borrowing in 2016 compared to 2015, including interest incurred on the Cantor Loan that was procured during the first quarter of 2016, a full year of interest expense incurred on third party debt and related party borrowings used to acquire facilities in 2015, the early termination fee of $0.3 million that was incurred related to the early pay-off of the Omaha facility debt, the amortization of debt issuance costs (recorded as interest expense) primarily incurred on the Cantor Loan, and full year of amortization of debt issuance costs that were incurred in connection with our West Mifflin and Tennessee acquisitions late in 2015.

The weighted average interest rate and term of our debt was 4.29% and 6.04 years, respectively, at December 31, 2016. The weighted average interest rate and term of our debt was 6.67% and 4.06 years, respectively, at December 31, 2015.

Net Loss

Net loss for the year ended December 31, 2016 was $6.4 million, compared with $1.6 million for the same period in 2015, an increase of $4.8 million. The increase in net loss was primarily the result of acquisition fees to unrelated parties incurred on our business combination transactions, an increase in non-cash compensation expense incurred related to LTIP units during the year ended December 31, 2016 as well as from an increase in costs incurred during the same year related to Sarbanes-Oxley implementation and public company related costs such as capital market advisory and investor relations. Additionally, during 2016 there was an increase in management fees incurred based on the terms of the Amended Management Agreement and an increase in depreciation expense resulting from the growth of our portfolio of properties during 2016. This increase in expenses was partially offset by anthe increase in rental revenue earned from the facilities we acquiredexpenses during the 2016, as well as from the recognition of a full year of rental revenue in 2016 from acquisitions that were completed during 2015.2019.

 


Assets and Liabilities

 

As of December 31, 20172019 and December 31, 2016,2018, our principal assets consisted of investments in real estate, net, of $457.9$849.0 million and $203.5$616.9 million, respectively, and our liquid assets consisted primarily of cash and cash equivalents and restricted cash of $5.1$7.2 million and $19.7$4.8 million, respectively.

46

 

The increase in our investments in real estate, net, to $457.9$849.0 million as of December 31, 2017,2019 compared to $203.5$616.9 million as of December 31, 2016,2018, was the result of the 2318 acquisitions that we completed during the year ended December 31, 2017.2019.

 

The decreaseincrease in our cash and cash equivalents and restricted cash balance to $5.1$7.2 million as of December 31, 2017,2019, compared to $19.7$4.8 million as of December 31, 2016,2018, was primarily due to $252.7net proceeds from our common stock offerings of $189.5 million, net borrowings from our Credit Facility in the amount of $71.1 million, and cash provided by our operating activities, partially offset by $255.0 million of cash used for the acquisitions that we completed during 2017, approximately $16the year ended December 31, 2019, $34.9 million of dividends paid during 2017, $2.9the year, and $1.0 million of cash paid for deferred financingdebt issuance costs during 2017the year related to the revolving credit facility, and approximately $0.5 million used to repay related party debt. These decreases in cash during 2017 were partially offset by net borrowings from the revolving credit facility in the amount of $137.2 million, net proceeds received from our common stock offering of $33.8 million, net proceeds received from our preferred stock offering of approximately $75 million, and an increase in cash provided by operating activities of $11.6 million.  Credit Facility.

 

The increase in our total liabilities to $215.6$424.6 million as of December 31, 20172019, compared to $72.3$336.3 million as of December 31, 2016,2018, was primarily the result of net borrowings from the revolving credit facilityour Credit Facility in the amount of $137.2$71.1 million as well as from increases in the derivative liability balance, the dividends payable balance, the security deposit liability balance, and the accounts payable and accrued expenses balance, the dividends payable balance, and the acquired lease intangible liability balance.

 

Liquidity and Capital Resources

 

General

 

Our short-term liquidity requirements include:

 

 ·Interest expense and scheduled principal payments on outstanding indebtedness;indebtedness, which includes near term (under one year) debt maturities of $7.2 million;
 ·General and administrative expenses;
 ·Operating expenses;
·Management fees; and
 ·Property acquisitions and tenant improvements.; and
·If we consummate an internalization transaction in 2020, the costs of such internalization transaction.

  

In addition, we require funds for future distributions expected to be paid to our common and preferred stockholders and OP and LTIP unitUnit holders in our Operating Partnership.

 

As of December 31, 2017,2019, we had $5.1$7.2 million of cash and alsocash equivalents and restricted cash and had borrowing capacity under our revolving credit facility as described below.Credit Facility of approximately $149 million. Our primary sources of cash include rent and reimbursements we collect from our tenants, borrowings under our revolving credit facility,Credit Facility, secured term loans and net proceeds received from equity issuances.

 

On September 15, 2017, we closed on an underwritten publicThe following table summarizes our equity issuances during 2019 (shares and dollars in thousands):

Date Offering Type 

Number of

Shares/Units Issued

  

Public Offering

Price

  Net Proceeds(2) 
March 2019 Underwritten Public Offering  8,233  $9.75  $76,255 
December 2019 Underwritten Public Offering  6,900  $13.00  $85,664 
Full Year 2019 ATM Offerings  2,632  $11.24(1) $29,073 
January 2019 OP Unit Issuance  49  $10.30  $506 
Total/Weighted Average    17,814  $11.23  $191,498 

(1)Represents the average offering of 3.1 million shares of our Series A Preferred Stock, $0.001 par value per share, with a liquidation preference of $25 per share, inclusive of 0.4 million shares issued in connection withprice for multiple issuances.

(2)Includes underwriters’ commissions but excludes offering expenses paid directly by the underwriters’ exercise of their over-allotment option. The issuance raised aggregate net proceeds of approximately $75 million. We used the proceeds from this transaction primarily to repay borrowings on our revolving credit facility.Company.


  

On August 25, 2017,September 30, 2019, the Company and the Operating Partnership entered into separate Sales Agreementsan amendment to its Credit Facility that, among other things, (i) increased the borrowings under the term-loan component (the “Sales Agreements”“Term Loan”) with eachfrom $175 million to $300 million, representing the exercise of Cantor Fitzgerald & Co.the remaining $75 million accordion feature and FBR Capital Markets & Co.a re-allocation of $50 million from the revolver component (the “Agents”“Revolver”), pursuant to whichthe Term Loan and (ii) added a new $150 million accordion feature. Upon execution of the first amendment to the Company’s Credit Facility, the Credit Facility consisted of a $200 million capacity Revolver, a $300 million Term Loan and a $150 million accordion. The term of the Company’s Credit Facility expires in August 2022, subject to a one-year extension option that the Company may issue and sell, from time to time, its common shares having an aggregate offering price of up to $50 million, through the Agents (the “ATM Program”). In accordance with the Sales Agreements, the Company may offer and sell its common shares through either of the Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the New York Stock Exchange or other existing trading market, sales made to or through a market maker, sales made through negotiated transactions or any other method permitted by law.controls. As of December 31, 2017, we2019, the Company had not made any salesoutstanding borrowings of our common shares through$347.5 million under the ATM Program.Credit Facility, net.

 

On June 30, 2017, we closed an underwritten public offering of our common stock and on July 20, 2017 we closed on the over-allotment option granted to the underwriters. These transactions resulted in an aggregate of 4 million shares of our common stock being issued at a public offering price of $9.00 per share, resulting in aggregate net proceeds of approximately $33.8 million. We used the proceeds from this transaction primarily to repay borrowings on our revolving credit facility.

On March 3, 2017, the Company, the Operating Partnership, as borrower, and the subsidiary guarantors of the Operating Partnership amended our revolving credit facility (the “Revolving Credit Facility”) with BMO Harris Bank N.A., as Administrative Agent, which increased the commitment amount to $200 million plus an accordion feature that allows for up to an additional $50 million of principal amountare subject to certain conditions. On September 28, 2017, certain of the Company’s lenders under the Revolving Credit Facility committed to fund all of the $50 million accordion feature. The subsidiary guarantors and the Company are guarantors of the obligations under the Revolving Credit Facility. The amount available to borrow from time to time under the Revolving Credit Facility is limited according to a quarterly borrowing base valuation of certain properties owned by the subsidiary guarantors. Our Operating Partnership is subject to ongoing compliance with a number of customary affirmative and negativefinancial covenants under the Revolvingour Credit Facility, including, limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales. The Operating Partnership must also maintainamong other things, (i) a maximum consolidated leverage ratio and as of the end of each fiscal quarter thereafter, of less than (y) 0.65:1.00 for each fiscal quarter ending prior to October 1, 2019 and (z) thereafter, 0.60:1.00, (ii) a minimum fixed charge coverage ratio of 1.50:1.00, (iii) a minimum net worth of $119,781$203.8 million plus 75% of all net proceeds raised through subsequent equity offerings subsequent to March 31, 2018 (which, as of December 31, 2019, equaled $247.6 million, for a total minimum net worth requirement as of December 31, 2019 of $389.1 million) and (iv) a ratio of total secured recourse debt to total asset value of not greater than 0.10:1.00. Additionally, beginning at the end of fourth quarter of 2020, our distributions to common stockholders will be limited to an amount equal to 95% of our AFFO. As of December 31, 2017 and 2016,2019, we were in compliance with all of the outstanding Revolvingfinancial covenants contained in the Credit Facility balance was $164.9 million and $27.7 million, respectively.Facility.

47

 

On March 6, 2018, we amendedOctober 3, 2019, the RevolvingCompany hedged its interest rate risk on the Term Loan by entering into two interest rate swaps with an aggregate notional amount of $130 million and a term of approximately five years, which effectively fixed the LIBOR component of the interest rate on a corresponding amount of the Term Loan at 1.21%. As of October 3, 2019, in total the Company had entered into five interest rate swaps with three counterparties to hedge the LIBOR component of its interest rate risk related to the Term Loan. Together, these swaps fix the LIBOR component of the entire $300 million Term Loan on a weighted average basis at 2.17%. An aggregate of $200 million of the swaps mature in August 2024 and an additional $100 million matures in August 2023.

In July 2017, the FCA that regulates LIBOR announced its intention to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the ARRC which identified the SOFR as its preferred alternative to USD-LIBOR in derivatives and other financial contracts. The Credit Facility provides that, on or about the LIBOR cessation date (subject to increasean early opt-in election), LIBOR shall be replaced as a benchmark rate in the aggregate size ofCredit Facility with a new benchmark rate to be agreed upon by the facility by $90 millionCompany and BMO Harris Bank N.A. (“BMO”), with such adjustments to $340 million.cause the new benchmark rate to be economically equivalent to LIBOR. We are not able to predict when LIBOR will cease to be available or when there will be enough liquidity in the SOFR markets.

 

With the exception ofExcept for funds required to make additional property acquisitions, we believe we will be able to satisfy our short-term liquidity requirements through our existing cash and cash equivalents and cash flow from operating activities. In order to continue acquiring healthcare properties, we will need to continue to have access to debt and equity financing.financing or have the ability to issue OP Units.

 

Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, recurringcapital and non-recurring capital expenditures,tenant improvements at our properties, scheduled debt maturities, general and administrative expenses, operating expenses, management fees, distributions, and dividends.the cost of internalization. We expect to satisfy our long-term liquidity needs through cash flow from operations, long-term secured and unsecured borrowings,debt financing, sales of additional equity securities, and, in connection with acquisitions of additional properties, the issuance of OP Units, and proceeds from select property dispositions and joint venture transactions. We currently do not expect to sell any of our properties to meet our liquidity needs, although we may do so in the future.

See “—Trends Which May Influence our Business and Results of Operations” for a discussion of the trends affecting our ability to incur debt and equity financing on a cost-effective basis or at all.

 

Cash Flow Information

 

Year Ended December 31, 20172019 Compared to Year Ended December 31, 20162018

 

Net cash provided by operating activities for the year ended December 31, 20172019 was $11.6$36.4 million, compared with net cash used inprovided by operating activities of $2.7$24.8 million for the same period in 2016. This2018. The increase in cash flows from operating activities was primarily derived fromdue to the increase in the size of our property portfolio at December 31, 20172019 compared to December 31, 2016.2018 and the resulting increase in our rental revenue.

 

Net cash used in investing activities for the year ended December 31, 20172019 was $252.7$258.2 million, compared with $150.4$151.6 million, for the same period in 2016. This2018. The increase was primarily the result of increasedmore real estate investment activity in 2017, specifically funds used for2019 compared to the 23 acquisitions that we completed during the year ended December 31, 2017. Cash flowssame period in 2018. Additionally, 2018 net cash used in investing activities are heavily dependent uponincludes net proceeds received from the sale of an investment in properties and real estate assets.property.

 

Net cash provided by financing activities for the year ended December 31, 20172019 was $226.5$224.1 million, compared with $163.6$124.5 million for the same period in 2016. Cash flows provided by financing activities for2018. The increase during 2019 compared to 2018 was primarily due to the year ended December 31, 2017 were derived primarily fromhigher net proceeds received from the Revolving Credit Facility, net proceeds received from our common stock offering, and net proceedsofferings received from our preferred stock offering,in 2019, partially offset by the payment oflower net draws on our Credit Facility in 2019 and higher dividends and deferred financing costs.

Year Ended December 31, 2016 Compared to Year Ended December 31, 2015

Net cash used in operating activities for the year ended December 31, 2016 was $2.7 million, compared with $0.2 million used in operating activities for the year ended December 31, 2015. The increasepaid during the 2016 year was primarily derived from increases in net loss, $1.4 million in management fees paid to the Advisor, and increases in operating assets. The net cash used in operating activities was partially offset by increases in non-cash expenses such as depreciation expense, amortization of debt issuance costs, and LTIP compensation expense.

Net cash used in investing activities for the year ended December 31, 2016 was $150.4 million, compared with $32.3 million used in investing activities for the year ended December 31, 2015. The increase during the 2016 year was primarily derived from the completed acquisitions of ten facilities during 2016. Cash flows used in investing activities are heavily dependent upon the investment in properties and real estate assets.2019.

 

48

45

 

 

Net cash provided by financing activities for the year ended December 31, 2016 was $163.6 million compared with $41.6 million provided by financing activities for the year ended December 31, 2015. The increase during the 2016 year was primarily derived from the net proceeds received from the initial public offering of $137.3 million, proceeds received from the revolving credit facility that was entered into and December 2016, and proceeds of $32.1 million received from the Cantor Loan. These financing cash inflows were partially offset by the full repayment of the Omaha and Asheville third party debt, a partial payment of the remaining Convertible Debenture balance, and payments of dividends, deferred debt issuance costs, and deferred public offering costs.

Common Stock Dividends

Since July 2016, our Board had declared cash dividends on our common stock as summarized in the following table.

Date Announced Record Date Applicable
Quarter
 Payment Date Dividend
Amount(1)
  Dividends
per Share
 
             
September 14, 2016 September 27, 2016 Q3 2016 October 11, 2016 $3,593  $0.20 
December 14, 2016 December 27, 2016 Q4 2016 January 10, 2017 $3,604  $0.20 
March 20, 2017 March 27, 2017 Q1 2017 April 10, 2017 $3,603  $0.20 
June 16, 2017 June 27, 2017 Q2 2017 July 10, 2017 $3,608  $0.20 
September 8, 2017 September 26, 2017 Q3 2017 October 9, 2017 $4,416  $0.20 
December 15, 2017 December 26, 2017 Q4 2017 January 10, 2018 $4,552  $0.20 

(1) Includes dividends on granted LTIP units and OP Units issued to third parties.

During the year ended December 31, 2017, we paid total dividends on our common stock, LTIP units and OP Units in the amount of $15.2 million, consisting of the dividends declared for the fourth quarter of 2016 through the third quarter of 2017. Additionally, during the year ended December 31, 2016, we paid total dividends in the amount of $3.9 million.

The amount of the dividends paid to our stockholders is determined by our Board and is dependent on a number of factors, including funds available for payment of dividends, our financial condition and capital expenditure requirements except that, in accordance with our organizational documents and Maryland law, we may not make dividend distributions that would: (i) cause us to be unable to pay our debts as they become due in the usual course of business; (ii) cause our total assets to be less than the sum of our total liabilities plus senior liquidation preferences; or (iii) jeopardize our ability to maintain our qualification as a REIT. See “Risk Factors—Subject to certain requirements under Maryland law and REIT requirements, our board of directors has sole discretion to determine if we will pay distributions and the amount and frequency of such distributions, and past distribution amounts may not be indicative of future distribution amounts.”

Preferred Stock Dividends

The holders of the Company’s Series A Preferred Stock will be entitled to receive dividend payments only when, as and if declared by the Board (or a duly authorized committee of the Board). Any such dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date. Additionally, the terms specify that dividends will be payable at a fixed rate per annum equal to 7.50% of the liquidation preference of $25 per share (equivalent to $1.875 per share on an annual basis). Dividends on the Series A Preferred Stock will be cumulative and will accrue whether or not funds are legally available for the payment of those dividends, whether or not the Company has earnings and whether or not those dividends are authorized.

The quarterly dividend payment dates on the Series A Preferred Stock are January 31, April 30, July 31 and October 31 of each year, commencing on October 31, 2017. During the year ended December 31, 2017 we paid dividends of $0.7 million on our preferred stock.

Non-GAAP Financial Measures

 

Funds from operations (“FFO”), Adjusted and adjusted funds from operations (“AFFO”), and Normalized AFFO are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO AFFO, and Normalized AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts’ (“NAREIT”) definition, FFO means net income or loss computed in accordance with GAAP before non-controllingnoncontrolling interests of holders of operating partnership unitsOP Units and LTIP units,Units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate relatedestate-related depreciation and amortization (excluding amortization of deferred financing costs)costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. The Company did not incur any gains or losses from the sales of property or record any adjustments for unconsolidated partnerships and joint ventures during the years ended December 31, 20172019, 2018, and 2016.2017. Because FFO excludes real estate relatedestate-related depreciation and amortization (other than amortization of deferred financing costs)costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

49

 

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company’s operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of deferred financing costs, recurring capital expenditures, recurring lease commissions, recurring tenant improvements, an advisory fee settled with the issuance of OP Units, and other items.

Management calculates Normalized AFFO, which is also a non-GAAP financial measure, by modifying AFFO by adjusting for non-recurring income and expenses. For the Company this item includes the costs of establishing a system of Sarbanes-Oxley compliant internal controls and procedures. During the second and third quarters of 2017, Normalized AFFO included the portion of our General Counsel and Secretary’s salary for 2017 that is reimbursable by the Company to the Advisor. During the fourth quarter of 2017, the Company learned that the Advisor may request that such reimbursement arrangement be extended; therefore, until the terms of such potential extension are finalized, the Company is removing such expense from Normalized AFFO.

 

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis. Management also considers Normalized AFFO to be a useful measure to evaluate the Company’s operating results excluding non-recurring income and expenses. Normalized AFFO can help investors compare the operating performance of the Company between periods or as compared to other companies. The Company’s FFO AFFO, and Normalized AFFO computations may not be comparable to FFO AFFO, and Normalized AFFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, that interpret the NAREIT definition differently than the Company does, or that compute FFO AFFO, and Normalized AFFO in a different manner.

 

A reconciliation of FFO AFFO, and Normalized AFFO for the years ended December 31, 2017, 2016,2019, 2018, and 20152017 is as follows:

 

  Year Ended December 31, 
  2017  2016  2015 
  (unaudited, in thousands except per share) 
       
Net loss $(87) $(6,353) $(1,609)
Less: Preferred stock dividends  (1,714)  -   - 
Depreciation and amortization expense  10,001   2,377   660 
Amortization of above market leases  129   (1)  - 
FFO $8,329  $(3,977) $(949)
Acquisition costs  2,523   2,322   627 
Straight line deferred rental revenue  (3,137)  (681)  (23)
Stock-based compensation expense  1,796   1,685   - 
Amortization of deferred financing costs  1,224   350   127 
Non-cash advisory fee  232   -   - 
AFFO $10,967  $(301) $(218)
Professional fees and services related to Sarbanes-Oxley implementation  430   73   - 
Normalized AFFO $11,397  $(228) $(218)
             
Net loss attributable to common stockholders per share – basic and diluted $(0.09) $(0.68) $(6.44)
FFO per Share $0.41  $(0.43) $(3.80)
AFFO per Share $0.54  $(0.03) $(0.87)
Normalized AFFO per Share $0.56  $(0.02) $(0.87)
             
Weighted Average Shares and Units Outstanding – basic and diluted  20,242   9,302   250 

  Year Ended December 31, 
  2019  2018  2017 
  (unaudited, in thousands except per share and unit amounts) 
Net income (loss) $9,588  $14,561  $(87)
Less: Preferred stock dividends  (5,822)  (5,822)  (1,714)
Depreciation and amortization expense  24,635   17,269   10,001 
Gain on sale of investment property  -   (7,675)  - 
FFO $28,401  $18,333  $8,200 
Amortization of above market leases, net(1)  881   688   129 
Straight line deferred rental revenue  (5,806)  (5,316)  (3,137)
Stock-based compensation expense  3,336   2,671   1,796 
Amortization of debt issuance costs and other  1,312   1,640   1,224 
Preacquisition fees  271   383   2,523 
Non-cash advisory fee  -   -   232 
AFFO $28,395  $18,399  $10,967 
             
Net income (loss) attributable to common stockholders per share – basic and diluted $0.10  $0.35  $(0.09)
FFO per share and unit $0.75  $0.76  $0.41 
AFFO per share and unit $0.75  $0.76  $0.54 
             
Weighted Average Shares and Units Outstanding – basic and diluted  37,789   24,261   20,242 

 

50

Reconciliation of Weighted Average Shares and Units Outstanding:         
          
Weighted Average Shares of Common Stock  33,865   21,971   19,617 
Weighted Average OP Units  3,144   1,704   204 
Weighted Average LTIP Units  780   586   421 
Weighted Average Shares and Units Outstanding – basic and diluted  37,789   24,261   20,242 

 

Reconciliation(1)The Company adopted the 2018 NAREIT FFO White Paper Restatement during the first quarter of Weighted Average Shares2019. Accordingly, amortization of above and Units Outstanding:below market leases is no longer included as a reconciling item in determining FFO.

Weighted Average Common Shares  19,617   9,302   250 
Weighted Average OP Units  204   -   - 
Weighted Average LTIP Units  421   -   - 
Weighted Average Shares and Units Outstanding – basic and diluted  20,242   9,302   250 

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

 

Contractual Obligations

 

We are a party to a management agreement with our Advisor. Pursuant to that agreement, our Advisor is entitled to receive a base management fee and an incentive fee and, in certain circumstances, a termination fee. Such fees and expenses do not have fixed and determinable payments. For a description of the management agreement provisions, see “Business—Our Advisor and our Management Agreement.”

 

The following table summarizes our material contractual payment obligations and commitments as of December 31, 2017:2019:

 

    Payments Due By Period     Payments Due By Period 
 Total  Less than 1
Year
  2019-2020  2021-2022  Thereafter  Total  Less than 1 Year  2021-2022  2023-2024  Thereafter 
Principal – fixed rate debt, gross $39,475  $22  $7,356  $764  $31,333  $339,317  $7,219  $729  $300,963  $30,406 
Principal – variable rate debt  164,900   -   164,900   -   -   51,350   -   -   51,350   - 
Interest – fixed rate debt  14,630   1,977   3,899   3,364   5,390   40,513   13,415   14,826   10,152   2,120 
Interest – variable rate debt  11,019   5,746   5,273   -   -   4,664   1,797   1,792   1,075   - 
Ground and other operating leases  2,202   78   164   164   1,796   4,944   116   232   245   4,351 
Total $232,226  $7,823  $181,592  $4,292  $38,519  $440,788  $22,547  $17,579  $363,785  $36,877 

 

As of December 31, 2017,2019, the Company had tenant improvement allowances of approximately $10 million. These tenant improvement allowances are$18 million, subject to contingencies that make it difficult to predict when such allowances will be utilized, if at all.

 

Inflation

 

Historically, inflation has had a minimal impact on the operating performance of our healthcare facilities. Many of our triple-net lease agreements contain provisions designed to mitigate the adverse impact of inflation. These provisions include clauses that enable us to receive payment of increased rent pursuant to escalation clauses which generally increase rental rates during the terms of the leases. These escalation clauses often provide for fixed rent increases or indexed escalations (based upon the consumer price indexCPI or other measures). However, some of these contractual rent increases may be less than the actual rate of inflation. Most of our triple-net lease agreements require the tenant-operator to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes and insurance. This requirement reduces our exposure to increases in these costs and operating expenses resulting from inflation.

 

51


 

ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. In pursuing our business and investment objectives, we expect that the primary market risk to which we will be exposed is interest rate risk.

 

We may be exposed to the effects of interest rate changes primarily as a result of debt used to acquire healthcare facilities, including borrowings under the restated credit facility.Credit Facility. The analysis below presents the sensitivity of the market value of our financial instruments to selected changes in market interest rates. The range of changes chosen reflects our view of changes which are reasonably possible over a one-year period.

 

As of December 31, 2017,2019, we had $164.9$51.4 million of unhedged borrowings outstanding under the Revolving Credit Facility, whichRevolver (before the netting of unamortized deferred financing costs) that bears interest at a variable rate, and $38.5 million outstanding, net of unamortized debt discount of $1 million on our third party debt.rate. See the “Liquidity and Capital Resources” section of our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sectionOperation — Liquidity and Capital Resources” for a detailed discussion of our Revolving Credit Facility. At December 31, 2017,2019, LIBOR on our outstanding floating-rate borrowings was 1.44%1.84%. Assuming no increase in the amount of our variable interest rate debt, if LIBOR increased 100 basis points, our cash flow would decrease by approximately $1.7$0.5 million annually. Assuming no increase in the amount of our variable rate debt, if LIBOR were reduced 100 basis points, our cash flow would increase by approximately $1.7$0.5 million annually.

As of December 31, 2018, we had $110.3 million outstanding under the Revolver (before the netting of unamortized deferred financing costs and excluding the Term Loan) that bears interest at a variable rate (before netting of unamortized deferred financing costs). See the “Management’s Discussion and Analysis of Financial Condition and Results of Operation —Liquidity and Capital Resources” for a detailed discussion of our Credit Facility. At December 31, 2018, LIBOR on our outstanding floating rate borrowings was 2.42%. Assuming no increase in the amount of our variable interest rate debt, if LIBOR increased 100 basis points, our cash flow would decrease by approximately $1.1 million annually. Assuming no increase in the amount of our variable rate debt, if LIBOR were reduced 100 basis points, our cash flow would increase by approximately $1.1 million annually.

Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings and cash flows and to lower overall borrowing costs. To achieve our objectives, we may borrow at fixed rates or variable rates. As of October 3, 2019, in total we had entered into five interest rate swaps with three counterparties to hedge the LIBOR component of our interest rate risk related to the Term Loan. Together, these swaps fix the LIBOR component of the entire $300 million Term Loan on a weighted average basis at 2.17%. See Note 4 – “Credit Facility, Notes Payable and Derivative Instruments” for further detail on our interest rate swaps. We also may enter into additional derivative financial instruments, such asincluding interest rate swaps and caps, in order to mitigate our interest rate risk on a related financial instrument.our future borrowings. We will not enter into derivative transactions for speculative purposes.

 

In addition to changes in interest rates, the value of our future investments is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants/operators and borrowers, which may affect our ability to refinance our debt if necessary.

 

52

ITEM 8.CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

ReportReports of Independent Registered Public Accounting FirmFirms5450
  
Consolidated Balance Sheets as of December 31, 20172019 and 201620185652
  
Consolidated Statements of Operations for the years ended December 31, 2017, 2016,2019, 2018, and 201520175753
  
Consolidated Statements of Stockholders’Comprehensive Income (Loss) for the years ended December 31, 2019, 2018, and 201754
Consolidated Statements of Equity for the years ended December 31, 2017, 2016,2019, 2018, and 201520175855
  
Consolidated Statements of Cash Flows for the years ended December 31, 2017, 2016,2019, 2018, and 201520175956
  
Notes to Consolidated Financial Statements6057

 

53


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of

Global Medical REIT Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Global Medical REIT Inc. and subsidiaries (the "Company") as of December 31, 2019, the related consolidated statements of operations, comprehensive loss, equity, and cash flows for the year ended December 31, 2019, and the related notes and the schedule listed in the Index at Item 15(a)(2) (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019, and the results of its operations and its cash flows for the year ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 9, 2020, expressed an unqualified opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ Deloitte & Touche LLP

McLean, VA

March 9, 2020

We have served as the Company's auditor since 2019.


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and Board of Directors of

Global Medical REIT Inc.

 

OpinionsOpinion on the Financial Statements and Internal Control Over Financial Reporting

 

We have audited the accompanyingconsolidated balance sheetssheet of Global Medical REIT Inc. and its subsidiaries (collectively, the “Company”) as of December 31, 2017 and 2016,2018, and the related consolidated statements of operations, stockholders’comprehensive income (loss), equity, and cash flows for each of the years in the three-yeartwo-year period ended December 31, 2017,2018, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the “consolidated financial“financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016,2018, and the results of their operations and their cash flows for each of the years in the three-yeartwo-year period ended December 31, 2017,2018, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control—Integrated Framework (2013) issued by COSO.

 

Basis for OpinionsOpinion

The Company’s management is responsible for these consolidatedThese financial statements for maintaining effective internal control over financial reporting, and for its assessmentare the responsibility of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control Over Financial Reporting.Company’s management. Our responsibility is to express opinions on the Company’s consolidated financial statements and an opinion on the Company’s internal control over financial reportingstatements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the auditsaudit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

fraud. Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respondsrespond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.opinion.

 

Definition and Limitations of Internal Control Over Financial Reporting/s/ MaloneBailey, LLP

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the consolidated financial statements.

54

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ MaloneBailey, LLP
www.malonebailey.com
Houston, Texas
March 12, 2018

We have served as the Company's auditor since 2011.

Houston, Texas

55

March 11, 2019

 


GLOBAL MEDICAL REIT INC.

Consolidated Balance Sheets

(in thousands, except par values)

 

 As of December 31,  As of December 31, 
 2017  2016  2019  2018 
Assets             
Investment in real estate:                
Land $42,701  $17,786  $95,381  $63,710 
Building  384,338   179,253   693,533   518,451 
Site improvements  4,808   1,465   9,912   6,880 
Tenant improvements  8,010   1,186   33,909   15,357 
Acquired lease intangible assets  31,650   7,187   72,794   43,152 
  471,507   206,877   905,529   647,550 
Less: accumulated depreciation and amortization  (13,594)  (3,367)  (56,503)  (30,625)
Investment in real estate, net  457,913   203,510   849,026   616,925 
Cash and cash equivalents  5,109   19,671   2,765   3,631 
Restricted cash  2,005   941   4,420   1,212 
Tenant receivables  704   212   4,957   2,905 
Due from related parties  50   - 
Escrow deposits  1,638   1,212   3,417   1,752 
Deferred assets  3,993   705   14,512   9,352 
Deferred financing costs, net  2,750   927 
Derivative asset  2,194   - 
Other assets  459   141   3,593   322 
Total assets $474,571  $227,319  $884,934  $636,099 
        
Liabilities and Stockholders’ Equity        
Liabilities and Equity        
Liabilities:                
Revolving credit facility $164,900  $27,700 
Notes payable, net of unamortized discount of $930 and $1,062 at December 31, 2017 and 2016, respectively  38,545   38,413 
Notes payable to related parties  -   421 
Credit Facility, net of unamortized debt issuance costs of $3,832 and $3,922 at December 31, 2019 and 2018, respectively $347,518  $276,353 
Notes payable, net of unamortized debt issuance costs of $667 and $799 at December 31, 2019 and 2018, respectively  38,650   38,654 
Accounts payable and accrued expenses  2,020   574   5,069   3,664 
Dividends payable  5,638   3,604   11,091   6,981 
Security deposits and other  2,128   720   6,351   4,152 
Due to related parties, net  1,036   581 
Due to related party  1,648   1,030 
Derivative liability  8,685   3,487 
Other liability  2,405   - 
Acquired lease intangible liability, net  1,291   278   3,164   2,028 
Total liabilities  215,558   72,291   424,581   336,349 
Stockholders' equity:        
Preferred stock, $0.001 par value, 10,000 shares authorized; 3,105 and no shares issued and outstanding at December 31, 2017 and 2016, respectively (liquidation preference of $77,625 and $0, respectively)  74,959   - 
Common stock, $0.001 par value, 500,000 shares authorized; 21,631 shares and 17,606 shares issued and outstanding at December 31, 2017 and 2016, respectively  22   18 
Commitments and Contingencies        
Equity:        
Preferred stock, $0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at December 31, 2019 and 2018, respectively (liquidation preference of $77,625 at December 31, 2019 and 2018, respectively)  74,959   74,959 
Common stock, $0.001 par value, 500,000 shares authorized; 43,806 shares and 25,944 shares issued and outstanding at December 31, 2019 and 2018, respectively  44   26 
Additional paid-in capital  205,788   171,997   433,330   243,038 
Accumulated deficit  (34,434)  (16,987)  (71,389)  (45,007)
Accumulated other comprehensive loss  (6,674)  (3,721)
Total Global Medical REIT Inc. stockholders' equity  246,335   155,028   430,270   269,295 
Noncontrolling interest  12,678   -   30,083   30,455 
Total equity  259,013   155,028   460,353   299,750 
Total liabilities and stockholders' equity $474,571  $227,319 
Total liabilities and equity $884,934  $636,099 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

56

GLOBAL MEDICAL REIT INC.

Consolidated Statements of Operations

(in thousands, except per share amounts)

 

 Year Ended December 31, 
 2017  2016  2015  Year Ended December 31, 
        2019  2018  2017 
Revenue                        
Rental revenue $28,511  $8,080  $2,049  $70,515  $53,138  $30,223 
Expense recoveries  1,712   -   - 
Other income  121   131   13   211   54   121 
Total revenue  30,344   8,211   2,062   70,726   53,192   30,344 
                        
Expenses                        
Acquisition fees  2,523   1,568   - 
Acquisition fees – related party  -   754   627 
General and administrative  5,489   4,219   425   6,536   5,537   5,489 
Operating expenses  1,860   73   80   5,958   3,720   1,860 
Management fees – related party  3,123   1,434   360   6,266   4,422   3,123 
Depreciation expense  7,929   2,335   660   19,066   13,644   7,929 
Amortization expense  2,072   42   -   5,569   3,625   2,072 
Interest expense  7,435   4,139   1,519   17,472   14,975   7,435 
Preacquisition fees  271   383   2,523 
Total expenses  30,431   14,564   3,671   61,138   46,306   30,431 
                        
Net loss $(87) $(6,353) $(1,609)
Income (loss) before gain on sale of investment property  9,588   6,886   (87)
Gain on sale of investment property  -   7,675   - 
            
Net income (loss) $9,588  $14,561  $(87)
Less: Preferred stock dividends  (1,714)  -   -   (5,822)  (5,822)  (1,714)
Less: Net loss attributable to noncontrolling interest  49   -   - 
Net loss attributable to common stockholders $(1,752) $(6,353) $(1,609)
Less: Net (income) loss attributable to noncontrolling interest  (354)  (1,071)  49 
Net income (loss) attributable to common stockholders $3,412  $7,668  $(1,752)
                        
Net loss attributable to common stockholders per share – basic and diluted $(0.09) $(0.68) $(6.44)
Net income (loss) attributable to common stockholders per share – basic and diluted $0.10  $0.35  $(0.09)
                        
Weighted average shares outstanding – basic and diluted  19,617   9,302   250   33,865   21,971   19,617 

The accompanying notes are an integral part of these consolidated financial statements.

53

GLOBAL MEDICAL REIT INC.

Consolidated Statements of Comprehensive Income (Loss)

(in thousands)

  Year Ended December 31, 
  2019  2018  2017 
Net income (loss) $9,588  $14,561  $(87)
Other comprehensive loss:            
Decrease in fair value of interest rate swap agreements, net  (2,953)  (3,721)  - 
Total other comprehensive loss  (2,953)  (3,721)  - 
Comprehensive income (loss)  6,635   10,840   (87)
Less: Preferred stock dividends  (5,822)  (5,822)  (1,714)
Less: Comprehensive (income) loss attributable to noncontrolling interest  (74)  (625)  49 
Comprehensive income (loss) attributable to common stockholders $739  $4,393  $(1,752)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

57

GLOBAL MEDICAL REIT INC.

Consolidated Statements of Stockholders’ Equity

(in thousands)

 

  Common Stock  Preferred Stock               
  Shares  

$
Amount

  Shares  

$

Amount

  

Additional
Paid-in

Capital

  

Accumulated

Deficit

  

GMR

Equity

  

Non-

controlling
Interest

  

Total

Equity

 
Balances, December 31, 2014  250  $-   -  $-  $3,012  $(1,286) $1,726  $-  $1,726 
                                     
Net loss  -   -   -   -   -   (1,609)  (1,609)  -   (1,609)
                                     
Dividends to stockholders  -   -   -   -   -   (256)  (256)  -   (256)
Balances, December 31, 2015  250   -   -   -   3,012   (3,151)  (139)  -   (139)
                                     
Net loss  -   -   -   -   -   (6,353)  (6,353)  -   (6,353)
                                     
Issuance of initial public offering shares of common stock  15,000   15   -   -   138,954   -   138,969   -   138,969 
                                     
Reclassification of deferred initial public offering costs  -   -   -   -   (1,681)  -   (1,681)  -   (1,681)
                                     
Conversion of convertible debenture due to related party to shares of common stock  2,356   3   -   -   30,027   -   30,030   -   30,030 
                                     
Stock-based compensation expense  -   -   -   -   1,685   -   1,685   -   1,685 
                                     
Dividends to stockholders  -   -   -   -   -   (7,483)  (7,483)  -   (7,483)
Balances, December 31, 2016  17,606   18   -   -   171,997   (16,987)  155,028   -   155,028 
                                     
Net loss  -   -   -   -   -   (38)  (38)  (49)  (87)
                                     
Issuance of shares of common stock  4,025   4   -   -   34,234   -   34,238   -   34,238 
                                     
Reclassification of deferred common stock offering costs  -   -   -   -   (443)  -   (443)  -   (443)
                                     
Stock-based compensation expense  -   -   -   -   -   -   -   1,796   1,796 
                                     
Issuance of shares of preferred stock  -   -   3,105   75,180   -   -   75,180   -   75,180 
                                     
Reclassification of deferred preferred stock offering costs  -   -   -   (221)  -   -   (221)  -   (221)
                                     
Dividends to common stockholders  -   -   -   -   -   (15,695)  (15,695)  -   (15,695)
                                     
Dividends to preferred stockholders  -   -   -   -   -   (1,714)  (1,714)  -   (1,714)
                                     
Dividends to noncontrolling interest  -   -   -   -   -   -   -   (601)  (601)
                                     
OP Units issued to third parties  -   -   -   -   -   -   -   11,532   11,532 
Balances, December 31, 2017  21,631  $22   3,105  $74,959  $205,788  $(34,434) $246,335  $12,678  $259,013 

  Common Stock  Preferred Stock  

Additional

    Accumulated
Other
  Global
Medical
REIT Inc.
  Non-    
  Shares  Amount  Shares  Amount  Paid-in
Capital
  Accumulated

Deficit

  Comprehensive
Loss
  Stockholders’
Equity
  controlling
Interest
  Total
Equity
 
Balances, January 1, 2017  17,606  $18  $-  $-  $171,997  $(16,987) $-  $155,028  $-  $155,028 
Net loss  -   -   -   -   -   (38)  -   (38)  (49)  (87)
Issuance of shares of common stock  4,025   4   -   -   34,234   -   -   34,238   -   34,238 
Reclassification of deferred common stock offering costs  -   -   -   -   (443)  -   -   (443)  -   (443)
Stock-based compensation expense  -   -   -   -   -   -   -   -   1,796   1,796 
Issuance of shares of preferred stock  -   -   3,105   75,180   -   -   -   75,180   -   75,180 
Reclassification of deferred preferred stock offering costs  -   -   -   (221)  -   -   -   (221)  -   (221)
Dividends to common stockholders ($0.80 per share)  -   -   -   -   -   (15,695)  -   (15,695)  -   (15,695)
Dividends to preferred stockholders ($0.552 per share)  -   -   -   -   -   (1,714)  -   (1,714)  -   (1,714)
Dividends to noncontrolling interest  -   -   -   -   -   -   -   -   (601)  (601)
OP Units issued to third parties  -   -   -   -   -   -   -   -   11,532   11,532 
Balances, December 31, 2017  21,631   22   3,105   74,959   205,788   (34,434)  -   246,335   12,678   259,013 
Net income  -   -   -   -   -   13,490   -   13,490   1,071   14,561 
Issuance of shares of common stock  4,313   4   -   -   37,823   -   -   37,827   -   37,827 
Reclassification of deferred common stock offering costs  -   -   -   -   (573)  -   -   (573)  -   (573)
Change in fair value of interest rate swap agreements          -   -   -   -   (3,721)  (3,721)  -   (3,721)
Stock-based compensation expense          -   -   -               2,671   2,671 
Dividends to common stockholders ($0.80 per share)          -   -   -   (18,241)  -   (18,241)  -   (18,241)
Dividends to preferred stockholders ($1.875 per share)          -   -   -   (5,822)  -   (5,822)  -   (5,822)
Dividends to noncontrolling interest  -   -   --   -   -   -   -   -   (2,065)  (2,065)
OP Units issued to third parties          -   -   -   -   -   -   16,363   16,363 
LTIP Units redeemed in cash  -   -   -   -   -   -   -   -   (263)  (263)
Balances, December 31, 2018  25,944   26   3,105   74,959   243,038   (45,007)  (3,721)  269,295   30,455   299,750 
Net income  -   -   -   -   -   9,234   -   9,234   354   9,588 
Issuance of shares of common stock, net  17,765   18   -   -   189,211   -   -   189,229   -   189,229 
LTIP Units and OP Units redeemed for common stock  97   -   -   -   1,081   -   -   1,081   (1,081)  - 
Change in fair value of interest rate swap agreements  -   -   -   -   -   -   (2,953)  (2,953)  -   (2,953)
Stock-based compensation expense  -   -   -   -   -   -   -   -   3,336   3,336 
Dividends to common stockholders ($0.80 per share)  -   -   -   -   -   (29,794)  -   (29,794)  -   (29,794)
Dividends to preferred stockholders ($1.875 per share)  -   -   -   -   -   (5,822)  -   (5,822)  -   (5,822)
Dividends to noncontrolling interest  -   -   -   -   -   -   -   -   (3,487)  (3,487)
OP Units issued to third parties  -   -   -   -   -   -   -   -   506   506 
Balances, December 31, 2019  43,806  $44   3,105  $74,959 ��$433,330  $(71,389) $(6,674) $430,270  $30,083  $460,353 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

58

GLOBAL MEDICAL REIT INC.

Consolidated Statements of Cash Flows

(in thousands)

 

 Year Ended December 31,  Year Ended December 31, 
 2017  2016  2015  2019  2018  2017 
Operating activities                        
Net loss $(87) $(6,353) $(1,609)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:            
Net income (loss) $9,588  $14,561  $(87)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:            
Depreciation expense  7,929   2,335   660   19,066   13,644   7,929 
Amortization of acquired lease intangible assets  2,072   42   -   5,569   3,625   2,072 
Amortization of above (below) market leases, net  129   (1)  - 
Amortization of deferred financing costs  1,224   350   127 
Amortization of above market leases, net  881   688   129 
Amortization of debt issuance costs and other  1,312   1,640   1,224 
Stock-based compensation expense  1,796   1,685   -   3,336   2,671   1,796 
Capitalized deal costs charged to expense  19   -   - 
Capitalized preacquisition costs charged to expense  231   110   19 
Noncash lease expense  111   -   - 
Advisory expense settled in OP Units  232   -   -   -   -   232 
Gain on sale of investment property  -   (7,675)  - 
Other  105   -   - 
Changes in operating assets and liabilities:                        
Restricted cash  (993)  (558)  - 
Tenant receivables  (492)  (212)  3   (2,142)  (2,201)  (492)
Deferred assets  (3,288)  (681)  (94)  (5,160)  (5,811)  (3,288)
Other assets  (144)  -   -   (110)  (40)  (144)
Accounts payable and accrued expenses  1,355   (40)  344   857   1,519   1,355 
Security deposits and other  1,408   719   -   2,199   2,024   1,408 
Accrued management fees due to related party  443   (9)  360   584   79   443 
Net cash provided by (used in) operating activities  11,603   (2,723)  (209)
Net cash provided by operating activities  36,427   24,834   12,596 
                        
Investing activities                        
Purchase of land, buildings, and other tangible and intangible assets and liabilities  (252,220)  (150,459)  (31,764)  (254,985)  (180,837)  (252,220)
Net proceeds from sale of investment property  -   31,629   - 
Escrow deposits for purchase of properties  (352)  104   (439)  (1,372)  174   (352)
Loans repayments from (made to) related party  21   138   (136)
Pre-acquisition costs for purchase of properties  (102)  (141)  - 
Loans (made to) repayments received from related parties  (16)  (85)  21 
Capital expenditures on existing real estate investments  (1,824)  (2,535)  - 
Preacquisition costs  -   36   (102)
Net cash used in investing activities  (252,653)  (150,358)  (32,339)  (258,197)  (151,618)  (252,653)
                        
Financing activities                        
Net proceeds received from common equity offerings  189,498   37,307   33,795 
Net proceeds received from preferred stock offering  74,959   -   -   -   -   74,959 
Net proceeds received from common equity offerings  33,795   137,288   - 
Change in restricted cash  (71)  64   (251)
Escrow deposits required by third party lenders  (74)  (862)  -   (293)  (288)  (74)
Loans (repaid to) from related party  (9)  (395)  292 
(Repayment of) proceeds from convertible debenture, due to related party  -   (10,000)  34,584 
Proceeds from notes payable from acquisitions  -   41,321   7,378 
Repayment of notes payable from acquisitions  -   (25,634)  (349)
Proceeds from note payable from related party  -   1,950   383 
Repayment of notes payable  (136)  (22)  - 
Repayment of note payable from related party  (421)  (1,950)  -   -   -   (421)
Proceeds from revolving credit facility, net  137,200   27,700   - 
Payments of deferred financing costs  (2,915)  (2,036)  (138)
Proceeds from Credit Facility  244,250   186,100   244,200 
Repayment of Credit Facility  (173,175)  (70,725)  (107,000)
Payments of debt issuance costs  (1,039)  (2,811)  (2,915)
Redemption of LTIP Units  -   (263)  - 
Loans repaid to related party  -   -   (9)
Dividends paid to common stockholders, and OP Unit and LTIP Unit holders  (15,231)  (3,878)  (256)  (29,171)  (18,964)  (15,231)
Dividends paid to preferred stockholders  (745)  -   -   (5,822)  (5,821)  (745)
Net cash provided by financing activities  226,488   163,568   41,643   224,112   124,513   226,559 
Net (decrease) increase in cash and cash equivalents  (14,562)  10,487   9,095 
Cash and cash equivalents—beginning of period  19,671   9,184   89 
Cash and cash equivalents—end of period $5,109  $19,671  $9,184 
Net increase (decrease) in cash and cash equivalents and restricted cash  2,342   (2,271)  (13,498)
Cash and cash equivalents and restricted cash—beginning of period  4,843   7,114   20,612 
Cash and cash equivalents and restricted cash—end of period $7,185  $4,843  $7,114 
Supplemental cash flow information:                        
Cash payments for interest $5,746  $4,099  $1,165  $16,282  $13,077  $5,746 
Noncash financing and investing activities:                        
Accrued dividends payable $5,638  $3,604  $-  $11,091  $6,981  $5,638 
Conversion of convertible debenture due to majority stockholder to common stock $-  $30,030  $- 
Initial recognition of lease liability related to right of use asset $3,143  $-  $- 
OP Units issued primarily for property acquisitions $506  $16,362  $11,300 
Interest rate swap agreements fair value change recognized in other comprehensive loss $2,953  $3,721  $- 
Accrued common stock offering costs $269  $-  $- 
Reclassification of common stock offering costs to additional paid-in capital $443  $1,681  $-  $-  $573  $443 
Reclassification of preferred stock offering costs to preferred stock balance $221  $-  $-  $-  $-  $221 
OP Units issued for noncash transaction $11,300  $-  $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

59

56

 

 

GLOBAL MEDICAL REIT INC.

Notes to Consolidated Financial Statements

(In thousands, except per share amounts)

 

Note 1 – Organization

 

Background

 

Global Medical REIT Inc. (the “Company”) is a Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of thesethose facilities to strong clinical operatorshealthcare systems and physician groups with leading market share. The Company is externally managed and advised by Inter-American Management LLC (the “Advisor”), a Delaware limited liability company and affiliate of the Company. ZH International HoldingsZensun Enterprises Limited, (formerly known as Heng Fai Enterprises, Ltd.) a Hong Kong limited liability company that is engaged in real estate development, investments, hospitality management and investments, and REIT management, is an 85% owner of the Advisor and the Company’s President, Chief Executive Officer and Chairman, Mr. Jeffrey Busch, owns the remaining 15% interest.

 

The Company holds its facilities and conducts its operations through a Delaware limited partnership subsidiary named Global Medical REIT L.P. (the “Operating Partnership”). The Company serves as the sole general partner of the Operating Partnership through a wholly-owned subsidiary of the Company named Global Medical REIT GP LLC, (the “GP”), a Delaware limited liability company. As of December 31, 2017,2019, the Company was the 93.63%91.82% limited partner of the Operating Partnership, with an aggregate of 6.37%8.18% of the Operating Partnership owned by holders of long-term incentive plan units (“LTIP”LTIP Units”) units and third-party holders oflimited partners who contributed properties or services to the Operating Partnership Unitsin exchange for common limited partnership units (“OP Units”). The Operating Partnership holds the Company’s healthcare facilities through separate wholly-owned Delaware limited liability company subsidiaries that were formed for each healthcare facility acquisition. The Company’s common stock is listed on the New York Stock Exchange under the ticker symbol “GMRE.��

The Company elected to be taxed as a REIT for U.S. federal income tax purposes commencing with its taxable year ended December 31, 2016.Company’s Series A Preferred Stock is listed on the New York Stock Exchange under the ticker symbol “GMRE PrA.”

 

Note 2 – Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company, including the Operating Partnership and its wholly-owned subsidiaries. The Company presents the portion of any equity it does not own but controls (and thus consolidates) as noncontrolling interest. Noncontrolling interest in the Company includes the LTIP unitsUnits that have been granted to directors, employeesofficers and affiliates of the Company and the OP Units held by third parties. Refer to Note 5 – “Stockholders’ Equity”“Equity” and Note 7 – “Stock-Based Compensation” and for additional information regarding the OP Units and LTIP units.Units.

 

The Company classifies noncontrolling interest as a component of consolidated equity on its Consolidated Balance Sheets, separate from the Company’s total stockholders’ equity. The Company’s net income or loss is allocated to noncontrolling interests based on the respective ownership or voting percentage in the Operating Partnership associated with such noncontrolling interests and is removed from consolidated income or loss on the Consolidated Statements of Operations in order to derive net income or loss attributable to common stockholders. The noncontrolling ownership percentage is calculated by dividing the aggregate number of LTIP unitsUnits and OP Units held by the total number of units and shares outstanding. Any future issuances of additional LTIP unitsUnits or OP Units would change the noncontrolling ownership interest.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Actual results could differ from those estimates.

 

Revenue Recognition

 

The Company’s operations currentlyprimarily consist mainly of rental revenue earned from tenants under leasing arrangements which provide for minimum rent and escalations. The leases have been accounted for as operating leases. For operating leases with contingent rental escalators, revenue is recorded based on the contractual cash rental payments due during the period. Revenue from leases with fixed annual rental escalators are recognized on a straight-line basis over the initial lease term, subject to a collectability assessment, with the difference between the contractual rental receipts and the straight-line amounts recorded as a “deferred rent receivable.” Additionally, the Company recognizes “expense recoveries” revenue, which represents revenue recognized related to tenant reimbursement of real estate taxes, insurance, and certain other operating expenses. The Company recognizes these reimbursements and related expenses on a gross basis in its Consolidated Statements of Operations, i.e., the Company recognizes an equivalent increase in revenue (“expense recoveries”) and expense (“operating expenses”).

 

60

57

 

The Company consistently assesses the need for an allowance for doubtful accounts, including an allowance for operating lease straight-line rent receivables, for estimated losses resulting from tenant defaults, or the inability of tenants to make contractual rent and tenant recovery payments. The Company also monitors the liquidity and creditworthiness of its tenants and operators on a continuous basis. This evaluation considers industry and economic conditions, property performance, credit enhancements and other factors. For operating lease straight-line rent amounts, the Company's assessment is based on amounts estimated to be recoverable over the term of the lease. As of December 31, 2017 and 2016 no allowance was recorded as one was not deemed necessary.

 

Purchase ofInvestment in Real Estate

TransactionsThe Company determines when an acquisition meets the definition of a business or alternatively should be accounted for as an asset acquisition in accordance with Accounting Standard Codification (“ASC”) Topic 805 “Business Combinations” (“ASC Topic 805”), which real estaterequires that, when substantially all of the fair value of an acquisition is concentrated in a single identifiable asset or a group of similar identifiable assets, the asset or group of similar identifiable assets does not meet the definition of a business and therefore is required to be accounted for as an asset acquisition. Transaction costs continue to be capitalized for asset acquisitions and expensed as incurred for business combinations. ASC Topic 805 resulted in all of our post-January 1, 2018 acquisitions being accounted for as asset acquisitions because substantially all of the fair value of the gross assets the Company acquires are purchasedconcentrated in a single asset or group of similar identifiable assets.

For asset acquisitions that are “owner occupied” (meaning that the seller either is the tenant or otherwise not subject to an existing lease are treated as asset acquisitions and recorded at theircontrols the tenant), the purchase price, including capitalized acquisition costs, which iswill be allocated to land and building based uponon their relative fair values atwith no value allocated to intangible assets or liabilities. For asset acquisitions where there is a lease in place but not “owner occupied,” the date of acquisition. Transactions in which real estateCompany will allocate the purchase price to tangible assets are acquired with an existing lease or as part of a portfolio level transaction with significant leasing activity are treated as a business combination under Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, and theany intangible assets acquired andor liabilities assumed including identified intangible assets and liabilities, are recorded atbased on their relative fair value.values. Fair value is determined based upon the guidance of ASC Topic 820, Fair“Fair Value Measurements and Disclosures, andgenerally are determined using Level 2 inputs, such as rent comparables, sales comparables, and broker indications. Although Level 3 Inputs are utilized, they are minor in comparison to the Level 2 data used for the primary assumptions.assumptions. The determination of fair value involves the use of significant judgment and estimates. The Company makesWe make estimates to determine the fair value of the tangible and intangible assets acquired and liabilities assumed using information obtained from multiple sources, including pre-acquisition due diligence, and the Companywe routinely utilize the assistance of a third-party appraiser. Initial valuations are subject to change until the information is finalized, no later than 12 months from the acquisition date. The Company expenses transaction costs associated with acquisitions accounted for as business combinations in the period incurred.

Valuation of tangible assets in business combination:assets:

 

The fair value of land is determined using the sales comparison approach whereby recent comparable land sales and listings are gathered and summarized. The available market data is analyzed and compared to the land being valued and adjustments are made for dissimilar characteristics such as market conditions, size, and location. The Company estimates the fair value of buildings acquired on an as-if-vacant basis and depreciatedepreciates the building value over its estimated remaining life. Fair value is primarily based on estimated cash flow projections that utilize discount and/or capitalization rates as well as available market information. The Company determines the fair value of site improvements (non-building improvements that include paving and other) using the cost approach, with a deduction for depreciation, and depreciatedepreciates the site improvements over their estimated remaining useful lives. Tenant improvements represent fixed improvements to tenant spaces, the fair value of which is estimated using prevailing market tenant improvement allowances that would be given to attract a new tenant, estimated based on the assumption that it is a necessary cost of leasing up a vacant building.allowances. Tenant improvements are amortized over the remaining term of the lease.

 

Valuation of intangible assets in business combination:assets:

 

In determining the fair value of in-place leases (the avoided cost associated with existing in-place leases) management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes reimbursable (based on market lease terms) real estate taxes, insurance, other operating expenses, as well as estimates of lost market rental revenue during the expected lease-up periods. The values assigned to in-place leases are amortized over the remaining term of the lease.

 

The fair value of above-or-below market leases is estimated based on the present value (using an interest rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. An above market lease is classified as an intangible asset and a below market lease is classified as an intangible liability. The capitalized above-market or below-market lease intangible isintangibles are amortized as a reduction of, rental revenue and the below-market lease intangible is amortized asor an addition to, rental revenueincome over the estimated remaining term of the respective leases.

 

Intangible assets related to leasing costs consist of leasing commissions and legal fees. Leasing commissions are estimated by multiplying the remaining contract rent associated with each lease by a market leasing commission. Legal fees represent legal costs associated with writing, reviewing, and sometimes negotiating various lease terms. Leasing costs are amortized over the remaining useful life of the respective leases.

 

61

Assets Held for Sale

The Company may sell properties from time to time for various reasons, including favorable market conditions. Assets, primarily consisting of real estate, are classified as held for sale when all the necessary criteria are met. The criteria include (i) management, having the authority to approve action, commits to a plan to sell the property in its present condition, (ii) the sale of the property is at a price reasonable in relation to its current fair value and (iii) the sale is probable and expected to be completed within one year. Real estate held for sale is carried at the lower of carrying amounts or estimated fair value less disposal costs. Depreciation and amortization is not recognized on real estate classified as held for sale.

 


Impairment of Long LivedLong-Lived Assets

 

The Company evaluates its real estate assets for impairment periodicallyat each reporting date or whenever events or circumstances indicate that its carrying amount may not be recoverable. If an impairment indicator exists, the Company compares the expected future undiscounted cash flows against the carrying amount of the asset. If the sum of the estimated undiscounted cash flows is less than the carrying amount of the asset, the Company would record an impairment loss for the difference between the estimated fair value and the carrying amount of the asset.

 

Cash and Cash Equivalents and Restricted Cash

 

The Company considers all demand deposits, cashier’s checks, money market accounts, and certificates of depositsdeposit with aan original maturity of three months or less to be cash equivalents. The Company maintains its cash and cash equivalents and escrow deposits at financial institutions. The combined account balances may exceed the Federal Depository Insurance Corporation insurance coverage, and, as a result, there may be a concentration of credit risk related to amounts on deposit. The Company does not believe that this risk is significant.

Restricted Cash

TheAmounts included in restricted cash balance as of December 31, 2017 and 2016 was $2,005 and $941, respectively. The restricted cash balance as of December 31, 2017 consisted of $454 of cash required by a third-party lender to be held by the Company as a reserve for debt service and $1,620 inrepresent (1) certain security deposits received from facility tenants at the inception of their leases, net of $69 in funds the Company paid for specific tenant expenses, such as real estate taxes and insurance, on the tenant’s behalf. The restrictedleases; (2) cash balance as of December 31, 2016 consisted of $383 of cash required to be held by a third-party lender to be held by the Company as a reserve for debt service, a security deposit of $320,service; and $238 in(3) funds held by the Company that were received from certain of its tenants that the Company collected to pay specific tenant expenses, such as real estate taxes and insurance.insurance, on the tenant’s behalf (“tenant reimbursements”). The following table provides a reconciliation of the Company’s cash and cash equivalents and restricted cash that sums to the total of those amounts at the end of the periods presented on the Company’s accompanying Consolidated Statements of Cash Flows for the years ended December 31, 2019 and 2018:

 

  2019  2018 
Cash and cash equivalents $2,765  $3,631 
Restricted cash  4,420   1,212 
Total cash and cash equivalents and restricted cash $7,185  $4,843 

Tenant Receivables

 

The tenant receivable balance as of December 31, 20172019 and 20162018 was $704$4,957 and $212,$2,905, respectively. The balance as of December 31, 20172019 consisted of $125$1,428 in funds owed from the Company’s tenants for rent that the Company had earned but had not yet received, and $579$2,342 of tenant reimbursements, as well as $125 in funds owed by certainmiscellaneous receivables included in the tenant receivables balance. Additionally, the balance as of December 31, 2019 included a $1,062 receivable for loans that were made to two of the Company’s tenants for amounts the Company collects to pay specific tenant expenses, such as real estate taxes and insurance, on the tenants’ behalf.tenants. The balance as of December 31, 20162018 consisted primarily of $51$783 in funds owed from the Company’s tenants for rent that the Company had earned but had not yet received, and $161 in funds owed by certain$1,062 of tenant reimbursements. Additionally, the balance as of December 31, 2018 included a $1,000 receivable for a loan that was made to one of the Company’s tenants. Additionally, there are $60 in miscellaneous receivables included in the tenant receivables balance. The collection of all tenant receivable amounts was deemed probable at December 31, 2019.

The Company assesses the likelihood of losses resulting from tenant defaults, or the inability of tenants for amountsto make contractual rent and tenant recovery payments at each reporting date. The Company also monitors the liquidity and creditworthiness of its tenants and operators on a continuous basis. Based on its consideration of these factors the Company collectsconcluded that collection of its receivables was probable.  However, because future events may adversely affect its tenants and operations, an allowance for doubtful accounts may need to pay specificbe established in the future or if the likelihood of a tenant expenses, such as real estate taxespaying its lease payments is determined to no longer be probable all tenant receivables including deferred rent would need to be written off against revenue and insurance, on the tenants’ behalf.any future revenue for that tenant would be recognized only upon receipt of cash.

 

Escrow Deposits

 

The escrow balance as of December 31, 2019 and 2018 was $3,417 and $1,752, respectively. Escrow deposits include funds held in escrow to be used for the acquisition of properties in the future and for the payment of taxes, insurance, and other amounts as stipulated by the Company’s Cantor Loan, as hereinafter defined. The escrow balance as of December 31, 2017 and 2016 was $1,638 and $1,212, respectively.

 

Deferred Assets

 

The deferred assets balance as of December 31, 20172019 and 20162018 was $3,993$14,512 and $705,$9,352, respectively. The balance as of December 31, 20172019 consisted of $3,842$14,204 in deferred rent receivables resulting from the recognition of revenue from leases with fixed annual rental escalations on a straight-line basis and the balance$308 of $151 represented other deferred costs. The balance as of December 31, 2016 balance of $7052018 consisted of $8,706 in deferred rent receivables.receivables resulting from the recognition of revenue from leases with fixed annual rental escalations on a straight-line basis and $646 of other deferred costs.


 

Other Assets

 

Other assets primarily consists of capitalized costs related to the Company’s property acquisitions. Costs that are incurred prior to the completion of the acquisition of a property are capitalized if all of the following conditions are met: (a) the costs are directly identifiable with the specific property, (b) the costs would be capitalized if the property were already acquired, and (c) acquisition of the property is probable. These costs are included with the value of the acquired property upon completion of the acquisition. The costs are charged to expense when it is probable that the acquisition will not be completed. The other assets balance was $459 as of December 31, 2017, which2019 and 2018 was $3,593 and $322, respectively. The balance as of December 31, 2019 consisted of $316$3,077 for a right of use asset that was recorded in connection with the implementation of ASC Topic 842 on January 1, 2019 (refer to Note 8 – “Leases” for additional details), $223 in capitalized preacquisition costs, related to property acquisitions and $143$293 in a prepaid asset. The balance as of December 31, 2016 was $141, and2018 consisted solely of $139 in capitalized costs related to property acquisitions.acquisitions and $183 in a prepaid asset.

62

 

Security Deposits and Other

 

The security deposits and other liability balance as of December 31, 20172019 and 20162018 was $2,128$6,351 and $720,$4,152, respectively. The balance as of December 31, 20172019 consisted of security deposits of $1,620$4,968 and a tenant impound liability of $508$1,383 related to amounts owed for specific tenant expenses, such as real estate taxes and insurance. The balance as of December 31, 20162018 consisted of security deposits of $320$3,272 and a tenant impound liability of $400$880 related to amounts owed for specific tenant expenses, such as real estate taxes and insurance.

 

Derivative Instruments - Interest Rate Swaps

As of December 31, 2019 and 2018, the Company’s net liability balance related to interest rate swap derivative instruments that were designated as cash flow hedges of interest rate risk was $6,491 and $3,487, respectively. In accordance with the Company’s risk management strategy, the purpose of the interest rate swaps is to manage interest rate risk for certain of the Company’s variable-rate debt. The interest rate swaps involve the Company’s receipt of variable-rate amounts from three counterparties in exchange for the Company making fixed-rate payments over the life of the agreement. The Company accounts for derivative instruments in accordance with the provisions of ASC Topic 815, “Derivatives and Hedging.” Refer to Note 4 – “Credit Facility, Notes Payable and Derivative Instruments” for additional details.

Net LossIncome (Loss) Attributable to Common Stockholders Per Share

 

The Company uses the treasury stock method to compute diluted net income or loss attributable to common stockholders per share. Basic net income or loss per share of common stock is computed by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income or loss per share of common stock is computed by dividing net income or loss attributable to common stockholders by the sum of the weighted average number of shares of common stock outstanding plus any potential dilutive shares for the period. As of December 31, 2017, 267 LTIP units had vested, none of which were converted into OP units, and there were 1,246 outstanding OP Units held by third parties. As of December 31, 2016, 137 LTIP units had vested, none of which were converted into OP Units and there were no outstanding OPLTIP Units held by third parties. The effectare not reflected in the diluted per share calculation because the exchange of the conversion of the vested LTIP units into OP Units and the conversion of OPLTIP Units into common stock is not reflected in the computation of basic and diluted earnings per share, as all units are exchangeable for common stock on a one-for-one basis, and both are anti-dilutiveallocated net income on a per share basis equal to the Company’scommon stock. Accordingly, any exchange would not have any effect on diluted net loss for the years ended December 31, 2017 and 2016. The Company had no LTIP units or OP Units during the year ended December 31, 2015.income (loss) available to common stockholders per share. The Company considered the requirements of the two-class method when computing earnings per share and determined that there would be no difference in its reported results if the two-classthat method was utilized.

 

Debt Issuance Costs

 

Debt issuancecosts include amounts paid to lenders and other third parties to obtain financingboth fixed term and revolving debt and are amortized to interest expense on a straight-line basis over the term of the related loan. Debt issuance costs related to a fixed term debt liability are presented as a debt discount in the Consolidated Balance Sheets and presented as a direct reduction from the carrying amount of that debt. Debt issuance costs incurred related to securing and modifying the Company’s revolving credit facility are recorded as an asset, net of accumulated amortization, entitled “deferred financing costs, net” in the Consolidated Balance Sheets. Refer to Note 4 – “Notes“Credit Facility, Notes Payable and Revolving Credit Facility”Derivative Instruments” for additional details.

 

Related Party Disclosures

 

The Company enters into transactions with affiliated entities, or “related parties,” which are recorded net as “Due to Related Parties”receivables or payables in the accompanying Consolidated Balance Sheets. Related party disclosures are governed by ASC Topic 850, Related“Related Party Disclosures. Refer to Note 6 – “Related Party Transactions” for additional information regarding the Company’s related party transactions.

 

Stock-Based Compensation

 

As disclosed in Note 7 – “Stock Based Compensation,” theThe Company grants LTIP unitUnit awards, including awards that vest over time and awards that vest based on achievement of specified performance criteria, to employees of its Advisor and its affiliates,(deemed to be non-employees of the Company), and to the Company’s independent directors.directors (deemed to be employees of the Company). The Company expenses the fair value ofaccounts for all LTIP units in accordance with the fair value recognition requirements ofthese awards under ASC Topic 718, Compensation-Stock“Compensation-Stock Compensation, and” (“ASC Topic 718”) after the 2018 adoption of ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”), which simplified several aspects of the accounting for non-employee transactions by stipulating that the existing accounting guidance for share-based payments to employees, accounted for under ASC Topic 718 will also apply to non-employee share-based transactions, previously accounted for under ASC Topic 505, Equity.“Equity.” (“ASC Topic 505”). Refer to Note 7 – “Stock Based Compensation” for additional details.

 


Depreciation Expense

 

Real estate and related assets are stated net of accumulated depreciation. Renovations, replacements and other expenditures that improve or extend the life of assets are capitalized and depreciated over their estimated useful lives. Expenditures for ordinary maintenance and repairs are charged to expense as incurred. Depreciation expense is computed using the straight-line method over the estimated remaining useful liveslife of the buildings, which are generally between 23 and 50 years, tenant improvements, which are generally between 4one and 4019 years, and site improvements, which are generally between three and 14 years.

 

Income Taxes

 

The Company elected to be taxed as a REIT for U.S. federal income tax purposes commencing with its taxable year ended December 31, 2016. REITs are generally not subject to U.S. federal income taxes if the Company can meet many specific requirements. If the Company fails to qualify as a REIT in any taxable year, the Company will be subject to U.S. federal and state income tax (including for 2017 and prior taxable years only, any applicable alternative minimum tax) on its taxable income at regular corporate tax rates, and the Company may be ineligiblecould not re-elect REIT status until the fifth calendar year after the year in which the failure occurred. Even if the Company continues to qualify as a REIT for subsequent tax years. Although the Company qualifies as a REIT, it may be subject to certain state or local income taxes, and if the Company creates a Taxable REIT Subsidiary (“TRS”),TRS, the TRS will be subject to U.S. federal, state and local taxes on its income at regular corporate rates. The Company recognizes the tax effects of uncertain tax positions only if the position is more likely than not to be sustained upon audit, based on the technical merits of the position. The Company has not identified any material uncertain tax positions and recognizes interest and penalties in income tax expense, if applicable. The Company is currently not under examination by any income tax jurisdiction.

63

 

Fair Value of Financial Instruments

 

Fair value is a market-based measurement and should be determined based on the assumptions that market participants would use in pricing an asset or liability. In accordance with ASC Topic 820, the valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels are defined as follows:

 

Level 1-1 -Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets;

Level 2-2 -Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument; and

Level 3-3 -Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company considers the carrying values of cash and cash equivalents, escrow deposits, accounts and other receivables, and accounts payable and accrued expenses to approximate the fair value for these financial instruments because of the short period of time since origination or the short period of time between origination of the instruments and their expected realization. Due to the short-term nature of these instruments, Level 1 and Level 2 inputs are utilized to estimate the fair value of these financial instruments. The fair values determined related to the Company’s interest rate swap transactions that are accounted for as business combinationsutilize Level 2 inputs, since there is heavy reliance on a variety of inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The fair values determined related to the Company’s acquisitions of real estate where the identification and recording of intangible assets and liabilities is required primarily utilize Level 2 inputs since there is heavy reliance on market observable data such as rent comparables, sales comparables, and broker indications. Although some Level 3 inputs are utilized they are minor in comparison to the Level 2 date used for the primary assumptions as it relates to business combination valuations.acquisitions of real estate.

 

Segment Reporting

 

ASC Topic 280, Segment“Segment Reporting, establishes standards for reporting financial and descriptive information about a public entity's reportable segments. The Company has determined that it has one reportable segment, with activities related to investing in medical properties. The Company evaluates the operating performance of its investments on an individual asset level basis.

 

Recent Accounting Pronouncements

In January 2017,June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-01, “Business Combinations (Topic 805): ClarifyingASU 2016-13, “Financial Instruments - Credit Losses” (“ASU-2016-03”), which changes the Definitionimpairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incur losses as required currently by the other-than-temporary impairment model. ASU 2016-13 will apply to most financial assets measured at amortized cost and certain other instruments, including certain receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses,” also clarifies that receivables arising from operating leases are not within the scope of a Business.” ASU 2017-01 provides revised guidance to determine when an acquisition meets the definitionSubtopic 326-20. Instead, impairment of a business orthese receivables should be accounted for as an asset acquisition.in accordance with ASC Topic 842. ASU 2017-01 requires that, when substantially all of the fair value of an acquisition is concentrated in a single identifiable asset or a group of similar identifiable assets, the asset or group of similar identifiable assets does not meet the definition of a business and therefore is required to be accounted for as an asset acquisition. Transaction costs will continue to be capitalized for asset acquisitions and expensed as incurred for business combinations. ASU 2017-01 likely will result in substantially all of the Company’s prospective acquisitions being accounted for as asset acquisitions due to the fact that substantially all of the fair value of the gross assets the Company acquires are concentrated in a single asset or group of similar identifiable assets. ASU 2017-012016-13 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company will adopt ASU 2017-01 effective January 1, 2018.

In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230) Restricted Cash” (“ASU 2016-18”),which requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash. Therefore, amounts generally described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for annual and interim periods beginning after December 15, 2017 and early adoption is permitted using a retrospective transition method to each period presented. The Company does not expect the adoption of ASU 2016-18 to have a material impact on its consolidated statements of cash flows.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments.” ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company does not expect the adoption of this standard to have a significant impact on its consolidated statements of cash flows and related disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases.” ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, currently consisting of only ground leases, on its consolidated balance sheets. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted.2019. The Company is evaluatingimplementation of this standard will not have a material impact on the impact of the adoption of ASU 2016-02 on itsCompany’s consolidated financial statements and related disclosures as well as the timing of adopting the standard.

statements.

 

64

61

 

 

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 creates a new Topic, ASC Topic 606, which is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle in ASU 2014-09 is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017, and allows for either full retrospective or modified retrospective adoption. Under the full retrospective method, the standard would be applied retrospectively to all reporting periods represented on the financial statements. The modified retrospective approach applies the standard in the year of initial application and presents the cumulative effect of prior periods with an adjustment to beginning retained earnings, with no restatement of comparative periods. The Company intends to implement the standard using the modified retrospective approach. As leasing arrangements, which are excluded from ASU 2014-09, represent the primary source of revenue for the Company, the impact of adopting this standard will be limited to the Company’s recognition and presentation of non-lease revenues. Accordingly, the Company does not expect the adoption of this standard to have a significant impact on its consolidated financial statements and related disclosures.

ReclassificationsReclassification

 

The Company reclassified the line item “Acquired Lease Intangible Assets, Net”“Expense Recoveries” on its Consolidated Balance Sheets as of December 31, 2016, to present the gross intangible assets acquired as part of its business combination transactions as a separate line item within the category “Investment in Real Estate” and also reclassified the related accumulated amortization balance on the intangible assets acquired to the line item “Accumulated Depreciation and Amortization.” This reclassification was made to conform to the Company’s presentation of those balances as of December 31, 2017.

The Company’s Consolidated Statements of Operations for the years ended December 31, 2018 and 2017, 2016,of $3,573 and 2015 include the expense line item “Operating Expenses” which primarily includes both reimbursable property operating expenses that the Company pays on behalf$1,712, respectively, to present this amount as a component of certain of its tenants, including real estate taxes and insurance, non-reimbursable property operating expenses, and other operating expenses. Reimbursements of tenant operating expenses are recorded on a gross basis, i.e., the Company recognizes an equivalent increase“Rental Revenue,” in revenue (expense recoveries) and expense (operating expenses). Priororder to conform to the current year ended December 31, 2017, the Company recorded property operating expenses in the “General and Administrative” expense line item. Accordingly for prior years these expenses have been reclassified from the “General and Administrative” expense line item into the “Operating Expenses” line item within the Company’s Consolidated Statements of Operations.presentation.

 

Note 3 – Property Portfolio

Summary of Properties Acquired During the Year Ended December 31, 20172019

 

During the year ended December 31, 2017,2019 the Company completed 2318 acquisitions. For each acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, each acquisition represents an asset acquisition. Accordingly, transaction costs for these acquisitions were capitalized.

A rollforward of the gross investment in land, building, improvements, and improvementsacquired lease intangible assets as of December 31, 2017,2019 resulting from these acquisitions is as follows:

 

  Land  Building  Site & Tenant
Improvements
  Acquired Lease
Intangibles
  Gross Investment in
Real Estate
 
Balances as of January 1, 2017 $17,786  $179,253  $2,651  $7,187  $206,877 
Facility Acquired – Date Acquired:                    
Cape Coral – 1/10/17  352   7,017   -   -   7,369 
Lewisburg – 1/12/17  471   5,819   505   505   7,300 
Las Cruces – 2/1/17  396   4,618   -   -   5,014 
Prescott – 2/9/17  791   3,821   -   -   4,612 
Clermont – 3/1/17  -   4,361   206   868   5,435 
Sandusky – 3/10/17  409   3,998   -   -   4,407 
Great Bend – 3/31/17  837   23,801   -   -   24,638 
Oklahoma City – 3/31/17  2,087   37,714   1,876   7,823   49,500 
Sandusky – 4/21/17  98   978   -   -   1,076 
Brockport – 6/27/17  413   6,885   492   1,295   9,085 
Flower Mound – 6/27/17  581   2,922   382   407   4,292 
Sherman facility – 6/30/17  1,601   25,011   -   -   26,612 
Sandusky facility – 8/15/17  56   1,215   -   -   1,271 
Lubbock facility – 8/18/17  1,303   5,042   947   908   8,200 
Germantown – 8/30/17  2,700   8,078   657   4,505   15,940 
Austin – 9/25/17  6,958   28,508   1,373   3,811   40,650 
Fort Worth – 11/10/17  1,487   3,334   643   786   6,250 
Albertville – 11/10/17  866   3,486   1,246   1,202   6,800 
Moline – 11/10/17  722   8,175   1,194   1,916   12,007 
Lee’s Summit – 12/18/17  428   2,426   646   437   3,937 
Amarillo – 12/20/17  1,437   7,254   -   -   8,691 
Wyomissing – 12/21/17  487   5,250   -   -   5,737 
Saint George – 12/22/17  435   5,372   -   -   5,807 
Total Additions1:  24,915   205,085   10,167   24,463   264,630 
Balances as of December 31, 2017 $42,701  $384,338  $12,818  $31,650  $471,507 
  Land  Building  Site Improvements  Tenant Improvements  Acquired Lease Intangible Assets  Gross Investment in Real Estate 
Balances as of December 31, 2018 $63,710  $518,451  $6,880  $15,357  $43,152  $647,550 
Facility Acquired – Date Acquired:                        
Zachary – 2/28/19  -   3,336   103   409   835   4,683 
Gilbert and Chandler – 3/19/19  4,616   11,643   -   -   -   16,259 
Las Vegas – 4/15/19  2,479   15,277   244   2,205   2,297   22,502 
Oklahoma Northwest – 4/15/19  2,364   19,501   143   3,044   3,155   28,207 
Mishawaka – 4/15/19  1,924   10,084   74   1,798   2,223   16,103 
Surprise – 4/15/19  1,738   18,737   228   4,119   3,860   28,682 
San Marcos – 7/12/19  2,322   6,934   126   404   2,188   11,974 
Lansing – 8/1/19  1,202   7,681   185   667   1,633   11,368 
Bannockburn – 8/5/19  763   3,566   132   1,134   1,382   6,977 
Aurora – 8/6/19  1,521   7,446   308   603   2,679   12,557 
Livonia – 8/14/19  980   7,629   201   442   1,340   10,592 
Gilbert – 8/23/19  2,408   2,027   62   362   733   5,592 
Morgantown – 9/26/19  883   5,286   373   506   902   7,950 
Beaumont – 10/1/19  3,022   24,836   399   1,036   4,446   33,739 
Bastrop – 10/25/19  1,975   8,436   64   276   1,314   12,065 
Panama City – 10/31/19  1,559   8,682   220   1,036   1,479   12,976 
Jacksonville – 11/15/19  1,023   7,846   -   -   -   8,869 
Greenwood – 12/17/19  892   4,956   -   -   -   5,848 
ASC Topic 842 Reclassification  -   -       -   (824)  (824)
Capitalized costs(1)  -   1,179   170   511   -   1,860 
Total Additions:  31,671   175,082   3,032   18,552   29,642   257,979 
Balances as of December 31, 2019 $95,381  $693,533  $9,912  $33,909  $72,794  $905,529 

1The Lubbock and Moline facility acquisitions included an aggregate of approximately $11,300 of OP Units issued as part of the total consideration. Additionally, an aggregate of $1,110 of intangible liabilities were acquired from the acquisitions that occurred during the year ended December 31, 2017, resulting in total gross investments funded using cash of $252,220

(1) Represents capital projects that were completed and placed in service during the year ended December 31, 2019 related to the Company’s existing facilities.

65

 

Depreciation expense was $7,929, $2,335,$19,066, $13,644, and $660$7,929, for the years ended December 31, 2017, 2016,2019, 2018, and 2015,2017, respectively.

 

As of December 31, 2017,2019, the Company had tenantaggregate capital improvement allowancescommitments and obligations to improve, expand, and maintain the Company’s existing facilities of approximately $10 million,$18 million. Many of these amounts are subject to contingencies that make it difficult to predict when they will be utilized, if at all. In accordance with the terms of the Company’s leases, capital improvement obligations in the next twelve months could total up to approximately $11 million.


The following is a summary of the acquisitions completed during the year ended December 31, 2019.

Zachary Facility

On February 28, 2019, the Company assumed the following leasehold interests in the real property located in Zachary, Louisiana for a purchase price of approximately $4.6 million: (i) the interest, as ground lessee, in an existing ground lease of the facility, with approximately 46 years remaining in the initial term with no extension options; and (ii) the interest, as landlord, in an existing lease of the facility with LTAC Hospital of Feliciana, LLC, as tenant, with approximately 16 years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $103 
Building and tenant improvements  3,745 
In-place leases  305 
Above-market lease intangibles  117 
Leasing costs  413 
Below-market lease intangibles  (34)
Total purchase price $4,649 

Gilbert and Chandler Facilities

On March 19, 2019, the Company purchased the following facilities located in Gilbert, Arizona and Chandler, Arizona for a total purchase price of approximately $16.3 million: (i) two medical office buildings located in Gilbert, Arizona; (ii) two medical office suites located in Chandler, Arizona; (collectively, the “Gilbert and Chandler Facilities”). Upon the closing of the acquisition, the Company assumed the seller’s interest, as lessor, in two existing leases and entered into three new leases, as lessor, at the Gilbert and Chandler Facilities. The Gilbert and Chandler leases have a weighted average remaining lease term of 10.5 years, exclusive of tenant renewal options.

IRF Portfolio

On April 15, 2019, the Company purchased four in-patient rehabilitation facilities located in Las Vegas, Nevada; Surprise, Arizona; Oklahoma City, Oklahoma and Mishawaka, Indiana (collectively, the “IRF Portfolio”) for a total purchase price of approximately $94.6 million. Upon the closing of the acquisition, the Company assumed the sellers’ interest, as lessor, in four existing leases at the properties (collectively, the “IRF Portfolio Leases”) with (i) Encompass Health (Las Vegas, Nevada facility); (ii) a joint venture between Cobalt Rehabilitation and Tenet Healthcare (the Surprise, Arizona facility); (iii) a joint venture between Mercy Health and Kindred Healthcare (the Oklahoma City, Oklahoma facility); and (iv) St. Joseph’s Health System (the Mishawaka, Indiana facility). The IRF Portfolio leases have a weighted average remaining lease term of approximately 8.3 years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

  Las Vegas  Surprise  Oklahoma
City
  Mishawaka 
Land and site improvements $2,723  $1,966  $2,507  $1,998 
Building and tenant improvements  17,482   22,856   22,545   11,882 
In-place leases  1,778   1,845   1,890   1,465 
Above-market lease intangibles  -   938   367   236 
Leasing costs  519   1,077   898   522 
Below-market lease intangibles  (863)  -   -   - 
Total purchase price $21,639  $28,682  $28,207  $16,103 

San Marcos Facility

On July 12, 2019, the Company purchased a medical office building located in San Marcos, California (the “San Marcos Facility”), for a purchase price of approximately $12.0 million. Upon closing, the Company assumed the existing lease of the San Marcos Facility with California Cancer Associates for Research and Excellence, Inc., as tenant. The lease has eight years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:


Land and site improvements $2,448 
Building and tenant improvements  7,338 
In-place leases  698 
Above-market lease intangibles  1,101 
Leasing costs  389 
Total purchase price $11,974 

Lansing Facilities

On August 1, 2019, the Company purchased the following real property and buildings thereon located in Lansing, Michigan for a total purchase price of approximately $11.1 million: (i) 3390 East Jolly Road; (ii) 3955 Patient Care Drive; and (iii) 3400 East Jolly Road (“collectively, the “Lansing Facilities”). Upon closing, the Company assumed sellers’ interest, as lessor, in four existing leases and entered into two new leases at the Lansing Facilities (the “Lansing Leases”). The Lansing Leases have a weighted-average remaining term of 8.5 years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $1,387 
Building and tenant improvements  8,348 
In-place leases  953 
Above-market lease intangibles  130 
Leasing costs  550 
Below-market lease intangibles  (248)
Total purchase price $11,120 

Bannockburn Facility

On August 5, 2019, the Company purchased an office building located in Bannockburn, Illinois (the “Bannockburn Facility”), for a purchase price of approximately $6.8 million. Upon closing, the Company assumed seller’s interest, as lessor, in 14 existing leases at the Bannockburn Facility (the “Bannockburn Leases”). The Bannockburn Leases have a weighted-average remaining term of 6.3 years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed.

Land and site improvements $895 
Building and tenant improvements  4,700 
In-place leases  796 
Above-market lease intangibles  250 
Leasing costs  336 
Below-market lease intangibles  (144)
Total purchase price $6,833 

Aurora Facility

On August 6, 2019, the Company purchased a medical office building located in Aurora, Illinois (the “Aurora Facility”), for a purchase price of approximately $12.6 million. Upon closing, the Company assumed the existing lease of the Aurora Facility with Dreyer Clinic Inc., as tenant (the “Dreyer Lease”). The Dreyer Lease has approximately six years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $1,829 
Building and tenant improvements  8,049 
In-place leases  1,417 
Above-market lease intangibles  861 
Leasing costs  401 
Total purchase price $12,557 

Livonia Facility

On August 14, 2019, the Company purchased a medical office building located in Livonia, Michigan (the “Livonia Facility”) for a purchase price of approximately $10.4 million. Upon closing, the Company assumed 10 existing leases at the Livonia Facility (the “Livonia Leases”). The Livonia Leases have a weighted-average remaining term of 3.2 years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:


Land and site improvements $1,181 
Building and tenant improvements  8,071 
In-place leases  1,252 
Above-market lease intangibles  53 
Leasing costs  35 
Below-market lease intangibles  (236)
Total purchase price $10,356 

Gilbert Facility

On August 23, 2019, the Company purchased certain condominium units within two medical office buildings located in Gilbert, Arizona (the “Gilbert Facility”) for a total purchase price of approximately $5.6 million. Upon closing, the Company leased the Gilbert Facility to Covenant Surgical Partners, Inc., a Delaware corporation (the “Covenant Lease”). The Covenant Lease has approximately 10 years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $2,470 
Building and tenant improvements  2,389 
In-place leases  121 
Above-market lease intangibles  300 
Leasing costs  312 
Total purchase price $5,592 

Morgantown Facility

On September 26, 2019, the Company purchased a parcel of land and an office building that is being constructed thereon, located in Morgantown, West Virginia (the ”Morgantown Facility”) for a total purchase price of approximately $8.0 million. Upon closing, the Company assumed the existing lease of the Morgantown Facility with Urgent Care MSO, LLC, as tenant (the “Urgent Care Lease”). The Urgent Care Lease has approximately ten years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $1,256 
Building and tenant improvements  5,792 
In-place leases  457 
Leasing costs  445 
Total purchase price $7,950 

Beaumont Facility

On October 1, 2019, the Company purchased a medical office building located in Beaumont, Texas (the “Beaumont Facility”) for a total purchase price of approximately $33.7 million. Upon closing, the Company assumed the existing lease of the Beaumont Facility with The Medical Center of Southeast Texas, LP, as tenant (the “Medical Center Lease”). The Medical Center Lease has 10 years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $3,421 
Building and tenant improvements  25,872 
In-place leases  3,304 
Leasing costs  1,142 
Total purchase price $33,739 

Bastrop Facility

On October 25, 2019, the Company purchased a medical emergency center located in Bastrop, Texas (the “Bastrop Facility”) for a total purchase price of approximately $12.1 million. Upon closing, the Company assumed the existing lease of the Bastrop Facility with St. David’s Healthcare Partnership, L.P., LLP, as tenant (the “St. David’s Lease”). The St. David’s Lease has approximately five years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:


Land and site improvements $2,039 
Building and tenant improvements  8,712 
In-place leases  990 
Leasing costs  324 
Total purchase price $12,065 

Panama City Facilities

On October 31, 2019, the Company purchased a medical office building located in Panama City, Florida (the “Panama City Facility”); (ii) a medical office building located in Panama City Beach, Florida (the “PCB Facility”); and (iii) a medical office building located in Chipley, Florida (the “Chipley Facility”) for a total purchase price of approximately $13.0 million. Upon closing, the Company assumed the existing leases with SCP Eye Care Services, LLC, as tenant (the “SCP Leases”), at the Panama City Facility, the PCB Facility and the Chipley Facility. The SCP Leases have approximately 15 years remaining in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $1,779 
Building and tenant improvements  9,718 
In-place leases  405 
Leasing costs  1,074 
Total purchase price $12,976 

Jacksonville Facilities

On November 15, 2019, the Company purchased a condominium unit located in Ponte Vedra, Florida (the “Ponte Vedra Facility”) and a medical office building located in Jacksonville, Florida (the “Riverside Facility”), for a total purchase price of approximately $8.9 million. Upon closing, the Company entered into new leases of the Ponte Vedra Facility and the Riverside Facility to Southeast Orthopedic Specialists, Inc., as tenant, with each lease having an initial term of 15 years, exclusive of tenant renewal options. The following table presents the details of the tangible assets acquired:

Land and site improvements $1,023 
Building and tenant improvements  7,846 
Total purchase price $8,869 

Greenwood Facility

On December 17, 2019, the Company purchased a medical office building located in Greenwood, Indiana (the “Greenwood Facility”), for a purchase price of approximately $5.8 million. Upon closing, the Company assumed the existing leases of the Greenwood Facility with (i) Indiana Eye Clinic, LLC, as tenant, (ii) Glasshouse Optical, Inc., as tenant, and (iii) The Ambulatory Surgery Center at the Indiana Eye Clinic, LLC, as tenant. Each lease has approximately 13 years remaining in the initial terms, exclusive of tenant renewal options. The following table presents the details of the tangible assets acquired:

Land and site improvements $892 
Building and tenant improvements  4,956 
Total purchase price $5,848 


Summary of Properties Acquired During the Year Ended December 31, 2018

During the year ended December 31, 2018, the Company completed 14 acquisitions. Substantially all of the fair value of the acquisitions was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, all of the acquisitions represent asset acquisitions. Accordingly, transaction costs for these acquisitions were capitalized.

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of December 31, 2018 resulting from these acquisitions is as follows:

  Land  Building  Site Improvements  Tenant Improvements  Acquired Lease Intangibles  Gross Investment in Real Estate 
Balances as of January 1, 2018 $42,701  $384,338  $4,808  $8,010  $31,650  $471,507 
Facility Acquired – Date Acquired:                        
Moline / Silvis – 1/24/18  -   4,895   249   967   989   7,100 
Freemont – 2/9/18  162   8,335   -   -   -   8,497 
Gainesville – 2/23/18  625   9,885   -   -   -   10,510 
Dallas – 3/1/18  6,272   17,012   -   -   -   23,284 
Orlando – 3/22/18  2,543   11,720   532   224   1,395   16,414 
Belpre – 4/19/18  3,025   50,526   972   2,994   7,166   64,683 
McAllen – 7/3/18  1,099   4,296   -   -   -   5,395 
Derby – 8/3/18  412   2,496   154   89   453   3,604 
Bountiful – 10/12/18  720   4,185   -   -   -   4,905 
Cincinnati – 10/30/18  1,745   1,336   79   474   492   4,126 
Melbourne – 11/16/18  645   5,950   86   31   1,007   7,719 
Southern IL – 11/30/18  1,830   12,660   -   -   -   14,490 
Vernon – 12/19/18  1,166   9,929   -   -   -   11,095 
Corona – 12/31/18  1,601   14,689   -   -   -   16,290 
Tenant improvements(1)  -   -   -   2,568   -   2,568 
Total Additions:  21,845   157,914   2,072   7,347   11,502   200,680 
Great Bend Disposition – 12/20/18  (836)  (23,801)  -   -   -   (24,637)
Balances as of December 31, 2018 $63,710  $518,451  $6,880  $15,357  $43,152  $647,550 

(1) Represents tenant improvements that were completed and placed in service during the year ended December 31, 2018 related to the Company’s existing facilities.

As of December 31, 2018, the Company had aggregate capital improvement commitments to improve or expand existing tenant space of $17 million. Many of these allowances are subject to contingencies that make it difficult to predict when such allowances will be utilized, if at all. In accordance with the terms of a number of the Company’s leases, tenant improvement obligations in 2019 could total approximately $9 million.

 

The following is a summary of the 14 acquisitions completed during the year ended December 31, 2017 were accounted for as business combinations under ASC Topic 805. The purchase price allocation for each acquisition is preliminary and subject to revision within the measurement period, not to exceed one year from the date of the acquisition:2018.

 

LewisburgMoline / Silvis Facilities

Moline Facility-On January 12, 2017, the Company purchased a medical office building located in Lewisburg, Pennsylvania, for a purchase price of $7.3 million. Upon the closing of the transaction, the Company assumed two leases. Both leases expire in 2023 and have two five-year tenant renewal options. The following table presents the preliminary purchase price allocation:

Land and site improvements $681 
Building and tenant improvements  6,114 
In place leases  373 
Leasing costs  132 
Total purchase price $7,300 

Clermont Facility -On March 1, 2017, the Company purchased the seller’s interest, as ground lessee, in certain real property and a medical building located in Clermont, Florida., for a purchase price of $5.23 million. The ground lease has a remaining term of approximately 71 years. Upon closing of this acquisition, the Company assumed four subleases: two subleases with South Lake Hospital, Inc. each expiring in 2024, each with two, five-year tenant renewal options, one sublease with Orlando Health, Inc. expiring in 2021 with two, five-year renewal options, and one sublease with Vascular Specialists of Central Florida expiring in 2024 with two, five-year renewal options. The following table presents the preliminary purchase price allocation:

Site improvements $145 
Building and tenant improvements  4,422 
In place leases  255 
Above market lease intangibles  488 
Leasing costs  125 
Below market lease intangibles  (210)
Total purchase price $5,225 

Oklahoma City Facilities -On March 31, 2017, the Company purchased a surgical hospital, a physical therapy center (together with the hospital, “OCOM South”), and an outpatient ambulatory surgery center (“OCOM North”) located in Oklahoma City, Oklahoma for an aggregate purchase price of $49.5 million. The purchase price consisted of $44.4 million for OCOM South and $5.1 million for OCOM North.

66

Upon closing of the acquisition of OCOM South, the Company entered into a new lease (the “Master Lease”) with the seller that expires in 2022 and assumed, as a sublease to the Master Lease, the existing absolute triple-net lease (the “OCOM South Lease”) with Oklahoma Center for Orthopedic & Multi-Specialty Surgery, LLC (“OCOM”) with a remaining term expiring in 2034, subject to three consecutive five-year tenant renewal options. Upon the expiration of the Master Lease, the OCOM South Lease will become a direct lease with the Company. A portion of the rent under the OCOM South sublease is guaranteed by United Surgical Partners International, Inc. and INTEGRIS Health, Inc.

Upon closing of the acquisition of OCOM North, the Company assumed the existing lease. The lease has a remaining term expiring in 2022, with two consecutive five-year tenant renewal options. The following table presents the preliminary purchase price allocation:

Land and site improvements $2,953 
Building and tenant improvements  38,724 
Above market lease intangibles  759 
In place leases  4,392 
Leasing costs  2,672 
Total purchase price $49,500 

Brockport Facility -On June 27, 2017, the Company purchased a medical office building located in Brockport, New York for a purchase price of $8.67 million. Upon the closing of this acquisition, the Company assumed the existing lease with The Unity Hospital of Rochester. The lease has a remaining term expiring 2030, with three consecutive five-year tenant renewal options. The following table presents the preliminary purchase price allocation:

Land and site improvements $693 
Building and tenant improvements  7,097 
In place leases  841 
Leasing costs  454 
Below market lease intangible  (415)
Total purchase price $8,670 

Flower Mound Facility -On June 27, 2017, the Company purchased a medical office building located in Flower Mound, Texas for a purchase price of $4.1 million. Upon the closing of this acquisition, the Company assumed the existing lease with Lone Star Endoscopy Center, LLC. The lease has a remaining term expiring in 2026, with two consecutive five-year tenant renewal options. The following table presents the preliminary purchase price allocation:

Land and site improvements $730 
Building and tenant improvements  3,155 
In place leases  222 
Leasing costs  185 
Below market lease intangible  (242)
Total purchase price $4,050 

Lubbock Facility -On August 18, 2017, the Company purchased a medical office building located in Lubbock, Texas for a purchase price of $8.2 million. Upon the closing of this acquisition, the Company entered into a new lease with Lubbock Heart Hospital, LLC. The lease has a remaining term expiring 2029,with two consecutive five-year tenant renewal options. The following table presents the preliminary purchase price allocation:

Land and site improvements $1,567 
Building and tenant improvements  5,725 
In-place leases  414 
Leasing costs  494 
Total purchase price $8,200 

Germantown Facility -On August 30, 2017, the Company purchased a medical office building located in Germantown, Tennessee for a purchase price of $15.94 million. Upon the closing of this acquisition, the Company assumed three existing leases with the Urology Center of the South. The leases have remaining terms of approximately seven years and each lease has two consecutive five-year tenant renewal options. The following table presents the preliminary purchase price allocation:

Land and site improvements $3,050 
Building and tenant improvements  8,385 
Above market lease intangible  3,284 
In-place leases  587 
Leasing costs  634 
Total purchase price $15,940 

67

Austin Facility -On September 25, 2017, the Company purchased a rehabilitation hospital located in Austin, Texas and approximately 1.27 acres of land adjacent to the hospital that has been planned to accommodate the development of a long-term, acute care hospital for an aggregate purchase price of $40.65 million. Upon the closing of the acquisition of the facility, the Company assumed the existing lease with CTRH, LLC. The lease has a remaining term of approximately 9.6 years, with four consecutive five-year tenant renewal options, and 80% of the lease payments are guaranteed by Kindred Healthcare. The following table presents the preliminary purchase price allocation:

Land and site improvements $7,223 
Building and tenant improvements  29,616 
Above market lease intangible  246 
In-place leases  1,680 
Leasing costs  1,885 
Total purchase price $40,650 

Fort Worth Facility -On November 10, 2017, the Company purchased a medical office building located in Fort Worth, Texas for a purchase price of $6.25 million. Upon the closing of the acquisition, the Company assumed the existing lease with Texas Digestive Disease Consultants, PLLC. The lease has a remaining term of approximately 10 years with two consecutive five year tenant renewal options. The following table presents the preliminary purchase price allocation:

Land and site improvements $1,738 
Building and tenant improvements  3,726 
Above market lease intangible  126 
In-place leases  314 
Leasing costs  346 
Total purchase price $6,250 

Albertville Facility -On November 10, 2017, the Company purchased a medical office building located in Albertville, Minnesota for a purchase price of $6.8 million. Upon the closing of the acquisition, the Company assumed the existing lease with Stellis Health, P.A. The lease has a remaining term of approximately 11 years with two consecutive five-year extension options. The following table presents the preliminary purchase price allocation:

Land and site improvements $1,154 
Building and tenant improvements  4,444 
Above market lease intangible  103 
In-place leases  802 
Leasing costs  297 
Total purchase price $6,800 

Moline Facility -On November 10, 2017,24, 2018, the Company purchased a medical office building located in Moline, Illinois, for a purchase price of $11.9 million.which included the seller’s interest, as ground lessee, in an existing ground lease. The ground lease has approximately 10 years remaining in the initial term, with 12 consecutive five-year renewal options. Upon the closing of thethis acquisition, the Company assumed two subleases: one sublease with Fresenius Medical Care Quad Cities, LLC (“Fresenius”) with approximately 13 years remaining in the existing leasesinitial term, with Heartland Clinic, LLC, RSC Illinois, LLC,three consecutive five-year renewal options; and Valley Laboratories, L.L.C. Each lease has aone sublease with Quad Cities Nephrology Associates, P.L.C. with approximately 15 years remaining in the initial term, of approximately 16 years with no tenantthree consecutive five-year renewal options. The following table presents the preliminary purchase price allocation:

 

Land and site improvements $854 
Building and tenant improvements  9,237 
Above market lease intangible  33 
In-place leases  1,050 
Leasing costs  833 
Below market lease intangible  (107)
Total purchase price $11,900 

68

Lee’s SummitSilvis Facility -On December 18, 2017,January 24, 2018, the Company purchased a medical office building located in Lee’s Summit, Missouri for a purchase price of $3.8 million.Silvis, Illinois from the same seller as the Moline facility, which included the seller’s interest, as ground lessee, in an existing ground lease. The ground lease has approximately 67 years remaining in the initial term, with no renewal options. Upon the closing of thethis acquisition, the Company assumed the existing leaseone sublease with Prime Healthcare Services Blue Springs, LLC. The lease has remaining term ofFresenius with approximately seven13 years remaining in itsthe initial term, with two three-year extensionthree consecutive five-year renewal options.


The aggregate purchase price for the Moline/Silvis facilities was $6.9 million. The following table presents the preliminary purchase price allocation:details of the tangible and intangible assets acquired and liabilities assumed for this acquisition:

 

Land and site improvements $571 
Site improvements $249 
Building and tenant improvements  2,929   5,862 
In-place leases  303   343 
Above market ground lease intangibles  219 
Leasing costs  134   427 
Below market lease intangible  (137)
Below market lease intangibles  (229)
Total purchase price $3,800  $6,871 

The following acquisitions completed during the year ended December 31, 2017 were accounted for as asset acquisitions:

Cape CoralFremont Facility -On January 10, 2017,February 9, 2018, the Company purchased a medical office building located in Cape Coral, Florida, for a purchase price of $7.25 million. Upon the closing of the acquisition, the Company entered into a new 10-year lease with The Sypert Institute, P.A. with three consecutive five-year tenant renewal options.

Las Cruces Facility -On February 1, 2017, the Company purchased a medical office building located in Las Cruces, New Mexico for a purchase price of $4.88 million. Upon closing of this acquisition, the Company entered into a new 12-year lease with Las Cruces Orthopedic Associates with four consecutive five-year tenant renewal options.

Prescott Facility -On February 9, 2017, the Company purchased a medical office building located in Prescott, Arizona, for a purchase price of $4.5 million. Upon the closing of this acquisition, the Company entered into a new 10-year lease with Thumb Butte Medical Center, PLLC with two consecutive seven-year renewal options.

Sandusky Facility -On March 10, 2017, the Company purchased one, out of a total of seven, properties for a purchase price of approximately $4.3 million. Upon the closing of this acquisition, the Company entered into a new 11-year master lease with the Northern Ohio Medical Specialists (NOMS) with four consecutive five-year tenant renewal options.

Great Bend Facility -On March 31, 2017, the Company purchased an acute-care hospital located in Great Bend, Kansas for a purchase price of $24.5 million. Upon the closing of the acquisition, the Company entered into a new 15-year lease with Great Bend Regional Hospital with two consecutive ten-year renewal options.

Sandusky Facility -On April 21, 2017, the Company purchased a medical property (out of a total portfolio of seven medical properties) in Sandusky,Fremont, Ohio for a purchase price of approximately $1.1 million. Upon the closing of this acquisition, the Company amended the existing master lease with NOMS to include the Sandusky facility

Sherman Facility -On June 30, 2017, the Company purchased a rehabilitation hospital and long-term acute care facility located in Sherman, Texas for a purchase price of $26 million. Upon closing of this acquisition, the Company entered into a new 20-year lease with SDB Partners, LLC. with two consecutive 10-year tenant renewal options.

Sandusky Facility (Ballville Facility) -On August 15, 2017, the Company purchased a medical office building located in Ballville, Ohio for a purchase price of $1.2 million. Upon the closing of this acquisition, the Company amended the existing master lease with NOMS to include the Ballville facility.

Amarillo Facility -On December 20, 2017, the Company purchased a medical office building located in Amarillo, Texas for a purchase price of $8.61$8.5 million. Upon the closing of this acquisition, the Company entered into a new 12-year lease with Amarillo Bone & Joint Clinic PLLC.Northern Ohio Medical Specialists, LLC (NOMS) with twofour consecutive 10-year tenantfive-year renewal options.

 

WyomissingGainesville Facility -On December 21, 2017,February 23, 2018, the Company purchased a medical office building and ambulatory surgery center located in Wyomissing, PennsylvaniaGainesville, Georgia for a purchase price of $5.6 million. Upon the closing of this acquisition, the Company entered into a new 10-year lease with Berks-Schuylkill Respiratory Specialists, Ltd. with two consecutive five year tenant renewal options.

Saint George Facility -On December 22, 2017, the Company purchased a medical office building located in St. George, Utah for a purchase price of $5.715approximately $10.5 million. Upon the closing of this acquisition, the Company entered into a new 12-year lease with Jason A. Ahee, M.D. P.C. doing business as ZionSCP Eye InstituteCare Services, LLC with four consecutive five-year tenant renewal options.

 

69

Dallas Facility -

Summary of Properties Acquired During the Year Ended December 31, 2016

During the year ended December 31, 2016,On March 1, 2018, the Company completed 10 acquisitions. A rollforwardpurchased a hospital, a three-story parking garage, and land all located in Dallas, Texas for an aggregate purchase price of approximately $23.3 million. In addition to the gross investment inhospital and the parking garage, the land building and improvements as of December 31, 2016, resulting from these acquisitions is as follows:

  Land  Building  Site & Tenant
Improvements
  Acquired Lease
Intangibles
  Gross Investment in
Real Estate
 
Balances as of January 1, 2016 $4,564  $51,574  $-  $-  $56,138 
Facility Acquired – Date Acquired:                    
Plano – 1/28/16  1,050   16,696   -   -   17,746 
Westland – 3/31/16  230   4,520   -   -   4,750 
Melbourne – 3/31/16  1,200   14,250   -   -   15,450 
Reading – 7/20/16  1,440   7,940   -   -   9,380 
East Orange – 9/29/16  2,150   10,112   -   -   12,262 
Watertown – 9/30/16  1,100   8,002   -   -   9,102 
Sandusky – 10/7/16  229   4,519   -   -   4,748 
Carson City – 10/31/16  761   3,268   -   -   4,029 
Ellijay – 12/16/16  777   2,929   544   870   5,120 
HealthSouth – 12/20/16  4,285   55,443   2,107   6,317   68,152 
Total Additions1:  13,222   127,679   2,651   7,187   150,739 
Balances as of December 31, 2016 $17,786  $179,253  $2,651  $7,187  $206,877 

1An aggregate of $280 of intangible liabilities were acquired from the acquisitions that occurred during the year ended December 31, 2016, resulting in total gross investments funded using cash of $150,459.

Additionally, during the year ended December 31, 2015underlays two medical office buildings that are not owned by the Company, funded acquisitions ineach of which is ground leased to the amounthospital. Upon the closing of $31,764.

The following acquisitions completed duringthis acquisition, the year ended December 31, 2016 were accounted for as business combinations under ASC Topic 805:Company entered into two leases with Pipeline East Dallas, LLC, with one lease relating to the hospital and the other lease relating to the underlying land and parking garage.

 

Westland Facility -Orlando FacilitiesOn March 31, 2016,22, 2018, the Company purchased five medical office buildings located in Orlando, Florida from five affiliated sellers for an aggregate purchase price of approximately $16.4 million. Upon the closing of this acquisition, the Company assumed five existing leases with Orlando Health, Inc. One lease has approximately one year remaining in its initial term, with one 10-year renewal option; one lease has approximately six years remaining in its initial term, with three consecutive five-year renewal options; one lease has approximately six years remaining in its initial term, with four consecutive five-year renewal options; one lease has approximately six years remaining in its initial term, with three consecutive five-year renewal options; and one lease was amended at closing to extend the remaining term to five years with four consecutive five-year renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $3,075 
Building and tenant improvements  11,944 
In-place leases  808 
Above market lease intangibles  229 
Leasing costs  358 
Below market lease intangibles  (10)
Total purchase price $16,404 

Belpre Portfolio- On April 19, 2018, the Company purchased a portfolio of four medical office buildings and a right of first refusal to purchase a fifth, yet to be built, medical office building on the same campus, for an aggregate purchase price of approximately $64.1 million. Upon the closing of the acquisition the Company assumed the existing leases with Marietta Memorial Hospital, a subsidiary of Memorial Health System and such leases had a weighted average remaining lease term of approximately 11.35 years, each with three consecutive five-year tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $3,997 
Building and tenant improvements  53,520 
In-place leases  2,660 
Above market lease intangibles  2,527 
Leasing costs  1,979 
Below market lease intangibles  (632)
Total purchase price $64,051 

McAllen Facility- On July 3, 2018, the Company purchased a medical office building and ambulatory surgery center(and adjacent condominium) located in Westland, MichiganMcAllen, Texas for an aggregatea purchase price of $4.75approximately $5.4 million. Upon the closing of this acquisition, the Company entered into a new 11-year lease with The Surgical Institute of Michigan, LLC. The lease has a remaining term expiring in 2026,Valley Ear, Nose, and Throat Specialists, PA, with two consecutive 10-year tenant renewal options. No intangible assets or liabilities were identified in connection with this acquisition and accordingly the purchase price was allocated entirely to land and building.


 

Ellijay FacilitiesDerby Facility -On December 16, 2016,August 3, 2018, the Company purchased onea medical office building and two ancillary healthcare-related buildings, located in Ellijay, Georgia,Derby, Kansas for a purchase price of $4.9approximately $3.6 million. Upon the closing of this acquisition, the Company assumed the existing lease with Piedmont Mountainside Hospital, Inc.Rock Surgery Center, LLC. The lease has aapproximately nine years remaining in its initial term, expiring in 2026, with two consecutiveone five-year tenant renewal options.option. The following table presents the preliminary purchase price allocation:details of the tangible and intangible assets acquired and liabilities assumed:

 

Land and site improvements $913  $566 
Building and tenant improvements  3,337   2,585 
In place leases  672 
Leasing commissions and legal fees  198 
In-place leases  299 
Leasing costs  154 
Below market lease intangibles  (220)  (23)
Total purchase price $4,900  $3,581 

 

Encompass (formerly HealthSouth) Facilities -Bountiful FacilityEncompass East Valley Rehabilitation Hospital – Mesa, AZ- On December 20, 2016,October 12, 2018, the Company purchased a rehabilitation hospitalmedical office building located in Mesa, ArizonaBountiful, Utah for a purchase price of $22.4 million. Upon the closing of this acquisition, the Company assumed the existing lease with Encompass Mesa Rehabilitation Hospital, LLC. The lease has a remaining term expiring in 2024 with four consecutive five-year tenant renewal options.

Encompass Rehabilitation Hospital of Altoona – Altoona, PA - On December 20, 2016, the Company purchased the a rehabilitation hospital located in Altoona, Pennsylvania for a purchase price of $21.5 million. Upon the closing of this acquisition, the Company assumed from existing lease with Encompass. The lease has a remaining term expiring in 2021 with two consecutive five-year tenant renewal options.

Encompass Rehabilitation Hospital of Mechanicsburg – Mechanicsburg, PA - On December 20, 2016, the Company (i) purchased a rehabilitation hospital in Mechanicsburg, Pennsylvania for a purchase price of $24.2 million; and (ii) accepted an assignment of the ground lessee’s interest in the ground lease dated May 1, 1996 from the assignor, whereby PENNSYLVANIA HRT, INC. ground leased the property to HR ACQUISITION OF PENNSYLVANIA, INC. Upon the closing of this acquisition, the Company assumed the existing lease with Encompass. The lease has a remaining term expiring in 2021 with two consecutive five-year tenant renewal options. Encompass has the option under the lease to purchase the property at the end of the initial lease term and at the end of each renewal term thereof, if any, upon the terms and conditions set forth in the lease. The following table presents the preliminary purchase price allocation:

70

Land and site improvements $5,615 
Building and tenant improvements  56,221 
In place leases  5,154 
Above market lease intangibles  74 
Leasing costs  1,088 
Below market lease intangibles  (59)
Total purchase price $68,093 

The following acquisitions completed during the year ended December 31, 2016 were accounted for as asset acquisitions:

Plano Facility -On January 28, 2016, the Company purchased a surgical hospital located in Plano, Texas for $17.5approximately $4.9 million. Upon the closing of this acquisition, the Company entered into a new 20-year lease with Star Medical Center, LLC.Ryan K. Anderson, D.P.M., P.C., a professional corporation doing business as Foot and Ankle Specialists of Utah. The lease has an initial term of 15 years, with two consecutive ten-year tenant renewal15 year extension options.

 

Also on January 28, 2016,Cincinnati Facility -On October 30, 2018, the Company entered intopurchased a Promissory Note and Deedmedical office building located in Cincinnati, Ohio, for a purchase price of Trust with East West Bank to borrow a totalapproximately $4.0 million. Upon the closing of $9.2 million. Deferred financing costs of $53 were incurred and capitalized bythe acquisition, the Company assumed the existing leases with TriHealth, Inc., as tenant as follows: (i) the lease of Unit A with seven years remaining in securing this loan.the initial term and three consecutive five year renewal options; (ii) the lease of Unit B with eight years remaining in the initial term and three consecutive five year renewal options; and (iii) the lease of Unit C with seven years remaining in the initial term and three consecutive five year renewal options. The loan was scheduled to mature on January 28, 2021, five years fromfollowing table presents the closing date. At closing the Company paid the lender a non-refundable deposit of $50 and a non-refundable commitment fee of $46. Interest expense of $65 was incurred on this note for the year ended December 31, 2016, prior to its repayment. As discussed in Note 4 – “Notes Payable and Revolving Credit Facility,” the Company used a portiondetails of the proceeds from another third party loan to repay the $9.2 million principal balance of the note with East West Bank in full as of December 31, 2016. The Company also wrote off the deferred financing costs of $53 as of December 31, 2016 related to this note.tangible and intangible assets acquired and liabilities assumed:

 

Additional funding for this transaction was received from ZH USA, LLC during the year ended December 31, 2015 in the amount of $9.4 million (consisting of $9.0 million funded directly for this transaction and $344 that was held in escrow from previous funding from ZH USA, LLC). The $9.4 million was recorded by the Company as unsecured Convertible Debentures due to related party on demand, bearing interest at eight percent per annum. ZH USA, LLC may elect to convert all or a portion of the outstanding principal amount of the Convertible Debenture into shares of the Company’s common stock in an amount equal to the principal amount of the Convertible Debenture, together with accrued but unpaid interest, divided by $12.748. Refer to Note 6 – “Related Party Transactions” for details regarding the conversion to common stock or pay-off of the Convertible Debentures balance as of December 31, 2016.

Land and site improvements $1,824 
Building and tenant improvements  1,810 
In-place leases  236 
Above market lease intangibles  131 
Leasing costs  125 
Below market lease intangibles  (52)
Total purchase price $4,074 

 

Melbourne Facility -On March 31, 2016,November 16, 2018, the Company purchased a medical office building located in Melbourne, Florida for a purchase price of $15.45 million. Upon the closing of this acquisition, the Company entered into a new 10-year lease with Marina Towers, LLC with two consecutive five-year tenant renewal options.

Reading Facilities -On July 20, 2016, the Company purchased a medical office building and eye surgery center located in Wyomissing, Pennsylvania for a combined purchase price of $9.20 million. Upon the closing of the transaction, the Company entered into two new 10-year leases for the medical office building with Berks Eye Physicians & Surgeons, Ltd., and the surgery center with Ridgewood Surgery Associates, LLC both with two consecutive five-year tenant renewal options.

East Orange Facility -On September 29, 2016, the Company purchased a medical office building in East Orange, New Jersey for a purchase price of $11.86 million. Upon the closing of this acquisition, the Company entered into a new 10-year lease with Prospect Medical Holdings, Inc. with four consecutive five-year tenant renewal options

Watertown Facilities -On September 30, 2016, the Company purchased a clinic, an administration building, and a medical office building located in Watertown South Dakota for a purchase price of $9.0 million. Upon the closing of the acquisition, the Company entered into a new 15-year lease with the Brown Clinic with two consecutive five-year tenant renewal options.

Sandusky Facilities -On September 29, 2016, the Company purchased a portfolio of five of the seven medical office buildings located in or near Sandusky, Ohio for a purchase price of $4.6 million. Upon the closing of this acquisition, the Company entered into a new 11-year lease with the Northern Ohio Medical Specialists, LLC with four consecutive five-year tenant renewal options.

Carson City Facilities -On October 31, 2016, the Company purchased two medical office buildings located in Carson City, Nevada for a purchase price of $3.8approximately $7.7 million. Upon the closing of the acquisition, the Company assumed the existing lease with the Carson Medical Group.Brevard Radiation Oncology, LLC, as tenant. The lease has five years remaining in the initial term, with two consecutive five year renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements $731 
Building and tenant improvements  5,981 
In-place leases  346 
Above market lease intangibles  504 
Leasing costs  157 
Total purchase price $7,719 

Southern IL Facilities - On November 30, 2018, the Company purchased six buildings at four locations in Southern Illinois, for an aggregate purchase price of approximately $14.5 million. Details regarding the six buildings and the Company’s tenants and lease terms are as follows:

Two of the six buildings are medical office buildings located in Shiloh, Illinois. Upon the closing of the acquisition, the Company assumed two leases at one of the buildings located in Shiloh as follows: (i) a lease of Suite 1 with SSM Health Care St. Louis with approximately seven years remaining in the initial term expiringand two consecutive five year renewal options; and (ii) a lease of Suite 2 with Metro East Dermatology and Skin Cancer Center, LLC with approximately one year remaining in 2023,the initial term and consecutive one year renewal options unless the Company or the tenant terminates the lease in writing prior to the expiration of the term. Upon the closing of the acquisition of the second building located in Shiloh, the Company assumed a lease of Suite 2 with one five-year tenantQuest Diagnostics Clinical Laboratories, Inc. with approximately nine months remaining in the initial term and two consecutive five year renewal options. The Company entered into a new lease of Suite 1 with Heartland Women’s Healthcare IL, P.C. having an initial term of 12 years and two consecutive five year renewal options. The tenant’s obligations under this lease are guaranteed by USA OBGYN Management, LLC.

One of the six buildings is a mixed-use, commercial building located in Carbondale, Illinois. At the time of the closing of the acquisition, portions of the building were leased to six different tenants for medical, general office and restaurant uses. Simultaneously with the closing, the Company entered into a lease with Seller’s affiliate, Heartland Women’s Healthcare, Ltd. (the “Master Tenant”) having an initial term of 12 years and two consecutive five year renewal options. For the first five years of the initial term, the Master Tenant master leases the entire building (with the leases existing at the time of closing being converted to subleases between the Master Tenant and such tenants). For the last seven years of the initial term and any renewal terms, the premises is reduced to 6,592 rentable square feet, and any other leases then in effect are assigned to the Company and become direct leases between the Company and the tenants under those leases. The Master Tenant’s obligations under this lease are guaranteed by USA OBGYN Management, LLC.


One of the six buildings is a medical office building located in Marion, Illinois. Upon the closing of the acquisition, the Company entered into a lease with Heartland Women’s Healthcare, Ltd. for the entire building, having an initial term of 12 years and two consecutive five year renewal options. The tenant’s obligations under this lease are guaranteed by USA OBGYN Management, LLC.

Two of the six buildings are medical office buildings located in Mount Vernon, Illinois. Upon the closing of the acquisition, the Company entered into a lease with Heartland Women’s Healthcare, Ltd. for both buildings, having an initial term of 12 years and two consecutive five year renewal options. The tenant’s obligations under this lease are guaranteed by USA OBGYN Management, LLC.

Vernon Facilities -On December 19, 2018, the Company purchased two medical office buildings located in Vernon, Connecticut for a total purchase price of approximately $10.9 million. Upon the closing of the acquisition, the Company leased the facilities to Prospect ECHN, Inc. One lease has an initial term of 15 years with two consecutive 10-year extension option, and the other lease has an initial term of 12 years with two consecutive 10-year extension options.

Corona Facility -On December 31, 2018, the Company purchased a medical office building located in Corona, California for a purchase price of approximately $17.2 million. Upon the closing of the acquisition, the Company entered into a lease with Citrus Valley Medical Associates, Inc. The lease has an initial term of 12 years with no renewal option.

Disposition

On December 20, 2018, the Company disposed of the Great Bend Regional Hospital receiving gross proceeds of $32.5 million, resulting in a gain of approximately $7.7 million. After commissions and expenses paid, net proceeds received were $31.6 million.

Intangible Assets and Liabilities

 

The following is a summary of the carrying amount of intangible assets and liabilities as of December 31, 2019 and 2018:

  As of December 31, 2019 
  Cost  

Accumulated

Amortization

  Net 
Assets         
In-place leases $39,429  $(7,851) $31,578 
Above market leases  12,246   (2,366)  9,880 
Leasing costs  21,119   (3,458)  17,661 
  $72,794  $(13,675) $59,119 
Liability            
Below market leases $3,861  $(697) $3,164 


  As of December 31, 2018 
  Cost  

Accumulated

Amortization

  Net 
Assets         
In-place leases $21,753  $(4,037) $17,716 
Above market ground lease  707   (28)  679 
Above market leases  8,009   (1,096)  6,913 
Leasing costs  12,683   (1,703)  10,980 
  $43,152  $(6,864) $36,288 
Liability            
Below market leases $2,336  $(308) $2,028 

The following is a summary of the acquired lease intangible amortization:

  Year Ended December 31, 
  2019  2018  2017 
Amortization expense related to in-place leases $3,814  $2,460  $1,542 
Amortization expense related to leasing costs $1,755  $1,165  $530 
Decrease in rental revenue related to above market ground lease $-  $22  $6 
Decrease in rental revenue related to above market leases $1,270  $876  $220 
Increase in rental revenue related to below market leases $(389) $(210) $(97)

Future aggregate net amortization of the acquired lease intangible assets and liabilities as of December 31, 2019, is as follows:

  Net Decrease in Revenue  Increase in Expense 
2020 $(986) $7,332 
2021  (988)  6,717 
2022  (997)  6,350 
2023  (1,024)  5,728 
2024  (634)  5,314 
Thereafter  (2,087)  17,798 
Total $(6,716) $49,239 

For the year ended December 31, 2019, the weighted average amortization period for asset lease intangibles and liability

lease intangibles are 6.70 years and 6.16 years, respectively.

Unaudited Pro Forma Financial Information

 

No acquisitions that occurred during 2019 and 2018 qualified for treatment as a business combination and therefore pro forma information is not provided for acquisitions that occurred during those years. The businesses acquired in 2017 and 2016 that were accounted for as business combinations were included in our results of operations from the dates of acquisition. The following table provides summary unaudited pro forma information as if the Company’s acquisitions during the yearsyear ended December 31, 2017 and 2016 that were accounted for as if business combinations had occurred as of January 1, 2016:2017:

 

71
  Year Ended December 31, 2017 
   (unaudited) 
Revenue $38,140 
Net income $1,828 
Net income attributable to common stockholders $41 
Income attributable to common stockholders per share – basic and diluted $- 
Weighted average shares outstanding – basic and diluted $19,617 

 


Note 4 – Credit Facility, Notes Payable and Derivative Instruments

 

  Year Ended December 31, 
  2017  2016 
  (unaudited) 
       
Revenue $38,140  $28,559 
Net income (loss) $1,828  $(1,191)
Net income (loss) attributable to common stockholders $41  $(1,191)
Income (loss) attributable to common stockholders per share – basic and diluted $-  $(0.13)
Weighted average shares outstanding – basic and diluted $19,617  $9,302 

Credit Facility

Intangible Assets and Liabilities

The followingCompany, the Operating Partnership, as borrower, and certain of its subsidiaries (such subsidiaries, the “Subsidiary Guarantors”) are parties to a syndicated credit facility with BMO, as administrative agent (the “Credit Facility”). Amounts outstanding under the Credit Facility bear interest at a floating rate that is based on LIBOR, plus a summaryspecified margin based on the Company’s leverage. On September 30, 2019, the Company entered into an amendment to the Credit Facility that, among other things, (i) increased the borrowings under the term-loan component (the “Term Loan”) from $175 million to $300 million, representing the exercise of the carryingremaining $75 million accordion feature and a re-allocation of $50 million from the revolver component (the “Revolver”) to the Term Loan and (ii) added a new $150 million accordion feature. Upon execution of the first amendment to the Company’s Credit Facility, the Credit Facility consisted of a $200 million capacity Revolver, a $300 million Term Loan and a $150 million accordion. The term of the Company’s Credit Facility expires in August 2022, subject to a one-year extension option. The amendment also amends the restricted payments financial covenant by deferring implementation of the 95% AFFO payout limitation contained in Section 8.24(a) of the Credit Facility from the fourth quarter of 2019 to the fourth quarter of 2020 and provides a mechanism for determining an alternative benchmark rate to LIBOR.

The Subsidiary Guarantors and the Company are guarantors of the obligations under the Credit Facility. The amount available to borrow from time to time under the Credit Facility is limited according to a quarterly borrowing base valuation of intangible assets and liabilitiescertain properties owned by the Subsidiary Guarantors.

The Operating Partnership is subject to a number of financial covenants under its Credit Facility, including, among other things, (i) a maximum consolidated leverage ratio as of the end of each fiscal quarter of less than 0.60:1.00, (ii) a minimum fixed charge coverage ratio of 1.50:1.00, (iii) a minimum net worth of $203.8 million plus 75% of all net proceeds raised through equity offerings subsequent to March 31, 2018 (which, as of December 31, 20172019, equaled $247.6 million) and 2016:

  Year Ended December 31, 2017 
  Cost  Accumulated
Amortization
  Net 
Assets            
In-place leases $17,061  $(1,577) $15,484 
Above market ground lease  488   (6)  482 
Above market leases  4,625   (220)  4,405 
Leasing costs  9,476   (538)  8,938 
  $31,650  $(2,341) $29,309 
Liabilities            
Below market leases $1,389  $(98) $1,291 

  Year Ended December 31, 2016 
  Cost  Accumulated
Amortization
  Net 
Assets            
In-place leases $5,827  $(35) $5,792 
Above market leases  74   -   74 
Leasing costs  1,286   (8)  1,278 
  $7,187  $(43) $7,144 
             
Liabilities            
Below market leases $279  $(1) $278 

The following is(iv) a summaryratio of total secured recourse debt to total asset value of not greater than 0.10:1.00. Additionally, beginning at the end of fourth quarter of 2020, the Company’s distributions to common stockholders will be limited to an amount equal to 95% of its AFFO. As of December 31, 2019, the Company was in compliance with all of the acquired lease intangible amortization:financial and non financial covenants contained in the Credit Facility.

  Year Ended December 31, 
  2017  2016 
Amortization expense related to in-place leases $1,542  $35 
Amortization expense related to leasing costs $530  $8 
Decrease in rental revenue related to above market ground lease $6  $- 
Decrease in rental revenue related to above market leases $220  $- 
Increase in rental revenue related to below market leases $(97) $(1)

 

The Company had no intangible assets as of December 31, 2015 and therefore no amortization expense was incurred forhas entered into interest rate swaps to hedge its interest rate risk on the Term Loan. For additional information related to the interest rate swaps, see the “Derivative Instruments - Interest Rate Swaps” section herein.

During the year ended December 31, 2015.

72

Future aggregate2019, the Company borrowed $244,250 under the Credit Facility and repaid $173,175, for a net amortizationamount borrowed of the acquired lease intangible as of December 31, 2017, is as follows:

  Net Decrease
in Revenue
  Net Increase
in Expenses
 
2018 $(449) $3,019 
2019  (449)  3,019 
2020  (449)  3,019 
2021  (452)  2,404 
2022  (453)  2,096 
Thereafter  (1,344)  10,865 
Total $(3,596) $24,422 

For$71,075. During the year ended December 31, 2017,2018 the weighted average amortization period for asset lease intangibles and liability lease intangibles are 8.09 years and 8.27 years, respectively.

Note 4 – Notes Payable and RevolvingCompany borrowed $186,100 under the Credit Facility and repaid $70,725, for a net amount borrowed of $115,375. Interest expense incurred on the Credit Facility was$14,237, $11,371, and $4,234 for the years ended December 31, 2019, 2018, and 2017, respectively. As of December 2019 and 2018, the Company had the following outstanding borrowings under the Credit Facility:

  December 31, 2019  December 31, 2018 
Revolver $51,350  $180,275 
Term Loan  300,000   100,000 
Less: Unamortized debt issuance costs  (3,832)  (3,922)
Credit Facility, net $347,518  $276,353 

Costs incurred related to the Credit Facility, net of accumulated amortization, are netted against the Company’s “Credit Facility, net of unamortized debt issuance costs” balance in the accompanying Consolidated Balance Sheets. The Company paid $1,039 and $2,811 during the years ended December 31, 2019 and 2018, respectively, related to modifications to the Credit Facility and borrowing base additions. Amortization expense incurred was $1,129, $1,639, and $1,092 for the years ended December 31, 2019, 2018, and 2017, respectively, and is included in the “Interest Expense” line item in the accompanying Consolidated Statements of Operations.

 

SummaryIn July 2017, the FCA, which regulates LIBOR, announced its intention to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the ARRC, which identified the SOFR as its preferred alternative to USD-LIBOR in derivatives and other financial contracts. The Credit Facility provides that, on or about the LIBOR cessation date (subject to an early opt-in election), LIBOR shall be replaced as a benchmark rate in the Credit Facility with a new benchmark rate to be agreed upon by the Company and BMO, with such adjustments to cause the new benchmark rate to be economically equivalent to LIBOR. The Company is not able to predict when LIBOR will cease to be available or when there will be sufficient liquidity in the SOFR markets.


The Company has interest rate swap agreements that are indexed to LIBOR and is monitoring and evaluating the related risks. These risks arise in connection with transitioning contracts to a new alternative rate, including any resulting value transfer that may occur. The value of loans, securities, or derivative instruments tied to LIBOR could also be impacted if LIBOR is limited or discontinued. For some instruments, the method of transitioning to an alternative rate may be challenging, as they may require negotiation with the respective counterparty.

If a contract is not transitioned to an alternative rate and LIBOR is discontinued, the impact on our interest rate swap agreements is likely to vary by agreement. If LIBOR is discontinued or if the methods of calculating LIBOR change from their current form, interest rates on our current or future indebtedness may be adversely affected.

While the Company expects LIBOR to be available in substantially its current form until the end of 2021, it is possible that LIBOR will become unavailable prior to that point. This could result, for example, if sufficient banks decline to make submissions to the LIBOR administrator. In that case, the risks associated with the transition to an alternative reference rate will be accelerated and potentially magnified.

Notes Payable, Net of DiscountDebt Issuance Costs

 

The Company’s notes payable, net, includes two loans: (1) the Cantor Loan and (2) the West Mifflin Note, described in detail below. The following table sets forth the aggregate balances of these loans as of December 31, 20172019 and 2016.2018.

 

 December 31, 2017 December 31, 2016  December 31,
2019
  December 31,
2018
 
Notes payable, gross $39,475  $39,475  $39,475  $39,475 
Less: Unamortized debt discount  (930)  (1,062)
Less: Unamortized debt issuance costs  (667)  (799)
Cumulative principal repayments  (158)  (22)
Notes payable, net $38,545  $38,413  $38,650  $38,654 

 

Costs incurred related to securing the Company’s fixed-rate debt instruments have been capitalized as a debt discount, net of accumulated amortization, and are netted against the Company’s Notes Payable balance in the accompanying Consolidated Balance Sheets. During the years ended December 31, 2017 and 2016, the Company incurred zero and $1,090 of financing costs capitalized as debt discount. Amortization expense incurred related to the debt discountissuance costs was $132, $331,$131, and $127$132, for the years ended December 31, 2017, 2016,2019, 2018, and 2015,2017, respectively, and is included in the “Interest Expense” line item in the accompanying Consolidated Statements of Operations.

 

Cantor Loan

 

On March 31, 2016, through certain of the Company’sits wholly owned subsidiaries, the Company entered into a $32,097 portfolio commercial mortgage-backed securities loan (the “Cantor Loan”) with Cantor Commercial Real Estate Lending, LP (“CCRE”). The subsidiaries are GMR Melbourne, LLC, GMR Westland, LLC, GMR Memphis, LLC, and GMR Plano, LLC (“GMR(the “GMR Loan Subsidiaries”). The Cantor Loan has cross-default and cross-collateral terms. The Company used the proceeds of the Cantor Loan to acquire the Marina Towers (Melbourne, FL) and the Surgical Institute of Michigan (Westland, MI) properties and to refinance the Star Medical (Plano, TX) assets by paying off the existing principal amount of the loan with East West bank in the amount of $9,224, and the Company granted a security interest in the Gastro One (Memphis, TN) assets.

The Cantor Loan has a maturity date of April 6, 2026 and accrues annual interest at 5.22%. The first five years of the term require interest onlyinterest-only payments and after thatthereafter payments will include interest and principal, amortized over a 30-year schedule. Prepayment can only occur within four months prior to the maturity date, except that after the earlier of (a) 2two years after the loan is placed in a securitized mortgage pool, or (b) May 6, 2020, the Cantor Loan can be fully and partially defeased upon payment of amounts due under the Cantor Loan and payment of a defeasance amount that is sufficient to purchase U.S. government securities equal to the scheduled payments of principal, interest, fees, and any other amounts due related to a full or partial defeasance under the Cantor Loan.

 

The Company is securingsecured the payment of the Cantor Loan with the assets, including property, facilities, and rents, held by the GMR Loan Subsidiaries and has agreed to guarantee certain customary recourse obligations, including findings of fraud, gross negligence, or breach of environmental covenants by the GMR Loan Subsidiaries. The GMR Loan Subsidiaries will be required to maintain a monthly debt service coverage ratio of 1.35:1.00 for all of the collateral properties in the aggregate.

 

73

No principal payments were made on this note for the years ended December 31, 2017 and 2016. The note balance as of December 31, 20172019 and 20162018 was $32,097. Interest expense incurred on this note was $1,699 for each of the years ended December 31, 2017, 2016,2019, 2018, and 2015 was $1,699, $1,280, and zero, respectively.2017.

 

As of December 31, 2017,2019, scheduled principal payments due for each fiscal year ended December 31 are listed below as follows:

 

2018 $- 
2019  - 
2020  -  $- 
2021  315   282 
2022  449   447 
2023  471 
2024  492 
Thereafter  31,333   30,405 
Total $32,097  $32,097 

73

 

West Mifflin Note

 

In order to finance a portion of the purchase price for the West Mifflin facility, onOn September 25, 2015, the Company, (throughthrough its wholly ownedwholly-owned subsidiary GMR Pittsburgh LLC, as borrower)borrower, entered into a Term Loan and Security Agreement with Capital One, National Association (“Capital One”) to borrow $7,378. The note bears interest at 3.72% per annum and all unpaid interest and principal is due on September 25, 2020. Interest is paid in arrears and interest payments beginbegan on November 1, 2015 and have continued on the first day of each calendar month thereafter. Principal payments beginbegan on November 1, 2018 and have continued on the first day of each calendar month thereafter based on an amortization schedule with the remaining principal balance due on the maturity date. The Company, at its option, may prepay the note at any time, in whole (but not in part) on at least thirty calendar days but not more than sixty calendar days advancewith advanced written notice. The note has an early termination fee of two percent if prepaid prior to September 25, 2018. TheWest Mifflin facility serves as collateral for the note. The note requires a quarterly fixed charge coverage ratio of at least 1:1, a quarterly minimum debt yield of 0.09:1.00, and annualized Operator EBITDAR (as defined in the note) measured on a quarterly basis of not less than $6,000. The Operator is Associates in Ophthalmology, Ltd. and Associates Surgery Centers, LLC. NoThe Company made principal payments were made on this note forof $136 and $22 during the years ended December 31, 20172019 and 2016.2018. The note balance as of December 31, 20172019 and 20162018 was $7,378.$7,220 and $7,356, respectively. The balance is scheduled to be paid in full during 2020.Interest expense incurred on this note was $278, $279,$274, $280, and $51$278, for the years ended December 31, 2017, 2016,2019, 2018, and 2015,2017, respectively.

 

Derivative Instruments - Interest Rate Swaps

As of December 31, 2017, scheduled principal payments due for each fiscal year ended December 31 are listed below as follows:

2018 $22 
2019  136 
2020  7,220 
Total $7,378 

Asheville Note Payable

In order to finance a portion of the purchase price of the Asheville facility, on September 15, 20142019, the Company entered intohad five interest rate swaps that are used to manage the interest rate risk and fix the LIBOR component of certain of its floating rate debt as follows: (i) on August 7, 2018 the Company executed an interest rate swap with BMO that was designated as a Promissory Note with the Bank of North Carolina to borrow $1,700 with interestcash flow hedge on the outstanding principal balance atTerm Loan, with a notional amount of $100 million, a fixed interest rate of 4.75% per annum. This note was paid in full2.88%, and a maturity date of August 8, 2023; (ii) on December 2, 2016 using proceeds fromNovember 16, 2018 the Company’s senior revolving credit facility. Company executed separate interest rate swaps with SunTrust Bank (“SunTrust”) and Citizens Bank of Pennsylvania (“Citizens”) that were each designated as cash flow hedges. The swap with SunTrust has a notional amount of $40 million and the swap with Citizens has a notional amount of $30 million and both have a fixed interest rate of 2.93% and a maturity date of August 7, 2024; and (iii) on October 3, 2019 the Company executed separate interest rate swaps with BMO and SunTrust that were each designated as cash flow hedges. The swap with BMO has a notional amount of $90 million and the swap with SunTrust has a notional amount of $40 million, which effectively fixed the LIBOR component of the interest rate on a corresponding amount of the Term Loan at 1.21%. These interest rate swaps fix the LIBOR component on a weighted average basis at 2.17%.

In accordance with the termsprovisions of ASC Topic 815, the Company records the swaps either as an asset or a liability measured at its fair value at each reporting period. When hedge accounting is applied, the change in the fair value of derivatives designated and that qualify as cash flow hedges is (i) recorded in accumulated other comprehensive loss in the equity section of the note there was no prepayment penaltyCompany’s Consolidated Balance Sheets and (ii) subsequently reclassified into earnings as interest expense for the payoffperiod that the hedged forecasted transactions affect earnings. If specific hedge accounting criteria are not met, changes in the Company’s derivative instruments’ fair value are recognized currently as an adjustment to net income.

The Company’s interest rate swaps are not traded on an exchange. The Company’s interest rate swaps are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis based on the expected size of future cash flows on a discounted basis and incorporating a measure of non-performance risk. The fair values are based on Level 2 inputs within the framework of ASC Topic 820, “Fair Value Measurement.” The Company considers its own credit risk, as well as the credit risk of its counterparty, when evaluating the fair value of its derivative instruments.

The fair value of the note. The balanceCompany’s interest rate swaps was a net liability of the note was $1,662$6,491 and $3,487 as of December 31, 2015.Interest expense incurred2019 and 2018, respectively. The gross balances are included in the “Derivative Asset’ and “Derivative Liability” line items on the note was zero, $76,Company’s Consolidated Balance Sheets as of December 31, 2019 and $812018, respectively.

The table below details the components of the loss presented on the accompanying Consolidated Statements of Comprehensive Income (Loss) recognized on the Company’s interest rate swap agreements designated as cash flow hedges for the years ended December 31, 2017, 2016,2019, 2018, and 2015 respectively.2017.

 

Omaha Note Payable

  Years Ended December 31, 
  2019  2018  2017 
Amount of loss recognized in other comprehensive loss $3,922  $3,919  $      - 
Amount of loss reclassified from accumulated other comprehensive loss into interest expense  (969)  (198)  - 
Total change in accumulated other comprehensive loss $2,953  $3,721  $- 

 


In order to finance a portion of the purchase price for the Omaha facility, on June 5, 2014During 2020, the Company entered into a Term Loan and Security Agreement with Capital Oneestimates that an additional $1,737 will be reclassified as an increase to borrow $15,060 with interest at 4.91% per annum. The note was paid in full on July 11, 2016 using the proceeds from the Company’s initial public offering. In accordance with the terms of the note the prepayment resulted in the Company being required to pay an early termination fee in the amount of $301 because the note was paid in full prior to its maturity date. This fee was also paid on July 11, 2016 and is recorded as “Interest Expense” in the accompanying Consolidated Statements of Operations for the year ended December 31, 2016. The balance of the note was $14,748 as of December 31, 2015.Interest expense incurred on this note was zero, $488 (excluding the $301 early termination fee amount disclosed above), and $680 forexpense. Additionally, during the years ended December 31, 2017, 2016,2019, 2018, and 2015.

Revolving Credit Facility

As of December 31, 2017 and 2016, the Company had $164,900 and $27,700 of outstanding borrowings under its Revolving Credit Facility (as defined below), respectively. As described below, as of December 31, 2017, the maximum amount that the Company can borrow under the facility is $250,000.

74

On December 2, 2016, the Company, the Operating Partnership, as borrower, and certain subsidiaries, (such subsidiaries, the “Subsidiary Guarantors”) of the Operating Partnership entered into a senior revolving credit facility (the “Credit Facility”) with BMO Harris Bank N.A., as Administrative Agent (“BMO”), which initially provided up to $75,000 in revolving credit commitments for the Operating Partnership. The Credit Facility included an accordion feature that provided the Operating Partnership with additional capacity, subject to the satisfaction of customary terms and conditions, of up to $125,000, for a total initial facility size of up to $200,000. On March 3, 2017, the Company the Operating Partnership, as borrower, and the Subsidiary Guarantors of the Operating Partnership entered into an amendment to the Credit Facility with BMO, which increased the commitment amount to $200,000 plus an accordion feature that allows for up to an additional $50,000 of principal amount subject to certain conditions, for arecorded total facility size of $250,000 (the “Revolving Credit Facility”). On September 28, 2017, the Company obtained commitments from certain of its lenders on the Revolving Credit Facility for the entire $50,000 accordion. The Subsidiary Guarantors and the Company are guarantors of the obligations under the Revolving Credit Facility. The amount available to borrow from time to time under the Revolving Credit Facility is limited according to a quarterly borrowing base valuation of certain properties owned by the Subsidiary Guarantors. The initial termination date of the Revolving Credit Facility is December 2, 2019, which could be extended for one year in the case that no event of default occurs.

Amounts outstanding under the Revolving Credit Facility bear annual interest at a floating rate that is based, at the Operating Partnership’s option, on (i) adjusted LIBOR plus 2.00% to 3.00% or (ii) a base rate plus 1.00% to 2.00%, in each case, depending upon the Company’s consolidated leverage ratio. In addition, the Operating Partnership is obligated to pay a quarterly fee equal to a rate per annum equal to (x) 0.20% if the average daily unused commitments are less than 50% of the commitments then in effect and (y) 0.30% if the average daily unused commitments are greater than or equal to 50% of the commitments then in effect and determined based on the average daily unused commitments during such previous quarter.

The Operating Partnership is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales. The Operating Partnership must also maintain (i) a maximum consolidated leverage ratio, commencing with the fiscal quarter ending December 31, 2016 and as of the end of each fiscal quarter thereafter, of less than (y) 0.65:1.00 for each fiscal quarter ending prior to October 1, 2019 and (z) thereafter, 0.60:1.00, (ii) a minimum fixed charge coverage ratio of 1.50:1.00, (iii) a minimum net worth of $119,781 plus 75% of all net proceeds raised through subsequent equity offerings and (iv) a ratio of total secured recourse debt to total asset value of not greater than 0.10:1.00.

During the year ended December 31, 2017, the Company borrowed $244,200 under the Revolving Credit Facility and repaid $107,000 using funds primarily from the follow-on common stock offering and the preferred stock offering, for a net amount borrowed of $137,200. During the year ended December 31, 2016, the Company borrowed $27,700 under the Revolving Credit Facility and made no repayments. For the years ended December 31, 2017 and 2016, interest incurred on the Revolving Credit Facility was $4,234 and $46, respectively. No interest expense was incurred under the Revolving Credit Facility for the year ended December 31, 2015 as the Revolving Credit Facility was not in place. For a detail of the facilities that serve as collateral for the Revolving Credit Facility refer to Schedule III – “Consolidated Real Estate and Accumulated Depreciation,” within Item 15 – “Exhibits and Financial Statement Schedules.”

Deferred Financing Costs, Net

Costs incurred related to securing the Company’s Revolving Credit Facility have been capitalized as a deferred financing asset, net of accumulated amortization, in the accompanying Consolidated Balance Sheets.

A rollforward of the deferred financing cost balance as of December 31, 2017, is as follows:

Balance as of January 1, 2017, net $927 
Additions – Revolving Credit Facility  2,915 
Deferred financing cost amortization expense  (1,092)
Balance as of December 31, 2017, net $2,750 

A rollforward of the deferred financing cost balance as of December 31, 2016 is as follows:

Balance as of January 1, 2016, net $- 
Additions – Revolving Credit Facility  946 
Deferred financing cost amortization expense  (19)
Balance as of December 31, 2016, net $927 

Amortization expense incurred related to the Revolving Credit Facility deferred financing costs was $1,092, $19, and zero for the years ended December 31, 2017, 2016, and 2015, respectively, and is included in the “Interest Expense” line item in the accompanyingits Consolidated Statements of Operations.Operations of $17,472, $14,975, and $7,435, respectively.

75

 

Weighted-Average Interest Rate and Term

 

The weighted average interest rate and term of ourthe Company’s debt was 3.72%3.90% and 2.943.76 years, respectively, at December 31, 2017,2019, compared to 4.29%4.64% and 6.044.24 years, respectively, atas of December 31, 2016.2018.

 

Note 5 – Stockholders’ Equity

 

Preferred Stock

 

General

 

The Company’s charter authorizes the issuance of 10,000 shares of preferred stock, par value $0.001 per share. As of December 31, 20172019 and December 31, 2016,2018, there were 3,105 and no shares of preferred stock, respectively, issued and outstanding.

 

On September 15, 2017, the Company closed on the issuance of 3,105 shares of its Series A Cumulative Redeemable Preferred Stock, $0.001 par value per share, with an initial liquidation preference of $25 per share (“Series A Preferred Stock”), inclusive of 405 shares issued in connection with the underwriters’ exercise of their over-allotment option. The Company may, at its option, redeem the Series A Preferred Stock for cash in whole or in part, from time to time, at any time on or after September 15, 2022, at a cash redemption price of $25 per share. The Series A Preferred Stock has no voting rights, except for limited voting rights if the Company fails to pay dividends for six quarterly periods. The issuance resulted in aggregate grossthe Company receiving net proceeds of $77,625. After deducting underwriting discounts and advisory fees of $2,445, and expenses paid by the Company that were directly attributable to the offering of $221 (which are both treated as a reduction of the “Preferred Stock” balance on the accompanying Consolidated Balance Sheets), the Company’s preferred stock balance as of December 31, 2017 was $74,959. The net proceeds received from the transaction$74,959, which were primarily used to repay borrowings on the Company’s Revolving Credit Facility. The Company assessed the characteristics of the Series A Preferred Stock in accordance with the provisions of ASC Topic 480 – “Distinguishing Liabilities from Equity,” and concluded that the Series A Preferred Stock isbe classified as permanent equity.

 

Preferred Stock Dividends

 

Since September 2017, our Board has declared cash dividendsDividend activity on our preferred stock asduring the years ended December 31, 2019 and 2018 is summarized in the following table:

 

Date Announced Record Date Applicable
Quarter
 Payment Date Dividend
Amount
 Dividends
per Share
  Record Date Applicable
Quarter
 Payment Date Quarterly
Dividend
  Dividends per
Share
 
           
September 29, 2017 October 15, 2017 Q3 2017 October 31, 2017 $745  $0.23960 
December 15, 2017 January 15, 2018 Q4 2017 January 31, 2018  9691 $0.46875  January 15, 2018 Q4 2017 January 31, 2018 $1,455  $0.46875 
March 7, 2018 April 15, 2018 Q1 2018 April 30, 2018 $1,456  $0.46875 
June 15, 2018 July 15, 2018 Q2 2018 July 31, 2018 $1,455  $0.46875 
September 10, 2018 October 15, 2018 Q3 2018 October 31, 2018 $1,455  $0.46875 
December 13, 2018 January 15, 2019 Q4 2018 January 31, 2019 $1,455  $0.46875 
March 6, 2019 April 15, 2019 Q1 2019 April 30, 2019 $1,455  $0.46875 
June 14, 2019 July 15, 2019 Q2 2019 July 31, 2019 $1,455  $0.46875 
September 13, 2019 October 15, 2019 Q3 2019 October 31, 2019 $1,455  $0.46875 
December 13, 2019 January 15, 2020 Q4 2019 January 31, 2020 $1,455(1) $0.46875 

 

1(1)Represents the November 2017 andTwo months of this amount, equal to $970, was accrued at December 2017 portion of the total $1,455 three month dividend amount.31, 2019.

 

The holders of the Company’s Series A Preferred Stock are entitled to receive dividend payments only when, as and if declared by the Board (or a duly authorized committee of the Board). Dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date at a fixed rate per annum equal to 7.50% of the liquidation preference of $25 per share (equivalent to $1.875 per share on an annual basis). Dividends on the Series A Preferred Stock will be cumulative and will accrue whether or not (i) funds are legally available for the payment of those dividends, whether or not(ii) the Company has earnings and whether or not(iii) those dividends are declared by the Board. The quarterly dividend payment dates on the Series A Preferred Stock are January 31, April 30, July 31 and October 31 of each year, commencingwhich commenced on October 31, 2017. During the yearyears ended December 31, 20172019 and 2018, the Company paid preferred dividends of $745.$5,822 and $5,821, respectively.

75

 

Common Stock

 

General

 

The Company has 500,000 of authorized shares of common stock, $0.001 par value. As of December 31, 20172019 and 2016,2018, there were 21,63143,806 and 17,60625,944 outstanding shares of common stock, respectively.

 

Common Stock Dividends

 

Since July 2016, our Board has declared cash dividendsDividend activity on our common stock asduring the years ended December 31, 2019 and 2018 is summarized in the following table:

 

76

Date Announced Record Date Applicable
Quarter
 Payment Date Dividend
Amount1
  Dividends
per Share
 
             
September 14, 2016 September 27, 2016 Q3 2016 October 11, 2016 $3,593  $0.20 
December 14, 2016 December 27, 2016 Q4 2016 January 10, 2017 $3,604  $0.20 
March 20, 2017 March 27, 2017 Q1 2017 April 10, 2017 $3,603  $0.20 
June 16, 2017 June 27, 2017 Q2 2017 July 10, 2017 $3,608  $0.20 
September 8, 2017 September 26, 2017 Q3 2017 October 9, 2017 $4,416  $0.20 
December 15, 2017 December 26, 2017 Q4 2017 January 10, 2018 $4,552  $0.20 
Date Announced Record Date Applicable
Quarter
 Payment Date Dividend
Amount(1)
  Dividends per
Share
 
December 15, 2017 December 26, 2017 Q4 2017 January 10, 2018 $4,552  $0.20 
March 7, 2018 March 22, 2018 Q1 2018 April 10, 2018 $4,691  $0.20 
June 15, 2018 June 26, 2018 Q2 2018 July 11, 2018 $4,786  $0.20 
September 10, 2018 September 20, 2018 Q3 2018 October 10, 2018 $4,889  $0.20 
December 13, 2018 December 26, 2018 Q4 2018 January 10, 2019 $5,695  $0.20 
March 6, 2019 March 26, 2019 Q1 2019 April 10, 2019 $7,688  $0.20 
June 14, 2019 June 26, 2019 Q2 2019 July 11, 2019 $7,699  $0.20 
September 13, 2019 September 25, 2019 Q3 2019 October 10, 2019 $8,004  $0.20 
December 13, 2019 December 26, 2019 Q4 2019 January 9, 2020 $9,541  $0.20 

 

1(1)Includes dividends on granted LTIP unitsUnits and OP Units issued to third parties.

 

During the year ended December 31, 2017,2019, the Company paid total dividends on its common stock, LTIP unitsUnits, and OP Units in the amount of $15,231,$29,171, consisting of the dividends declared for the fourth quarter of 20162018 through the third quarter of 2017.2019. Additionally, during the year ended December 31, 2016,2018, the Company paid total dividends on its common stock, LTIP Units and OP Units in the amount of $3,878, and during$18,918, consisting of the year ended December 31, 2015,dividends declared for the Company paid total dividends on its common stock infourth quarter of 2017 through the amountthird quarter of $256.2018.

 

As of December 31, 2017,2019 and 2018, the Company had an accrued $117dividend balance of $580 and $316 for dividends payable on the aggregate annual and long-term LTIP unitsUnits that are subject to retroactive receipt of dividends on the amount of LTIPsLTIP Units ultimately earned. See Note 7 – Stock-Based Compensation for additional information.During the year ended December 31, 2019, $349 of dividends were accrued and $85 of dividends were paid related to these LTIP Units. During the year ended December 31, 2018, $245 of dividends were accrued and $46 of dividends were paid related to these units.

 

The amount of the dividends paid to the Company’s stockholders is determined by ourthe Company’s Board and is dependent on a number of factors, including funds available for payment of dividends, the Company’s financial condition and capital expenditure requirements except that, in accordance with the Company’s organizational documents and Maryland law, the Company may not make dividend distributions that would: (i) cause it to be unable to pay its debts as they become due in the usual course of business; (ii) cause its total assets to be less than the sum of its total liabilities plus senior liquidation preferences; or (iii) jeopardize its ability to maintain its qualification as a REIT.

 

Other Common Stock Activity During 2019

 

On December 13, 2019, the Company closed an underwritten public offering of its common stock and on December 26, 2019 the Company closed on the related over-allotment option granted to the underwriters. These transactions resulted in the issuance of 6,900 shares of the Company’s common stock at a public offering price of $13.00 per share, generating net proceeds of $84,702.

On March 18, 2019, the Company closed an underwritten public offering of its common stock and on March 25, 2019, the Company closed on part of the related over-allotment option granted to the underwriters. These transactions resulted in the issuance of 8,233 shares of the Company’s common stock at a public offering price of $9.75 per share, generating net proceeds of $75,723.

The Company, its Advisor, and the Operating Partnership have entered into a Sales Agreement with a number of financial institutions, pursuant to which the Company may offer and sell, from time to time, up to $50 million of its common stock (the “ATM Program”), inclusive of any amounts sold under its prior sales agreement. During the year ended December 31, 2019, the Company issued 2,632 shares of its common stock at an average offering price of $11.24 per share pursuant to the ATM Program, generating net proceeds of $29,073.


Other Common Stock Activity During 2018

On December 14, 2018, the Company closed an underwritten public offering of its common stock and on December 26, 2018 the Company closed on the related over-allotment option granted to the underwriters. These transactions resulted in the issuance of 3,651 shares of the Company’s common stock at a public offering price of $9.00 per share, generating net proceeds of $31,540.

During the year ended December 31, 2018, the Company issued 662 shares of its common stock at an average offering price of $9.41 per share pursuant to the ATM Program, generating net proceeds of $5,767.

On June 30, 2017, the Company closed an underwritten public offering of its common stock and on July 20, 2017, the Company closed on the related over-allotment option granted to the underwriters. These transactions resulted in an aggregatethe issuance of 4,025 shares of its common stock being issued at a public offering price of $9 per share, resulting in aggregate gross proceeds of $36,225. After deducting underwriting discounts and advisory fees of $1,987, and expenses paid by the Company that were directly attributable to the offering of $443 (both of which are treated as a reduction of the Company’s additional paid-in capital balance), the Company received net proceeds from the transactions of $33,795.

On March 2, 2016, ZH USA, LLC converted $15,000 of principal under the Convertible Debenture into 1,177 shares of the Company’s then unregistered common stockbased on a conversion rate of $12.748 per share.

On July 1, 2016, the Company closed its initial public offering and issued 13,043 shares of its common stock at a price of $10.00 per share resulting in gross proceeds of $130,435. After deducting underwriting discounts and commissions, advisory fees, and other offering expenses, the Company received net proceeds from the offering of $120,774. Additionally, on July 11, 2016, the underwriters exercised their over-allotment option in full, resulting in the issuance by the Company of an additional 1,957 shares of the Company’s common stock at a public offering price of $10.00$9.00 per share, for grossgenerating net proceeds of $19,565. After deducting underwriting discounts and expenses, advisory fees, and other offering expenses, the Company received net proceeds from the over-allotment option shares of $18,195. Total shares issued by the Company in the initial public offering, including over-allotment option shares, were 15,000 shares and the total net proceeds received were $137,288, which represented gross proceeds received of $138,969 net of $1,681 in costs directly attributable to the initial public offering that were deferred and paid.

On July 1, 2016, ZH USA, LLC converted $15,030 of the principal under the Convertible Debenture into 1,179 shares of the Company’s registered common stock based on a conversion rate of $12.748 per share.$33,795.

 

In order to help the Company qualify as a REIT, among other purposes, the Company’s charter, subject to certain exceptions, restricts the number of shares of the Company’s common stock that a person may beneficially or constructively own. The Company’s charter provides that, subject to certain exceptions, no person may beneficially or constructively own more than 9.8%, in value or in number of shares, whichever is more restrictive, of the outstanding shares of any class or series of the Company’s capital stock. On June 27, 2016, the Board approved a waiver of the 9.8% ownership limit in the Company’s charter allowing ZH USA, LLC to own up to 16.9% of the Company’s outstanding shares of common stock.

 

77

OP Units

 

OP Units are limited partnership interests in the Company’s Operating Partnership. OP Units are redeemable by the holder for cash or, at the Company’s option, an equivalent number of shares of the Company’s common stock. During the year ended December 31, 2019, the Company issued an aggregate of 49 OP Units with a value of $506 in connection with a facility acquisition. Additionally, during the year ended December 31, 2019, two OP Unit holders redeemed an aggregate of 51 OP Units that were issued during 2017 in connection with a facility acquisition. The Company redeemed such OP Units for shares of its common stock with a value of $519. During the year ended December 31, 2018, the Company issued an aggregate of 1,899 OP Units with a value of $16,363 in connection with three facility acquisitions. As of December 31, 2017,2019 and 2018, there were 1,2463,143 and 3,145 OP Units issued and held by third partiesoutstanding, respectively, with an aggregate value of $11,532. There were 1,221$27,881 and $27,894, respectively. The OP Units issued in connection with the acquisition of two separate facilities, which were valued in aggregate at $11,300 using the measurement date represented by the closing date of the respective acquisitions using the Company’s closing stock price on each respective measurement date. Additionally, 25 OP Units were issued pursuant to a third party advisory agreement and were valued in aggregate at $232 using the three contractual installment dates of their issuanceUnit value is based on the Company’s closing common stock price on eachthe date of the respective installment / measurement dates.transaction and is included as a component of noncontrolling interest in the Company’s Consolidated Balance Sheets as of December 31, 2019 and 2018. The Company has a sufficient number of common shares authorized to cover the redemption of outstanding OP Units.

 

Note 6 – Related Party Transactions

 

Initial Management Agreement

On November 10, 2014,the Company entered into a management agreement, with an effective date of April 1, 2014, with the Advisor. Under the terms of this initial management agreement, the Advisor was responsible for designing and implementing the Company’s business strategy and administering its business activities and day-to-day operations. For performing these services, the Company was obligated to pay the Advisor a base management fee equal to the greater of (a) 2.0% per annum of the Company’s net asset value (the value of the Company’s assets less the value of the Company’s liabilities), or (b) $30 per calendar month.

In addition pursuant to the initial management agreement the Company owed the Advisor an acquisition fee computed at a rate of 2% of the purchase price of an acquired facility.

Amended Management Agreement

 

Upon completion of the Company’s initial public offering on July 1, 2016, the Company and the Advisor entered into an amended and restated management agreement (the “Amended Management Agreement”). Certain material terms of the Amended Management Agreement are summarized below:

Term and Termination

 

The Amended Management Agreement hashad an initial term of three years expiringthat expired on the third anniversary of the closing date of the initial public offering but will automatically renew forJuly 1, 2019, and is currently subject to an unlimited number of successive one-year renewal periods, thereafter, unless the agreement is not renewed or is terminated in accordance with its terms. If the Board decides to terminate or not renew the Amended Management Agreement, the Company will generally be required to pay the Advisor a termination fee equal to three times the sum of the average annual base management fee and the average annual incentive compensation with respect to the previous eight fiscal quarters ending on the last day of the fiscal quarter prior to termination. Subsequent to the initial term, the Company may terminate the Amended Management Agreement only under certain circumstances.

 

Base Management Fee

 

The Company pays its Advisor a base management fee in an amount equal to 1.5% of its stockholders’ equity per annum, calculated quarterly for the most recently completed fiscal quarter and payable in quarterly installments in arrears in cash.

 

For purposes of calculating the base management fee, the Company’s stockholders’ equity means: (a) the sum of (1) the Company stockholders’ equity as of March 31, 2016, (2) the aggregate amount of the conversion price (including interest) for the conversion of the Company’s outstanding convertible debentures into common stock and OP Units upon completion of the initial public offering, and (3) the net proceeds from (or equity value assigned to) all issuances of equity and equity equivalent securities (including common stock, common stock equivalents, preferred stock, LTIP unitsUnits and OP Units issued by the Company or the Operating Partnership) in the initial public offering, or in any subsequent offering (allocated on a pro rata daily basis for such issuances during the fiscal quarter of any such issuance), less (b) any amount that the Company pays to repurchase shares of its common stock or equity securities of the Operating Partnership. Stockholders’ equity also excludes (1) any unrealized gains and losses and other non-cash items (including depreciation and amortization) that have impacted stockholders’ equity as reported in the Company’s financial statements prepared in accordance with GAAP, and (2) one-time events pursuant to changes in GAAP, and certain non-cash items not otherwise described above, in each case after discussions between the Advisor and its independent directors and approval by a majority of the Company’s independent directors. As a result, the Company’s stockholders’ equity, for purposes of calculating the base management fee, could be greater or less than the amount of stockholders’ equity shown on its financial statements.

 

78

The base management fee of the Advisor shall be calculated within 3045 days after the end of each quarter and such calculation shall be promptly delivered to the Company. The Company is obligated to pay the quarterly installment of the base management fee calculated for that quarter in cash within five15 business days after delivery to the Company of the written statement of the Advisor setting forth the computation of the base management fee for such quarter.

Incentive Fee

 

The Company paysmay also be required to pay its Advisor an incentive fee with respect to each calendar quarter (or part thereof that the management agreementAmended Management Agreement is in effect) in arrears. The incentive fee is an amount, not less than zero, equal to the difference between (1) the product of (x) 20% and (y) the difference between (i) the Company’s AFFO (as defined below) for the previous 12-month period, and (ii) the product of (A) the weighted average of the issue price of equity securities issued in the initial public offering and in future offerings and transactions, multiplied by the weighted average number of all shares of common stock outstanding on a fully-diluted basis (including any restricted stock units, any restricted shares of common stock, OP Units, LTIP units,Units, and shares of common stock underlying awards granted under the 2016 Equity Incentive Plan (the “2016 Equity Plan”) or any future plan in the previous 12-month period, and (B) 8%, and (2) the sum of any incentive fee paid to the Advisor with respect to the first three calendar quarters of such previous 12-month period; provided, however, that no incentive fee is payable with respect to any calendar quarter unless AFFO is greater than zero for the four most recently completed calendar quarters.

 

Per the terms of the Amended Management Agreement, AFFO is calculated by adjusting the Company’s funds from operations, or FFO, by adding back acquisition and disposition costs, stock-based compensation expenses, amortization of deferred financing costs and any other non-recurring or non-cash expenses, which are costs that do not relate to the operating performance of the Company’s properties, and subtracting loss on extinguishment of debt, straight line rent adjustment, recurring tenant improvements, recurring leasing commissions and recurring capital expenditures. To dateAs of December 31, 2019, the Company hashad not incurred or paid an incentive fee.

 

Management Fees, Acquisition Fees and Accrued Management Fees

 

For the years ended December 31, 2017, 2016,2019, 2018, and 20152017, management fees of $3,123$6,266, $4,422, and $1,434, and $360,$3,123, respectively, were incurred and expensed by the Company. During the years ended December 31, 2017 and 2016 management fees of $2,680 and $1,443, respectively, were paid to the Advisor, resulting in accruedAccrued management fees due to the Advisor of $1,064were $1,727 and $621,$1,143 as of December 31, 20172019 and 2016,2018, respectively.

During No incentive management fee was incurred by the Company during the years ended December 31, 2016 and 2015, acquisition fees of $754 and $627, respectively were expensed and paid by the Company.2019, 2018, or 2017.

 

Allocated General and Administrative Expenses

 

Effective May 8, 2017, the Company and the Advisor entered into an agreement pursuant to which, for a period of one year commencing on May 8, 2017, the Company agreed to reimburse the Advisor for $125 of the annual salary of the General Counsel and Secretary of the Company for so long as he continuescontinued to be primarily dedicated to the Company in his capacity as its General Counsel and Secretary. This reimbursement agreement expired in May 2018 and was not renewed. In the future, the Company may receive additional allocations of general and administrative expenses from the Advisor that are either clearly applicable to or were reasonably allocated to the operations of the Company. There were no allocated general and administrative expenses from the Advisor for the year ended December 31, 2019. Other than via the terms of the reimbursement agreement noted above, there were no allocated general and administrative expenses from the Advisor for the years ended December 31, 20172018 and 2016.2017.

 

79

78

 

 

Due to Related Parties, NetParty Balances

 

AllA rollforward of the due from related parties and due to related party balances are due on demand and non-interest-bearing.balance, net, as of December 31, 2019 is as follows:

  

Due From

Related Parties

  Due to Related Party, Net 
  Funds for Various
Purposes
  Mgmt. Fees
due to
Advisor
  Other
Funds due
from
Advisor
  Due to
Related
Party, net
 
Balance as of January 1, 2019 $61  $(1,143)  52  $(1,091)
Management fee expense incurred  -   (6,266)  -   (6,266)
Management fees paid to Advisor  -   5,682   -   5,682 
Loans to Advisor  -   -   27   27 
Loan repayments from related parties  (11)  -   -   - 
Balance as of December 31, 2019 $50  $(1,727)  79  $(1,648)

 

A rollforward of the due (to) from related parties balance, net, as of December 31, 2017,2018, is as follows:

 

  Due to
Advisor –
Mgmt. Fees
  Due (to) from
Advisor – Other
Funds
  Due (to) from
Other Related
Party
  Total Due (To)
From Related
Parties, Net
 
Balance as of January 1, 2017 $(621)  -   40  $(581)
Management fee expense incurred1  (3,123)  -   -   (3,123)
Management fees paid to Advisor1  2,680   -   -   2,680 
Loan repaid to Advisor2  -   9   -   9 
Loan repaid by other related party3  -   -   (21)  (21)
Balance as of December 31, 2017 $(1,064)  9   19  $(1,036)

1Net amount accrued of $443 consists of $3,123 in management fee expense incurred, net of $2,680 of accrued management fees that were paid to the Advisor. This represents a cash flow operating activity.

2Amount represents the overpayment of expenses that were previously paid by the Advisor on the Company’s behalf. This represents a cash flow financing activity.

3Amount represents the net receipt by the Company of previous loans made by the Company to those related parties. This represents a cash flow investing activity.

A rollforward of the due (to) from related parties balance, net as of December 31, 2016 is as follows:

  Due from
Advisor
  Due to
Advisor –
Mgmt. Fees
  Due to Advisor –
Other Funds
  Due (to) from
Other Related
Party
  Total Due (To)
From Related
Parties, Net
 
Balance as of January 1, 2016 $178   (630)  (240)  (155) $(847)
Management fees incurred1      (1,434)          (1,434)
Management fees paid to Advisor1  -   1,443   -   -   1,443 
Funds repaid to Advisor2  -   -   240   -   240 
Funds repaid to Other Related Party2  -   -   -   155   155 
Funds loaned to Other Related Party3              1   1 
Funds repaid by Advisor3  (178)              (178)
Funds loaned to ZH USA, LLC3  -   -   -   39   39��
Balance as of December 31, 2016 $-   (621)  -   40  $(581)

1Net amount repaid of $9 consists of $1,434 in management fee expense incurred, net of $1,443 of accrued management fees that were repaid to the Advisor. This is a cash flow operating activity.

2Total amount of $395 consists of $240 repaid by the Company to the Advisor and $155 repaid by the Company to another related party. This is a cash flow financing activity.

3Net amount of $138 consists of loan repaid by Advisor in the amount of $178, net of $39 that the Company loaned to a related party for its general use, and $1 in additional funds loaned to related party. This is a cash flow investing activity.

Convertible Debenture, due to Related Party

Prior to 2016, the Company received funds from its prior majority stockholder, ZH USA, LLC, in the form of a convertible interest-bearing notes (8% per annum, payable in arrears) which was due on demand unsecured debt.The Company had the option to prepay the note at any time, in whole or in part, and ZH USA, LLC had the ability to convert all or a portion of the outstanding principal amount of the note into shares of common stock in an amount equal to the principal amount of the note, together with accrued but unpaid interest, divided by $12.748. The outstanding balance on the convertible debenture was zero as of December 31, 2017 and 2016.

A rollforward of the funding from ZH USA, LLC classified as convertible debenture, due to related party as of December 31, 2016 is as follows:

Balance as of January 1, 2016 $40,030 
Conversion of convertible debenture to common shares (March 2, 2016)1  (15,000)
Conversion of convertible debenture to common shares (July 1, 2016)1  (15,030)
Pay-off of remaining principal balance  (10,000)
Balance as of December 31, 2016 $- 

1 Total amount converted to common shares equals $30,030

On March 2, 2016, ZH USA, LLC converted $15,000 of principal under the Convertible Debenture into 1,177 shares of the Company’s then unregistered common stockbased on a conversion rate of $12.748 per share.  

80

On June 15, 2016, in anticipation of its initial public offering, the Company entered into a Pay-Off Letter and Conversion Agreement (the “Pay-Off Letter and Conversion Agreement”) with ZH USA, LLC with regards to the Convertible Debentures loaned to the Company. Under the terms of the Pay-Off Letter and Conversion Agreement, upon the closing date of the initial public offering on July 1, 2016, ZH USA, LLC converted $15,030 of the principal under the Convertible Debenture into 1,179 shares of the Company’s registered common stock based on a conversion rate of $12.748 per share. Additionally, in accordance with the Pay-Off Letter and Conversion Agreement, on July 8, 2016 the Company paid off the remaining principal amount of $10,000 outstanding under the Convertible Debentures.

On July 8, 2016, also in accordance with the Pay-Off Letter and Conversion Agreement, the Company paid all accrued interest owed and outstanding on the Convertible Debentures in the amount of $1,717. Accrued interest was included in the line item “Accrued Expenses” in the accompanying Consolidated Balance Sheets.

Additionally, during the year ended December 31, 2015, the Company received aggregate funds in the amount of $34,584, which were accounted for as Convertible Debentures. The funds were received in four separate transactions as follows: $20,900 to acquire the Tennessee facilities, $4,546 for the West Mifflin acquisition, $9,000 for the Plano acquisition, and $138 held by the Company to be used for future acquisitions.

Interest expense on the Convertible Debentures was zero, $1,243, and $581 for the years ended December 31, 2017, 2016, and 2015, respectively.

Notes Payable to Related Parties

During the year ended December 31, 2016, the Company received $450 in the form of an interest bearing note payable from a related party. The note incurred interest at 4% per annum and was due on demand. Interest expense incurred on this note was $10 for the year ended December 31, 2016. This note was paid in full during the year ended December 31, 2016 and therefore had a zero balance as of December 31, 2017 and 2016, respectively.

Prior to 2016 the Company received funds from ZH USA, LLC in the form of a non-interest bearing, due on demand note payable. The Company repaid this loan in full during 2017 and accordingly the balance of this note was zero and $421 as of December 31, 2017 and 2016, respectively.

ZH USA, LLC Intercompany Loan

On June 7, 2016, the Company received an interest free intercompany loan from ZH USA, LLC in the principal amount of $1.5 million, which was repaid in full on July 8, 2016, using a portion of the proceeds from the initial public offering.

  Due to
Advisor –
Mgmt. Fees
  Due (to) from
Advisor – Other
Funds
  Due (to) from
Other Related
Party
  Total Due (To)
From Related
Parties, Net
 
Balance as of January 1, 2018 $(1,064)  9   19  $(1,036)
Management fee expense incurred  (4,422)  -   -   (4,422)
Management fees paid to Advisor  4,343   -   -   4,343 
Loans to Advisor  -   43   -   43 
Loans to other related parties  -   -   42   42 
Balance as of December 31, 2018 $(1,143)  52   61  $(1,030)

 

Note 7 – Stock-Based Compensation

 

2016 Equity Incentive Plan

 

The 2016 Equity Incentive Plan, as amended (the “Plan”), is intended to assist the Company and its affiliates in recruiting and retaining employees of the Manager, members of the Board, executive officers of the Company, and other individuals who provide services to the Company, the Manager, the Operating Partnershipthose entities or an Affiliateaffiliates of the Company, the Manager or the Operating Partnership.those entities.

 

ThisThe Plan is intended to permit the grant of both options qualifying and non-qualified options and the grant of stock appreciation rights, restricted stock, unrestricted stock, awards of restricted stock units, performance awards and other equity-based awards (including LTIP units)Units) for up to an aggregate of 1,2321,763 shares of common stock, subject to increase under certain provisions of the plan. The Company’s executive officers, employees, employees of its Advisor and its affiliates, consultants and non-employee directors are eligible to participate in the Plan.

Based on the grants outstanding as of December 31, 2017,2019, there are 614 shares584 units that remain available to be granted under the Plan. SharesUnits subject to awards under the Plan that are forfeited, cancelled, lapsed, settled in cash or otherwise expired (excluding shares withheld to satisfy exercise prices or tax withholding obligations) are available for grant.

 

Time-Based Grants

 

The time-based vesting LTIP units grantedUnit activity under the Plan during the yearsyear ended December 31, 2016 and 2017are2019 was as follows:

 

LTIP units granted on July 1, 2016358
LTIP units granted on December 21, 201657
Total Plan LTIP units granted as of January 1, 2017415
LTIP units granted during the year ended December 31, 201760
LTIP units forfeited during the year ended December 31, 2017(39)
Net LTIP unitsUnits outstanding as of December 31, 20172018  436588
LTIP Units earned and granted via the 2018 performance program – Annual Awards(1)108
LTIP Units granted on a discretionary basis related to the Annual Awards(2)28
LTIP Units granted as 2019 long-term time based awards(3)54
LTIP Units granted to independent directors of the Board(4)22
LTIP Units – other grant and forfeitures, net(5)(42)
LTIP Units outstanding as of December 31, 2019758 

 

81(1)The 108 LTIP Units represents earned and granted units from the previously disclosed 2018 annual awards (the “Annual Awards”). On March 5, 2019 the Compensation Committee of the Board (the “Compensation Committee”) determined the extent to which the Company achieved the performance goals related to the 2018 Annual Awards and determined the number of LTIP Units that each grantee was entitled to receive. These grants vested 50% on March 5, 2019, the determination date, and 50% vest on March 5, 2020.

(2)The 28 LTIP Units represents a discretionary grant by the Board. These grants vested 50% on March 5, 2019, the grant date, and 50% vest on March 5, 2020.

(3)The 54 LTIP Units represent grants approved by the Board on March 5, 2019 pursuant to the Company’ 2019 Long-Term Incentive Plan. These grants are valued based on the Company’s common stock price on the date of grant of $10.07 and vest in equal one-third increments on each of March 5, 2020, March 5, 2021, and March 5, 2022.

(4)The 22 LTIP Units represent a grant to the independent directors of the Board made on May 29, 2019, which vest on May 29, 2020.

(5)The net decrease of 42 LTIP Units net represents 45 LTIP Units redeemed for the Company’s common stock and one LTIP Unit that was forfeited, partially offset by three LTIP Units that were granted on March 15, 2019 and one LTIP Unit granted on December 9, 2019, both related to new hires. The LTIP Units granted to the new hires vest in equal one-third increments from the date of grant.

 


Of these 436A detail of the vested and unvested LTIP units that wereUnits outstanding as of December 31, 2017, 267 are vested and 169 are unvested. Of the unvested LTIP units, 153 units were granted to employees of the Advisor and its affiliates deemed to be non-employees in accordance with ASC Topic 505 and vest over periods of 24 months to 53 months, from the grant date,2019 is as well as 16 units granted to the Company’s independent directors on May 18, 2017 (who were treated as employees in accordance with ASC Topic 718), and vest over a period of 12 months from the grant date.follows:

 

The Company expenses the fair value of all LTIP unit awards in accordance with the fair value recognition requirements of ASC Topic 718, Compensation-Stock Compensation, for “employees,” and ASC Topic 505, Equity, for “non-employees.”

For the time-based LTIP units granted to non-employees, in accordance with the provisions of ASC Topic 505, the grant date fair value is utilized for expense recognition; however, the accounting after the measurement date requires a fair value re-measurement each reporting period until the awards vest.

Total vested units516
Unvested units:
Granted to employees of the Advisor220
Granted to the Company’s independent directors22
Total unvested units242
LTIP Units outstanding as of December 31, 2019758

 

Performance Based Awards—2017 ProgramAwards

 

During 2017,For each of the past three years the Company’s Board has approved the 2017 annual performance-based equity incentive award targets in the form of LTIP units (the “Annualawards (“Annual Awards”) and long-term performance-based LTIP awards (the “Long-Term(“Long-Term Awards”) to the executive officers of the Company and other employees of the Company’s external managerAdvisor who perform services for the Company (togetherCompany. As described below, the “2017 Program”). NoneAnnual Awards have one-year performance periods and the Long-Term Awards have three-year performance periods. In addition to meeting specified performance metrics, vesting in both the Annual Awards and the Long-Term Awards is subject to service requirements.

A detail of the LTIP units awardedAnnual Awards and Long-Term Awards under the 2017, Program had been earned by the participants2018, and 2019 programs as of December 31, 2017.

The LTIP unit awards under the 2017 Program and subsequent activity during the year ended December 31, 2017, are2019 is as follows:

 

  Annual  Long-Term  Total 
          
Awards on February 28, 2017  97   147   244 
Awards on August 23, 2017 and May 8, 2017  8   18   26 
Total 2017 Program LTIP units awarded as of December 31, 2017  105   165   270 
2017 Program LTIP units forfeited  (21)  (67)  (88)
Net 2017 Program LTIP awards as of December 31, 2017  84   98   182 
  2017 Program  2018 Program  2019 Program    
  Long-Term  Annual  Long-Term  Annual  Long-Term  Total 
Net annual and long-term LTIP awards as of December 31, 2018 (at target)  96   161   110   -   -   367 
LTIP Unit target grants via the 2019 Performance Program – Annual Awards and Long-Term Awards(1)  -   -   -   133   82   215 
LTIP Units earned and granted via the 2018 Performance Program – Annual Awards(2)  -   (108)  -   -   -   (108)
LTIP Units granted on a discretionary basis via the 2018 Performance Program – Annual Awards(2)  -   (28)  -   -   -   (28)
LTIP Units not earned under the 2018 Performance Program – Annual Awards(3)  -   (25)  -   -   -   (25)
Net annual and long-term LTIP awards as of December 31, 2019 (at target)  96   -   110   133   82   421 

(1)These target Annual Awards and Long-Term Awards were approved by the Board on March 5, 2019.

(2)These amounts represent grants from the 2018 program Annual Awards. Refer to the “Time-Based Grants” table above which presents these grants as earned and time-based.

(3)On March 5, 2019 the Compensation Committee determined the extent to which the Company achieved the performance goals and concluded that these target awards were not achieved.

 

The number of target LTIP unitsUnits comprising each 2019 program Annual Award target grant was based on the closing price of the Company’s common stock reported on the New York Stock Exchange (“NYSE”) on the datesdate of grant and thegrant. The number of target LTIP unitsUnits comprising each Long-Term Award target grant was based on the fair value of the Long-Term Awards as determined by an independent valuation consultant, in each case rounded to the nextnearest whole LTIP unitUnit in order to eliminate fractional units.


 

Annual Awards. The Annual Awards are subject to the terms and conditions of LTIP Annual Award Agreements (“LTIP Annual Award Agreements”) between the Company and each grantee.

The Company’s Compensation Committee and Board established various operating performance goals for calendarfiscal year 2017,2019, as set forth in Exhibit A to the 2019 LTIP Annual Award Agreements (the “Performance Goals”), that will be used to determine the actual number of LTIP unitsUnits earned by each grantee under each LTIP Annual Award Agreement.grantee. As of December 31, 2017,2019, management estimated that the Performance Goals would be met at a 55%100% level, and accordingly, applied 55%100% to the net target 2019 program Annual Awards to estimate the 2019 program Annual Awards expected to be earned at the end of the performance period. Cumulative stock basedstock-based compensation expense during the year ended December 31, 20172019 reflects management’s estimate that 55%100% of these awards will vest.be earned. As soon as reasonably practicable duringfollowing the first quarterlast day of 2018,the 2019 fiscal year, the Compensation Committee and Board will determine the extent to which the Company has achieved each of the Performance Goals (expressed as a percentage) and, based on such determination, will calculate the number of LTIP unitsUnits that each grantee is entitled to receive underreceive. Each grantee may earn up to 150% of the grantee’snumber of his/her target LTIP Units. Any 2019 Annual Award based on the performance percentages described in the grantee’s LTIP Annual Award Agreement. Any target LTIP unitsUnits that are not earned will be forfeited and cancelled.

 

AsVesting.LTIP Units that are earned as of the Annual Awards were grantedend of the applicable performance period will be subject to non-employees,vesting, subject to continued employment through each vesting date, in accordance withtwo installments as follows: 50% of the provisions of ASC Topic 505, the Annual Awards utilize the grant date fair value for expense recognition; however, the accounting after the measurement date requires a fair value re-measurement each reporting period until the awards vest. Since these are performance based awards with no market condition, the closing priceearned LTIP Units will become vested on the valuation date in 2020 that the Board approves the number of LTIP Units to be awarded pursuant to the performance components set forth in the 2019 LTIP Annual Award Agreements and revaluation date50% of the earned LTIP Units become vested on the one year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a “change-in-control” transaction or a “qualified termination” event.

Distributions.Distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the maximum number of LTIP Units that the grantee could earn and will be used for expense recognition purposes.paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

 

Long-Term AwardsAwards.. The Long-Term Awards are subject to the terms and conditions of 2017, 2018 and 2019 LTIP Long-Term Award Agreements (“LTIP(collectively the “LTIP Long-Term Award Agreements”) between the Company and each grantee. The number of LTIP unitsUnits that each grantee is entitled to earn under the LTIP Long-Term Award Agreements will be determined following the conclusion of a three-year performance period based on the Company’s total shareholderstockholder return (“TSR”), which is determined based on a combination of appreciation in stock price and dividends paid during the performance period (“TSR”).period. Each grantee may earn up to 200% of the number of target LTIP unitsUnits covered by the grantee’s Long-Term Award. Any target LTIP unitsUnits that are not earned will be forfeited and cancelled. The number of LTIP unitsUnits earned under the Long-Term Awards will be determined as soon as reasonably practicable following the end of the applicable three-year performance period (2020, 2021, or 2022 depending on the program) based on the Company’s TSR on an absolute basis (as to 75% of the Long-Term Award) and relative to the SNL Healthcare REIT Index (as to 25% of the Long-Term Award).

 

82

Vesting.LTIP Units that are earned as of the end of the applicable three-year performance period will be subject to forfeiture restrictions that will lapse (“vesting”), subject to continued employment through each vesting date as follows; 50% of the earned LTIP Units will vest upon the third anniversary of the respective grant dates and the remaining 50% will vest on the fourth anniversary of the respective grant dates. Vesting may be accelerated under certain circumstances such as a “change-in-control” transaction or a “qualified termination” event.

 

Distributions.Pursuant to the LTIP Long-Term Award Agreements, distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the maximum number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

Stock-Based Compensation Expense

Under the provisions of ASU 2018-07, the Company’s prospective compensation expense for all unvested LTIP Units, Annual Awards, and Long-Term Awards is recognized using the adoption date fair value of the awards, with no remeasurement required. Compensation expense for future LTIP Unit grants, Annual Awards, and Long-Term Awards is based on the grant date fair value of the units/awards, with no subsequent remeasurement required.

 

As the Long-Term Awards were granted to non-employees and involvedinvolve market-based performance conditions, in accordance with the provisions of ASC Topic 505, the Long-Term Awards utilizeCompany utilizes a Monte Carlo simulation to provide a grant date fair value for expense recognition; however, the accounting after the measurement date requires a fair value re-measurement each reporting period until the awards vest. The fair value re-measurement will be performed by calculating a Monte Carlo produced fair value at the conclusion of each reporting period until vesting.

recognition. The Monte Carlo simulation is a generally accepted statistical technique used, in this instance, to simulate a range of possible future stock prices for the Company and the members of the SNL Healthcare REIT Index (the “Index”) over the Performance Period (February 28, 2017 to February 27, 2020; May 8, 2017 to May 7, 2020; and August 23, 2017 to August 22, 2020, respectively).Periods. The purpose of this modeling is to use a probabilistic approach for estimating the fair value of the performance share award for purposes of accounting under ASC Topic 718. ASC Topic 505 does not provide guidance on how to derive a fair value, so the valuation defaults to that described in ASC Topic 718.

 


The assumptions used in the Monte Carlo simulation include beginning average stock price, valuation date stock price, expected volatilities, correlation coefficients, risk-free rate of interest, and expected dividend yield. The beginning average stock price is the beginning average stock price for the Company and each member of the Index for the five trading days leading up to the grant date.date of the Long-Term Award. The valuation date stock price is the closing stock price of the Company and each of the peer companies in the Index on the grant date fordates of the grant date fair value, and the closing stock price on December 31, 2017 for revaluation.Long-Term Awards. The expected volatilities are modeled using the historical volatilities for the Company and the members of the Index. The correlation coefficients are calculated using the same data as the historical volatilities. The risk-free rate of interest is taken from the U.S. Treasury website and relates to the expected life of the remaining performance period on valuation or revaluation. Lastly, the dividend yield assumption is 0.0%, which is mathematically equivalent to reinvesting dividends in the issuing entity, which is part of the Company’s award agreement assumptions.

 

Vesting.LTIP units thatBelow are earned asdetails regarding certain of the end ofassumptions for the applicable performance period will be subject to forfeiture restrictions that will lapse (“vesting”), subject to continued employment through each vesting date, in two installments as follows: 50% of the earned LTIP units will vest upon being earned as of the end of the applicable performance period and the remaining 50% will vest on the first anniversary of the date on which such LTIP units are earned.Long-Term Awards using Monte Carlo simulations:

 

Distributions.Pursuant to both the LTIP Annual Award Agreements and LTIP Long-Term Award Agreements, distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the maximum number of LTIP units that the grantee could earn and will be paid with respect to all of the earned LTIP units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP units at the discretion of the Compensation Committee.

Stock Compensation Expense

  2019 Long-Term
Awards
  2018 Long-Term
Awards
  2017 Long-Term
Awards
 
Fair value $10.07  $8.86  $8.86 
Target awards  82   110   96 
Volatility  31.7%  33.8%  33.8% - 35.4% 
Risk-free rate  2.5%  2.6%  2.4% - 2.6% 
Dividend assumption  reinvested   reinvested   reinvested 
Expected term in years  3   2.7   1.7 – 2.7 

 

The Company incurred stock compensation expense of $1,796$3,336, $2,671, and $1,685 for the years ended December 31, 2017 and 2016,$1,796, respectively, related to the grants awarded under the Plan. Compensation expense is included within “General and Administrative” expense in the Company’s Consolidated Statements of Operations. A detail

As of compensation expense recognized during the years ended December 31, 2017 and 2016, is as follows:

  Year Ended December 31, 
  2017  2016 
2016 Plan – Time Based Grants:        
Service LTIPs – non-employee $1,111  $1,615 
Service LTIPs – employee  163   70 
2017 Program – Performance Based Award Targets:        
Annual Awards – non-employee  306   - 
Long-Term Awards – non-employee  216   - 
Total compensation expense $1,796  $1,685 

Total2019, total unamortized compensation expense related to these awards of approximately $1.5$2.7 million is expected to be recognized subsequent to December 31, 2017 over a weighted average remaining period of 2.131.4 years.

83

 

Note 8 – Rental RevenueLeases

 

On January 1, 2019, the Company adopted ASC Topic 842, which supersedes Accounting Standards Codification Topic 840 “Leases” (“ASC Topic 840”). Information in this note with respect to the Company’s leases and lease-related costs as both lessee and lessor and lease-related receivables as lessor is presented under ASC Topic 842 as of and for the years ended December 31, 2019.

The Company adopted ASC Topic 842 using the modified retrospective approach whereby the cumulative effect of adoption was recognized on the adoption date and prior periods were not restated. There was no net cumulative effect adjustment to accumulated deficit as of January 1, 2019 as a result of this adoption. ASC Topic 842 sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The Company operates as both a lessor and a lessee. As a lessor, the Company is required under ASC Topic 842 to account for leases using an approach that is substantially similar to ASC Topic 840's guidance for operating leases and other leases such as sales-type leases and direct financing leases. In addition, ASC Topic 842 requires lessors to capitalize and amortize only incremental direct leasing costs. As a lessee, the Company is required under the new standard to apply a dual approach, classifying leases, such as ground leases, as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC Topic 842 also requires lessees to record a right of use asset and a lease liability for all leases with an initial term of greater than a year regardless of their classification. The Company has also elected the practical expedient not to recognize right of use assets and lease liabilities for leases with a term of a year or less.

On adoption of the standard, we elected all practical expedients provided for in ASC Topic 842, including:

·No reassessment of whether any expired and existing contracts were or contained leases;

·No reassessment of the lease classification for any expired and existing leases; and

·No reassessment of initial direct costs for any existing leases.

The package of practical expedients was made as a single election and was consistently applied to all existing leases as of January 1, 2019. The Company also elected the practical expedient provided to lessors in a subsequent amendment to ASC Topic 842 that removed the requirement to separate lease and nonlease components, provided certain conditions were met.


Information as Lessor Under ASC Topic 842(As of and for the year ended December 31, 2019)

To generate positive cash flow, as a lessor, the Company leases its facilities to tenants in exchange for fixed monthly payments that cover rent, property taxes, insurance and certain cost recoveries, primarily common area maintenance (“CAM”). The Company’s leases were determined to be operating leases and have a portfolio average lease years remaining of approximately 10 years. Payments from the Company’s tenants for CAM are considered nonlease components that are separated from lease components and are generally accounted for in accordance with the revenue recognition standard. However, the Company qualified for and elected the practical expedient related to combining the components because the lease component is classified as an operating lease and the timing and pattern of transfer of CAM income, which is not the predominant component, is the same as the lease component, for all asset classes. As such, consideration for CAM is accounted for as part of the overall consideration in the lease. Payments from customers for property taxes and insurance are considered noncomponents of the lease and therefore no consideration is allocated to them because they do not transfer a good or service to the customer. Fixed contractual payments from the Company’s leases are recognized on a straight-line basis over the terms of the respective leases. This means that, with respect to a particular lease, actual amounts billed in accordance with the lease during any given period may be higher or lower than the amount of rental revenue recognized for the period. Straight-line rental revenue is commenced when the tenant assumes control of the leased premises. Accrued straight-line rents receivable represents the amount by which straight-line rental revenue exceeds rents currently billed in accordance with lease agreements. Rental revenue for the year ended December 31, 2019 included variable revenues of $5,341.

Some of the Company’s leases are subject to annual changes in the CPI. Although increases in CPI are not estimated as part of the Company’s measurement of straight-line rental revenue, for leases with base rent increases based on CPI, the amount of rent revenue recognized is adjusted in the period the changes in CPI are measured and effective. Additionally, some of the Company’s leases have extension options.

Initial direct costs, primarily commissions, related to the leasing of our facilities are capitalized when material as incurred. Capitalized leasing costs are amortized on a straight-line basis over the remaining useful life of the respective leases. All other costs to negotiate or arrange a lease are expensed as incurred.

Lease-related receivables, which include accounts receivable and accrued straight-line rents receivable, are reduced for credit losses, if applicable. To date the Company’s receivables have not had any credit losses. Such amounts would be recognized as a reduction to rental and other revenues. The Company regularly evaluates the collectability of its lease-related receivables. The Company’s evaluation of collectability primarily consists of reviewing past due account balances and considering such factors as the credit quality of our tenant, historical trends of the tenant and changes in tenant payment terms. If the Company’s assumptions regarding the collectability of lease-related receivables prove incorrect, the Company could experience credit losses in excess of what was recognized in rental and other revenues.

The Company recognized $70,515 of rental and other revenues related to operating lease payments for the year ended December 31, 2019. The aggregate annual cash to be received by the Company on the noncancelable operating leases related to its portfolio as of December 31, 2019 is as follows for the subsequent years ended December 31:

2020 $71,888 
2021  70,621 
2022  69,242 
2023  67,763 
2024  63,781 
Thereafter  356,694 
Total $699,989 

Information as Lessor Under ASC Topic 840(As of and for the year ended December 31, 2018)

The Company’s operations consist of rental revenue earned from tenants under leasing arrangements which provide for minimum rent and escalations. These leases were accounted for as operating leases. For operating leases with contingent rental escalators, revenue was recorded based on the contractual cash rental payments due during the period. Revenue from leases with fixed annual rental escalators were recognized on a straight-line basis over the initial lease term, subject to a collectability assessment. If the Company determined that collectability of rents was not reasonably assured, future revenue recognition was limited to amounts contractually owed and paid, and, when appropriate, an allowance for estimated losses was established.

The Company consistently assessed the need for an allowance for doubtful accounts, including an allowance for operating lease straight-line rent receivables, for estimated losses resulting from tenant defaults, or the inability of tenants to make contractual rent and tenant recovery payments. The Company also monitored the liquidity and creditworthiness of its tenants and operators on a continuous basis. This evaluation considered industry and economic conditions, property performance, credit enhancements and other factors. For operating lease straight-line rent amounts, the Company’s assessment was based on amounts estimated to be recoverable over the term of the lease. As of December 31, 2018, no allowance was recorded as it was not deemed necessary. 


The Company’s real estate assets are leased to tenants under operating leases. The rental amounts under the leases were generally subject to scheduled fixed increases. The aggregate annual minimum cash to be received by the Company on its noncancelable operating leases as of December 31, 2017 are2018 were as follows:

 

2018 $36,005 
2019  36,708  $50,527 
2020  37,412   51,450 
2021  35,654   49,926 
2022  34,446   48,862 
2023  47,743 
Thereafter  247,065   330,180 
Total $427,290  $578,688 

 

ForInformation as Lessee Under ASC Topic 842(As of and for the year ended December 31, 2017,2019)

The Company has six buildings located on land that is subject to operating ground leases with a weighted average remaining term of approximately 24 years. Rental payments on these leases are adjusted periodically based on either the HealthSouth facilities constituted approximately 20%CPI or on a pre-determined schedule. The monthly payments on a pre-determined schedule are recognized on a straight-line basis over the terms of the Company’srespective leases. Changes in the CPI are not estimated as part of our measurement of straight-line rental revenue,expense. Upon initial adoption of ASC Topic 842, the OCOM facilities constituted approximately 12%Company recognized a lease liability of $2.2 million (included in “Other Liabilities”) and a related right of use asset of $2.2 million (included in “Other Assets”) on our Consolidated Balance Sheets equal to the present value of the Company’ rental revenue, the Great Bend facility constituted approximately 7% of the Company’s rental revenue, the Omaha and Plano facilitiesminimum lease payments required under each constituted approximately 6% of the Company’s rental revenue, and the Tennessee and Sherman facilities each constituted approximately 5% of the Company’s rental revenue. All other facilities in the Company’s portfolio constituted the remaining 39% of the total rental revenue with no individual facility constituting greater than approximately 4% of total rental revenue.

Forground lease. During the year ended December 31, 2016,2019, the Omaha facility constitutedCompany recorded an additional $0.1 million right of use asset and recognized an additional lease liability of $0.1 million. The Company used a weighted average discount rate of approximately 21%4.4%, which was derived, using a portfolio approach, from our assessment of the credit quality of the Company and adjusted to reflect secured borrowing, estimated yield curves and long-term spread adjustments over appropriate tenors. Some of the Company’s rental revenue,ground leases contain extension options and, where we determined it was reasonably certain that an extension would occur, they were included in our calculation of the Plano facility constitutedright of use asset and liability. The Company recognized approximately 18%$107 of rental revenue, the Tennessee facilities constituted approximately 17% of rental revenue, the West Mifflin facility constituted approximately 11% of rental revenue, the Melbourne facility constituted approximately 11% of rental revenue, the Reading facility constituted approximately 4% of rental revenue, and the Westland facilities constituted approximately 4% of rental revenue. The Asheville, East Orange, and Watertown facilities constituted approximately 3% of rental revenue each. The remaining 5% of rental revenueground lease expense, which was derived from the other facilitiespaid in the Company’s portfolio.

Forcash, during the year ended December 31, 2015, the Omaha facility constituted approximately 80% of the Company’s rental revenue and the West Mifflin and Asheville facilities constituted approximately 10% each.2019.

 

Note 9 – OmahaThe following table sets forth the undiscounted cash flows of our scheduled obligations for future lease payments on operating ground leases at December 31, 2019 and Clermont Land Leasesa reconciliation of those cash flows to the operating lease liability at December 31, 2019:

2020 $116 
2021  116 
2022  116 
2023  120 
2024  125 
Thereafter  4,351 
Total  4,944 
Discount  (2,539)
Lease liability $2,405 

Information as Lessee Under ASC Topic 840(As of and for the year ended December 31, 2018)

 

In connection with its acquisition of the Omaha facility, theThe Company acquired an interest, as ground lessee, in the ground lease related to that facility. The Omaha ground lease expires in 2033, subject to future renewal options by the Company. The ground lease commenced in April 2017 and annual rents under the ground lease will increase by 12.5% beginning in June 2018, and will increase by 12.5% every fifth anniversary thereafter. During the years ended December 31, 2017, 2016, and 2015, the Company expensed $73, $73, and $80, respectively, related to the Omaha land lease.

and Clermont facilities at their dates of acquisition. In connection with its acquisitionthe acquisitions of the ClermontMoline facility the Company acquired anthe seller’s interest, as ground lessee, in thean existing ground lease related to that facility. The Clermonthas approximately 10 years remaining in the initial term, with 12 consecutive five-year renewal options. In connection with the acquisition of the Silvis facility the Company acquired the seller’s interest, as ground lessee, in an existing ground lease commencedthat has approximately 67 years remaining in 2013 and has anthe initial term, of seventy-five years.with no renewal options.

 

The aggregate minimum cash payments to be made by the Company on the Omahathese land lease and the Clermont land leaseleases as of December 31, 2017, are2018, were as follows:

 

2018 $78 
2019  82  $109 
2020  82   109 
2021  82   109 
2022  82   109 
2023  113 
Thereafter  1,796   2,121 
Total $2,202  $2,670 


Note 9 – Rent Concentration

The Company’s facilities with a concentration of rental revenue of 5% or greater is as follows for the years ended December 31, below:

2019  2018  2017 
Facility %  Facility %  Facility % 
Encompass(1)% 10  Encompass(1)% 11  Encompass(1)% 20 
Belpre  8  OCOM  9  OCOM  12 
OCOM  7  Belpre  8  Great Bend  7 
Austin  5  Austin  7  Omaha  6 
Sherman  5  Sherman  6  Plano  6 
All other facilities  65  Dallas  5  Sherman  5 
Total% 100  Great Bend  5  Tennessee  5 
      All other facilities  49  All other facilities  39 
      Total% 100  Total% 100 

(1)Four facilities and four locations.

 

Note 10 – Commitments and Contingencies

 

Litigation

 

The Company is not presently subject to any material litigation nor, to its knowledge, is any material litigation threatened against the Company, which if determined unfavorably to the Company, would have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

 

Environmental Matters

 

The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any environmental liability with respect to its properties that would have a material effect on its financial position, results of operations, or cash flows. Additionally, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that management believes would require additional disclosure or the recording of a loss contingency.

84

Note 11 – Income Taxes

Beginning with the 2016 tax year, the Company has qualified as a REIT under the Internal Revenue Code.  To qualify as a REIT, the Company must meet a number of organizational and operational requirements, including a requirement that the Company distribute at least 90% of its adjusted taxable income to its stockholders.  It is management’s current intention to adhere to these requirements and be eligible to be a REIT for the year ended December 31, 2017.  As a REIT, the Company generally will not be subject to corporate level federal income tax on taxable income currently distributed to stockholders.  If the Company fails to qualify as a REIT for the 2017 tax year, it will be subject to federal and state income taxes at corporate tax rates.  Even if the Company qualifies to be taxed as a REIT for 2017, it may be subject to federal and state taxes on any undistributed taxable income. 

On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was enacted.  The TCJA reduces the statutory federal tax rate from 35.0% to 21.0% effective for tax year 2018 in addition to various other tax law changes that affect the Company.

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company had federal and state net operating loss carry forwards of approximately $3.7 million, which begin expiring in 2033. The Company has adopted ASC Topic 740, “Accounting for Income Taxes,” as of its inception. Pursuant to ASC Topic 740, the Company is required to compute tax asset benefits for non-capital losses carried forward. The potential benefit of the net operating loss has not been recognized in these financial statements because it cannot be assured it is more likely than not it will utilize the loss carried forward in future years.

Significant components of the deferred tax assets and liabilities as of December 31, 2017 and 2016, after applying enacted corporate income tax rates, are as follows:

  December 31, 
  2017  2016 
Deferred income tax asset:        
Net operating and passive activity loss carry forward $778  $1,438 
Valuation allowance  (778)  (1,438)
Net deferred tax asset $-  $- 

The Company periodically assesses the likelihood that it will be able to recover its deferred tax assets. The Company considers all available evidence, both positive and negative, including expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible profits. As a result of this analysis of all available evidence, both positive and negative, the Company concluded that it is not likely that its net deferred tax assets will ultimately be recovered; as such, it recorded a valuation allowance for the net operating and passive activity losses and a reserve due to the anticipated REIT election for calendar year 2017.  

The Company follows ASC Topic 740 to recognize, measure, present and disclose in its consolidated financial statements uncertain tax positions that it has taken or expects to take on a tax return. As of December 31, 2017 and December 31, 2016, the Company did not have any liabilities for uncertain tax positions that it believes should be recognized in its financial statements. The Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for the years 2013 and earlier. The Company is not currently under examination by any taxing jurisdiction.

 

Note 1211 – Subsequent Events

2018 Investment Activity

From January 1, 2018 through March 1, 2018, the Company purchased four facilities for an aggregate purchase price of $48.4 million.

On March 6, 2018, we entered into a purchase and sale agreement to purchase a portfolio of four medical office buildings located in Belpre, Ohio for $64.2 million. The portfolio is 100% leased to Memorial Health System pursuant to four, triple-net leases with aggregate annual base rent of approximately $5 million.

On January 24, 2018, we entered into a purchase and sale agreement to purchase a portfolio of five medical office buildings located in Orlando, Florida for $16.2 million. The portfolio is 100% leased to Orlando Health pursuant to five, triple-net leases with aggregate annual base rent of approximately $1.3 million.

Increase in Capacity of our Revolving Credit Facility

On March 6, 2018, the Company amended its revolving credit facility to increase the aggregate size of the facility by $90 million to $340 million. As of December 31, 2017, the Company had $164.9 million of outstanding borrowings under this facility.

85

 

Dividends

 

On March 7, 2018,4, 2020, the Company announced the declaration of a cash dividend for the first quarter of 20182020 of $0.20 per share of common stock to stockholders of record as of March 22, 2018,25, 2020, to be paid on April 10, 2018.9, 2020.

 

On March 7, 2018,4, 2020, the Company announced the declaration of a cash dividend of $0.46875 per share to holders of its Series A Cumulative Redeemable Preferred Stock, $0.001 par value per share (the “Series A Preferred Stock”), of record as of April 15, 2018,2020, to be paid on April 30, 2018.2020. This dividend represents the Company’s quarterly dividend on its Series A Preferred Stock for the period from January 31, 20182020 through April 29, 2018.2020.

Equity Awards Approved in 2018

On March 5, 2018, the Board approved the recommendations of the Compensation Committee of the Board with respect to the granting of Long-Term Performance-Based Incentive LTIP Awards (the “Long-Term Performance Awards”) and Long-Term Time-Based Incentive LTIP Awards (the “Long-Term Time-Based Awards”) to certain executive officers of the Company and employees of the Advisor who perform services for the Company, both of which were granted pursuant to the Company’s 2016 Equity Incentive Plan.

Long-Term Performance-Based Awards

The Long-Term Performance-Based Awards are subject to the terms and conditions of LTIP Long-Term Performance-Based Award Agreements (“LTIP Long-Term Performance-Based Award Agreements”) between the Company and each grantee. The number of LTIP Units that each grantee is entitled to earn under the LTIP Long-Term Performance-Based Award Agreements will be determined following the conclusion of a three-year performance period based on the Company’s total shareholder return, which is determined based on a combination of appreciation in stock price and dividends paid during the performance period (“TSR”). Each grantee may earn up to 200% of the number of target LTIP units covered by the grantee’s Long-Term Performance-Based Award. Any target LTIP Units that are not earned will be forfeited and cancelled. The number of LTIP Units earned under the Long-Term Performance-Based Awards will be determined as soon as reasonably practicable following the end of the three-year performance period based on the Company’s TSR on an absolute basis (as to 75% of the Long-Term Performance-Based Award) and relative to the SNL Healthcare REIT Index (as to 25% of the Long-Term Performance-Based Award).

Vesting.LTIP units that are earned as of the end of the applicable performance period will be subject to forfeiture restrictions that will lapse (“vesting”), subject to continued employment through each vesting date, in two installments as follows: 50% of the earned LTIP units will vest upon being earned as of the end of the applicable performance period and the remaining 50% will vest on the first anniversary of the date on which such LTIP units are earned.

Distributions.Pursuant to the LTIP Long-Term Performance-Based Award Agreements, distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the maximum number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee of the Board.

Long-Term Time-Based Awards

The Long-Term Time-Based Awards will be subject to the terms and conditions of LTIP Unit Award Agreements between the Company and each grantee. Long-Term Time-Based Awards become vested, and cease to be subject to forfeiture, in equal one-third increments on each of the first, second and third anniversaries of the date of grant, which was March 5, 2018.

86

 

Note 1312 – Selected Quarterly Financial Data (Unaudited)

 

The following unaudited quarterly data has been prepared on the basis of a December 31 year-end. As a result of acquisition activity and equity offerings throughout 20172019 and 2016,2018, the quarterly periods presented are not comparable quarter over quarter. The amounts below represent the Company’s actual quarterly results. ForAdditionally, the pro forma impacttotal for the year may differ from the sum of the Company’s acquisitions that were accounted for as business combination for the full years ended December 31, 2017 and 2016, referquarters due to Note 3 – “Property Portfolio.” Amounts are in thousands except per share amounts.rounding.

 


 

  Year Ended December 31, 2017 
  First Quarter  Second Quarter  Third Quarter  Fourth Quarter 
             
Total revenue $4,659  $7,423  $8,389  $9,874 
Total expenses  5,9771  8,046   7,783   8,625 
Net (loss) income  (1,318)1  (623)  606   1,249 
Less: Preferred stock dividends  -   -   (259)  (1,456)
Less: Net loss attributable to noncontrolling interest  -   -   34   14 
Net (loss) income attributable to common stockholders $(1,318) $(623) $381  $(193)
                 
Net (loss) income attributable to common stockholders per share – basic and diluted $(0.07) $(0.04) $0.02  $(0.01)
                 
Weighted average shares outstanding – basic and diluted  17,606   17,644   21,523   21,631 

1In the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 that was filed with the SEC on May 11, 2017, $1.2 million of costs incurred in connection with the Company’s Revolving Credit Facility were erroneously expensed and included in the General and Administrative line item within the Company’s Consolidated Statement of Operations for the three months ended March 31, 2017. The Company corrected this error by removing the approximately $1.2 million from expense and capitalizing it as deferred financing costs on the Company’s Consolidated Balance Sheet as of June 30, 2017, which was included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 that was filed with the SEC on August 10, 2017. Based upon evaluation and consideration of provisions under ASC Topic 250 – Accounting Changes and Error Corrections, that incorporates SEC Staff Accounting Bulletin (SAB) No. 99 - Materiality, the Company determined that the impact of the error and its subsequent correction as described above, did not have a material impact on previously issued financial statements for the quarter ended March 31, 2017. The total expense and net (loss) income lines in the table above properly reflect the adjusted amounts after correcting this item.

  Year Ended December 31, 2019 
  First Quarter  Second Quarter  Third Quarter  Fourth Quarter 
Total revenue $15,200  $16,880  $18,195  $20,452 
Total expenses  13,157   14,418   15,887   17,677 
Net income  2,043   2,462   2,308   2,775 
Less: Preferred stock dividends  (1,455)  (1,455)  (1,455)  (1,455)
Less: Net income attributable to noncontrolling interest  (60)  (103)  (83)  (108)
Net income attributable to common stockholders $528  $904  $770  $1,212 
                 
Net income attributable to common stockholders per share – basic and diluted $0.02  $0.03  $0.02  $0.03 
                 
Weighted average shares outstanding – basic and diluted  27,380   34,559   35,512   37,876 

 

 Year Ended December 31, 2016 
 First Quarter  Second Quarter  Third Quarter  Fourth Quarter  Year Ended December 31, 2018 
          First Quarter  Second Quarter  Third Quarter  Fourth Quarter 
Total revenue $1,314  $1,771  $2,002  $3,123  $11,564  $13,249  $14,003  $14,376 
Total expenses  3,261   2,265   3,985   5,053   9,663   11,865   12,230   12,547 
Net loss  (1,947)  (494)  (1,983)  (1,930)
Income before gain on sale of investment property  1,901   1,384   1,773   1,829 
Gain on sale of investment property  -   -   -   7,675 
Net income  1,901   1,384   1,773   9,504 
Less: Preferred stock dividends  -   -   -   -   (1,455)  (1,455)  (1,455)  (1,455)
Less: Net loss attributable to noncontrolling interest  -   -   -   - 
Net loss attributable to common stockholders $(1,947) $(494) $(1,983) $(1,930)
Less: Net (income) loss attributable to noncontrolling interest  (35)  7   (32)  (1,013)
Net income (loss) attributable to common stockholders $411  $(64) $286  $7,036 
                                
Net loss attributable to common stockholders per share – basic and diluted $(3.11) $(0.35) $(0.11) $(0.11)
Net income (loss) attributable to common stockholders per share – basic and diluted $0.02  $(0.00) $0.01  $0.31 
                                
Weighted average shares outstanding – basic and diluted  625   1,427   17,372   17,606   21,631   21,631   21,797   22,815 

 

87

ITEM 9.CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A.CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that the information required to be disclosed in our reports filed or submitted to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that information is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer) as appropriate, to allow timely decisions regarding required disclosures. Our Chief Executive Officer (our “CEO”) and Chief Financial Officer (our “CFO”) evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2017.2019. Based on that evaluation, our CEO and CFO concluded that, as of the end of the period covered by this Report, the Company’s disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the fourth quarter of 2019 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for the preparation of our consolidated financial statements and related information. Management uses its best judgment to ensure that the consolidated financial statements present fairly, in all material respects, our financial position and results of operations in conformity with generally accepted accounting principles. Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in the Exchange Act. These internal controls are designed to provide reasonable assurance that the reported financial information is presented fairly, that disclosures are adequate and that the judgments inherent in the preparation of financial statements are reasonable. There are inherent limitations in the effectiveness of any system of internal controls including the possibility of human error and overriding of controls. Consequently, even an effective internal control system can only provide reasonable, not absolute, assurance with respect to reporting financial information.

 

Our internal control over financial reporting includes policies and procedures that: (i) pertain to maintaining records that, in reasonable detail, accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements in accordance with generally accepted accounting principles and that the receipts and expenditures of company assets are made in accordance with our management and directors’ authorization; and (iii) provide reasonable assurance regarding the prevention of or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.

 

Under the supervision of management, including our CEO and CFO, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal controls over financial reporting were effective as of December 31, 2017.2019.  

 

The effectivenessDeloitte & Touche LLP, an independent registered public accounting firm, audited our consolidated financial statements included in this Annual Report on Form 10-K and our internal control over financial reporting, and that firm’s report on our internal control over financial reporting is set forth below.

March 9, 2020


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of

Global Medical REIT Inc.

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of Global Medical REIT Inc. and subsidiaries (the “Company”) as of December 31, 2019, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017 has been audited2019, based on criteria established in Internal Control — Integrated Framework (2013) issued by MaloneBailey LLP, our independent registered public accounting firm, as stated in their report included in Part II Item 8. of this Annual Report on Form 10-K.COSO.

 

ChangesWe have also audited, in Internal Control over Financial Reporting

In connectionaccordance with our Annual Report on Form 10-Kthe standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2016,2019, of the Company and our report dated March 9, 2020, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company’s management concluded that ouris responsible for maintaining effective internal controlscontrol over financial reporting were not effective asand for its assessment of December 31, 2016.the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our then CEOresponsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and CFO concludedare required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we hadplan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness due to lackexists, testing and evaluating the design and operating effectiveness of segregation of duties in multiple areas withininternal control based on the Company. Beginningassessed risk, and performing such other procedures as we considered necessary in the first quartercircumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of 2017,Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the Company beganreliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to undertake remedial measuresthe maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to addresspermit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material weaknesseffect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in its internal controls. To beginconditions, or that the remediation process, the Company engaged an independent consulting firm that specializes indegree of compliance with the Sarbanes Oxley Act to undertake a full review and evaluation of our personnel levels, key processes, andpolicies or procedures and to complete documentation that can be monitored and independently tested. During the first and second quarters of 2017, each department of the Company conducted a thorough review of its control processes and updated all of its internal controls. In the third quarter of 2017, the Company (i) hired a new CFO who has extensive experience with internal controls over financial reporting (ii) added a new staff member to its accounting team both increasing the capacity of the team and enhancing segregation of duties, and (iii) finalized each department’s control narratives and internal controls necessary to begin testing internal controls over financial reporting. No changes were made to our internal controls over financial reporting during the fourth quarter of 2017 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.may deteriorate.

/s/ Deloitte & Touche LLP

Mclean, VA

March 9, 2020

 

88

ITEM 9B.Other Information

 

ADDITIONAL MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS

The following is a summary of additional material U.S. federal income tax considerations with respect to the ownership of our stock. This summary supplements and should be read together with the discussion under “Material U.S. Federal Income Tax Considerations” in the prospectus dated June 15, 2017 and filed as part of our Registration Statement on Form S-3 (No. 333-217360).

 

The Tax Cuts and Jobs Act

 

Enactment of the TCJA

 

On December 22, 2017, President Trump signed into law H.R. 1, informally titled the Tax Cuts and Jobs Act, or the TCJA. The TCJA, makeswhich made major changes to the Internal Revenue Code, as amended, or the Code, including several provisions of the Code that may affect the taxation of REITs and their security holders. The most significant of these provisions are described below. The individual and collective impact of these changes on REITs and their security holders is uncertain, and may not become evident for some period. Prospective investors should consult their tax advisors regarding the implications of the TCJA on their investment.

 

Revised Individual Tax Rates and Deductions

 

The TCJA createscreated seven income tax brackets for individuals ranging from 10% to 37% that generally apply at higher thresholds than currentprior law. For example, the highest 37% rate applies to joint return filer incomes above $600,000, instead of the highest 39.6% rate that appliesapplied to incomes above $470,700 under pre-TCJA law. The maximum 20% rate that applies to long-term capital gains and qualified dividend income is unchanged, as is the 3.8% Medicare tax on net investment income.income (see “Material U.S. Federal Income Tax Considerations — Taxation of Taxable U.S. Stockholders” in the prospectus).

 

The TCJA also eliminateseliminated personal exemptions, but nearly doublesdoubled the standard deduction for most individuals (for example, the standard deduction for joint return filers risesrose from $12,700 in 2017 to $24,000 upon the TCJA’s effectiveness)in 2018). The TCJA also eliminateseliminated many itemized deductions, limitslimited individual deductions for state and local income, property and sales taxes (other than those paid in a trade or business) to $10,000 collectively for joint return filers, (with a special provision to prevent 2017 deductions for prepayment of 2018 taxes), and limitslimited the amount of new acquisition indebtedness on principal or second residences for which mortgage interest deductions are available to $750,000. Interest deductions for new home equity debt arewere eliminated. Charitable deductions arewere generally preserved. The phaseout of itemized deductions based on income iswas eliminated.

 

The TCJA doesdid not eliminate the individual alternative minimum tax, but it raisesraised the exemption and exemption phaseout threshold for application of the tax.

 

These individual income tax changes arewere generally effective beginning in 2018, but without further legislation, they will sunset after 2025.

 

Pass-Through Business Income Tax Rate Lowered through Deduction

 

Under the TCJA, individuals, trusts, and estates generally may deduct 20% of “qualified business income” (generally, domestic trade or business income other than certain investment items) of a partnership, S corporation, or sole proprietorship.certain pass-through entities. In addition, “qualified REIT dividends” (i.e., REIT dividends other than capital gain dividends and portions of REIT dividends designated as qualified dividend income, which in each case are already eligible for capital gain tax rates) and certain other income items are eligible for the deduction by the taxpayer. The overall deduction is limited to 20% of the sum of the taxpayer’s taxable income (less net capital gain) and certain cooperative dividends, subject to further limitations based on taxable income. In addition, for taxpayers with income above a certain threshold (e.g., $315,000 for joint return filers), the deduction for each trade or business is generally limited to no more than the greater of (i) 50% of the taxpayer’s proportionate share of total wages from a partnership, S corporation or sole proprietorship,the pass-through entity, or (ii) 25% of the taxpayer’s proportionate share of such total wages plus 2.5% of the unadjusted basis of acquired tangible depreciable property that is used to produce qualified business income and satisfies certain other requirements. The deduction for qualified REIT dividends is not subject to these wage and property basis limits.limits that apply to other types of “qualified business income.” However, to qualify for this deduction, the U.S. stockholder receiving such dividends must hold the dividend-paying REIT stock for at least 46 days (taking into account certain special holding period rules) of the 91-day period beginning 45 days before the stock becomes ex-dividend and cannot be under an obligation to make related payments with respect to a position in substantially similar or related property. Consequently, the deduction equates to a maximum 29.6% tax rate on ordinary REIT dividends. As with the other individual income tax changes under the TCJA, the deduction provisions arewere effective beginning in 2018. Without further legislation, the deduction wouldwill sunset after 2025.

 

Net Operating Loss Modifications

 

NetThe net operating loss (“NOL”) provisions arewere modified by the TCJA. The TCJA limitslimited the NOL deduction to 80% of taxable income (before the deduction). It also generally eliminateseliminated NOL carrybacks for individuals and non-REIT corporations (NOL carrybacks did not apply to REITs under prior law), but allows indefinite NOL carryforwards. The new NOL rules apply to losses arising in taxable years beginning in 2018.

89

89

 

 

Maximum Corporate Tax Rate Lowered to 21%; Elimination of Corporate Alternative Minimum Tax

 

The TCJA reducesreduced the 35% maximum U.S. federal corporate income tax rate to a maximum of 21% corporate rate,, and reducesreduced the dividends-received deduction for certain corporate subsidiaries. The reduction of the corporate tax rate to 21% also resultsresulted in the reduction of the maximum rate of withholding with respect to our distributions to non-U.S. stockholders that are treated as attributable to gains from the sale or exchange of U.S. real propertyinterestsfrom 35% to 21%. The TCJA also permanently eliminateseliminated the corporate alternative minimum tax. These provisions arewere effective beginning in 2018.

 

Limitations on Interest Deductibility; Real Property Trades or Businesses Can Elect Out Subject to Longer Asset Cost Recovery Periods

 

The TCJA limitslimited a taxpayer’s net interest expense deduction to 30% of the sum of adjusted taxable income, business interest, and certain other amounts. Adjusted taxable income does not include items of income or expense not allocable to a trade or business, business interest or expense, the new deduction for qualified business income, NOLs, and for years prior to 2022, deductions for depreciation, amortization, or depletion. For partnerships, the interest deduction limit is applied at the partnership level, subject to certain adjustments to the partners for unused deduction limitationlimitations at the partnership level. The TCJA allows a real property trade or business to elect out of this interest limit so long as it uses a 40-year recovery period for nonresidential real property, a 30-year recovery period for residential rental property, and a 20-year40-year recovery period for related improvements described below. For this purpose, a real property trade or business is any real property development, redevelopment, construction, reconstruction, acquisition, conversion, rental, operating, management, leasing, or brokerage trade or business. We believe this definition encompasses our business and thus will allow us the option of electing out of the limits on interest deductibility should we determine it is prudent to do so. Disallowed interest expense is carried forward indefinitely (subject to special rules for partnerships). The interest deduction limit applieswas effective beginning in 2018.

 

MaintainsMaintained Cost Recovery Period for Buildings; Reduced Cost Recovery Periods for Tenant Improvements; Increased Expensing for Equipment

 

For taxpayers that do not use the TCJA’s real property trade or business exception to the business interest deduction limits, the TCJA maintainsretained the current 39-year and 27.5-year straight line recovery periods for nonresidential real property and residential rental property, respectively, and providesprovided that tenant improvements for such taxpayers are subject to a general 15-year recovery period. Also, the TCJA temporarily allows 100% expensing of certain new or used tangible property through 2022, phasing out at 20% for each following year (with an election available for 50% expensing of such property if placed in service during the first taxable year ending after September 27, 2017). Theyear. These changes apply, generally, to property acquired after September 27, 2017 and placed in service after September 27, 2017.

 

Like KindLike-Kind Exchanges Retained for Real Property, but Eliminated for Most Personal Property

 

The TCJA continues the deferral of gain from the like kindlike-kind exchange of real property, but provides that foreign real property is no longer “like kind”“like-kind” to domestic real property. Furthermore, the TCJA eliminates like kindeliminated like-kind exchanges for most personal property. These changes arewere effective generally for exchanges completed after December 31, 2017, with a transition rule allowing such exchanges where one part of the exchange is completed prior to December 31, 2017.

 

International Provisions: Modified Territorial Tax Regime

 

The TCJA movesmoved the United States from a worldwide to a modified territorial tax system, with provisions included to prevent corporate base erosion. We currently do not have any foreign subsidiaries or properties, but these provisions could affect any such future subsidiaries or properties.

 

Other Provisions

 

The TCJA makesmade other significant changes to the Code. These changes include provisions limiting the ability to offset dividend and interest income with partnership or S corporation net active business losses. These provisions arewere effective beginning in 2018, but without further legislation, will sunset after 2025.

 

PART III

 

ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The information required by this Item is incorporated herein by reference to the Company’s definitive Proxy Statement to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.10-K.

 

90

ITEM 11.EXECUTIVE COMPENSATION

 

The information required by this Item is incorporated herein by reference to the Company’s definitive Proxy Statement to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.10-K.

 

ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The information required by this Item is incorporated herein by reference to the Company’s definitive Proxy Statement to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.10-K.

 

ITEM 13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by this Item is incorporated herein by reference to the Company’s definitive Proxy Statement to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.10-K.

 

ITEM 14.PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The information required by this Item is incorporated herein by reference to the Company’s definitive Proxy Statement to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.10-K.

 

PART IV

 

ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)(2) Financial Statement Schedule

(a)(2)Financial Statement Schedule

 

91

91

 

 

SCHEDULE III

CONSOLIDATED REAL ESTATE AND ACCUMULATED DEPRECIATION

(dollars and OP Units in thousands)

 

   Gross Amount Carried at December 31, 20171            Initial Costs  Costs Capitalized Subsequent to Acquisition  Gross Value at Close of Period             
Description Encum-
brances
 Land and
Improvements
 Buildings and
Improvements
 Intangible
Assets, Gross
 Total Accumulated
Depreciation
at 12/31/17
 Year Built /
Renovated
 Year
Acquired
 Life on
Which
Depreciation
in Income
Statement is
Computed
 Encumbrances Land & Improv  Building & Improv  Land & Improv  Building & Improv  Land & Improv  Building & Improv  Total Assets  Acc Depr at 12/31/19  Year Built / Renov  

Year

Acquired

  Life on Which Depreciation in Income Statement is Computed 
Omaha-LTAC (4) $-  $21,867  $-  $21,867  $1,952  2008 2014 (1)
Asheville-ASC (4)  572   1,934   -   2,506   159  1981/2002 2014 (1)
Pittsburgh-MOB/ASC (5)  1,287   10,322   -   11,609   585  2006 2015 (1)
Memphis-MOB/ASC (6)(7)  2,705   17,451   -   20,156   874  (9) 2015 (1)
Plano-Surgical Hospital (6)  1,050   16,696   -   17,746   804  2013 2016 (1)
Westland-MOB/ASC (6)  230   4,520   -   4,750   198  1974/2002/2009 2016 (1)
Melbourne-MOB/Imaging (6)  1,200   14,250   -   15,450   624  1994/2005 2016 (1)
Reading-MOB/ASC (4)  1,440   7,940   -   9,380   287  1992/2001/2008 2016 (1)
East Orange-MOB (4)  2,150   10,112   -   12,262   318  1996 2016 (1)
Watertown-MOB/Imaging (4)  1,100   8,002   -   9,102   251  2011 2016 (1)
Sandusky-MOB (4)(7)  791   10,710   -   11,501   278  1999/2015/2016/2017 2016/2017 (1)
Carson City-MOB (4)  760   3,268   -   4,028   96  1991 2016 (1)
Ellijay-MOB (4)  914   3,337   870   5,121   231  2005/2012/2015 2016 (1)(2)(3)
Altoona-IRF (4)  1,184   18,505   1,856   21,545   991  1986 2016 (1)(2)(3)
Mechanicsburg-IRF (4)  810   21,451   1,996   24,257   1,097  1986 2016 (1)(2)(3)
Mesa-IRF (4)  3,620   16,265   2,465   22,350   872  2009 2016 (1)(2)(3)
Lewisburg-MOB/Imaging (4)  681   6,114   505   7,300   310  2006 2017 (1)(2)(3)
Cape Coral-MOB (4)  353   7,017   -   7,370   134  2007 2017 (1)
Las Cruces-MOB (4)  397   4,618   -   5,015   121  1987/1992/2012 2017 (1)
Prescott-MOB (4)  791   3,821   -   4,612   68  2016 2017 (1)
Clermont-MOB (4)  145   4,422   868   5,435   149  2014 2017 (1)(2)(3)
Great Bend-Hospital (4)  837   23,801   -   24,638   512  2001 2017 (1)
Oklahoma City-Hospital/ASC (4)  2,953   38,724   7,823   49,500   1,232  2002 2017 (1)(2)(3)
Brockport-MOB (4)  693   7,097   1,295   9,085   172  2011 2017 (1)(2)(3)
Flower Mound-ASC (4)  730   3,155   407   4,292   77  2014 2017 (1)(2)(3)
Sherman-IRF/LTAC (4)  1,601   25,011   -   26,612   299  2009 2017 (1)
Lubbock-MOB (4)  1,566   5,725   908   8,199   112  2004 2017 (1)(2)(3)
Germantown-MOB/ASC (4)  3,050   8,385   4,505   15,940   341  2002 2017 (1)(2)(3)
Austin-Rehab Hospital (4)  7,223   29,616   3,811   40,650   311  2012 2017 (1)(2)(3)
Fort Worth-MOB (4)  1,738   3,726   786   6,250   29  2016 2017 (1)(2)(3)
Albertville-MOB (4)  1,154   4,444   1,202   6,800   48  2007 2017 (1)(2)(3)
Moline-MOB/ASC (4)  854   9,237   1,916   12,007   62  1994/2004 2017 (1)(2)(3)
Lee’s Summit-MOB (8)  571   2,929   437   3,937   -  2007 2017 (1)(2)(3)
Amarillo-MOB (8)  1,437   7,254   -   8,691   -  2011 2017 (1)
Wyomissing-MOB (8)  487   5,250   -   5,737   -  2001/2004 2017 (1)
Saint George-MOB/ASC (8)  435   5,372   -   5,807   -  1997 2017 (1)
Omaha-LTACH  (4) $-  $21,867  $-  $-  $-  $21,867  $21,867  $3,045   2008   2014   (1)
Asheville-ASC  (4)  572   1,934   -   -   572   1,934   2,506   256   2002   2014   (1)
Pittsburgh-MOB/ASC  (5)  1,287   10,322   -   -   1,287   10,322   11,609   1,101   2006   2015   (1)
Memphis-MOB/ASC  (6)(7)  2,705   17,451   -   -   2,705   17,451   20,156   1,730   2009   2015   (1)
Plano-Surgical Hospital  (6)  1,050   16,696   -   -   1,050   16,696   17,746   1,639   2013   2016   (1)
Westland-MOB/ASC  (6)  230   4,520   -   -   230   4,520   4,750   424   2009   2016   (1)
Melbourne-MOB/Imaging  (6)  1,200   14,250   -   -   1,200   14,250   15,450   1,337   2012   2016   (1)
Reading-MOB/ASC  (4)  1,440   7,940   -   --   1,440   7,940   9,380   685   1992/2002  2016   (1)
East Orange-MOB  (4)  2,150   10,112   -   -   2,150   10,112   12,262   823   1996   2016   (1)
Watertown- MOB/Imaging  (4)  1,100   8,002   45   90   1,145   8,092   9,237   658   2011/2015  2016   (1)(3)
Sandusky-MOB  (4)(7)  791   10,710   -   -   791   10,710   11,501   901   2010   2016/  (1)
Carson City-MOB  (4)  760   3,268   -   -   760   3,268   4,028   259   1991   2016   (1)
Ellijay-MOB  (4)  914   3,337   -   -   914   3,337   4,251   395   2015   2016   (1)(2)(3)
Altoona-IRF  (4)  1,184   18,505   -   -   1,184   18,505   19,689   1,613   2000   2016   (1)(2)(3)
Mechanicsburg-IRF  (4)  810   21,451   -   -   810   21,451   22,261   1,825   2011   2016   (1)(2)(3)
Mesa-IRF  (4)  3,620   16,265   -   -   3,620   16,265   19,885   1,609   2011   2016   (1)(2)(3)
Lewisburg-MOB/Imaging  (4)  681   6,114   -   -   681   6,114   6,795   708   2006   2017   (1)(2)(3)
Cape Coral-MOB  (4)  353   7,017   -   -   353   7,017   7,370   415   2007   2017   (1)(3)
Las Cruces-MOB  (4)  397   4,618   40   -   437   4,618   5,055   385   2012   2017   (1)
Prescott-MOB  (4)  791   3,821   -   -   791   3,821   4,612   221   2016   2017   (1)
Clermont-MOB  (4)  145   4,422   -   -   145   4,422   4,567   302   2014   2017   (1)(2)(3)
Oklahoma City-Surgical Hospital/ Physical Therapy/ASC  (4)  2,953   38,724   -   -   2,953   38,724   41,677   3,077   2002/2007  2017   (1)(2)(3)
Brockport-MOB  (4)  693   7,097   -   -   693   7,097   7,790   604   2011   2017   (1)(2)(3)
Flower Mound-ASC  (4)  730   3,155   -   -   730   3,155   3,885   269   2014   2017   (1)(2)(3)
Sherman-IRF/ LTACH  (4)  1,601   25,011   -   2,447   1,601   27,458   29,059   1,664   2009   2017   (1)(2)
Lubbock-MOB  (4)  1,566   5,725   -   -   1,566   5,725   7,291   539   2004   2017   (1)(2)(3)
Germantown-MOB/ASC  (4)  3,050   8,385   -   -   3,050   8,385   11,435   810   2002   2017   (1)(2)(3)
Austin-IRF  (4)  7,223   29,616   -   -   7,223   29,616   36,839   1,738   2012   2017   (1)(2)(3)
Fort Worth-MOB  (4)  1,738   3,726   -   -   1,738   3,726   5,464   279   2016   2017   (1)(2)(3)
Albertville-MOB  (4)  1,154   4,444   -   -   1,154   4,444   5,598   494   2007   2017   (1)(2)(3)
Moline-MOB/ASC  (4)  854   9,237   -   -   854   9,237   10,091   674   2004   2017   (1)(2)(3)
Lee’s Summit-MOB  (4)  571   2,929   -   -   571   2,929   3,500   311   2007   2017   (1)(2)(3)
Amarillo-MOB  (4)  1,437   7,254   -   -   1,437   7,254   8,691   330   2011   2017   (1)
Wyomissing-MOB  (4)  487   5,250   -   -   487   5,250   5,737   233   2004   2017   (1)
Saint George-MOB/ASC  (4)  435   5,372   -   -   435   5,372   5,807   269   1997   2017   (1)
Silvis-MOB  (7)  249   5,862   -   561   249   6,423   6,672   514   1997/2006  2018   (1)(2)(3)
Fremont-MOB  (4)  162   8,335   -   -   162   8,335   8,497   376   2018   2018   (1)
Gainesville-MOB/ASC  (4)  625   9,885   -   554   625   10,439   11,064   462   2002   2018   (1)
East Dallas-Acute Hospital  (4)  6,272   17,012   -   -   6,272   17,012   23,284   1,040   1994   2018   (1)
Orlando-MOB  (4)  3,075   11,944   -   -   3,075   11,944   15,019   676   2007/2008/ 2009   2018   (1)(2)(3)
Belpre-MOB/ Imaging/ER/ASC  (4)  3,997   53,520   -   -   3,997   53,520   57,517   2,491   2011/2013/ 2014/ 2017   2018   (1)(2)(3)
McAllen-MOB  (4)  1,099   4,296   -   -   1,099   4,296   5,395   214   2000   2018   (1)
Derby-ASC  (4)  567   2,585   -   55   567   2,640   3,207   155   2005   2018   (1)(2)(3)
Bountiful-MOB  (4)  720   4,185   -   25   720   4,210   4,930   135   2004   2018   (1)(2)
Cincinnati-MOB  (4)  1,823   1,811   -   -   1,823   1,811   3,634   153   2016   2018   (1)(2)(3)
Melbourne Pine-Cancer Center  (4)  732   5,980   -   146   732   6,126   6,858   210   1993   2018   (1)(2)(3)
Southern IL-MOB  (4)  1,830   12,660   -   -   1,830   12,660   14,490   400   2011   2018   (1)
Vernon-MOB/ Dialysis/ Administrative  (4)  1,166   9,929   -   -   1,166   9,929   11,095   348   1993/1999  2018   (1)
Corona  (4)  1,601   14,689   -   -   1,601   14,689   16,290   368   2009   2018   (1)
Zachary-LTACH  (4)  103   3,745   -   -   103   3,745   3,848   96   2015   2019   (1)(2)(3)
Chandler -MOB/ASC  (4)  4,616   11,643   -   -   4,616   11,643   16,259   273   2004/2007  2019   (1)
GMR Surprise-IRF  (4)  1,966   22,856   -   -   1,966   22,856   24,822   559   2015   2019   (1)(2)(3)
South Bend-IRF  (4)  1,998   11,882   -   -   1,998   11,882   13,880   440   2009   2019   (1)(2)(3)
Las Vegas-IRF  (4)  2,723   17,482   -   -   2,723   17,482   20,205   573   2007   2019   (1)(2)(3)
Oklahoma Northwest-IRF  (4)  2,507   22,545   -   -   2,507   22,545   25,052   577   2012   2019   (1)(2)(3)
San Marcos-Cancer Center  (4)  2,448   7,338   -   -   2,448   7,338   9,786   115   2009   2019   (1)(2)(3)
Lansing Patient-MOB /ASC  (4)  1,387   8,348   -   -   1,387   8,348   9,735   150   1997/2000
/2002
  2019   (1)(2)(3)
Bannockburn-MOB  (4)  895   4,700   85   215   980   4,915   5,895   156   1999   2019   (1)(2)(3)
Aurora-Office  (4)  1,829   8,049   -   -   1,829   8,049   9,878   132   2015   2019   (1)(2)(3)
Livonia-MOB/Urgent Care  (4)  1,181   8,071   -   165   1,181   8,236   9,417   183   1995   2019   (1)(2)(3)
Gilbert-MOB/ASC  (4)  2,470   2,389   -   -   2,470   2,389   4,859   37   2006   2019   (1)(2)(3)
Morgantown-Office  (4)  1,256   5,792   -   -   1,256   5,792   7,048   55   2019   2019   (1)(2)(3)
Beaumont-Surgical Hospital  (4)  3,421   25,872   -   -   3,421   25,872   29,293   181   2013   2019   (1)(2)(3)
Bastrop-Freestanding ED  (4)  2,039   8,712   -   -   2,039   8,712   10,751   51   2012   2019   (1)(2)(3)
Panama City-MOB/ASC  (4)  1,779   9,718   -   -   1,779   9,718   11,497   61   2008/2009/
2019
  2019   (1)(2)(3)
Jacksonville-MOB  (4)  1,023   7,846   -   -   1,023   7,846   8,869   25   2003/2004  2019   (1)
Greenwood-MOB/ASC     892   4,956   -   -   892   4,956   5,848   -   1986   2019   (1)
Totals   $47,509  $392,348  $31,650  $471,507  $13,594           $105,123  $723,184  $170  $4,258  $105,293  $727,442  $832,735  $42,828             

 


1No costs have been capitalized subsequent to acquisitionThe cost basis for income tax purposes of aggregate gross land, building, site improvements, and therefore the gross amount that the investments are carried attenant improvements as of December 31, 2017 represents their initial cost to the Company.2019 was $891.4 million.

(1) Estimated useful life for buildings is 3023 to 51 years.years 

(2) Estimated useful life for tenant improvements is 31 to 16 years.18 years

(3) Estimated useful life for site improvements is 42 to 15 years.13 years

(4) The facility serves as collateral for the Revolving Credit Facility, which had a balance of $164,900$351,350 as of December 31, 2017.2019

(5) The facility serves as collateral for the West Mifflin note, which had a balance of $7,378$7,219 as of December 31, 20172019

(6) The facility serves as collateral for the Cantor Loan, which had a balance of $32,097 as of December 31, 2017.2019

(7) OneThe facility did not serve as collateral as of December 31, 2017.2019

(8) Was notBecame collateral under the Revolving Credit Facility as of December 31, 2017 but became collateral during the first quarter of 2018.2019

(9) Years of: 2001, 1984, 2001, 2003, 2006, 2009, 2011.2011

(10) Years of: 1953, 1982, 2000, 1998, 2017

(11) Years of: 2002, 2006, 2012, 2014, 2015, 2016

(12) During the year ended December 31, 2019, the Company issued 49 OP Units valued at $506 for one acquisition. During the year ended December 31, 2018, the Company issued 1,899 OP Units valued at $16,363 for three acquisitions.

 

  Year Ended December 31, 
  2019  2018  2017 
Real Estate Assets:            
Balance, beginning of period $604,398  $439,857  $199,690 
Additions through acquisitions  228,337   189,178   240,167 
Deductions  -   (24,637)  - 
Balance, end of period $832,735  $604,398  $439,857 
             
Accumulated Depreciation:            
Balance, beginning of period $23,762  $11,253  $3,324 
Additions through expense  19,066   13,644   7,929 
Deductions  -   (1,135)  - 
Balance, end of period $42,828  $23,762  $11,253 

92

93

 

 

  Year Ended December 31, 2017 
  2017  2016  2015 
Real Estate Assets:            
Balance, beginning of period $206,877  $56,138  $24,373 
Additions through acquisitions  264,630   150,739   31,765 
Deductions  -   -   - 
Balance, end of period $471,507  $206,877  $56,138 
            ��
Accumulated Depreciation:            
Balance, beginning of period $3,367  $989  $329 
Additions through expense  10,227   2,378   660 
Deductions  -   -   - 
Balance, end of period $13,594  $3,367  $989 

 

(a)(3) Exhibits

 

Exhibit
No.
 Description
   
3.1 Articles of IncorporationRestatement of Global Medical REIT Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Report on Form 10-Q as filed with the CommissionSEC on April 22, 2014)August 8, 2018).
   
3.2 SecondThird Amended and Restated Bylaws of Global Medical REIT Inc., adopted as of December 14, 2017August 13, 2019 (incorporated herein by reference to Exhibit 3.2(i)3.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on December 15, 2017)August 14, 2019).
   
3.34.1  ArticlesSpecimen of Amendment to Articles of Incorporation filed with the Secretary of State of MarylandCommon Stock Certificate (incorporated herein by reference to Annex A to the Company’s Definitive Information Statement on Schedule 14C as filed with the Commission on October 3, 2014).
3.4Certificate of Correction of Articles of Incorporation of Global Medical REIT Inc. (incorporated by reference to Exhibit 3.34.1 to the Company’s Registration Statement on Form S-11/A as filed with the CommissionSEC on June 15, 2016).
   
3.5Certificate of Correction of Articles of Incorporation of Global Medical REIT Inc. (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form S-11/A as filed with the Commission on June 15, 2016).
3.6Articles Supplementary for the 7.50% Series A Cumulative Redeemable Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the Commission on September 14, 2017).
4.14.2 Specimen of 7.50% Series A Cumulative Redeemable Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on September 14, 2017).
4.3*Description of Securities.
   
10.1† Amended and Restated Management Agreement dated as of July 1, 2016, by and among Global Medical REIT Inc. and Inter-American Management LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on July 7, 2016).
   
10.2† Global Medical REIT Inc. 2016 Equity Incentive Plan (as amended through May 29, 2019) (incorporated herein by reference to Exhibit 4.610.1 to the Company’s Registration StatementCurrent Report on Form S-88-K as filed with the CommissionSEC on June 30, 2016)3, 2019).
   
10.3† Form of Restricted Share Award Agreement (Time Vesting) (incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-11/A filed with the CommissionSEC on June 15, 2016).
   
10.4† Form of LTIP Unit Award Agreement (Officer) (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-11/A filed with the CommissionSEC on June 15, 2016).
   
10.5† Form of LTIP Unit Award Agreement (Director) (incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-11/A filed with the CommissionSEC on June 15, 2016).
   
10.6† LTIP Award Agreement (Annual Award): For Grantees with an Employment Agreement with the Manager (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on March 6, 2017).

 93 

10.7† LTIP Award Agreement (Annual Award): For Grantees without an Employment Agreement with the Manager (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on March 6, 2017).
   
10.8† Form of LTIP Vesting Agreement: For Grantees without an Employment Agreement with the Advisor (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on December 22, 2016).
   
10.9† Form of LTIP Vesting Agreement: For Grantees with an Employment Agreement with the Advisor (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on December 22, 2016).
   
10.10† LTIP Award Agreement (Long-Term Award): For Grantees with an Employment Agreement with the Manager (incorporated by reference toExhibit 99.3 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on March 6, 2017)2017 andExhibit 10.3 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on May 9, 2018).
   
10.11† LTIP Award Agreement (Long-Term Award): For Grantees without an Employment Agreement with the Manager (incorporated by reference toExhibit 99.4 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on March 6, 2017)2017 andExhibit 10.4 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on May 9, 2018).
   
10.12† Form of Indemnification Agreement between Global Medical REIT Inc. and its directors and officers (incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-11/A filed with the CommissionSEC on June 15, 2016).
   
10.13 Agreement of Limited Partnership, dated March 14, 2016, of Global Medical REIT L.P. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on March 18, 2016).


10.14 Contribution and AssignmentFirst Amendment to Agreement dated March 14, 2016, by and betweenof Limited Partnership of Global Medical REIT Inc. and Global Medical REIT L.P. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on March 18, 2016).
10.15Purchase Agreement, dated May 17, 2017, by and between Global Medical REIT Inc. and SDB Partners, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on May 23,September 14, 2017).
10.15Second Amendment to Agreement of Limited Partnership of Global Medical REIT L.P., dated August 21, 2019 (incorporated herein by reference to Exhibit 10.2 to the Company’s Report on Form 10-Q as filed with the SEC on November 7, 2019).
   
10.16 Lease Agreement, dated JuneJanuary 30, 2017,2006, by and between Global Medical REIT Inc.LVRH Properties LLC, a Nevada limited liability company, and SDB Partners,Las Vegas Rehabilitation Hospital, a Nevada limited liability company, and amendments (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the SEC on April 18, 2019).
10.17Lease Agreement, dated December 30, 2015, by and between CHP Surprise AZ Rehab Owner, LLC, a Delaware limited liability company, and Cobalt Rehabilitation Hospital IV, LLC, a Texas limited liability company (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on July 6, 2017)April 18, 2019).
   
10.1710.18Lease Agreement, dated October 17, 2011, by and between TST Oklahoma City, LLC and Mercy Rehabilitation Hospital, LLC, an Oklahoma limited liability company (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed with the SEC on April 18, 2019).
10.19Build to Suit Facility Lease Agreement, dated February 27, 2009, by and between Elm Road MOB, II, LLC, an Indiana limited liability company, and Saint Joseph Regional Medical Center-South Bend Campus, Inc., an Indiana not for profit corporation, and amendments (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K as filed with the SEC on April 18, 2019).
10.20 Term Loan and Security Agreement between GMR Pittsburgh, LLC and Capital One, National Association dated as of September 25, 2015 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on October 1, 2015).
   
10.18Agreement Regarding Reimbursement of Certain Expenses, dated May 8, 2017, by and between the Company and Inter-American Management LLC (incorporated herein by reference to Exhibit 10.11 to the Company’s Quarterly Report on Form 10-Q as filed with the Commission on May 11, 2017).
10.1910.21 Lease Agreement, dated June 30, 2017, between SDB Partners, LLC and GMR Sherman, LLC. (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on July 6, 2017).
   
10.20Purchase Agreement, effective July 5, 2017, between Norvin Austin Rehab LLC and Global Medical REIT Inc. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on July 6, 2017).
10.21Separation Agreement and General Release, dated August 20, 2017, between Inter-American Management LLC and David A. Young (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on August 21, 2017).

94

10.22Form of Consulting Agreement, dated September 19, 2017, between Inter-American Management LLC and David A. Young (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the Commission on August 21, 2017).
10.23 Loan Agreement dated March 31, 2016 between GMR Memphis, LLC, GMR Plano, LLC, GMR Melbourne, LLC, and GMR Westland, LLC and Cantor Commercial Real Estate Lending, L.P. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on April 6, 2016).
   
10.24First Amendment to Agreement of Limited Partnership of Global Medical REIT L.P. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on September 14, 2017).
10.2510.23 Lease Agreement, dated September 17, 2010, between Prevarian Hospital Partners, LP and CTRH, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on September 29, 2017).
   
10.2610.24 UnderwritingLease Agreement, dated as of June 28, 2017,December 27, 2010, by and among Global Medical REIT Inc., Inter-American Management LLC, Global Medical REIT L.P.between 601 Plaza L.L.C. and Janney Montgomery Scott LLC, as representative of the several underwriters named thereinMarietta Memorial Hospital and amendments and addendums (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on June 30, 2017)April 24, 2018).
   
10.2710.25 Asset Purchase Agreement between Global Medical REIT Inc. and Marina Towers LLC dated as of January 7, 2016 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on January 14, 2016).
10.28Asset PurchaseLease Agreement, dated March 31, 2016,December 19, 2012, by and between Global Medical REIT, Inc.Belpre II, LLC and Chery Hill Real Estate, LLCMarietta Memorial Hospital and addendums (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on April 6, 2016)24, 2018).
   
10.2910.26 Lease Agreement, dated March 16, 2015, by and between an affiliate of Global Medical REIT, Inc.Belpre III, LLC and The Surgical Institute of Michigan, LLCMarietta Memorial Hospital and amendment (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on April 6, 2016)24, 2018).
   
10.3010.27 Asset PurchaseLease Agreement, dated April 19, 2016,June 11, 2013, by and between Global Medical REIT, Inc.Belpre IV, LLC and Paper Mill Partners, L.P.Marietta Memorial Hospital and amendment (incorporated herein by reference to Exhibit 10.110.4 to the Company’s Current Reportcurrent report on Form 8-K as filed with the CommissionSEC on April 25, 2016)24, 2018).
   
10.3110.28 Underwriting Agreement dated as of June 28, 2016, byAmended and among Global Medical REIT Inc., Inter-American Management LLC and Wunderlich Securities, Inc., as representative of the several underwriters named therein (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K as filed with the Commission on July 5, 2016). 
10.32Purchase Agreement dated as of November 29, 2016, between GMR MESA, LLC and HR ACQUISITION I CORPORATION (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on November 30, 2016).
10.33Purchase Agreement dated as of November 29, 2016, between GMR ALTOONA, LLC and HR ACQUISITION OF PENNSYLVANIA, INC. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the Commission on November 30, 2016).
10.34Purchase Agreement dated as of November 29, 2016, between GMR MECHANICSBURG, LLC, HR ACQUISITION OF PENNSYLVANIA, INC. and PENNSYLVANIA HRT, INC. (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed with the Commission on November 30, 2016).
10.35Restated Credit Facility Agreement, dated December 2, 2016August 7, 2018, by and among Global Medical REIT L.P., Global Medical REIT INC.Inc., the certain Subsidiaries from time to time party thereto as Guarantors, and BMO Harris Bank N.A., as Administrative Agent (incorporated herein by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on August 8, 2018).


10.29First Amendment to Amended and Restated Credit Facility Agreement, dated September 30, 2019, by and among Global Medical REIT L.P., Global Medical REIT Inc., the certain Subsidiaries from time-to-time party thereto as Guarantors, and BMO Harris Bank N.A., as Administrative Agent (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on December 5, 2016)October 3, 2019).
   
10.3610.30* FirstSecond Amendment to Amended and Restated Credit Facility Agreement, dated March 3, 2017October 12, 2019, by and among Global Medical REIT L.P.,  Global Medical REIT INC.Inc., the certain Subsidiaries from time to time party thereto as Guarantors, and BMO Harris Bank N.A., as Administrative AgentAgent.
10.31Sales Agreement, dated August 17, 2018 by and among the Company, Global Medical REIT L.P. and Inter-American Management LLC, on the one hand, and Cantor Fitzgerald & Co., B. Riley FBR, Inc., BMO Capital Markets Corp., D.A. Davidson & Co., H.C. Wainwright & Co., LLC, The Huntington Investment Company and Robert W. Baird & Co. Incorporated, on the other hand (incorporated herein by reference to Exhibit 10.11.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on March 6, 2017)August 17, 2018).

 95 

10.3710.32Second Amendment to Lease Agreement, dated December 27, 2010, by and between 601 Plaza L.L.C. and Marietta Memorial Hospital (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on November 6, 2018).
10.33First Amendment to Lease Agreement, dated as of April 19, 2018, by and between Belpre II, LLC and Marietta Memorial Hospital (incorporated herein by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on November 6, 2018).
10.34Second Amendment to Lease Agreement, dated as of April 19, 2018, by and between Belpre III, LLC and Marietta Memorial Hospital (incorporated herein by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on November 6, 2018).
10.35Third Amendment to Lease Agreement, dated as of April 19, 2018, by and between Belpre IV, LLC and Marietta Memorial Hospital (incorporated herein by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q as filed with the SEC on November 6, 2018).
10.36 Amended and Restated Building Lease between CRUSE-TWO, L.L.C. and OKLAHOMA CENTER FOR ORTHOPEDIC & MULTI-SPECIALTY SURGERY, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on February 2, 2017).
   
10.38Lease Agreement between HR Acquisition I Corporation and GMR Mesa LLC. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on December 23, 2016).
10.3910.37 Master Lease Agreement by and between GMR OKLAHOMA, LLC and CRUSE-TWO, L.L.C. (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on February 2, 2017).
   
10.40Lease Agreement between HR Acquisition of Pennsylvania, Inc. and GMR Altoona, LLC. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the Commission on December 23, 2016).
10.41Lease Agreement between HR Acquisition of Pennsylvania, Inc. and GMR Mechanicsburg, LLC. (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed with the Commission on December 23, 2016).
10.42Purchase Agreement dated as of December 30, 2016, by and between GLOBAL MEDICAL REIT, INC. and GREAT BEND SURGICAL PROPERTIES, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on January 4, 2017).
10.43Purchase and Sale Agreement dated as of January 30, 2017, between CRUSE-TWO, L.L.C., CRUSE-SIX, L.L.C., and GMR OKLAHOMA CITY, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on February 2, 2017).
10.4410.38 Lease Agreement between TC CONCORD PLACE I, INC. and SPECIALISTS SURGERY CENTER (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on February 2, 2017).
   
10.4516.1 Lease AgreementLetter of MaloneBailey, LLP dated March 31, 2017, between GMR Great Bend, LLC, a Delaware limited liability company, and Great Bend Regional Hospital, L.L.C., a Kansas limited liability companyApril 11, 2019 (incorporated herein by reference to Exhibit 10.116.1 to the Company’s Current Report on Form 8-K as filed with the CommissionSEC on April 5, 2017)12, 2019).
12*Statement Re: Computation of Ratio of Earnings to Combined Fixed Charges.
   
21* Subsidiaries of the Company.
   
23.1*Consent of Deloitte & Touche, LLP
23.2* Consent of MaloneBailey, LLP
   
31.1* Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
31.2* Certification of Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
32.1* Certification of Principal Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS * XBRL Instance Document
   
101.SCH * XBRL Taxonomy Schema


101.CAL * XBRL Taxonomy Calculation Linkbase
   
101.DEF * XBRL Taxonomy Definition Linkbase
   
101.LAB * XBRL Taxonomy Label Linkbase
   
101.PRE * XBRL Taxonomy Presentation Linkbase

† Management contract or compensatory plan or arrangement.

* Filed herewith

 

ITEM 16.FORM 10-K SUMMARY

 

None.

 

96

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 Global Medical REIT Inc.
   
Dated: March 12, 20189, 2020By:/s/ Jeffrey M. Busch
  Jeffrey M. Busch
  Chief Executive Officer (Principal Executive Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated and on the date indicated.

 

Signature Title Date
     
/s/ Jeffrey M. Busch    
Jeffrey M. Busch Chief Executive Officer (Principal Executive Officer) and Director March 12, 20189, 2020
     
/s/ Robert J. Kiernan    
Robert J. Kiernan Chief Financial Officer (Principal Financial and Accounting Officer) March 12, 20189, 2020
     
/s/ Zhang Jingguo    
Zhang Jing Guo Director March 12, 20189, 2020
     
/s/ Zhang Huiqi    
Zhang Huiqi Director March 12, 20189, 2020
     
/s/ Kurt HarringtonLori Wittman    
Kurt HarringtonLori Wittman Director March 12, 20189, 2020
     
/s/ Matthew Cypher    
Matthew Cypher Director March 12, 20189, 2020
     
/s/ Ronald Marston    
Ronald Marston Director March 12, 20189, 2020
     
/s/ Dr. Roscoe Moore    
Dr. Roscoe Moore Director March 12, 20189, 2020
     
/s/ Henry Cole    
Henry Cole Director March 12, 20189, 2020
/s/ Paula Crowley
Paula CrowleyDirectorMarch 9, 2020

 

97